0001437749-22-004467.txt : 20220225 0001437749-22-004467.hdr.sgml : 20220225 20220225161321 ACCESSION NUMBER: 0001437749-22-004467 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 74 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220225 DATE AS OF CHANGE: 20220225 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NATURAL HEALTH TRENDS CORP CENTRAL INDEX KEY: 0000912061 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-MISCELLANEOUS NONDURABLE GOODS [5190] IRS NUMBER: 592705336 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36849 FILM NUMBER: 22680101 BUSINESS ADDRESS: STREET 1: UNITS 1205-07, 12F, MIRA PLACE TOWER A STREET 2: 132 NATHAN ROAD, TSIMSHATSUI, KOWLOON CITY: HONG KONG STATE: K3 ZIP: 00000 BUSINESS PHONE: 852-3107-0800 MAIL ADDRESS: STREET 1: UNITS 1205-07, 12F, MIRA PLACE TOWER A STREET 2: 132 NATHAN ROAD, TSIMSHATSUI, KOWLOON CITY: HONG KONG STATE: K3 ZIP: 00000 10-K 1 nhtc20211231_10k.htm FORM 10-K nhtc20211231_10k.htm
0000912061 Natural Health Trends Corp. false --12-31 FY 2021 0.001 0.001 5,000,000 5,000,000 0 0 0 0 0.001 0.001 50,000,000 50,000,000 12,979,414 12,979,414 1,556,875 1,556,875 2 5 3 5 5 7 299,000 14 1 1 5 0 10 3 0.20 0.20 0.20 0.20 0.20 0.20 0.20 9.1 1 90 4.5 100 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors”. FASB Topic 820, Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. 00009120612021-01-012021-12-31 iso4217:USD 00009120612021-06-30 xbrli:shares 00009120612022-02-22 thunderdome:item 00009120612021-12-31 00009120612020-12-31 iso4217:USDxbrli:shares 00009120612020-01-012020-12-31 0000912061us-gaap:PreferredStockMember2019-12-31 0000912061us-gaap:CommonStockMember2019-12-31 0000912061us-gaap:AdditionalPaidInCapitalMember2019-12-31 0000912061us-gaap:RetainedEarningsMember2019-12-31 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-31 0000912061us-gaap:TreasuryStockMember2019-12-31 00009120612019-12-31 0000912061us-gaap:PreferredStockMember2020-01-012020-12-31 0000912061us-gaap:CommonStockMember2020-01-012020-12-31 0000912061us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-31 0000912061us-gaap:RetainedEarningsMember2020-01-012020-12-31 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-31 0000912061us-gaap:TreasuryStockMember2020-01-012020-12-31 0000912061us-gaap:PreferredStockMember2020-12-31 0000912061us-gaap:CommonStockMember2020-12-31 0000912061us-gaap:AdditionalPaidInCapitalMember2020-12-31 0000912061us-gaap:RetainedEarningsMember2020-12-31 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-31 0000912061us-gaap:TreasuryStockMember2020-12-31 0000912061us-gaap:PreferredStockMember2021-01-012021-12-31 0000912061us-gaap:CommonStockMember2021-01-012021-12-31 0000912061us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-31 0000912061us-gaap:RetainedEarningsMember2021-01-012021-12-31 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-31 0000912061us-gaap:TreasuryStockMember2021-01-012021-12-31 0000912061us-gaap:PreferredStockMember2021-12-31 0000912061us-gaap:CommonStockMember2021-12-31 0000912061us-gaap:AdditionalPaidInCapitalMember2021-12-31 0000912061us-gaap:RetainedEarningsMember2021-12-31 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-31 0000912061us-gaap:TreasuryStockMember2021-12-31 utr:D 0000912061srt:MinimumMember2021-01-012021-12-31 0000912061srt:MaximumMember2021-01-012021-12-31 iso4217:VND 0000912061country:VN2019-11-30 0000912061country:VN2021-12-31 0000912061country:VN2020-12-31 xbrli:pure 0000912061country:KP2021-12-31 utr:Y 0000912061nhtc:OfficeEquipmentOfficeSoftwareAndCapitalizedInternaluseSoftwareDevelopmentMembersrt:MinimumMember2021-01-012021-12-31 0000912061nhtc:OfficeEquipmentOfficeSoftwareAndCapitalizedInternaluseSoftwareDevelopmentMembersrt:MaximumMember2021-01-012021-12-31 0000912061us-gaap:FurnitureAndFixturesMembersrt:MinimumMember2021-01-012021-12-31 0000912061us-gaap:FurnitureAndFixturesMembersrt:MaximumMember2021-01-012021-12-31 0000912061us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-12-31 0000912061us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-12-31 0000912061us-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMembercountry:HK2021-01-012021-12-31 0000912061nhtc:UnshippedProductMember2021-12-31 0000912061nhtc:UnshippedProductMember2020-12-31 0000912061nhtc:AutoShipAdvancesMember2021-12-31 0000912061nhtc:AutoShipAdvancesMember2020-12-31 0000912061us-gaap:ProductAndServiceOtherMember2021-12-31 0000912061us-gaap:ProductAndServiceOtherMember2020-12-31 0000912061country:CN2021-12-31 0000912061us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2021-12-31 0000912061us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2020-12-31 0000912061us-gaap:FairValueInputsLevel2Memberus-gaap:BankTimeDepositsMember2021-12-31 0000912061us-gaap:FairValueInputsLevel2Memberus-gaap:BankTimeDepositsMember2020-12-31 0000912061us-gaap:FairValueInputsLevel2Memberus-gaap:MunicipalBondsMember2021-12-31 0000912061us-gaap:FairValueInputsLevel2Memberus-gaap:MunicipalBondsMember2020-12-31 0000912061us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2021-12-31 0000912061us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2020-12-31 utr:sqft 0000912061country:HK2021-12-31 0000912061nhtc:RollingHillsEstatesMember2021-12-31 0000912061nhtc:RollingHillsEstatesMember2020-06-30 0000912061nhtc:RichmondBritishColumbiaMember2021-12-31 0000912061nhtc:MetuchenNewJerseyMember2021-12-31 0000912061nhtc:DepartmentForInternationalTaxCooperationMember2021-01-012021-12-31 0000912061nhtc:DepartmentForInternationalTaxCooperationMember2020-01-012020-12-31 0000912061us-gaap:InlandRevenueHongKongMember2021-01-012021-12-31 0000912061us-gaap:InlandRevenueHongKongMember2020-01-012020-12-31 0000912061us-gaap:StateAdministrationOfTaxationChinaMember2021-01-012021-12-31 0000912061us-gaap:StateAdministrationOfTaxationChinaMember2020-01-012020-12-31 0000912061us-gaap:DomesticCountryMember2021-12-31 0000912061us-gaap:StateAndLocalJurisdictionMember2021-12-31 0000912061us-gaap:ForeignCountryMember2021-12-31 0000912061nhtc:EquityIncentivePlan2016Member2021-12-31 0000912061us-gaap:RestrictedStockMember2019-12-31 0000912061us-gaap:RestrictedStockMember2020-01-012020-12-31 0000912061us-gaap:RestrictedStockMember2020-12-31 0000912061us-gaap:RestrictedStockMember2021-01-012021-12-31 0000912061us-gaap:RestrictedStockMember2021-12-31 0000912061nhtc:ThePhantomPlanMember2021-03-152021-03-15 0000912061nhtc:PhantomSharesMembernhtc:ThePhantomPlanMembernhtc:EmployeesAndNonEmployeeDirectorsMember2021-03-152021-03-15 utr:M 0000912061nhtc:PhantomSharesMembernhtc:ThePhantomPlanMembersrt:MaximumMembernhtc:EmployeesAndNonEmployeeDirectorsMember2021-03-15 0000912061nhtc:PhantomSharesMembernhtc:ThePhantomPlanMembernhtc:NewnonemployeedirectorsMember2021-05-142021-05-14 0000912061nhtc:PhantomSharesMembernhtc:ThePhantomPlanMembernhtc:EmployeesAndNonEmployeeDirectorsMember2021-01-012021-12-31 00009120612020-01-012020-03-31 00009120612020-04-012020-06-30 00009120612020-07-012020-09-30 00009120612020-10-012020-12-31 00009120612021-01-012021-03-31 00009120612021-04-012021-06-30 00009120612021-07-012021-09-30 00009120612021-10-012021-12-31 00009120612015-07-28 00009120612016-01-12 0000912061us-gaap:AccumulatedTranslationAdjustmentMember2020-12-31 0000912061us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-12-31 0000912061us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-12-31 0000912061us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-01-012021-12-31 0000912061us-gaap:AccumulatedTranslationAdjustmentMember2021-12-31 0000912061us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-12-31 0000912061srt:DirectorMember2021-12-31 0000912061nhtc:RoyaltyAgreementAndLicenseMembernhtc:BHSMember2021-01-012021-12-31 0000912061nhtc:RoyaltyAgreementAndLicenseMembernhtc:BHSMember2020-01-012020-12-31 0000912061nhtc:PrimaryReportingSegmentMember2021-01-012021-12-31 0000912061nhtc:PrimaryReportingSegmentMember2020-01-012020-12-31 0000912061country:CN2021-01-012021-12-31 0000912061country:CN2020-01-012020-12-31 0000912061nhtc:RussiaAndKazakhstanMember2021-01-012021-12-31 0000912061nhtc:RussiaAndKazakhstanMember2020-01-012020-12-31 0000912061us-gaap:OperatingSegmentsMembernhtc:PrimaryReportingSegmentMember2021-01-012021-12-31 0000912061us-gaap:OperatingSegmentsMembernhtc:PrimaryReportingSegmentMember2020-01-012020-12-31 0000912061us-gaap:OperatingSegmentsMembercountry:CN2021-01-012021-12-31 0000912061us-gaap:OperatingSegmentsMembercountry:CN2020-01-012020-12-31 0000912061us-gaap:OperatingSegmentsMembernhtc:RussiaAndKazakhstanMember2021-01-012021-12-31 0000912061us-gaap:OperatingSegmentsMembernhtc:RussiaAndKazakhstanMember2020-01-012020-12-31 0000912061us-gaap:OperatingSegmentsMember2021-01-012021-12-31 0000912061us-gaap:OperatingSegmentsMember2020-01-012020-12-31 0000912061us-gaap:IntersegmentEliminationMember2021-01-012021-12-31 0000912061us-gaap:IntersegmentEliminationMember2020-01-012020-12-31 0000912061country:US2021-01-012021-12-31 0000912061country:US2020-01-012020-12-31 0000912061country:CA2021-01-012021-12-31 0000912061country:CA2020-01-012020-12-31 0000912061country:PE2021-01-012021-12-31 0000912061country:PE2020-01-012020-12-31 0000912061country:HK2021-01-012021-12-31 0000912061country:HK2020-01-012020-12-31 0000912061country:TW2021-01-012021-12-31 0000912061country:TW2020-01-012020-12-31 0000912061srt:EuropeMember2021-01-012021-12-31 0000912061srt:EuropeMember2020-01-012020-12-31 0000912061nhtc:OtherForeignCountriesMember2021-01-012021-12-31 0000912061nhtc:OtherForeignCountriesMember2020-01-012020-12-31 0000912061us-gaap:ProductMember2021-01-012021-12-31 0000912061us-gaap:ProductMember2020-01-012020-12-31 0000912061nhtc:AdministrativeFeesFreightAndOtherMember2021-01-012021-12-31 0000912061nhtc:AdministrativeFeesFreightAndOtherMember2020-01-012020-12-31 0000912061country:US2021-12-31 0000912061country:US2020-12-31 0000912061country:GB2021-12-31 0000912061country:GB2020-12-31 0000912061country:CN2020-12-31 0000912061nhtc:OtherForeignCountriesMember2021-12-31 0000912061nhtc:OtherForeignCountriesMember2020-12-31 0000912061us-gaap:SubsequentEventMember2022-02-072022-02-07
 

 



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

 

FORM 10-K

 

(Mark One) 

 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2021

or

 

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                 to                

 

Commission file number: 001-36849

NATURAL HEALTH TRENDS CORP. 

(Exact name of registrant as specified in its charter) 

Delaware

59-2705336

(State or other jurisdiction of

(I.R.S. Employer

incorporation or organization)

Identification No.)

 

Units 1205-07, 12F

Mira Place Tower A

132 Nathan Road, Tsimshatsui

Kowloon, Hong Kong

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: +852-3107-0800

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

NHTC

The NASDAQ Stock Market LLC

 

Securities registered pursuant to Section 12(g) of the Act: None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☑

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☑

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

Accelerated filer

Non-accelerated filer

 

Smaller reporting company

 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No ☑

 

The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the closing price of such common equity on June 30, 2021: $48,628,270

 

At February 22, 2022, the number of shares outstanding of the registrant’s common stock was 11,422,539 shares.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

Portions of the registrant’s definitive proxy statement to be filed with the United States Securities and Exchange Commission no later than 120 days after the end of the registrant’s fiscal year end to which this report relates are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.



 

 

 

NATURAL HEALTH TRENDS CORP.

Annual Report on Form 10-K

December 31, 2021

 

TABLE OF CONTENTS

 

 

 

Page

PART I

 

Item 1.

Business

1

Item 1A.

Risk Factors

12

Item 1B.

Unresolved Staff Comments

22

Item 2.

Properties

22

Item 3.

Legal Proceedings

22

Item 4.

Mine Safety Disclosures

22

 

 

 

PART II

 

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

23

Item 6.

[Reserved]

23

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

24

Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

32

Item 8.

Financial Statements and Supplementary Data

33

Item 9.

Changes In and Disagreements with Accountants on Accounting and Financial Disclosure

56

Item 9A.

Controls and Procedures

56

Item 9B.

Other Information

56

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 56

 

 

 

PART III

 

Item 10.

Directors, Executive Officers and Corporate Governance

57

Item 11.

Executive Compensation

57

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

57

Item 13.

Certain Relationships and Related Transactions, and Director Independence

57

Item 14.

Principal Accountant Fees and Services

57

 

 

 

PART IV

 

Item 15.

Exhibits and Financial Statement Schedules

58

Item 16.

Form 10-K Summary

58

 

 

 

Signatures

59

 

 

 

FORWARD-LOOKING STATEMENTS

 

This Annual Report on Form 10-K, in particular “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and “Item 1. Business,” include “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). When used in this report, the words or phrases “will likely result,” “expect,” “intend,” “will continue,” “anticipate,” “estimate,” “project,” “believe” and similar expressions are intended to identify “forward-looking statements” within the meaning of the Exchange Act. These statements represent our expectations or beliefs concerning, among other things, future revenue, earnings, growth strategies, new products and initiatives, future operations and operating results, and future business and market opportunities.

 

Forward-looking statements in this report speak only as of the date hereof, and forward-looking statements in documents incorporated by reference speak only as of the date of those documents. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. We caution and advise readers that these statements are based on certain assumptions that may not be realized and involve risks and uncertainties that could cause actual results to differ materially from the expectations and beliefs contained herein.

 

For a summary of certain risks related to our business, see “Item 1A. Risk Factors” in this report. Additional factors that could cause actual results to differ materially from our forward-looking statements are set forth in this report, including under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and in our financial statements and the related notes.

 

Unless otherwise noted, the terms “we,” “our,” “us,” and “Company,” refer to Natural Health Trends Corp. and its subsidiaries. References to “dollars” and “$” are to United States dollars.

 

 

 

Part I

 

Item 1. BUSINESS

 

Overview of Business

 

Natural Health Trends Corp. is an international direct-selling and e-commerce company. Subsidiaries controlled by us sell personal care, wellness, and “quality of life” products under the “NHT Global” brand. Our wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Malaysia, Singapore and Thailand; South Korea; Japan; India; and Europe. We also operate in Russia and Kazakhstan through our engagement with a local service provider.

 

Most of our order volume, particularly in our Hong Kong subsidiary, is for personal consumption through existing members’ referrals. Our objectives are to enrich the lives of our customers and enable our members to benefit financially from the sale of our products.

 

We are incorporated in Delaware and maintain our corporate headquarters in Hong Kong.

 

Our common stock is currently traded on the NASDAQ Capital Market under the symbol “NHTC.”

 

Available Information

 

Our website is located at www.naturalhealthtrendscorp.com. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to such reports are available, free of charge, on our website as soon as reasonably practicable after we file electronically such material with, or furnish it to, the United States Securities and Exchange Commission, or SEC. The information provided on our website should not be considered part of this report. The SEC maintains an internet website at http://www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.

 

Our Principal Products

 

We offer a line of “NHT Global” branded products in six distinct categories: wellness, herbal, beauty, lifestyle, home, and daily. These product categories, along with the business opportunity we offer in most of our markets, provide our members a platform to further their goal of achieving and maintaining healthy, quality lifestyles complete with product supplementation and the opportunity for financial rewards.

 

The following table summarizes our product offering by category:

 

Product Category

 

Description

 

Products

 

 

 

 

 

 

 

Wellness

 

Products formulated and designed to meet specific wellness goals of our customers. Includes targeted nutrition for joint health, antioxidant support, digestive health, heart health, vision health, immune support and cellular health.

 

Liquid, encapsulated, tableted and powder dietary and nutritional supplements, vitamins, minerals

 

Premium Noni Juice, Triotein™, Cluster X2™, Children’s Chewable Multivitamin, ReStor Silver™, ReStor Vital™, Trifusion Max™, Glucosamine 2200™, FibeRich™, Energin, Enhanced Essential Probiotics, Omega-3 Essential Fatty Acids, StemRenu®, OcuFocus™, CurcuMore™, AdaptoGin™, Biotic Trio, Ultra B Complex, CalComplex, Colostrum Chewable Tablets

 

 

 

 

 

 

 

Herbal

 

Products formulated incorporating ingredients commonly found in traditional Chinese medicine.

 

Herbal supplements

 

LivaPro™, Cordyceps Mycelia CS-4™, Purus, RespFactor™

 

 

 

Beauty

 

Products to help improve skin health and bring an appearance of youthful vibrancy. This product line includes age-defying and hydrating cleansers, creams, lotions, serums and toners to moisturize, protect and improve the appearance of skin.

 

Facial skin care and hand and body care

 

Skindulgence™ 30 Minute Firming System, BioCell SC Mask, Skindulgence™ Essence Gel, Valesce™ Eye Cream and Eye Mask, Floraeda Toner and Primer, Botanical Hand Protector™, Airelle® Age-Defying Facial Serum, Airelle® Intense Hydrating Repair Complex, Airelle® Age-Defying Eye & Lip Treatment, Color Awakening Lipstick™, Adamas™ Brightening Series, Micellion Cleansing Water, Skindulgence™ Probiotic Ampoule, Skindulgence™ Daily Gentle Facial Cleanser

 

 

 

 

 

 

 

Lifestyle

 

Products uniquely formulated to improve overall quality of life and to support active, physical and healthy lifestyles including weight management, and energy enhancing supplements.

 

Supplements and topical gels for improved vitality

 

Alura Lux™ by NHT Global, Valura Lux, LaVie, TwinSlim™ Probiotics, NaturalGlo

 

 

 

 

 

 

 

Home

 

Products designed to create a clean and natural living environment for the home.

 

Home appliances

 

Air Purifier, AquaPur Desktop Water Purifier

 

 

 

 

 

 

 

Daily

 

Daily care products designed to cleanse and protect the body and promote personal hygiene.

 

Oral care, hair care, and body care

 

FE Enzyme Toothpaste™, Bontanesse™ Shampoo, Smart Sonic Toothbrush

 

 

We continuously source unique, proprietary and immediate impact products to offer to our members and customers. Our product development is an ongoing process that is fueled by marketplace trends, new technologies and scientific findings, members’ input, research and vendor proposals.

 

 

Working closely with raw material manufacturers and contract manufacturers, our mission is to co-develop and bring to market the highest quality products. Our manufacturers are primarily located in the United States, as well as a few in South Korea, Hong Kong, Taiwan and China. Our raw materials are sourced from reputable suppliers around the world. All current and new products introduced into the market are tested to ensure country and state regulatory compliance requirements are met where the products are sold. This includes proper handling, shipping, and shelf-life recommendations for our products. In addition, raw material Certificates of Analyses are reviewed to ensure that appropriate testing has been performed and are within required ingredient specifications.

 

Operations of the Business

 

Operating Strategy

 

Our objective is to help our members succeed in achieving their life objectives; be it personal health, beauty, happiness or financial rewards. Our employees focus on assisting our members in attaining their goals.

 

We believe we have a competitive business model applicable to the markets in which we conduct business based on six key competencies:

 

 

Our field leaders are experienced and culturally coherent. They work effectively with our management, implementing our strategies and providing continuous feedback to improve our services.

 

 

A discipline and capability has been established to continue launching high-quality consumer products that are designed to facilitate the accomplishment of our corporate objectives.

 

 

We have developed and rolled out a comprehensive training system that provides a complete advancement path appropriate for our members. Our training material covers the needs of our members, be they prospects, new recruits, product evangelists, sales leaders or dream builders.

 

 

We have developed a year-round, multi-faceted promotional plan that targets different segments of our membership.

 

 

We have implemented a commission structure that makes it as easy as possible to join our business, while giving existing members a chance to start earning money as quickly as possible in multiple ways.

 

 

The continuously improving mentality and methodology in our customer services have not only distinguished us as an organization, but have also given us a constant flow of information as to how we can do better to service our members.

 

Sourcing of Products

 

Our staff works with research and development personnel of our manufacturers and other prospective vendors to create product concepts and develop the product ideas into actual products. We then may enter into supply agreements with the vendors pursuant to which we obtain rights to sell the products under private labels (or trademarks) that are owned by us. In addition, some of our local markets introduce their own products from time to time and these products are sometimes adopted by our other markets.

 

We generally purchase finished goods from third-party manufacturers and sell them to our members for retail and personal consumption. We believe that in the event we are unable to timely source products from our current or alternate suppliers, our revenue, income and cash flow could be adversely and materially impacted. See “Item 1A. Risk Factors - We rely on a limited number of independent third parties to manufacture and supply our products on a timely basis.” We have some contracts with our suppliers with automatic renewal rights.

 

 

Marketing and Distribution

 

We distribute our products internationally primarily through a network marketing system, which is a form of person-to-person direct selling.  Under this system, members primarily refer our products to prospective consumers or they may buy at wholesale or discounted prices for personal consumption or for resale to consumers.  The concept of network marketing is based on the strength of personal recommendations that frequently come from friends, neighbors, relatives, and close acquaintances.  We believe that network marketing is an effective way to distribute our products because it allows person-to-person product education and testimonials as well as higher levels of customer service, all of which are not as readily available through other distribution channels. It should be noted, however, that the restrictive measures imposed in response to the COVID-19 pandemic have tempered some of the benefits associated with network marketing. In this document, we generically use the term “member” to refer to members who purchase for their own consumption or for resale, or both, as well as to members who only sign up to consume our products.

 

Each of our products is designated a specified number of bonus volume points. Commissions are paid to members based on total personal and group bonus volume points per weekly sales period. Bonus volume points are essentially a percentage of a product’s wholesale price.

 

Virtually all of our members are independent full-time or part-time contractors who purchase products directly from our subsidiaries via the internet for their own personal consumption or for resale to retail consumers. Purchasers of our products in some of our smaller markets and purchasers of our products from our China subsidiary may purchase only for their own personal consumption and not for resale.

 

The following table sets forth the number of active members by market as of the dates indicated. We consider a member “active” if they have placed at least one product order with us during the preceding year. Members may not necessarily reside in the market for which they sign up as a member.

 

   

December 31,

 
   

2021

   

2020

 

Americas1

    5,650       4,760  

Hong Kong (including those members residing in China)2

    33,510       41,130  

Taiwan

    2,410       2,550  

South Korea

    80       90  

Japan

    700       220  

Malaysia and Singapore

    420       290  

Russia and Kazakhstan

    1,090       1,340  

Europe

    1,210       1,300  

India

    690       550  

Total

    45,760       52,230  

 


1 United States, Canada, Mexico and Peru

2 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors.”

 

Members must agree to the terms and conditions of our member agreement posted on our website. The member agreement sets forth our policies and procedures, and we may elect to terminate a member for non-compliance.

 

We pay commissions to eligible members based on product purchases by such members’ down-line customers and members during a given commission period. To be eligible to receive commissions, members in some countries may be required to make nominal monthly or other periodic purchases of products. See “Working with Members.

 

Members generally place orders through the internet and pay by credit card prior to shipment. Accordingly, we carry minimal accounts receivable and credit losses are historically negligible.

 

 

Although we have been required to modify or curtail some of our marketing strategies and programs in response to the COVID-19 pandemic, we generally sponsor promotional meetings, product education, motivational and personal development training events for current and potential members. These events are designed to inform and train prospective and existing members about our product lines and new product launches, our latest marketing and promotional plans, and new services improvements. These events also serve as a venue for recognition of member accomplishments. Members typically share their experiences in using our products and developing their business at these events. We are continually developing and updating our marketing strategies and programs to motivate our members.

 

Recent Disruptions to our Business

 

Our normal business operations have recently been disrupted by a series of events, including the COVID-19 pandemic and related measures to control it, the Chinese government’s 100-day campaign focused on companies involved in the sale of health products in China, and recent political and social developments in Hong Kong. See “Item 1A. Risk Factors - Epidemics, such as the COVID-19 pandemic, or natural disasters, terrorist attacks or acts of war…”, “Risk Factors - Our business in China is subject to compliance with a myriad of applicable laws and regulations...”, “Risk Factors - Our Hong Kong operations are being adversely affected by recent political and social developments in Hong Kong…”, and “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations - Business Overview.”

 

Management Information Systems

 

Our business uses a proprietary web-based system to process orders and to communicate bonus volume activity and commissions to members. We have automated a substantial amount of our financial reporting processes through implementation of Oracle’s E-Business Suite, and have integrated other critical business processes such as inventory management, purchasing and costing in our most significant markets.

 

Employees

 

At December 31, 2021, we employed 140 individuals, including 138 total full-time employees worldwide. Of the full-time employees, 89 were located in Greater China (Hong Kong, China, and Taiwan), 26 in the Americas (United States, Canada, Cayman Islands, and Peru), four in Europe, five in India, five in Malaysia and Singapore, two in South Korea, three in Russia, three in Japan, and one in Vietnam.

 

Seasonality

 

From quarter to quarter, we are somewhat impacted by seasonal factors and trends such as major cultural events and vacation patterns. For example, most Asian markets celebrate their respective local New Year in the first quarter. This generally has a significant impact on the services of our third-party providers, and can negatively impact our net sales. We believe that net sales can also be negatively impacted during the third quarter, when many of our members traditionally take time off for vacations. In addition, the national holidays in Hong Kong, China and Taiwan in early October tend to have an adverse effect on sales in those markets.

     

Our spending, as well as to some extent revenue, is affected by the major events planned at different times of the year. A major promotional event could significantly increase the reported expenses during the quarter in which the event actually takes place, while the revenue that might be generated by the event may not occur in the same reporting period.

 

Intellectual Property

 

Most of our products are packaged under a “private label” arrangement. We have obtained or applied for trademark registration for certain names, logos and various product names in several countries in which we are doing business or considering expanding. We also rely on common law trademark rights to protect our unregistered trademarks. These common law trademark rights do not provide us with the same level of protection as afforded by a United States federal trademark. Common law trademark rights are limited to the geographic area in which the trademark is actually utilized, while a United States federal registration of a trademark enables the registrant to discontinue the unauthorized use of the trademark by a third party anywhere in the United States even if the registrant has never used the trademark in the geographic area where the trademark is being used; provided, however, that the unauthorized third party user has not, prior to the registration date, perfected its common law rights in the trademark within that geographic area.

 

We have United States and foreign holding and operating company structures for our businesses, which involve the division of our United States and non-United States operations. Under this structure, the foreign holding company retains the economic ownership of the intangible property outside of the United States, including trademarks, trade secrets and other proprietary information.

 

 

Working with Members

 

Sponsorship

 

Enrolling new members creates multiple levels in our direct selling structure. The persons that a member enrolls within the network are referred to as “sponsored” members, who may purchase product solely for their own personal consumption, for resale, or both. Persons newly enrolled are assigned into network positions that can be “under” other members, and thus they can be called “down-line” members. If down-line members also enroll new members, they create additional levels within the structure, but their down-line members remain in the same down-line network as the original member that introduced them to our business.

 

While we provide informational brochures and other sales materials, members are primarily responsible for enrolling and educating their new members with respect to products, the compensation plan and how to build a successful membership network.

 

Members are not required to enroll other members as their down-line, and we do not pay any commissions for enrolling new members. However, because of the financial incentives provided to those who succeed in building a member network that consumes and resells products, we believe that many of our members attempt, with varying degrees of effort and success, to enroll additional members. Because they are seeking new opportunities for income, people are often attracted to become members after using our products or after attending introductory seminars. Once a person becomes a member, he or she is able to purchase products directly from us at wholesale prices via the internet. The member is also entitled to enroll other members in order to build a network of members and customers.

 

In certain markets members also enroll preferred customers. Preferred customers purchase products at a discount but are not able to enroll new members or preferred customers, resell product, earn commissions or qualify for incentives or rewards.

 

Compensation Plans

 

We employ what is commonly referred to as a binary compensation plan, enhanced with certain unilevel features. Under our compensation plan, members are paid weekly commissions by our subsidiary in which they are enrolled for product purchases by their down-line member network across all geographic markets. Our China subsidiary maintains an e-commerce retail platform and does not pay commissions, although our Chinese members may participate in our compensation plan through our other subsidiaries. This “seamless” compensation plan enables a member located in one country to sponsor other members located in other countries. Currently, there are basically two ways in which members can earn income:

 

 

Through commissions paid on the accumulated bonus volume from product purchases made by their down-line members and customers; and

 

 

Through retail profits on sales of products purchased by members at discount and wholesale prices and resold at retail prices (for purchasers in some of our smaller markets and purchasers from our China subsidiary, sales are for personal consumption only and income may not be earned through retail profits).

 

Each of our products is designated a specified number of bonus volume points. Commissions are based on total personal and group bonus volume points per sales period. Bonus volume points are essentially a percentage of a product’s wholesale price. As the member’s business expands, the member receives higher commissions from purchases made by an expanding down-line network. To be eligible to receive commissions, a member may be required to make nominal monthly or other periodic purchases of our products. Certain of our subsidiaries do not require these nominal purchases for a member to be eligible to receive commissions. In determining commissions, the number of levels of down-line members included within the member’s commissionable group increases as the number of memberships directly below the member increases. Under our current compensation plan, some of our commission payout may be limited to a hard cap dollar amount per week or a specific percentage of the total product sales. In some markets, commissions may be further limited.

 

In some markets, we also pay certain bonuses on purchases by up to three generations of personally sponsored members, as well as bonuses on commissions earned by up to seven generations of personally sponsored members. Members can also earn income, trips and other prizes in specific time-limited promotions and contests we hold from time to time.

 

Occasionally, we make modifications and enhancements to our compensation plan to help motivate members, which can have an impact on member commissions. We may also enter into agreements for business or market development, which could result in additional compensation to specific members.

 

 

Member Support

 

We are committed to providing a high level of support services tailored to the needs of our members in each market we are serving. We attempt to meet the needs and build the loyalty of members by providing personalized member services and by maintaining a generous product return policy (see “Product Warranties and Returns”). We believe that maximizing a member’s efforts by providing effective member support has been, and could continue to be, important to our success.

 

We seek to understand and satisfy the needs of our members through virtual and in-person product training meetings, significant member events, web-based messages, member focus groups, regular telephone conference calls and other personal contacts with members. Via our platform, we may provide product fulfillment and tracking services that result in user-friendly and timely product distribution.

 

To help maintain communication with our members, we offer the following support programs:

 

 

Teleconferences – we hold teleconferences with member field leadership on various subjects such as technical product discussions, member organization building and management techniques.

 

 

Internet – we maintain a website at www.nhtglobal.com. On this website, the user can read company news, learn more about various products, sign up to be a member, place orders, and track the fulfillment and delivery of their orders.

 

 

Product Tools – we offer a variety of marketing tools to members, including product catalogs, videos, informational brochures, pamphlets and posters for individual products, which are both printed and available online.

 

 

Broadcast E-mail and Text Messages – we send announcements via e-mail and/or text messages to members who opt in to receive this form of communication.

 

 

Social Media Tools – in some countries we maintain country-specific social media sites to foster a community environment around our product offering and business opportunity.

 

Technology and Internet Initiatives

 

We believe that the internet is important to our business as more consumers communicate online and purchase products over the internet as opposed to traditional retail and direct sales channels. As a result, we have committed significant resources to our e-commerce capabilities and the abilities of our members to take advantage of the internet. Substantially all of our sales take place via the internet. We offer a global platform that allows a member to have a personalized replicating website through which he or she can sell products in all of the countries in which we do business. Links to these websites can be found at our main website for members at www.nhtglobal.com. The information provided on these websites should not be considered part of this report.

 

Rules Affecting Members

 

Our member policies and procedures establish the rules that members must follow in each market. We also monitor member activity in an attempt to provide our members with a “level playing field” so that one member may not be disadvantaged by the activities of another. We require our members to present products and business opportunities in an ethical and professional manner. Members further agree that their presentations to customers must be consistent with, and limited to, the product claims and representations made in our literature.

 

Our policies and procedures require that we produce or pre-approve all sales aids used by members such as presentations, videos, audio recordings, brochures and promotional clothing. Further, members may not use any form of media advertising to promote products unless it is pre-approved by us. Members are not entitled to use our trademarks or other intellectual property without our prior consent. If we are made aware of unapproved materials being used, we notify and direct the relevant members to cease using such materials. In addition to regularly communicating to our members what is and is not appropriate to say about product or income claims, we have engaged a third-party service provider to assist us in monitoring the internet and various social media to identify potential misconduct or violations of our policies and procedures.

 

Our compliance and member services department reviews reports of alleged member misbehavior. If we determine that a member has violated our member policies or procedures, we may terminate the member’s rights completely. Alternatively, we may impose sanctions, such as warnings, probation, withdrawal or denial of an award, suspension of privileges of the membership, fines, withholding commissions, until specified conditions are satisfied or other appropriate injunctive relief. Virtually all of our members are independent contractors, not employees, and may act independently of us. Further, our members may resign or terminate their membership at any time without notice. See “Item 1A. Risk Factors - Our recent loss of a significant number of members is adversely affecting our business...”.

 

 

Government Regulations

 

Direct Selling Activities

 

Direct selling, or multi-level marketing, activities are regulated by various federal, state and local governmental agencies in the United States and other countries. These laws and regulations are generally intended to prevent fraudulent or deceptive schemes. The laws and regulations in our current markets often:

 

 

impose cancellation/product return, inventory buy-backs and cooling-off rights for consumers and members;

 

 

require us or our members to obtain a license from, or register with, governmental agencies;

 

 

impose reporting requirements; and

 

 

impose upon us requirements, such as requiring members to maintain levels of retail sales to qualify to receive commissions, to avoid pyramid schemes by ensuring that members are being compensated for sales of products and not for recruiting new members.

 

The laws and regulations governing direct selling are modified from time to time, and, like other direct selling companies, we may be subject from time to time to government reviews, examinations or investigations in our various markets related to our direct selling activities. This can require us to make changes to our business model and aspects of our global compensation plan in the markets impacted by such changes and examinations.

 

China has direct selling and anti-pyramiding regulations that are restrictive and contain various limitations, including a restriction on the ability to pay multi-level compensation to independent members and engage in certain member recruitment activities. The regulatory environment in China is complex, and our business in China can receive regulatory and media attention.

 

The Chinese government scrutinizes activities of direct selling companies. Our business continues to be subject to regulations and examinations by municipal and provincial level regulators. At times, actions by government regulators have impacted our members’ activities in certain locations, and have resulted in a few cases of enforcement actions. In each of these cases, we helped our members with their defense in the legality of their conduct. We expect that our business model will continue to evolve, as we work with our professional advisors and regulators to make any changes that need to be made to comply with direct selling and other regulations.

       

We believe that neither our Hong Kong-based e-commerce direct selling platform nor our e-commerce retail platform in China require a direct selling license in China, which we currently do not hold. We previously submitted a preliminary application for a direct selling license in China in August 2015, but in 2019 a Chinese governmental authority recommended that we withdraw our application. We understand that the governmental authorities recommended that other companies with pending direct selling license applications also withdraw their applications. We applied to withdraw our application in November 2019, and the governmental authorities approved the withdrawal of our application shortly thereafter. In connection with the withdrawal of our application, we received a refund in March 2020 of a consumer protection fund deposit of CNY 20 million ($2.9 million) that we made upon submission of our application. We expect to reapply for a direct selling license in China when we believe that circumstances are again ripe for doing so.

 

Regulation of Our Products

 

Our products and related promotional and marketing activities are subject to extensive governmental regulation by numerous governmental agencies and authorities in the United States, including the U.S. Food and Drug Administration (the “FDA”), the Federal Trade Commission (the “FTC”), the Consumer Product Safety Commission, the U.S. Department of Agriculture, state attorneys general and other state regulatory agencies.  In our foreign markets, the products are generally regulated by similar government agencies.

 

 

Our personal care products are subject to various laws and regulations that regulate cosmetic products and set forth regulations for determining whether a product can be marketed as a “cosmetic” or requires further approval as an over-the-counter (OTC) cosmetic. In the United States, regulation of cosmetics is under the jurisdiction of the FDA and the FTC.  The Food, Drug and Cosmetic Act defines cosmetics by their intended use, as “articles intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body . . . for cleansing, beautifying, promoting attractiveness, or altering the appearance.”  Among the products included in this definition are skin moisturizers, eye and facial makeup preparations, perfumes, lipsticks, fingernail polishes, shampoos, permanent waves, hair colors, toothpastes and deodorants, as well as any material intended for use as a component of a cosmetic product.  Conversely, a product will not be considered a cosmetic, but may be considered a drug if it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, or is intended to affect the structure or any function of the body. A product’s intended use can be surmised from marketing or product claims.  The other markets in which we conduct business have similar regulations.  Additionally, the requirement that claims for products must be truthful and substantiated is enforced by the FTC.

 

In Japan, the Ministry of Health, Labor and Welfare regulates the sale and distribution of cosmetics and requires us to have an import business license and to register each personal care product imported into Japan.  In Taiwan, all “medicated” cosmetic products require registration.  In China, personal care products are placed into one of two categories, “general” and “drug.”  Products in both categories require submission of formulas and other information with the health authorities, and drug products require human clinical studies.  The product registration process in China for these products can take from nine to more than 18 months or longer.  Such regulations in any given market can limit our ability to import products and can delay product launches as we go through the registration and approval process for those products.  The sale of cosmetic products is regulated in the European Union under the European Union Cosmetics Directive, which requires a uniform application for foreign companies making personal care product sales. In Peru, this is managed by the governing arm DIGEMID (Dirección General de Medicamentos, Insumos y Drogas) and can take up to three months to fully register as saleable. Similarly, in Mexico, the governing arm is COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) and can also take three to six months to fully register as saleable.

 

The markets in which we conduct business all have varied regulations that distinguish foods and nutritional health supplements from “drugs” or “pharmaceutical products.”  Because of the varied regulations, some products or ingredients that are recognized as a “food” in certain markets may be treated as a “pharmaceutical” in other markets.  These regulations may require us to either modify a product or refrain from selling the product in a given market. As a result, we must regularly modify the ingredients and/or the levels of ingredients in our products to ensure all applicable regulatory restrictions are addressed.  In some circumstances, the regulations in foreign markets may require us to obtain regulatory approval prior to introduction of a new product or limit our uses of certain ingredients altogether. There has been an increased movement in the United States and other markets to expand the regulation of dietary supplements. This could impose additional restrictions or requirements in the future.  Because of this increased regulatory focus, our internal regulatory staff has grown and review efforts have been enhanced in order to comply with our understanding of current regulations.

 

FDA regulations require current good manufacturing practices (cGMP) for dietary supplements.  The regulations seek to ensure personnel are routinely and properly trained, that dietary supplements are produced in a quality manner, do not contain contaminants or impurities, and are accurately labeled. The regulations include requirements for establishing quality control procedures for us and our vendors and suppliers, designing and constructing manufacturing plants, and testing ingredients and finished products.  The regulations also include requirements for record keeping and handling consumer product complaints.  If dietary supplements contain contaminants or do not contain the type or quantity of dietary ingredient they are represented to contain, the FDA would consider those products to be adulterated or misbranded. We seek to ensure compliance with all regulatory requirements through our periodic manufacturer and warehouse audits, as well as our corrective action request (CAR) program, if needed. The cGMP also extend to logistics where we seek to minimize any safety risks associated with product distribution.

 

Our business is subject to additional FDA regulations, such as those implementing an adverse event reporting system (“AERS”), which requires us to document and track adverse events and report serious adverse events, which are events involving hospitalization or death, associated with consumers’ use of our products.  

 

 

Most of our major markets also regulate advertising and product claims regarding the efficacy of products. This is particularly true with respect to our dietary supplements because we typically market them as foods or health functional foods. For example, in the United States, we are unable to claim that any of our nutritional supplements will diagnose, cure, mitigate, treat or prevent disease. In the United States, the Dietary Supplement Health and Education Act, however, permits substantiated, truthful and non-misleading statements of nutritional support to be made in labeling, such as statements describing general well-being resulting from consumption of a dietary ingredient or the role of a nutrient or dietary ingredient in affecting or maintaining a structure or a function of the body. Most of the other markets in which we conduct business have not adopted similar legislation, so distribution of U.S. products may be subject to more restrictive limitations on the claims we can make about our products in these markets.

 

China’s 100-Day Campaign Focusing on Health Products and Services

 

In January 2019 the Chinese government announced a 100-day campaign focusing on companies involved in the sale of food, equipment, daily necessities, small home electrical appliances and services that are claimed to promote health. The Chinese government ministries in charge of this campaign indicated that they are targeting illegal practices in the industry, particularly the manufacture and sale of counterfeit and substandard products, and false advertising and misleading claims as to the health benefits of products and services. It is understood that the campaign is specifically focused on the business practices of direct selling companies. During the campaign, we understand that the government is not issuing any additional direct selling licenses, is not issuing certifications of quality or other approvals of various healthcare products, and is reviewing its regulatory oversight of the industry. Although the 100-day campaign was due to expire on or about April 18, 2019, we are not aware of any information indicating that the campaign has formally concluded. However, on August 27, 2019, the Chinese government announced that it would conduct a “look-back review” to evaluate the 100-day campaign. As part of this review, we understand that various Chinese governmental agencies formed a working group to assess the 100-day campaign, particularly focusing on the health market and its supervision in certain provinces. We understand that during September 2019 the working group evaluated the performance and results of a number of organizations and governmental departments in these provinces and made recommendations for various improvements. It was noted that each province had opened a number of investigative cases, had successfully closed numerous cases, and had imposed various fines and penalties. We understand that the look-back review continued after September 2019, and we are not aware that this review has been completed. As a result, the business environment in China for health product companies continues to be challenging, which has been exacerbated by negative social media sentiment expressed for these types of companies.

 

The 100-day campaign, including its extension and aftermath, has and is expected to continue negatively impacting our business in China in the near-term, but we believe will ultimately benefit us and Chinese consumers in the long-term as purveyors of substandard products are driven from the market. See “Item 1A. Risk Factors - Our business in China is subject to compliance with a myriad of applicable laws and regulations...” and “Item 7. - Management’s Discussion and Analysis of Financial Condition and Results of Operations - Business Overview.”

 

Other Regulatory Issues

 

As we operate through many subsidiaries in foreign jurisdictions, we are subject to foreign exchange control, transfer pricing and custom laws that regulate the flow of funds between our entities for product purchases, management services and contractual obligations, such as the payment of member commissions. As is the case with most companies that operate in direct sales, we might receive inquiries or scrutiny from time to time from government regulatory authorities regarding the nature of our business and other issues, such as compliance with local direct selling, pyramid selling, transfer pricing, customs, taxation, foreign exchange control, securities and other laws. See “Item 1A. Risk Factors - Legal, Regulatory, Tax, Currency and Trade Policy Risks.”

 

Product Warranties and Returns

 

Our refund policies and procedures closely follow industry and country-specific standards, which vary greatly by country. For example, in the United States, the Direct Selling Association recommends that direct sellers permit returns during the twelve-month period following the sale, while in Hong Kong the standard return policy is 14 days following the sale. Our return policies typically conform to local laws or the recommendation of the local direct selling association. In most cases, members who timely return unopened product that is in resalable condition may receive a refund. The amount of the refund may be dependent on the country in which the sale occurred, the timeliness of the return, and any applicable re-stocking fee. We must be notified of the return in writing and such written requests would be considered a termination notice of the membership. We may alter our return policy in response to special circumstances.

 

 

Significant Customers

 

Sales are made to our members and no single customer accounted for 10% or more of our net sales. However, our business model can result in a concentration of sales to several different members and their network of members. Although no single member accounted for 10% or more of net sales, the loss of a key member or that member’s network could have an adverse effect on our net sales and financial results.

 

Our Industry

 

We are engaged in the direct selling industry, selling wellness, herbal, beauty, lifestyle, home, and daily products. More specifically, we are engaged in what is called network marketing or multi-level marketing. This type of organizational structure and approach to marketing and sales include companies selling lifestyle enhancement products, cosmetics and dietary supplements, or selling other types of consumer products. Generally, direct selling is based upon an organizational structure in which independent members purchasing a company’s products are compensated for sales made directly to consumers.

 

Our members are compensated based on sales generated by members they have enrolled and all subsequent members enrolled by their “down-line” network of members. The experience of the direct selling industry has been that once a sizeable network of members is established, new and alternative products and services can be offered to those members for sale to consumers and additional members.

 

Competition

 

The network marketing industry is very diverse, with giant multinational corporations as well as smaller, local operators, some of which are direct-selling subsidiaries of much larger conglomerates. Big network marketing companies include Nu Skin Enterprises, Inc., USANA Health Sciences, Inc., and Herbalife Nutrition Ltd., which have much greater name recognition and financial resources than we do and also have many more members. They are publicly traded and therefore serve as informational benchmarks, but we don’t overlap with them in terms of marketplace or product range. On the other hand, many medium- and small-sized privately held Chinese, Taiwanese and Hong Kong companies are fierce competitors and are much closer to directly competing with us. Also, a number of our former employees and members now work for competitors and sometimes try to use relationships and knowledge obtained to compete with us.

 

Our ability to compete with other network marketing companies depends, in significant part, on our success in attracting and retaining members.  There can be no assurance that our programs for attracting and retaining members will be successful.  The pool of individuals interested in network marketing is limited in each market and is reduced to the extent other network marketing companies successfully attract these individuals into their businesses.  Although we believe that we offer an attractive opportunity for our members, there can be no assurance that other network marketing companies will not be able to recruit our existing members or deplete the pool of potential members in a given market.

 

The direct selling channel tends to sell products at a higher price compared to traditional retailers, which poses a degree of competitive risk. There is no assurance that we would continue to compete effectively against retail stores, internet-based retailers or other direct sellers.

 

 

 

Item 1A. RISK FACTORS

 

We are exposed to a variety of risks that are present in our business and industry. The following are some of the more significant factors that could affect our business, results of operations and financial condition.

 

Business, Product and Market Risks, Including COVID-19 Risks

 

Because our Hong Kong operations account for a substantial portion of our overall business, and substantially all of our Hong Kong business is derived from the sale of products to members in China, any material adverse change in our business relating to either Hong Kong or China would likely have a material adverse impact on our overall business.

 

In 2021 and 2020, approximately 78% and 79% of our revenue, respectively, was generated in Hong Kong. Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. This geographic concentration in our business means that events or conditions that could negatively impact this geographic region or our operations in this region, including the current economic challenges facing China and Hong Kong, are having and could in the future have a greater adverse impact upon our overall business and financial results than would be the case with a company having greater geographic diversification.  

 

Epidemics, such as the COVID-19 pandemic, or natural disasters, terrorist attacks or acts of war may seriously harm our business.

 

Epidemics, natural disasters, terrorist attacks or acts of war may cause damage or disruption to us, our employees, our facilities and our members and customers, which could negatively impact our revenues, results of operations and financial condition.  For example, in late 2019 or early 2020 an outbreak of COVID-19 was first identified in China and subsequently spread around the world, being declared a global pandemic by the World Health Organization in March 2020. The outbreak caused the Chinese government to implement powerful measures to control the virus, such as requiring businesses to close throughout areas of China and restricting public gatherings and certain travel within the country. We have significant business in China and in 2021 generated approximately 78% of our revenue in Hong Kong, substantially all of which was derived from the sale of products to members in China. The Chinese government continues to adjust the restrictive measures that it imposes to control COVID-19 based on then-current local circumstances, as have the governments of the other countries in which we operate. The severity of the impact on us of the COVID-19 pandemic will depend on future developments, including the duration and spread of the virus, and related control measures, which we are unable to accurately predict. Regardless, these disruptions have materially negatively impacted our financial results throughout 2020 and 2021, and we expect that our financial results for the near-term may be adversely affected. These disruptions have also adversely affected the operations of our third-party logistics providers, and we expect that the future operations of these logistics providers and other third parties with whom we work may be adversely affected by these disruptions.

 

This and other epidemics, such as the avian influenza, or natural disasters have in the past and could in the future adversely affect our business, results of operations and financial condition. Terrorist attacks, the national and international responses to terrorist attacks, and other acts of war or hostility, such as challenges to Chinese sovereignty claims in the South China Sea or Chinese objection to the Taiwan independence movement and the resultant tension in the Taiwan Strait, could materially and adversely affect our business, results of operations, and financial condition in ways that we currently cannot predict.

 

Our Hong Kong operations are being adversely affected by recent political and social developments in Hong Kong, and the negative impact on our operations and financial performance could continue or intensify.

 

Our headquarters and a significant number of our employees are based in Hong Kong, and our Hong Kong subsidiary generates a substantial portion of our overall business. Hong Kong has in recent years experienced significant political unrest and social strife, including a series of large-scale protests. These developments, along with the impact of the COVID-19 pandemic, led us in 2020 to cease conducting member meetings and events in Hong Kong. Inasmuch as member meetings and events located in Hong Kong have in the past served as an important component of our product marketing and distribution efforts, we believe that this action has negatively affected our operations and financial performance. If current conditions continue or further deteriorate, we anticipate that our business, results of operations and financial condition will be adversely affected.

 

We experienced negative operating cash flows during the year ended December 31, 2019, and only modest positive operating cash flows during the years ended December 31, 2021 and 2020. Unless our operating cash flows improve, this negative financial performance could have a material adverse effect on our business and our stock price.

 

We experienced negative operating cash flows during the year ended December 31, 2019, and only modest positive operating cash flows during the years ended December 31, 2021 and 2020. This cash flow performance was primarily due to declines in our revenues being greater than the decreases in expenditures that we could manage. If we again experience negative operating cash flows or our cash balance is substantially diminished, we may not be able to continue paying cash dividends to our stockholders, our ability to support our operations could be impaired and we may be required to seek debt or equity financing. However, we may not be able to obtain additional debt or equity financing on satisfactory terms, or at all, and any new financing could have a dilutive effect to our existing stockholders. Negative operating cash flows could have a material adverse effect on our business, results of operations and financial condition, as well as our stock price, and could eventually threaten our solvency. Negative operating cash flows and any related adverse market perception may also negatively affect our ability to attract new members and/or sell our products. There can be no assurance that we will be successful in maintaining an adequate level of cash resources.

 

Adverse publicity associated with our products, ingredients or network marketing program, or those of similar companies, could harm our financial condition and operating results.

 

Adverse publicity concerning any actual or claimed failure by us or our members to comply with applicable laws and regulations regarding product claims and advertising, good manufacturing practices, the regulation of our network marketing program, the licensing and distribution of our products for sale in our target markets or other aspects of our business, whether or not resulting in enforcement actions or the imposition of penalties, could have an adverse effect on our goodwill and could negatively affect our ability to attract, motivate and retain members, which would negatively impact our ability to generate revenue.  There have been several instances where adverse publicity in China has harmed our business. For example, in January 2019 Central China Television (CCTV) aired a segment alleging, among other things, that we conduct an illegal pyramid scheme in China, and we believe that this media coverage had a short-term negative impact on our business. See “Item 1A. Risk Factors - Our business in China is subject to compliance with a myriad of applicable laws and regulations…”.

 

 

 

In addition, our members’ and consumers’ perception of the safety and quality of our products and ingredients, as well as similar products and ingredients distributed by other companies, can be significantly influenced by media attention, publicized scientific research or findings, widespread product liability claims and other publicity concerning our products or ingredients or similar products and ingredients distributed by other companies.  Adverse publicity, whether or not accurate or resulting from consumers’ use or misuse of our products, that associates consumption of our products or ingredients or any similar products or ingredients with illness or other adverse effects, questions the benefits of our or similar products or claims that any such products are ineffective, inappropriately labeled or have inaccurate instructions as to their use, could negatively impact our reputation or the market demand for our products.

 

We are subject to risks relating to product concentration and lack of revenue diversification.

 

Although we have in recent years expanded our line of products, we derive at least 10% of our total revenue from each of our Premium Noni Juice, Enhanced Essential Probiotics and Triotein™ products. Further, we currently source each of these products from a single supplier. If demand decreases significantly, government regulation restricts their sale, we are unable to adequately source or deliver the products, or we are unable to offer the products for any reason without suitable replacements, our business, results of operations and financial condition could be materially and adversely affected. Our future success will also depend on our ability to reduce our dependence on these few products by developing and introducing new products and product or feature enhancements in a timely manner. Even if we are able to develop and commercially introduce new products and enhancements, they may not achieve market acceptance and the revenue generated from these new products and enhancements may not offset the costs, which could substantially impair our business, results of operations and financial condition.

 

The high level of competition in our industry could adversely affect our business.

 

The business of marketing personal care, cosmetic, nutritional supplements, and lifestyle enhancement products is highly competitive.  This market segment includes numerous manufacturers, members, marketers, and retailers that actively compete for the business of consumers both in the United States and abroad.  The market is highly sensitive to the introduction of new products, which may rapidly capture a significant share of the market.  Sales of similar products by competitors may materially and adversely affect our business, results of operations and financial condition.

 

We are subject to significant competition for the recruitment of members from other direct selling organizations, including those that market similar products.  Many of our competitors are substantially larger than we are, offer a wider array of products, have far greater financial resources and many more active members than we have.  Even more numerous are those medium- and small-sized, all privately held Chinese, Taiwanese and Hong Kong companies, some of which are direct-selling subsidiaries of much larger conglomerates, that are fierce competitors and are much closer to directly competing with us. Our ability to remain competitive depends, in significant part, on our success in recruiting and retaining members with our products, attractive compensation plan and other incentives.  We believe that we have an attractive product line and that our compensation and incentive programs provide our members with significant earning potential.  However, we cannot be sure that our programs for recruitment and retention of members will be successful.

 

Some of our competitors have employed or otherwise contracted for the services of our former officers, employees, consultants, and members, who may try to use information and contacts obtained while under contract with us for competitive advantage. While we seek to protect our information through contractual and other means, there can be no assurance that we will timely learn of such activity, have the resources to attempt to stop it, or have adequate remedies available to us.

 

Failure of new products to gain member and market acceptance could harm our business.

 

An important component of our business is our ability to develop new products that create enthusiasm among our member force.  If we fail to introduce new products on a timely basis, our member productivity could be harmed.  In addition, if any new products fail to gain market acceptance, are restricted by regulatory requirements, or have quality problems, this would harm our results of operations.  Factors that could affect our ability to continue to introduce new products include, among others, limited capital and human resources, government regulations, proprietary protections of competitors that may limit our ability to offer comparable products and any failure to anticipate changes in consumer tastes and buying preferences.

 

We rely on a limited number of independent third parties to manufacture and supply our products on a timely basis.

 

All of our products are manufactured by a limited number of independent third parties.  There is no assurance that our current manufacturers will continue to reliably supply products to us at the level of quality we require or to do so on a timely basis. Some of our third-party manufacturers have recently experienced difficulty sourcing product ingredients or components on a timely basis, resulting in delays in the timely delivery of products to us. If a key manufacturer suffers liquidity problems or experiences operational or other problems assisting with our products, our results could suffer.  In the event any of our third-party manufacturers become unable or unwilling to timely provide the products in required volumes and quality levels at acceptable prices, we will be required to identify and obtain acceptable replacement manufacturing sources or replacement products.  There is no assurance that we will be able to obtain alternative manufacturing sources or products or be able to do so on a timely basis.  An extended interruption in the supply of certain of our products may result in a substantial loss of revenue.  In addition, any actual or perceived degradation of product quality as a result of our reliance on third-party manufacturers may have an adverse effect on revenue or result in increased product returns.  

 

Growth may be impeded by the political and economic risks of entering and operating in foreign markets.

 

Our ability to achieve future growth is dependent, in part, on our ability to continue our international expansion efforts.  However, there can be no assurance that we would be able to grow in our existing international markets, enter new international markets on a timely basis, or that new markets would be profitable.  We must overcome significant regulatory and legal barriers before we can begin marketing in any foreign market.

 

 

 

Also, it is difficult to assess the extent to which our products and sales techniques would be accepted or successful in any given country.  In addition to significant regulatory barriers, we may also encounter problems conducting operations in foreign markets with different cultures and legal systems from those elsewhere.  There are substantial uncertainties in many such legal systems around the world, including in China, which could limit our ability to enforce third-party contractual arrangements and have other negative consequences. We may also be required to reformulate certain of our products before commencing sales in a given country.  Once we have entered a market, we seek to adhere to the regulatory and legal requirements of that market.  No assurance can be given that we would be able to successfully reformulate our products in any of our current or potential international markets to meet local regulatory requirements or attract local customers.  The failure to do so could have a material adverse effect on our business, results of operations and financial condition. There can be no assurance that we would be able to obtain and retain necessary permits and approvals.

 

In many markets, other direct selling companies already have significant market penetration, the effect of which could be to desensitize the local member population to a new opportunity or to make it more difficult for us to recruit qualified members. There can be no assurance that, even if we are able to commence operations in foreign countries, there would be a sufficiently large population of potential members inclined to participate in a direct selling system offered by us.  We believe our future success could depend in part on our ability to seamlessly integrate our business methods, including member compensation plan, across all markets in which our products are sold.  There can be no assurance that we would be able to further develop and maintain a seamless compensation program.

 

Failure to maintain effective internal controls in accordance with the Sarbanes-Oxley Act of 2002 could negatively impact our business and the market price of our common stock.

 

We are required by federal securities laws to document and test our internal control procedures in order to satisfy the requirements of the Sarbanes-Oxley Act of 2002 (“Sarbanes-Oxley”), which requires annual management assessments of the effectiveness of internal control over financial reporting. Effective internal controls are necessary for us to provide reliable financial reports and to effectively prevent fraud. The SEC’s Sarbanes-Oxley rules require us to include a report by management on the effectiveness of our internal control over financial reporting in our Annual Reports on Form 10-K. Although we review internal control over financial reporting in order to ensure compliance with the SEC’s Sarbanes-Oxley rules, if we fail to maintain effective internal control over financial reporting, we could be required to take costly and time-consuming corrective measures to remedy any number of deficiencies, significant deficiencies or material weaknesses, be required to restate the affected historical financial statements, be subjected to investigations and/or sanctions by federal and state securities regulators, and be subjected to civil lawsuits by stockholders. For instance, as described in “Item 9A. - Controls and Procedures” in our Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2018, we identified a material weakness in our internal control over financial reporting as of December 31, 2018. Management, with oversight from the Audit Committee, implemented a plan to remediate this material weakness and completed remediation during 2019. While the existence of this material weakness did not result in a restatement of previously issued interim or annual consolidated financial statements, we incurred substantial costs and utilized meaningful resources to remediate the material weakness during 2019. Any future failure to maintain effective internal control over financial reporting could result in the foregoing identified consequences and could cause investors to lose confidence in our reported financial information and in our company and could cause a decline in the market price of our common stock.

 

Management and Member Network Risks

 

We could be adversely affected by management changes or an inability to attract and retain key management, directors and consultants.

 

We incur a low level of overhead and are run by a small number of executives, who rely on a small group of employees. Our future success depends to a significant degree on the skills, experience and efforts of our top management and directors.  We also depend on the ability of our executive officers and other members of senior management to work effectively as a team.  The loss of one or more of our executive officers, members of our senior management or directors could have a material adverse effect on our business, results of operations and financial condition.  Moreover, as our business evolves, we may require additional or different management members, directors or consultants, and there can be no assurance that we will be able to locate, attract and retain them if and when they are needed.

 

Our recent loss of a significant number of members is adversely affecting our business, and if we cannot stabilize or increase the number of members our business could be further negatively impacted.

 

We distribute our products through independent members, and we depend upon them directly for all of our sales in most of our markets. Accordingly, our success depends in significant part upon our ability to attract, retain and motivate a large base of members, as well as a relatively small number of key members.  Our members may terminate their services with us at any time and, like most direct selling organizations, we have a high rate of attrition. We had 12% fewer active members at December 31, 2021 as compared to the end of 2020, and 9% fewer active members at the end of 2020 as compared to the end of 2019. These losses in the number of active members were a significant factor contributing to the decrease in our recent year-over-year sales. If we cannot stabilize or increase the number of our members, or if we lose one or more key member leaders, sales of our products could be further materially and adversely affected. The replacement of members could be difficult because, in our efforts to attract and retain members, we compete with other direct selling organizations, including but not limited to those in the personal care, cosmetic product and nutritional supplement industries.

 

Our number of active members or their productivity could further decline in the future.  We cannot accurately predict fluctuations in the number or the productivity of members because we primarily rely upon existing members to train new members and to motivate new and existing members. Operating results could be adversely affected if our existing and new business opportunities and products do not generate sufficient economic incentive or interest to retain existing members and to attract new members.

 

 

The number and productivity of our members could be harmed by several factors, including:

 

 

adverse publicity or negative perceptions regarding us, our products, our method of distribution or our competitors;

 

 

lack of interest in, or the technical failure of, existing or new products;

 

 

lack of interest in our existing compensation plan for members or in enhancements or other changes to that compensation plan;

 

 

our actions to enforce our policies and procedures;

 

 

regulatory actions or charges or private actions against us or others in our industry, such as the 100-day campaign initiated in China in January 2019 (as well as its extension and aftermath, including the related look-back review);

 

 

general economic, business and political conditions, including the recent political unrest in Hong Kong;

 

 

changes in management or the loss of one or more key member leaders;

 

 

entry of new competitors, or new products or compensation plan enhancements by existing competitors, in our markets; and

 

 

potential saturation or maturity levels in a given country or market which could negatively impact our ability to attract and retain members in such market.

 

Although virtually all of our members are independent contractors, improper member actions that violate laws or regulations could harm our business.

 

Virtually all of our members are independent contractors and, accordingly, we are not in a position to directly provide the same direction, motivation and oversight as we would if these members were our own employees.  As a result, there can be no assurance that our members will participate in our marketing strategies or plans, accept our introduction of new products, or comply with our member policies and procedures.  Extensive federal, state, local and foreign laws regulate our business, our products and our network marketing program.  Because we operate in a number of foreign countries, our policies and procedures for our members differ due to the different legal requirements of each country in which we do business.  While we have implemented member policies and procedures designed to govern member conduct and to protect the goodwill associated with our trademarks and trade names, it can be difficult to enforce these policies and procedures because of the large number of members and their independent status.

 

Given the size and diversity of our member force, we experience problems with members from time to time, especially with respect to our members in foreign markets. For example, if our members engage in illegal activities in China, those actions could be attributed to us. Chinese laws regarding how and when members may assemble and the activities that they may conduct, or the conditions under which the activities may be conducted, are subject to significant regulatory discretion resulting in interpretations and enforcement that sometimes vary from province to province, among different levels of government, and from time to time. Members can be accused of violating one or more of the laws regulating these activities, notwithstanding training that we attempt to provide. Enforcement measures regarding these violations, which can include arrests, raise the uncertainty and perceived risk associated with conducting this business, especially among those who are aware of the enforcement actions but not the specific activities leading to the enforcement action. We believe that this has led some existing members in China (who are signed up as members in Hong Kong) to leave the business or curtail their selling activities and has led some potential members to choose not to participate. Among other things, we are managing this risk with more training and public relations efforts that are designed, among other things, to distinguish our company from businesses that make no attempt to comply with the law. This environment creates uncertainty about the future of doing this type of business in China generally and under our current business model, specifically.

 

In addition, members often desire to enter a market before we have received approval to do business in order to gain an advantage in the marketplace.  Improper member activity in new geographic markets could result in adverse publicity and can be particularly harmful to our ability to ultimately enter these markets.  Violations by our members of applicable law or of our policies and procedures in dealing with customers could reflect negatively on our products and operations, and harm our business reputation.  In addition, it is possible that a judicial or administrative body could hold us civilly or criminally accountable based on vicarious liability because of the actions of our members.  If any of the above or related events involving our members occur, our business, results of operations or financial condition could be materially adversely affected.

 

An increase in the amount of compensation paid to members would reduce profitability.

 

We incur significant expense in the payment of compensation to our members, which represented approximately 43% and 42% of net sales during 2021 and 2020, respectively.  We compensate our members by paying commissions, bonuses, and certain awards and prizes.  Factors impacting the overall commission payout include the growth and depth of the member network, the member retention rate, the type and scope of promotions and incentives, local promotional programs and business development agreements.  Long-term promotions and incentives (lasting up to one year) can, in particular, result in uncertain ultimate cost. Any increase in compensation payments to members as a percentage of net sales will reduce our profitability. 

 

Our compensation plan includes a cap that may be enforced on member compensation paid out on a weekly dollar limit or as a percentage of product sales. There can be no assurance that enforcement of this cap will ensure profitability (which depends on many other factors).  Moreover, enforcement of this cap could cause key members affected by the cap to leave and join other companies.

 

We may be held responsible for certain taxes or assessments relating to the activities of our members and service providers, which could harm our financial condition and operating results.

 

Our members and service providers are subject to taxation, and in some instances, legislation or governmental agencies impose an obligation on us to collect the taxes, such as value added taxes, and to maintain appropriate records.  In addition, we are subject to the risk in some jurisdictions of being responsible for social security and similar taxes with respect to our members.

 

 

Legal, Regulatory, Tax, Currency and Trade Policy Risks

 

Our business in China is subject to compliance with a myriad of applicable laws and regulations, and any actual or alleged violations of those laws or government actions otherwise directed at us could have a material adverse impact on our business and the value of our company.

 

In contrast to our operations in other parts of the world, our China subsidiary has not implemented a direct sales model in China. The Chinese government permits direct selling only by organizations that have a license and has also adopted anti-pyramid selling and multi-level marketing legislation. We operate an e-commerce direct selling platform in Hong Kong and recognize the revenue derived from sales to both Hong Kong and Chinese members as being generated in Hong Kong. Products purchased by members in China are delivered to third parties that act as the importers of record under agreements to pay applicable duties.  In addition, through a Chinese entity, we sell products in China using an e-commerce retail platform. Chinese members may elect to participate in either or both of the Chinese entity and the Hong Kong entity.

 

We previously submitted a preliminary application for a direct selling license in China in August 2015, but in 2019 a Chinese governmental authority recommended that we withdraw our application. We understand that the governmental authorities recommended that other companies with pending direct selling license applications also withdraw their applications. We applied to withdraw our application in November 2019, and the governmental authorities approved the withdrawal of our application shortly thereafter. We expect to reapply for a direct selling license in China when we believe that circumstances are again ripe for doing so. We are unable to predict whether and when we will be successful in obtaining a direct selling license to operate in China, and if we are successful, when we will be permitted to conduct direct selling operations and whether such operations would be profitable.

 

We continually evaluate our business in China and Hong Kong for compliance with applicable laws and regulations, including seeking the input of outside professionals and certain Chinese authorities. This process can and has resulted in the identification of certain matters of potential noncompliance. We work on a continuing basis to satisfactorily address such matters, however there can be no assurance that adequate steps are taken or that applicable laws and regulations are properly interpreted.

 

Should the government authorities determine that our activities violate applicable laws and regulations, including China’s direct selling, pyramid selling or multi-level marketing laws and regulations, or should new laws or regulations be adopted, there could be a material adverse effect on our business, results of operations and financial condition.

 

The Chinese government scrutinizes the activities of direct selling companies. Our business continues to be subject to regulations and examinations by municipal and provincial level regulators. At times, actions by government regulators have impacted our members’ activities in certain locations and have resulted in a few cases of enforcement actions. In each of these cases, we helped our members with their defense of the legality of their conduct.

 

Our business and the value of our company can be adversely affected by Chinese government scrutiny, even if that scrutiny does not result in investigations of our business. For example, one or more parties encouraged the Beijing City governmental authorities to conduct an investigation of our business, which resulted in a meeting in January 2016 involving members of our Beijing office staff, Beijing City governmental officials, and two complainants. Even though the Beijing City governmental officials advised our staff and the complainants at that meeting that there was insufficient evidence to warrant an investigation of us, mischaracterizations of the meeting immediately appeared in several “news reports.” Similarly, a subsequent meeting between several Guangzhou City government officials and members of our Guangzhou office staff that resulted in our providing routine information about our business to the government officials was mischaracterized in an online posting made immediately following the meeting. Although we remain in regular contact with Chinese government officials and take other steps to address the risks posed by these events, these government officials have significant discretion in the application and enforcement of laws and regulations. As a result, our business and the value of our company remain vulnerable to Chinese government scrutiny, whether or not initiated by third parties, which scrutiny could result in changes to our business and/or the Chinese or Hong Kong government taking action against us.

 

Various other factors could harm our business in Hong Kong and China, such as worsening economic conditions in Hong Kong or China, adverse developments relating to the industry in which we conduct our business, adverse local publicity, negative changes to our business and/or social media coverage, geopolitical or trade tensions between the United States and China or other events that may be out of our control. For example, in January 2019 the Chinese government announced a 100-day campaign focusing on companies involved in the sale of food, equipment, daily necessities, small home electrical appliances and services that are claimed to promote health. The Chinese government ministries in charge of this campaign indicated that they are targeting illegal practices in the industry, particularly the manufacture and sale of counterfeit and substandard products, and false advertising and misleading claims as to the health benefits of products and services. During the campaign, we understand that the government is not issuing any additional direct selling licenses, is not issuing certifications of quality or other approvals of various healthcare products, and is reviewing its regulatory oversight of the industry. It is further understood that the campaign is specifically focused on the business practices of direct selling companies. Similarly, during the third quarter of 2007, we learned that the Chinese government was expected to impose a more intense enforcement program against illegal pyramid scheme activities (or “chain sale” activities in transliterated Chinese terms). In January 2019 we, like some of our peers, voluntarily decided to temporarily suspend our member activities, such as product roadshows, product trainings and larger company-sponsored events, in China as we did in 2007. We did this because we learned that the 100-day campaign was announced in broad outlines by the central government, and the interpretation and enforcement of the campaign was delegated to the provincial and local governments. We consider it a top priority for our business to develop an understanding of and cooperate with all levels and jurisdictions of the government agencies and did not want to run the risk of being inadvertently entangled in the government enforcement actions as the provincial and local government formulate and implement their interpretive guidance and rule-making. Although we have been able to relax some restrictions on member activities in certain markets, it may again in the future be necessary or advisable to suspend member activities or take similar actions, and the resulting periods of reduced activity may have a material adverse effect on our business.

 

 

Although the 100-day campaign was due to expire on or about April 18, 2019, we are not aware of any information indicating that the campaign has formally concluded. However, on August 27, 2019, the Chinese government announced that it would conduct a “look-back review” to evaluate the 100-day campaign. As part of this review, we understand that various Chinese governmental agencies formed a working group to assess the 100-day campaign, particularly focusing on the health market and its supervision in certain provinces. We understand that during September 2019 the working group evaluated the performance and results of a number of organizations and governmental departments in these provinces and made recommendations for various improvements. It was noted that each province had opened a number of investigative cases, had successfully closed numerous cases, and had imposed various fines and penalties. We understand that the look-back review continued after September 2019, and we are not aware that this review has been completed. As a result, the business environment in China for health product companies continues to be challenging, which has been exacerbated by negative social media sentiment expressed for these types of companies. We believe that the campaign, as well as its extension and aftermath (including the look-back review), will continue to negatively impact our business in China in the near-term, but will ultimately benefit us and Chinese consumers as purveyors of substandard products are driven from the market.

 

Although we attempt to work closely with both national and local Chinese governmental agencies in conducting our business, our efforts to comply with national and local laws may be harmed by a rapidly evolving regulatory climate, concerns about activities resembling violations of direct selling, pyramid selling or multi-level marketing legislation, subjective interpretations of laws and regulations, and activities by individual members that may violate laws notwithstanding our policies prohibiting such activities.

 

Any determination that our operations or activities, or the activities of our individual members, employee sales representatives, or importers of record are not in compliance with applicable laws and regulations could result in the imposition of substantial fines, extended interruptions of business, restrictions on our future ability to obtain business licenses or expand into new locations, changes to our business model, the termination of required licenses to conduct business, or other actions, any of which could materially harm our business, results of operations and financial condition. 

 

Changes in government trade and economic policies, including the imposition or threatened imposition of tariffs and other restrictive trade policies, and ongoing political and economic disputes between the United States and other jurisdictions, particularly China, may have a negative effect on global economic conditions and our business, financial results and financial condition.

 

The United States has in recent years enacted tariffs on certain items. Further, there are ongoing discussions and activities regarding changes to other U.S. trade policies and treaties. In response, a number of our markets, particularly China, have implemented tariffs on U.S. imports or otherwise imposed non-tariff barriers such as slow-walking custom clearance of American-made products in response to these U.S. actions. These developments, together with the threat of new tariffs and other restrictive trade policies, may have a material adverse effect on global economic conditions and the stability of global financial markets, and they may significantly reduce global trade and, in particular, adversely affect trade and economic relations between China and the United States.

 

Tensions between China and the United States have become particularly acute following the China legislature’s passage of a national security law in June 2020 that changes the way Hong Kong has been governed since the territory was handed over by the United Kingdom to China in 1997. This law criminalizes secessionist activities, subversion, terrorism, and collusion with a foreign country or with external elements to endanger national security in Hong Kong. The U.S. State Department has announced that the United States no longer considers Hong Kong to have significant autonomy from China, and the U.S. administration is taking action to end many of the U.S. government’s special trade and economic relations with Hong Kong. Further, on July 14, 2020 the United States enacted the Hong Kong Autonomy Act (and the U.S. President issued a related executive order), authorizing the U.S. administration to impose sanctions against individuals and entities determined to materially contribute to the erosion of Hong Kong's autonomy, as well as to punish financial institutions that facilitate certain significant transactions.   The United States has since imposed sanctions on a number of individuals, and China has responded in kind.  These and other recent actions may represent an escalation in political and economic tensions involving the United States, China and Hong Kong, which could harm our business. A continued deterioration in these political or economic relations or other future unforeseen problems could disrupt our China and Hong Kong business (including our Hong Kong office and employees), adversely affect the distribution of our products, reduce our net sales, increase the cost of conducting our operations, or result in retaliatory actions against U.S. interests, any of which could have a material adverse effect on our business, results of operations and financial condition.

 

In addition, any actions by non-U.S. markets to implement further trade or economic policy changes, including limiting foreign investment or trade, imposing currency controls restricting the international transfer of funds, increasing regulatory scrutiny or taking other actions which impact U.S. companies' ability to obtain necessary licenses or approvals could negatively impact our business.

 

Trade and economic policy changes are subject to a number of uncertainties and are only one part of the larger dynamic of political and economic relations amongst countries. The ultimate reaction of other countries, and the individuals in each of these countries, and the impact of actions on the United States, China, Hong Kong, the global economy and our business, financial condition and results of operations, cannot be predicted at this time.

 

Direct-selling laws and regulations may prohibit or severely restrict our direct sales efforts and cause our revenue and profitability to decline, and regulators could adopt new regulations that harm our business.

 

Our direct selling system is subject to extensive laws, governmental regulations, administrative determinations, court decisions and similar constraints.  These laws and regulations are generally intended to prevent fraudulent or deceptive schemes, often referred to as “pyramid” schemes, which compensate participants for recruiting additional participants irrespective of product sales, use high pressure recruiting methods and/or do not involve legitimate products. They also seek to ensure that claims regarding the ability of participants to earn money are truthful and substantiated.

 

Complying with these widely varying and sometimes inconsistent rules and regulations can be difficult and may require the devotion of significant resources on our part.  There can be no assurance that we or our members are in compliance with all of these regulations.  Our failure or our members’ failure to comply with these regulations or new regulations could lead to the imposition of significant penalties or claims and could negatively impact our business.  If we are unable to continue business in existing markets or commence operations in new markets because of these laws, our revenue and profitability may decline.

 

We are also subject to the risk that new laws or regulations might be implemented or that current laws or regulations might change, which could require us to change or modify the way we conduct our business in certain markets or the loss of necessary licenses.  This could be particularly detrimental to us if we have to change or modify the way we conduct business, or cannot conduct any business, in markets that represent a significant percentage of our revenue.

 

Our business is subject to a variety of laws, regulations and other obligations regarding privacy, data protection and information security.  Any actual or perceived failure by us or our third-party vendors to comply with such laws, regulations or other obligations could materially adversely affect our business.

 

We collect certain personal information, including payment data, from members and consumers, as well as our employees.   We also develop and maintain sensitive and proprietary business information.  We are therefore subject to numerous laws, regulations and other obligations that address privacy, data protection and information security in the various markets in which we conduct business.   We are particularly focused on the evolving state of laws and regulations in China and Hong Kong applicable to privacy, data protection and information security.   Of particular note is that on June 10, 2021, the Standing Committee of the National People's Congress of China promulgated the Data Security Law, which took effect in September 2021. The Data Security Law imposes data security and privacy obligations on entities and individuals carrying out data activities, and introduces a data classification and hierarchical protection system based on the importance of data in economic and social development, as well as the degree of harm it will cause to national security, public interests, or legitimate rights and interests of individuals or organizations when such data is tampered with, destroyed, leaked, or illegally acquired or used. The Data Security Law also provides for a national security review procedure for data activities that may affect national security and imposes export restrictions on certain data and information. Similarly, Hong Kong also has its data privacy legislation that regulates the collection, use and handling of personal data. Under the relevant Hong Kong legislation, data users are required to comply with various data protection principles in relation to the requirement of lawful and fair collection of personal data, consent of data subjects, retention of personal data, use and disclosure of personal data, security of personal data, personal data policies and practices, and rights to access and correction of personal data.

 

The interpretation, application and enforcement of privacy, data security and information security laws, regulations and other obligations evolve from time to time and their scope may continually change, through new legislation, amendments to existing legislation and changes in interpretation and enforcement. We have incurred, and will continue to incur, significant expenses in an effort to comply with such laws, regulations and other obligations, as well as related security standards and protocols.  Despite our compliance efforts, we may not meet all of the requirements imposed on us.  Any failure on our part or on the part of our third-party vendors to comply with applicable laws, regulations or other obligations relating to privacy, data protection or information security could damage our reputation, result in investigations, fines or other penalties imposed by governmental authorities and private claims or litigation, any of which could materially adversely affect our business, results of operations and financial condition. Even if our practices or those of our third-party vendors are not subject to legal challenge, the perception of data or privacy concerns, whether or not valid, may harm our reputation and brand and adversely affect our business, results of operations and financial condition.

 

 

Challenges by third parties to the legality of our business operations could harm our business.

 

We are also subject to the risk of private party challenges to the legality of our operations, including our direct selling system.  The regulatory requirements concerning direct selling systems generally do not include “bright line” rules and are inherently fact-based and subject to judicial or administrative interpretation. An adverse judicial or administrative determination against us with respect to our direct selling system, or in proceedings not involving us directly but which challenge the legality of other direct selling marketing systems, could have a material adverse effect on our business.  There is also risk that challenges and settlements involving other parties could provide incentives for similar actions by members against us and other direct selling companies.  Moreover, challenges to our business system and operations in important markets may come from short sellers, hedge funds, other investors, bloggers and reporters.  Other companies in our industry have also faced such challenges.  Any challenges regarding us or others in our industry could harm our business if such challenges result in the imposition of any fines or damages on our business, create adverse publicity, increase scrutiny or investigations of us or our industry, detrimentally affect our efforts to recruit or motivate members and attract customers, or interpret laws in a manner inconsistent with our current business practices.

 

We have in the past been involved in, and may in the future face, lawsuits, claims, and governmental proceedings and inquiries that could harm our business.

 

We have in the past been, and may in the future be, a party to lawsuits, claims and governmental proceedings and inquiries. Prosecuting and defending these matters may require significant expense and attention of our management and can expose us to adverse publicity, regardless of the outcome. Further, in the event of an adverse outcome, we could be required to pay substantial damages, fines or penalties and cease or be prevented from conducting certain practices or activities.

 

Such matters can be complex, can extend for a protracted period of time, and can result in unpredictable expense. There can be no assurance that we will be able to successfully defend or resolve any such litigation, claims or governmental proceedings or inquiries, or that the significant money, time and effort spent in defending these matters, or any related adverse publicity, will not adversely affect our business, results of operations and financial condition.

 

Currency exchange rate fluctuations could lower our revenue and net income.

 

In 2021, 97% of our revenue was recorded by subsidiaries located outside of North America.  Revenue transactions and related commission payments, as well as other incurred expenses, are typically denominated in the local currency.  Accordingly, our international subsidiaries generally use the local currency as their functional currency.  The results of operations of our international subsidiaries are exposed to foreign currency exchange rate fluctuations during consolidation since we translate into U.S. dollars using the average exchanges rates for the period.  As exchange rates vary, revenue and other operating results may differ materially from our expectations.  Additionally, we may record significant gains or losses related to foreign-denominated cash and cash equivalents and the re-measurement of inter-company balances.  

 

Our most significant foreign exchange exposure, the Hong Kong dollar, is for now pegged to the U.S. dollar.  We also purchase a significant majority of inventories in U.S. dollars.  Our foreign currency exchange rate exposure to the South Korean won, Taiwan dollar, Japanese yen, Chinese yuan, Russian ruble, Kazakhstani tenge, Singaporean dollar, Malaysian ringgit, Vietnamese dong, Thai baht, Indian rupee, Canadian dollar, Mexican peso, Peruvian sol and European euro collectively represented approximately 20% and 18% of our revenue in 2021 and 2020, respectively.  Our foreign currency exchange rate exposure may increase in the near future as we develop opportunities in Southeast Asia, India, Canada, Central America, South America and Europe.  Additionally, our foreign currency exchange rate exposure would significantly increase if the Hong Kong dollar were no longer pegged to the U.S. dollar.  Finally, we also experience indirect exchange rate exposure due to the concentration of our sales to members residing in China and the impact of fluctuations in the value of the Chinese yuan on our members’ purchasing power.

 

Given our inability to predict the degree of exchange rate fluctuations, we cannot estimate the effect these fluctuations may have upon future reported results, product pricing or our overall financial condition.  Further, to date we have not attempted to reduce our exposure to short-term exchange rate fluctuations by using foreign currency exchange contracts.

 

Changes in tax or duty laws, and unanticipated tax or duty liabilities, could adversely affect our net income.

 

In the course of doing business we may be subject to various taxes, such as sales and use, value-added, and franchise. We are also subject to income taxes in the United States and numerous foreign jurisdictions. We earn a substantial portion of our income in foreign jurisdictions. Economic and political conditions make tax rules in any jurisdiction, including the United States, subject to significant change. There have been recent changes in U.S. tax law that impact how U.S. multinational corporations are taxed on foreign earnings. There have also been proposals to reform foreign tax laws that could significantly affect the Company’s tax position. Although we cannot predict whether or in what form these proposals will pass, several of the proposals considered, if enacted into law, could have an adverse impact on our income tax expense and cash flows.

 

Our parent corporation is domiciled in the United States. Under tax treaties, we are eligible to receive foreign tax credits in the United States for taxes paid abroad. Taxes paid to foreign taxing authorities may exceed the credits available to us, resulting in the payment of a higher overall effective tax rate on our worldwide operations.

 

Our effective income tax rate in the future could be adversely affected by a number of factors, including changes in the mix of earnings in countries with differing statutory tax rates, changes in the valuation of deferred tax assets and liabilities, changes in tax laws, and the outcome of income tax audits in various jurisdictions around the world.

 

 

We have in the past, and may in the future be subject to examinations of our tax returns and other tax matters by the U.S. Internal Revenue Service and other tax authorities and governmental bodies. We regularly assess the likelihood of an adverse outcome resulting from these examinations to determine the adequacy of our provision for taxes, which is subject to significant discretion. There can be no assurance as to the outcome of these examinations. If our effective tax rates were to increase, particularly in the United States, or if the ultimate determination of taxes owed is for an amount in excess of amounts previously accrued, our financial results or operations could be adversely affected.

 

In addition, our operations are subject to regulations designed to ensure that appropriate levels of customs duties are assessed on the importation of our products. The failure to properly calculate, report and pay such duties when we are subject to them could have a material adverse effect on our results of operations and financial condition. Any change in the laws or regulations regarding such duties, or any interpretation thereof, could result in an increase in the cost of doing business.

 

Transfer pricing regulations affect our business and results of operations.

 

In many countries, including the United States, we are subject to transfer pricing and other tax regulations designed to ensure that appropriate levels of income are reported as earned by our United States or local entities and are taxed accordingly. We have adopted transfer pricing agreements with most of our subsidiaries to regulate inter-company transfers, which agreements are subject to transfer pricing laws that regulate the flow of funds between the subsidiaries and the parent corporation for product purchases, management services, and contractual obligations, such as the payment of member compensation. There can be no assurance that we will be found to be operating in compliance with transfer pricing laws, or that those laws would not be modified, which, as a result, may require changes in our operating procedures or otherwise may have a material adverse effect on our financial results or operations.

 

Our products and related activities are subject to extensive government regulation, which could delay, limit or prevent the sale of some of our products in some markets. 

 

The formulation, manufacturing, packaging, labeling, importation, advertising, distribution, sale and storage of certain of our products are subject to extensive regulation by various federal agencies, including the FDA, the FTC, the Consumer Product Safety Commission and the U.S. Department of Agriculture and by various agencies of the states, localities and foreign countries in which our products are manufactured, distributed and sold.  For example, the FDA requires us and our suppliers to meet relevant current good manufacturing practice (cGMP) regulations for the preparation, packing and storage of foods and over-the-counter (OTC) drugs.  We are also now required to report serious adverse events associated with consumer use of certain of our products.  Other laws and regulations govern or restrict the claims that may be made about our products and the information that must be included and excluded on labels.

 

In markets outside the United States, prior to commencing operations or marketing new products, we may be required to obtain approvals, licenses, or certifications from a ministry of health or a comparable agency. Moreover, a foreign jurisdiction may pass laws that would prohibit the use of certain ingredients in their particular market.  Compliance with these regulations can create delays and added expense in introducing new products to certain markets.

 

Failure by our members or us to comply with those regulations could lead to the imposition of significant penalties or claims and could materially and adversely affect our business.  If we are not able to satisfy the various regulations, then we would have to cease sales of that product in that market.  In addition, the adoption of new regulations or changes in the interpretation of existing regulations may result in significant compliance costs or discontinuation of product sales and may adversely affect the marketing of our products, resulting in significant loss of revenues.

 

We cannot predict the nature of any future laws, regulations, interpretations, or applications, nor can we determine what effect additional governmental regulations or administrative orders, when and if promulgated, could have on our business.  These potential effects could include, however, requirements for the reformulation of certain products to meet new standards, the recall or discontinuance of certain products, additional recordkeeping and reporting requirements, expanded documentation of the properties of certain products, expanded or different labeling, or additional scientific substantiation.  Any or all of these requirements could have a material adverse effect on our business, results of operations or financial condition.

 

New regulations governing the marketing and sale of nutritional supplements could harm our business.

 

There has been an increasing movement in the United States and other markets to increase the regulation of dietary supplements, which could impose additional restrictions or requirements in the future.  In the United States, for example, some legislators and industry critics continue to push for increased regulatory authority by the FDA over nutritional supplements.   Our business could be harmed if more restrictive legislation is successfully introduced and adopted in the future.  In particular, the adoption of legislation requiring FDA approval of supplements or ingredients could delay or inhibit our ability to introduce new supplements.  We face similar pressures in our other markets, particularly in China where certain government ministries announced in January 2019 a comprehensive 100-day campaign focusing on companies involved in the sale of certain products, including nutritional supplements and health products.  This campaign, which may not have formally concluded, and may still be the subject of a “look-back review” being conducted by various Chinese governmental agencies, could result in new legislation or regulation.  In the United States, the FTC's Guides Concerning the Use of Endorsements and Testimonials in Advertising (the “Guides”) require disclosure of material connections between an endorser and the company they are endorsing and require the disclosure of typical results when these are different from those reported by the endorser.  The requirements and restrictions of the Guides may diminish the impact of our marketing efforts and negatively impact our sales results.  If we or our members fail to comply with these Guides, the FTC could bring an enforcement action against us and we could be fined and/or forced to alter our operations.  Our operations also could be harmed if new laws or regulations are enacted that restrict our ability to market or distribute nutritional supplements or impose additional burdens or requirements on nutritional supplement companies or require us to reformulate our products.

 

 

Regulations governing the production and marketing of our personal care products could harm our business.

 

Our personal care products are subject to various domestic and foreign laws and regulations that regulate cosmetic products and set forth regulations for determining whether a product can be marketed as a “cosmetic” or requires further approval as an over-the-counter drug.  A determination that our cosmetic products impact the structure or function of the human body, or improper marketing claims by our members, may lead to a determination that such products require pre-market approval as a drug.  Such regulations in any given market can limit our ability to import products and can delay product launches as we go through the registration and approval process for those products.  Furthermore, if we fail to comply with these regulations, we could face enforcement action against us and we could be fined, forced to alter or stop selling our products and/or required to adjust our operations.  Our operations also could be harmed if new laws or regulations are enacted that restrict our ability to market or distribute our personal care products or impose additional burdens or requirements on the contents of our personal care products or require us to reformulate our products.

 

If we are found not to be in compliance with good manufacturing practices our operations could be harmed.

 

Regulations on good manufacturing practices and adverse event reporting requirements for the nutritional supplement industry are in effect and require good manufacturing processes for us and our vendors, including stringent vendor qualifications, ingredient identification, manufacturing controls and record keeping.   We are also required to report serious adverse events associated with consumer use of our products.  Our operations could be harmed if regulatory authorities make determinations that we or our vendors are not in compliance with the regulations.  A finding of noncompliance may result in administrative warnings, penalties or actions impacting our ability to continue selling certain of our products.  In addition, compliance with these regulations has increased and may further increase the cost of manufacturing certain of our products as we work with our vendors to assure they are qualified and in compliance.

 

Failure to comply with domestic and foreign laws and regulations governing product claims and advertising could harm our business.

 

Our failure to comply with FTC or state regulations, or with regulations in foreign markets that cover our product claims and advertising, including direct claims and advertising by us, as well as claims and advertising by members for which we may be held responsible, may result in enforcement actions and imposition of penalties or otherwise materially and adversely affect the distribution and sale of our products. Our claims about the level of financial success that can be expected by our members are also subject to FTC review and enforcement.  Member activities in our existing markets that violate applicable governmental laws or regulations could result in governmental or private actions against us in markets where we operate. Given the size of our member force, we cannot ensure that our members will comply with applicable legal requirements.

 

We are subject to anti-bribery laws, including the U.S. Foreign Corrupt Practices Act.

 

We are subject to anti-bribery laws, including the U.S. Foreign Corrupt Practices Act (“FCPA”), which generally prohibit companies and their intermediaries from making improper payments for the purpose of obtaining or retaining business as well as requiring companies and their intermediaries to maintain accurate books and records. In recent years there has been a substantial increase in anti-bribery law enforcement activity by the U.S. Department of Justice (the "DOJ") and the SEC relating to certain countries in which we have business, including China. For example, in 2017, a U.S. based direct selling company announced that it was the target of an investigation being conducted by the SEC to determine whether certain activities related to the direct selling company's operations in China violated the FCPA. Also, in 2017, another U.S. based direct selling company announced that it had initiated a voluntary probe of its operations in China to determine if violations of the FCPA had occurred.

 

Our policies mandate compliance with anti-bribery laws by our employees and agents, including the requirements to maintain accurate information and internal controls. However, we may be liable for actions of our employees and agents, even if such actions are inconsistent with our policies. Being subject to an investigation by the DOJ or the SEC for an alleged violation of the FCPA could cause us to incur significant expenses and distractions that could adversely affect our business. Violations of the FCPA, or a similar anti-bribery law, may result in criminal or civil sanctions, including contract cancellations or debarment, and loss of reputation, which could have a material adverse effect on our results of operations and financial condition.

 

We do not have a comprehensive product liability insurance program and product liability claims could hurt our business.

 

Currently, we do not have a comprehensive product liability insurance program, although the insurance carried by our suppliers may cover certain product liability claims against us.  As a marketer of dietary supplements, cosmetics and other products that are ingested by consumers or applied to their bodies, we may become subjected to various product liability claims, including that:

 

 

our products contain contaminants or unsafe ingredients;

 

 

our products include inadequate instructions as to their uses; or

 

 

our products include inadequate warnings concerning side effects and interactions with other substances.

 

If our suppliers’ product liability insurance fails to cover product liability claims or other product liability claims, or any product liability claims exceeds the amount of coverage provided by such policies or if we are unsuccessful in any third-party claim against the manufacturer or if we are unsuccessful in collecting any judgment that may be recovered by us against the manufacturer, we could be required to pay substantial monetary damages which could materially harm our business, results of operations and financial condition. As a result, we may become required to pay high premiums and accept high deductibles in order to secure adequate insurance coverage in the future.  Especially since we do not have direct product liability insurance, it is possible that product liability claims and the resulting adverse publicity could negatively affect our business.

 

 

Intellectual Property, Information Technology and Cybersecurity Risks

 

We may be unable to protect or use our intellectual property rights.

 

We rely on trade secret, copyright and trademark laws and confidentiality agreements with employees and third parties, all of which offer only limited protection of our confidential information and trademarks.  Moreover, the laws of some countries in which we market our products, including China, may not afford effective protection of our intellectual property rights.  The unauthorized copying, use or other misappropriation of our confidential information, trademarks and other intellectual property could enable third parties to benefit from such property without paying us for it.  This could have a material adverse effect on our business, operating results and financial condition.  If we resort to legal proceedings to enforce our intellectual property rights, the proceedings could be burdensome, expensive and result in inadequate remedies.  It is also possible that our use of our intellectual property rights could be found to infringe on prior rights of others and, in that event, we could be compelled to stop or modify the infringing use, which could be burdensome and expensive.

 

We rely on and are subject to risks associated with our reliance upon information technology systems.

 

Our success is dependent on the accuracy, reliability, and proper use of information processing systems and management information technology.  Our information technology systems are designed and selected to facilitate order entry and customer billing, maintain member records, accurately track purchases and member compensation payments, manage accounting operations, generate reports, and provide customer service and technical support.  Any interruption in these systems could have a material adverse effect on our business, financial condition, and results of operations.

 

There can be no assurance that there will not be delays or interruptions in our information technology services.  An interruption or delay in availability of these services could, if it lasted long enough, prevent us from accepting orders, cause members to leave our business, or otherwise materially adversely affect our business.

 

System disruptions or failures, cybersecurity risks, and compromises of data, or the failure to comply with related laws and regulations, could harm our business.

 

Because of our diverse geographic operations and our internationally applicable member compensation plans, our business is highly dependent on the secure and efficient functioning of our information technology systems, and the security of personal and sensitive business data. We collect certain personal information, including payment data, from members and consumers, as well as our employees. We also develop and maintain sensitive and proprietary business information. Any systems failure or interruption, breach in security, or loss of data, whatever the cause, could adversely affect our operations and financial results.

 

Systems disruptions and data breaches can derive from natural disasters, accidental technological events or human error, but can also result from fraud or malice on the part of external or internal parties.  Our systems, networks and software, like those of other companies, have been and are likely to continue to be, the target of cybersecurity threats and attacks, which may range from isolated or random attempts to sophisticated and targeted measures directed specifically at us. The risk of a systems disruption or data breach, particularly through cyber-attack or cyber intrusion, has increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. A material systems disruption or data breach affecting us could damage our reputation, deter members from purchasing our products, and result in cost and liability to us.

 

Although we have implemented technical and administrative safeguards to maintain the security and integrity of our information technology systems and data, there can be no assurance that our security efforts and measures will be effective in a continually evolving threat environment. In addition to the risks presented by malicious actors and natural disasters, many systems disruptions and data breaches are reportedly caused by human error. Therefore, despite our security policies and mandatory training, our systems and data are exposed to the risk that human error could either create a vulnerability that could be exploited by an attacker, or expose our systems and data to unintended risk of compromise. In addition, as described below, most of our information technology systems and data are hosted by third-party vendors over which we have limited control. We anticipate that we will be required to expend additional resources in order to continue to enhance our technical and administrative safeguards, and to investigate and remediate any vulnerabilities in our systems, networks and software. 

 

In any case, a data breach or other significant disruption of our information systems or those related to our third-party vendors, including as a result of cyber-attacks, could (1) disrupt the proper functioning of our systems and networks and therefore operations, (2) result in the unauthorized access to, and destruction, loss, theft, misappropriation or release of personal, confidential, sensitive or otherwise valuable data or other information, (3) result in a violation of applicable privacy, cybersecurity, data breach notification requirements under applicable laws, regulations and contractual provisions, subjecting us to additional regulatory scrutiny, and exposing us to possible fines, lawsuits and related financial liability, (4) require significant management attention and financial resources to investigate and remedy the breach or disruption, and (5) harm our reputation, cause a decrease in the number of our members and revenue, and otherwise damage our business.  The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition and results of operations.

 

Finally, we are subject to numerous laws, regulations and other obligations that address privacy, data collection and information security in the various markets in which we conduct business and, despite our compliance efforts, we or our third-party vendors may not comply with all applicable requirements. See “Item 1A. Risk Factors - Our business is subject to a variety of laws, regulations and other obligations regarding privacy, data protection and information security…”.

 

Our systems, software and data reside on third-party servers, exposing us to risks that disruption or intrusion of those servers could temporarily or permanently interrupt our access and damage our business.

 

Most of our systems, software and data reside in the “cloud” on servers operated by third-party vendors to which we have limited access.  We assess the risks presented by these third-party vendors, and our contracts with them contain representations, warranties and other provisions related to the security of our data, and of the systems and software on which we rely. We are, however, limited in our ability to mitigate the risks of a systems disruption or data breach affecting our third-party vendors.  Moreover, any delay or failure in payment of the third-party vendors, disputes with such vendors, or business interruption or failure of the third-party vendors could result in loss of or interruption in access to our systems, software or data.  It is possible that our systems, software and data could in the future be moved to servers of different third parties or to our own servers.  Any such move could result in temporary or permanent loss of access to our systems, software or data.  Any protracted loss of such access would materially and adversely affect our business, financial condition and results of operations.

 

 

 

Common Stock Risks

 

Our common stock is particularly subject to volatility because of the industry and markets in which we operate.

 

The market prices of securities of direct selling companies have been extremely volatile, particularly those of companies that derive a substantial portion of their revenue from China and/or Hong Kong. These companies have experienced stock market price fluctuations that have often been disproportionate to their operating performance.  These broad fluctuations could adversely affect the market price of our common stock.

 

Our common stock continues to experience wide fluctuations in trading volumes and prices. This may make it more difficult for holders of our common stock to sell shares when they want and at prices they find attractive.

 

The public market for our common stock has historically been very volatile experiencing wide fluctuations in trading volumes and prices. There are a number of factors that may contribute to this volatility, including the following:

 

 

active participation of speculative traders in our stock (including short sellers);

 

 

limited trading activity in our common stock;

 

 

the sale of a large number of shares of our common stock from time to time;

 

 

market rumors regarding our business operations;

 

 

government scrutiny of our business;

 

 

adverse publicity related to our business or industry; and

 

 

fluctuations in our operating results.

 

This market volatility for our common stock may make it more difficult for holders of our stock to sell shares when they want and at prices they find attractive. There can be no assurance that a larger or more liquid market will be developed or maintained for our common stock.

 

Item 1B. UNRESOLVED STAFF COMMENTS

 

Not applicable.

 

Item 2. PROPERTIES

 

In January 2019 we relocated our corporate headquarters from Rolling Hills Estates, California, to Hong Kong. We renewed our lease for 7,300 square feet of office space in Hong Kong in July 2020 with a term expiring in June 2023. In June 2020, we extended our lease for 4,900 square feet of office space in Rolling Hills Estates, California with a term now expiring in September 2030. To help further develop the market for our products in North America, we lease retail space in Rowland Heights, California; Richmond, British Columbia; and Metuchen, New Jersey.

 

We lease seven branch offices throughout China, and additional office space in Peru, Japan, Taiwan, South Korea, Malaysia, Singapore, Thailand, India, and the Cayman Islands. We also lease a factory in Zhongshan, China. We contract with third parties for fulfillment and distribution operations in all of our international markets. We believe that our existing office space is in good condition, and is suitable and adequate for the conduct of our business.

 

Item 3. LEGAL PROCEEDINGS

 

None.

 

Item 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

 

Part II

 

Item 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Our common stock is currently traded on the NASDAQ Capital Market (“Nasdaq”) under the symbol “NHTC.” On February 22, 2022, the closing price of our common stock as reported by Nasdaq was $7.14 per share.

 

At February 22, 2022, there were approximately 90 record holders of our common stock (although we believe that the number of beneficial owners of our common stock is substantially greater).

 

The Company expects to pay a quarterly cash dividend of $0.20 on each share of common stock outstanding for the foreseeable future. However, any future cash dividends will be at the sole discretion of the Board of Directors, and will depend on the Company's financial condition, results of operations, capital requirements and other factors considered relevant by the Board of Directors.

 

Item 6. [RESERVED]

 

 

 

Item 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Business Overview

 

We are an international direct-selling and e-commerce company. Subsidiaries controlled by us sell personal care, wellness, and “quality of life” products under the “NHT Global” brand. Our wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Malaysia, Singapore and Thailand; South Korea; Japan; India; and Europe. We also operate in Russia and Kazakhstan through our engagement with a local service provider. See Note 13 of the Notes to Consolidated Financial Statements in “Item 8. Financial Statements and Supplementary Data” of this report for further information about our net sales by geographic area.

 

As of December 31, 2021, we were conducting business through 45,760 active members, compared to 52,230 at the end of 2020. We consider a member “active” if they have placed at least one product order with us during the preceding year. Our priority is to focus our resources in our most promising markets, which we consider to be Greater China and countries where our existing members have the connections to recruit prospects and sell our products, such as Southeast Asia, India, South America and Europe. For further information regarding some of the risks associated with our loss of members, see “Item 1A. Risk Factors - Our recent loss of a significant number of members is adversely affecting our business…”.

 

We generate approximately 93% of our net sales from subsidiaries located outside the Americas, with sales of our Hong Kong subsidiary representing 78% of net sales in the latest fiscal year. Because of the size of our foreign operations, operating results can be impacted negatively or positively by factors such as foreign currency fluctuations, and economic, political and business conditions around the world. In addition, our business is subject to various laws and regulations, in particular, regulations related to direct selling activities that create uncertain risks for our business, including improper claims or activities by our members and our potential inability to obtain necessary product registrations. We continually evaluate our business for compliance with applicable laws and regulations, and this process can and has resulted in the identification of certain matters of potential noncompliance, which we work to satisfactorily address. For further information regarding some of the risks associated with the conduct of our business in China and Hong Kong, see “Item 1A. Risk Factors,” and more specifically under the captions “Risk Factors - Because our Hong Kong operations account for a substantial portion of our overall business...”, “Risk Factors - Our Hong Kong operations are being adversely affected by recent political and social developments in Hong Kong….”, and “Risk Factors - Our business in China is subject to compliance with a myriad of applicable laws and regulations...”.

 

China has been and continues to be our most important business development project. We operate an e-commerce direct selling platform in Hong Kong that generates revenue derived from the sale of products to members in Hong Kong and elsewhere, including China. Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. Through a separate Chinese entity, we operate an e-commerce retail platform in China. We believe that neither of these activities require a direct selling license in China, which we do not currently hold. We previously submitted a preliminary application for a direct selling license in China in August 2015, but in 2019 a Chinese governmental authority recommended that we withdraw our application. We understand that the governmental authorities recommended that other companies with pending direct selling license applications also withdraw their applications. We applied to withdraw our application in November 2019, and the governmental authorities approved the withdrawal of our application shortly thereafter. In connection with the withdrawal of our application, we received a refund in March 2020 of a consumer protection fund deposit of CNY 20 million ($2.9 million) that we made upon the submission of our application. We expect to reapply for a direct selling license in China when we believe that circumstances are again ripe for doing so. If we are ultimately able to obtain a direct selling license in China, we believe that the incentives inherent in the direct selling model in China would incrementally benefit our existing business. We do not expect that any increased sales in China derived from obtaining a direct selling license would initially be material and, in any event may be partially offset by the higher fixed costs associated with the establishment and maintenance of required service centers, branch offices, manufacturing facilities, certification programs and other legal requirements. We are unable to predict whether and when we will be successful in obtaining a direct selling license to operate in China, and if we are successful, when we will be permitted to conduct direct selling operations and whether such operations would be profitable.

 

 

In January 2019 the Chinese government announced a 100-day campaign focused on companies involved in the sale of food, equipment, daily necessities, small home electrical appliances and services that are claimed to promote health. The Chinese government ministries in charge of this campaign indicated that they are targeting illegal practices in the industry, particularly the manufacture and sale of counterfeit and substandard products, and false advertising and misleading claims as to the health benefits of products and services. It is understood that the campaign is specifically focused on the business practices of direct selling companies. During the campaign, we understand that the government is not issuing any additional direct selling licenses, is not issuing certifications of quality or other approvals of various healthcare products, and is reviewing its regulatory oversight of the industry. Since it was implemented, the campaign and associated negative media coverage have had a significant adverse impact on our business, as consumers have widely curtailed their purchases within the affected industries. We, like some of our peers, voluntarily decided in January 2019 to temporarily suspend our member activities, such as product roadshows, product trainings and larger company-sponsored events, in China. We did this because we learned that the 100-day campaign was announced in broad outlines by the central government, and the interpretation and enforcement of the campaign was delegated to the provincial and local governments. We consider it a top priority for our business to develop an understanding of and cooperate with all levels and jurisdictions of the government agencies, and did not want to run the risk of being inadvertently entangled in government enforcement actions as the provincial and local governments formulate and implement their interpretive guidance and rule-making. Although we have been able to relax some restrictions on member activities in certain markets, it may again in the future be necessary or advisable to suspend member activities or take similar actions from time to time, and such periods of reduced activity may have a material adverse effect on our business.

 

Although the 100-day campaign was due to expire on or about April 18, 2019, we are not aware of any information indicating that the campaign has formally concluded. However, on August 27, 2019, the Chinese government announced that it would conduct a “look-back review” to evaluate the 100-day campaign. As part of this review, we understand that various Chinese governmental agencies formed a working group to assess the 100-day campaign, particularly focusing on the health market and its supervision in certain provinces. We understand that during September 2019 the working group evaluated the performance and results of a number of organizations and governmental departments in these provinces and made recommendations for various improvements. It was noted that each province had opened a number of investigative cases, had successfully closed numerous cases, and had imposed various fines and penalties. We understand that the look-back review continued after September 2019, and we are not aware that this review has been completed. As a result, the business environment in China for health product companies continues to be challenging, which has been exacerbated by negative social media sentiment expressed for these types of companies. We believe that the campaign, as well as its extension and aftermath (including the look-back review), will continue to negatively impact our business in China in the near-term, but will ultimately benefit us and Chinese consumers in the long-term as purveyors of substandard products are driven from the market.

 

In late 2019 or early 2020 an outbreak of COVID-19 was first identified in China and subsequently spread around the world. On March 11, 2020 the World Health Organization declared the COVID-19 outbreak a global pandemic. The outbreak caused the Chinese government to implement powerful measures to control the virus, such as requiring businesses to close throughout various areas of China and restricting public gatherings and certain travel within the country. We have significant business in China and in 2021 generated approximately 78% of our revenue in Hong Kong, substantially all of which was derived from the sale of products to members in China. The Chinese government continues to adjust the restrictive measures that it imposes to control COVID-19 based on then-current local circumstances, as have the governments of the other countries in which we operate. The scope and impact of the pandemic and related control measures are uncertain, but we have taken steps to adapt some of our marketing programs, such as relying on certain product promotions and webcast training, to overcome the physical restrictions imposed in response to the pandemic. We have also canceled or rescheduled a number of in-person member events over the course of the pandemic. The severity of the impact on us of the COVID-19 pandemic will depend on future developments, including the duration and spread of the virus, and related control measures, which we are unable to accurately predict. Regardless, these disruptions have materially negatively impacted our financial results throughout 2020 and 2021, and we expect that our financial results for the near-term may be adversely affected. For example, in February 2021 several COVID-19 outbreaks caused the Chinese government to abruptly reintroduce restrictions on personal mobility and strongly discourage gatherings and travel ahead of the Chinese New Year. These measures effectively lengthened the traditional holiday and reduced the number of working days in the first quarter of 2021, which had a significant short-term effect on the level of our net sales. Further, due to scattered outbreaks of COVID-19 and the Chinese government's imposition of restrictions, the quarter ended September 30, 2021 marked the first quarter since the beginning of the pandemic that we were unable to sponsor any in-person member events in China, Macau or Hong Kong, which we believe also had a negative effect on net sales. The disruptions associated with the COVID-19 pandemic have also adversely affected the operations of some of our third-party logistics providers, and we expect that the future operations of these logistics providers and other third parties with whom we work may be adversely affected by these disruptions. We will continue to assess the operational and financial impact of the COVID-19 pandemic. See “Item 1A. Risk Factors - Epidemics, such as the COVID-19 pandemic, or natural disasters, terrorist attacks or acts of war…”.

 

Recent political and social developments in Hong Kong, along with the impact of the COVID-19 pandemic and related government control measures, are also adversely affecting our Hong Kong operations and led us in 2020 to cease conducting member meetings and events in Hong Kong. Inasmuch as member meetings and events located in Hong Kong have in the past served as an important component of our product marketing and distribution efforts, we believe that this action has negatively affected our operations and financial performance. If current conditions continue or further deteriorate, we anticipate that our business, financial condition and results of operations will be adversely affected. See “Item 1A. Risk Factors - Our Hong Kong operations are being adversely affected by recent political and social developments in Hong Kong...”. 

 

 

Our Hong Kong net sales (substantially all of which were derived from products shipped to members residing in China) for 2021 were lower than 2020. The decline in net sales during 2021 resulted in modest income from operations for the year, as well as modest positive cash flows from operations. We anticipate that our financial performance for the near-term may continue to be adversely impacted.

 

Statement of Operations Presentation

 

We mainly derive revenue from sales of products. Substantially all of our product sales are to independent members at published wholesale prices. Product sales are recognized when the products are shipped and title passes to independent members, which generally is upon our delivery to the carrier that completes delivery to the members. We estimate and accrue a reserve for product returns based on our return policies and historical experience. We bill members for shipping charges and recognize the freight revenue in net sales. We have elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrue for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Event and training revenue is deferred and recognized as the event or training occurs.

 

Cost of sales consists primarily of products purchased from third-party manufacturers, freight cost for transporting products to our foreign subsidiaries and shipping products to members, import duties, packing materials, product royalties, costs of promotional materials sold to our members at or near cost, and provisions for slow moving or obsolete inventories. Cost of sales also includes purchasing costs, receiving costs, inspection costs and warehousing costs.

 

Member commissions are our most significant expense and are classified as an operating expense. Under our compensation plan, members are paid weekly commissions by our subsidiary in which they are enrolled, generally in their home country currency, for product purchases by their down-line member network across all geographic markets. Our China subsidiary maintains an e-commerce retail platform and does not pay commissions, although our Chinese members may participate in our compensation plan through our other subsidiaries. This “seamless” compensation plan enables a member located in one country to enroll other members located in other countries where we are authorized to conduct our business. Currently, there are basically two ways in which our members can earn income:

 

 

through commissions paid on the accumulated bonus volume from product purchases made by their down-line members and customers; and

 

 

through retail profits on sales of products purchased by members at wholesale prices and resold at retail prices (for purchasers in some of our smaller markets and purchasers from our China subsidiary, sales are for personal consumption only and income may not be earned through retail profits).

 

Each of our products is designated a specified number of bonus volume points. Commissions are based on total personal and group bonus volume points per weekly sales period. Bonus volume points are essentially a percentage of a product’s wholesale price. As the member’s business expands from successfully enrolling other members who in turn expand their own businesses by selling product to other members, the member receives higher commissions from purchases made by an expanding down-line network. In some of our markets, to be eligible to receive commissions, a member may be required to make nominal monthly or other periodic purchases of our products. Certain of our subsidiaries do not require these nominal purchases for a member to be eligible to receive commissions. In determining commissions, the number of levels of down-line members included within the member’s commissionable group increases as the number of memberships directly below the member increases.

 

 

Under our current compensation plan, certain of our commission payouts may be limited to a hard cap dollar amount per week or a specific percentage of total product sales. In some markets, commissions may be further limited. In some markets, we also pay certain bonuses on purchases by up to three generations of personally sponsored members, as well as bonuses on commissions earned by up to seven generations of personally sponsored members. Members can also earn additional income, trips and other prizes in specific time-limited promotions and contests we hold from time to time. Member commissions are dependent on the sales mix and, for fiscal 2021 and 2020 represented 43% and 42% of net sales, respectively. Occasionally, we make modifications and enhancements to our compensation plan to help motivate members, which can have an impact on member commissions. We may also enter into performance-based agreements for business or market development, which can result in additional compensation to specific members.

 

Selling, general and administrative expenses consist of administrative compensation and benefits, travel, credit card fees and assessments, professional fees, certain occupancy costs, and other corporate administrative expenses (including stock-based compensation). In addition, this category includes selling, marketing, and promotion expenses (including the costs of member training events and conventions that are designed to increase both product awareness and member recruitment). Because our various member conventions are not always held at the same time each year, interim period comparisons will be impacted accordingly. 

 

The functional currency of our international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates.  The resulting translation adjustments are recorded directly into stockholders' equity.

 

Sales by our foreign subsidiaries are generally transacted in the respective local currencies and are translated into U.S. dollars using average rates of exchange for each monthly accounting period to which they relate.  Most of our product purchases from third-party manufacturers are transacted in U.S. dollars.  Consequently, our sales and net earnings are affected by changes in currency exchange rates, with sales and earnings generally increasing with a weakening U.S. dollar and decreasing with a strengthening U.S. dollar. 

 

Results of Operations

 

The following table sets forth our operating results as a percentage of net sales for the periods indicated:

 

   

Year Ended December 31,

 
   

2021

   

2020

 

Net sales

    100.0 %     100.0 %

Cost of sales

    25.0       27.4  

Gross profit

    75.0       72.6  

Operating expenses:

               

Commissions expense

    42.6       42.2  

Selling, general and administrative expenses

    29.8       29.3  

Total operating expenses

    72.4       71.5  

Income from operations

    2.6       1.1  

Other income (expense), net

    (0.1 )     1.3  

Income before income taxes

    2.5       2.4  

Income tax provision

    0.7       1.0  

Net income

    1.8 %     1.4 %

 

 

Net Sales

 

The following table sets forth revenue by market for the periods indicated (in thousands):

 

   

Year Ended December 31,

 
   

2021

   

2020

 

Americas1

  $ 4,283       7.2 %   $ 3,791       6.1 %

Hong Kong2

    46,699       77.8       49,169       79.2  

China

    2,237       3.7       2,940       4.7  

Taiwan

    2,706       4.5       3,034       4.9  

South Korea

    251       0.4       280       0.5  

Japan

    938       1.6       260       0.4  

Malaysia and Singapore

    458       0.8       358       0.6  

Russia and Kazakhstan

    854       1.4       888       1.4  

Europe

    1,136       1.9       1,050       1.7  

India

    443       0.7       301       0.5  

Total

  $ 60,005       100.0 %   $ 62,071       100.0 %

 


1 United States, Canada, Mexico and Peru.

2 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors.”

 

Net sales were $60.0 million for the year ended December 31, 2021 compared with $62.1 million a year ago, a decrease of $2.1 million, or 3%.  Hong Kong net sales, substantially all of which were derived from the sale of products shipped to members residing in China, decreased $2.5 million, or 5%, over the prior year. The overall decrease in Hong Kong net sales was enhanced by the recognition of lower administrative fees in 2021 compared with the prior year. However, the decrease in Hong Kong net sales resulted primarily from the increase in deferred revenue, as unredeemed product vouchers and unshipped product orders increased $5.5 million from December 31, 2020. This increase was due to the launch of a product voucher program in October 2020; the voucher program has been well received by our members, but resulted in a significant increase in unredeemed product vouchers and unshipped product orders at December 31, 2021. Additionally, we believe that our Hong Kong net sales will continue to be negatively impacted by scattered outbreaks of COVID-19 in China and the Chinese government's imposition of related measures to control the virus, including the required closure of some businesses and restrictions on public gatherings and travel. These restrictions have caused us to limit the number and scope of our in-person member events, which are designed to generate interest in our products. Clearly, the operating environment for our business in China remains restrictive. Outside of our Hong Kong business, net sales increased $404,000, or 3%, compared with the prior year.

 

As of December 31, 2021, deferred revenue was $8.5 million, which primarily consisted of $6.5 million pertaining to unshipped product orders and unredeemed product vouchers, as well as $1.9 million in auto ship advances.

 

Gross Profit

 

Gross profit was 75.0% of net sales for the year ended December 31, 2021 compared with 72.6% of net sales for the year ended December 31, 2020. Excluding the impact of decreased administrative fee revenue referred to above, gross profit margin increased primarily due to our negotiation of lower logistics costs and offer of fewer product promotions.

 

Commissions Expense

 

Commissions were 42.6% of net sales for the year ended December 31, 2021 compared with 42.2% of net sales for the year ended December 31, 2020. Excluding the impact of decreased administrative fee revenue referred to above, commissions as a percentage of net sales was relatively consistent as compared to the prior year.

 

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses were $17.8 million for the year ended December 31, 2021 compared with $18.2 million for the year ended December 31, 2020. Selling, general and administrative expenses decreased by $362,000, or 2%, mainly due to lower professional fees and lease costs offset by higher employee-related costs and event costs, as we held our first major in-person member event in June 2021 since the initial COVID-19 outbreak.

 

Income Taxes

 

An income tax provision of $425,000 was recognized for the year ended December 31, 2021 compared with $647,000 for the year ended December 31, 2020. The tax provision for 2021 primarily resulted from the impact of the Global Intangible Low-Taxed Income (“GILTI”) inclusion offset by income tax benefits recognized for GILTI-related return to provision true-ups related to the year ended December 31, 2020, as well as the permanent benefit recognized for carrying back net operating losses generated from the year ended December 31, 2020 to the year ended December 31, 2016. We booked a tax benefit of $84,000 during 2021 due to the net operating loss generated in the tax year ended December 31, 2020 for the rate differential resulting from the carryback. We booked a tax benefit of $512,000 during 2020 due to the net operating loss generated in the tax year ended December 31, 2019. The Company's effective tax rate for the year ended December 31, 2021 differs from the year ended December 31, 2020 primarily as a result of a reduction in income in our foreign operations during the year ended December 31, 2021.

 

Liquidity and Capital Resources

 

At December 31, 2021, our cash and cash equivalents totaled $83.8 million. Total cash and cash equivalents decreased by $8.5 million from December 31, 2020 to December 31, 2021, primarily due to dividends paid during 2021. We consider all highly liquid investments with original maturities of three months or less, when purchased, to be cash equivalents. As of December 31, 2021, we had $66.6 million in available-for-sale investments classified as cash equivalents. In addition, cash and cash equivalents included $4.1 million held in banks located in China subject to foreign currency controls. In April 2021, the Company adjusted the registered capital of its primary Chinese subsidiary and repatriated $9.0 million from China.

 

As of December 31, 2021, the ratio of current assets to current liabilities was 3.79 to 1.00 and we had $68.8 million of working capital. Working capital as of December 31, 2021 decreased $9.4 million compared to our working capital as of December 31, 2020.

 

Cash provided by operations was $1.0 million and $1.9 million during 2021 and 2020, respectively. Cash used in investing activities totaled $225,000 and $211,000 during 2021 and 2020, respectively.

 

 

Cash used in financing activities during 2021 and 2020 consisted solely of quarterly dividend payments of $0.20 per common share, totaling $9.1 million in each period. Subsequent to December 31, 2021, on February 7, 2022, the Board of Directors declared another quarterly cash dividend of $0.20 on each share of common stock outstanding. The dividend will be payable on March 4, 2022 to stockholders of record on February 22, 2022. We expect to continue paying a quarterly cash dividend of $0.20 on each share of common stock outstanding for the foreseeable future. However, any future cash dividends will be at the sole discretion of the Board of Directors, and will depend on our financial condition, results of operations, capital requirements and other factors considered relevant by the Board of Directors.

 

On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Any repurchases will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. As of December 31, 2021, $21.9 million of the $70.0 million stock repurchase program remained available for future purchases, inclusive of related estimated income tax.

 

We believe that our existing internal liquidity, supported by cash and cash equivalents, as well as cash flows from operations should be adequate to fund normal business operations and address our financial commitments for the foreseeable future.

 

We do not have any significant unused sources of liquid assets. If necessary, we may attempt to generate more funding from the capital markets, but currently do not believe that will be necessary.

 

Our priority is to focus our resources on investing in our most important markets, which we consider to be Greater China and countries where our existing members may have the connections to recruit prospects and sell our products, such as Southeast Asia, India, South America and Europe. We will continue to invest in our Mainland China entity for such purposes as establishing China-based manufacturing capabilities, increasing public awareness of our brand and our products, sourcing more Chinese-made products, building a chain of service stations, opening additional Healthy Lifestyle Centers or branch offices, adding local staffing and other requirements for a prospective China direct selling license application.

 

 

Critical Accounting Policies and Estimates 

 

A summary of our significant accounting policies is provided in Note 1 of the Notes to Consolidated Financial Statements in “Item 8. Financial Statements and Supplementary Data” of this report. The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.

 

Critical accounting policies and estimates are defined as both those that are material to the portrayal of our financial condition and results of operations and as those that require management’s most subjective judgments.  Management believes our critical accounting policies and estimates are those related to revenue recognition, as well as those used in the determination of liabilities related to member commissions and income taxes.

 

Revenue Recognition.  All revenue is recognized when the performance obligations under a contract, including product vouchers sold on a stand-alone basis in Hong Kong, are satisfied. Product sales are recorded when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon our delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” We primarily receive payment by credit card at the time members place orders. Our sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. Amounts received for unshipped product orders and unredeemed product vouchers are recorded as deferred revenue. Such amounts totaled $6.5 million and $1.0 million at December 31, 2021 and 2020, respectively. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs.

 

Additionally, deferred revenue includes advances for auto ship orders. In certain markets, when a member’s cumulative commission income reaches a certain threshold, a percentage of the member’s weekly commission is held back as an advance and applied to an auto ship order once the accumulated amount of the advances is sufficient to pay for the pre-selected auto ship package of the member.  Such advances were $1.9 million and $2.0 million at December 31, 2021 and 2020, respectively.

 

 

Commissions Expense. Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.  Each of our products are designated a specified number of bonus volume points, which is essentially a percentage of the product’s wholesale price.  We accrue commissions when earned and as the related revenue is recognized and pay commissions on product sales generally two weeks following the end of the weekly sales period.

 

Independent members may also earn incentives based on meeting certain qualifications during a designated incentive period, which may range from several weeks to up to a year.  For each individual incentive, we estimate the total number of qualifiers as well as the expected per qualifier cost and accrue all costs associated with incentives throughout the qualification period. We regularly review and update, if necessary, the estimates of both qualifiers and cost as more information is obtained during the qualification period. Any resulting change in total cost is recognized over the remaining qualification period. Long-term promotions and incentives (lasting up to one year) can, in particular, result in uncertain ultimate cost. Accrued commissions, including the estimated cost of our international recognition incentive program and other supplemental programs, totaled $3.6 million and $3.5 million at December 31, 2021 and 2020, respectively.

 

Income Taxes.  Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory rates for the years in which the temporary differences are expected to be recovered or settled. We evaluate the probability of realizing the future benefits of any of our deferred tax assets and record a valuation allowance when we believe a portion or all of our deferred tax assets may not be realized. Deferred tax expense or benefit is a result of changes in deferred tax assets and liabilities. Based on the technical merits of our tax position, tax benefits may be recognized if we determine it is more likely than not that our position will be sustained on examination by tax authorities. The complex nature of these estimates requires us to anticipate the likely application of tax law and make judgments on the largest benefit that has a greater than fifty percent likelihood of being realized prior to the completion and filing of tax returns for such periods. As of December 31, 2021, we do not have a valuation allowance against our U.S. deferred tax assets. We maintain a valuation allowance in certain foreign jurisdictions with an overall tax loss. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision.

 

Provision for income taxes depends on the statutory tax rates in each of the jurisdictions in which we operate. As a result of capital return activities, we determined that a portion of our current undistributed foreign earnings are no longer deemed reinvested indefinitely by our non-U.S. subsidiaries. The U.S. Tax Cuts and Jobs Act (the “Tax Act”), enacted on December 22, 2017 by the U.S. government, required a one-time repatriation tax on certain un-repatriated earnings of foreign subsidiaries at a rate of 15.5% tax on post-1986 foreign earnings held in cash and an 8% rate on all other post-1986 earnings. Due to the adoption of a territorial tax regime, any foreign source portion of a qualified dividend received by a 10% U.S. corporate shareholder is exempt from U.S. federal tax, therefore resulting in any future repatriation having a minimal effect on our effective tax rate. For state income tax purposes, we will continue to periodically reassess the needs of our foreign subsidiaries and update our indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, we expect to recognize additional income tax provision at the applicable U.S. state corporate tax rate(s). As of December 31, 2021, we have not recorded a state deferred tax liability for earnings to be repatriated in the future because the portion of all earnings which are no longer deemed reinvested indefinitely as of December 31, 2021 have already been repatriated. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of December 31, 2021.

 

The U.S. Coronavirus Aid, Relief, and Economic Security (“CARES”) Act was enacted on March 27, 2020. The CARES Act was enacted to provide tax relief to companies impacted by the COVID-19 pandemic. In addition to other broad changes, the CARES Act allows for a 5-year carryback period for net operating losses arising in tax years beginning after 2017 and before 2021, effectively taking advantage of differences in tax rate as a result of enactment of the Tax Act. We booked a tax benefit of $84,000 during 2021 due to the net operating loss generated in the tax year ended December 31, 2020 for the rate differential resulting from the carryback. We booked a tax benefit of $512,000 during 2020 due to the net operating loss generated in the tax year ended December 31, 2019.

 

We estimate what our effective tax rate will be for the full fiscal year at each interim reporting period and record a quarterly tax provision based on that estimated effective tax rate. Throughout the year that estimated rate may change based on variations in our business, changes in our corporate structure, changes in the geographic mix and amount of income, applicable tax laws and regulations, communications with tax authorities, as well as our estimated and actual level of annual pre-tax income. We adjust our income tax provision in the reporting period in which the change in our estimated rate occurs so that the year-to-date provision is consistent with the anticipated annual tax rate. The Company's effective tax rate for the year ended December 31, 2021 differs from the year ended December 31, 2020 primarily as a result of a reduction in income in our foreign operations during the year ended December 31, 2021.

 

Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable under smaller reporting company disclosure rules.

 

 

 

Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

NATURAL HEALTH TRENDS CORP.

 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

 

Page

 

 

Report of Independent Registered Public Accounting Firm (Marcum LLP, PCAOB ID No. 688)

34

Consolidated Balance Sheets

35

Consolidated Statements of Operations

36

Consolidated Statements of Comprehensive Income

37

Consolidated Statements of Stockholders’ Equity

38

Consolidated Statements of Cash Flows

39

Notes to Consolidated Financial Statements

40

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

  

To the Shareholders and Board of Directors of

Natural Health Trends Corp.

 

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of Natural Health Trends Corp. (the “Company”) as of December 31, 2021 and 2020, the related consolidated statements of operations, comprehensive income, stockholders’ equity and cash flows for each of the two years in the period ended December 31, 2021, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB.  Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

 

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

 

Commissions Expense and the Related Accrued Commissions, Including Amounts Held in eWallets

 

As described in Note 1 to the consolidated financial statements, the Company accrues weekly commissions when earned, and estimates and accrues all costs associated with certain incentives independent members may earn during a designated incentive period as the members meet the qualification requirements, which may range from several weeks to up to a year.  

 

The principal consideration for our determination that performing procedures related to commissions expense and the related accrued commissions, including amounts held in eWallets, is a critical audit matter is there were specialized skills required to test the information technology controls surrounding the computation of the commission expense and significant judgment by management in determining the amounts to accrue for each of its member compensation programs, which in turn, led to significant audit judgement, subjectivity, and effort in performing audit procedures and evaluating audit evidence related to these accounts.

 

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included, among others, (i) testing the Company’s information technology controls, (ii) testing the internal controls over the algorithm used to compute commissions expense and recomputed the algorithm on a test basis; and (iii) obtaining an understanding of the Company’s estimation process relating to commissions and testing the Company's process by performing procedures to test and evaluate the methods, data, and significant assumptions used in developing the estimates.

 

 

/s/ Marcum LLP

Marcum LLP

 

We have served as the Company’s auditor since 2017.

 

Los Angeles, CA

February 25, 2022

 

 

 

NATURAL HEALTH TRENDS CORP.

 

CONSOLIDATED BALANCE SHEETS

(In Thousands, Except Share Data)

 

  

December 31,

 
  

2021

  

2020

 

ASSETS

        

Current assets:

        

Cash and cash equivalents

 $83,843  $92,367 

Inventories

  5,257   3,779 

Other current assets

  4,369   3,595 

Total current assets

  93,469   99,741 

Property and equipment, net

  463   539 

Operating lease right-of-use assets

  3,021   3,745 

Restricted cash

  522   525 

Deferred tax asset

  309   731 

Other assets

  571   661 

Total assets

 $98,355  $105,942 

LIABILITIES AND STOCKHOLDERS’ EQUITY

        

Current liabilities:

        

Accounts payable

 $761  $580 

Income taxes payable

  1,345   1,481 

Accrued commissions

  3,636   3,496 

Other accrued expenses

  1,933   1,922 

Deferred revenue

  8,536   3,091 

Amounts held in eWallets

  6,341   8,503 

Operating lease liabilities

  1,239   1,163 

Other current liabilities

  865   1,270 

Total current liabilities

  24,656   21,506 

Income taxes payable

  12,130   13,748 

Deferred tax liability

  153   216 

Operating lease liabilities

  1,928   2,775 

Total liabilities

  38,867   38,245 

Commitments and contingencies (Note 8)

          

Stockholders’ equity:

        

Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding

      

Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at December 31, 2021 and 2020

  13   13 

Additional paid-in capital

  86,102   86,102 

Retained earnings (accumulated deficit)

  (231)  7,822 

Accumulated other comprehensive loss

  (492)  (336)

Treasury stock, at cost; 1,556,875 shares at December 31, 2021 and 2020

  (25,904)  (25,904)

Total stockholders’ equity

  59,488   67,697 

Total liabilities and stockholders’ equity

 $98,355  $105,942 

 

See accompanying notes to consolidated financial statements.

 

 

 

NATURAL HEALTH TRENDS CORP.

 

CONSOLIDATED STATEMENTS OF OPERATIONS

(In Thousands, Except Per Share Data)

 

  

Year Ended December 31,

 
  

2021

  

2020

 

Net sales

 $60,005  $62,071 

Cost of sales

  15,010   16,990 

Gross profit

  44,995   45,081 

Operating expenses:

        

Commissions expense

  25,578   26,204 

Selling, general and administrative expenses

  17,846   18,208 

Total operating expenses

  43,424   44,412 

Income from operations

  1,571   669 

Other income (expense), net

  (61)  821 

Income before income taxes

  1,510   1,490 

Income tax provision

  425   647 

Net income

 $1,085  $843 

Net income per common share:

        

Basic

 $0.10  $0.08 

Diluted

 $0.09  $0.07 

Weighted-average number of common shares outstanding:

        

Basic

  11,017   10,630 

Diluted

  11,424   11,424 

 

See accompanying notes to consolidated financial statements.

 

 

 

NATURAL HEALTH TRENDS CORP.

 

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In Thousands)

 

   

Year Ended December 31,

 
   

2021

   

2020

 

Net income

  $ 1,085     $ 843  

Other comprehensive income (loss), net of tax:

               

Foreign currency translation adjustments

    (149 )     920  

Unrealized gains (losses) on available-for-sale securities

    (7 )     8  

Comprehensive income

  $ 929     $ 1,771  

 

See accompanying notes to consolidated financial statements.

 

 

 

NATURAL HEALTH TRENDS CORP.

 

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In Thousands, Except Share Data)

 

   

Preferred Stock

   

Common Stock

   

Additional Paid-In

   

Retained Earnings (Accumulated

   

Accumulated Other Comprehensive

   

Treasury Stock

         
   

Shares

   

Amount

   

Shares

   

Amount

   

Capital

   

Deficit)

   

Loss

   

Shares

   

Amount

   

Total

 

BALANCE, December 31, 2019

        $       12,979,414     $ 13     $ 86,102     $ 16,117     $ (1,264 )     (1,556,875 )   $ (25,904 )   $ 75,064  

Net income

                                  843                         843  

Dividends declared, $0.80/share

                                  (9,138 )                       (9,138 )

Foreign currency translation adjustments

                                        920                   920  

Unrealized gains on available-for-sale securities

                                        8                   8  

BALANCE, December 31, 2020

                12,979,414       13       86,102       7,822       (336 )     (1,556,875 )     (25,904 )     67,697  

Net income

                                  1,085                         1,085  

Dividends declared, $0.80/share

                                  (9,138 )                       (9,138 )

Foreign currency translation adjustments

                                        (149 )                 (149 )

Unrealized losses on available-for-sale securities

                                        (7 )                 (7 )

BALANCE, December 31, 2021

        $       12,979,414     $ 13     $ 86,102     $ (231 )   $ (492 )     (1,556,875 )   $ (25,904 )   $ 59,488  

 

See accompanying notes to consolidated financial statements. 

 

 

 

NATURAL HEALTH TRENDS CORP.

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In Thousands)

 

   

Year Ended December 31,

 
   

2021

   

2020

 

CASH FLOWS FROM OPERATING ACTIVITIES:

               

Net income

  $ 1,085     $ 843  

Adjustments to reconcile net income to net cash provided by operating activities:

               

Depreciation and amortization

    299       410  

Noncash lease expense

    1,163       1,532  

Deferred income taxes

    362       1,339  

Changes in assets and liabilities:

               

Inventories

    (1,547 )     2,700  

Other current assets

    (803 )     2,322  

Other assets

    68       181  

Accounts payable

    182       (102 )

Income taxes payable

    (1,753 )     (311 )

Accrued commissions

    212       566  

Other accrued expenses

    20       (471 )

Deferred revenue

    5,482       (1,433 )

Amounts held in eWallets

    (2,122 )     (4,491 )

Operating lease liabilities

    (1,237 )     (1,427 )

Other current liabilities

    (395 )     227  

Net cash provided by operating activities

    1,016       1,885  

CASH FLOWS FROM INVESTING ACTIVITIES:

               

Purchases of property and equipment

    (225 )     (211 )

Net cash used in investing activities

    (225 )     (211 )

CASH FLOWS FROM FINANCING ACTIVITIES:

               

Dividends paid

    (9,138 )     (9,138 )

Net cash used in financing activities

    (9,138 )     (9,138 )

Effect of exchange rates on cash, cash equivalents and restricted cash

    (180 )     931  

Net decrease in cash, cash equivalents and restricted cash

    (8,527 )     (6,533 )

CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period

    92,892       99,425  

CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period

  $ 84,365     $ 92,892  

SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION:

               

Cash paid (refunded) for income taxes, net

  $ 1,865     $ (2,097 )

Right-of-use assets obtained in exchange for operating lease liabilities

  $ 472     $ 2,747  

 

See accompanying notes to consolidated financial statements.

 

 

NATURAL HEALTH TRENDS CORP.

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

 

1.     NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Nature of Operations

 

Natural Health Trends Corp., a Delaware corporation (whether or not including its subsidiaries, the “Company”), is an international direct-selling and e-commerce company. Subsidiaries controlled by the Company sell personal care, wellness, and “quality of life” products under the “NHT Global” brand.

 

The Company’s wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Malaysia, Singapore and Thailand; South Korea; Japan; India; and Europe. The Company also operates in Russia and Kazakhstan through an engagement with a local service provider.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.

 

Use of Estimates

 

The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period.

 

The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates associated with revenue recognition, as well as those used in the determination of liabilities related to sales returns, commissions and income taxes. Various assumptions and other factors prompt the determination of these significant estimates. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. The actual results may differ materially and adversely from the Company’s estimates. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.

 

Cash and Cash Equivalents

 

Cash and cash equivalents include the Company’s investments in money market funds, government and municipal debt securities, and corporate debt securities. The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Debt securities classified as cash equivalents are required to be accounted for in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 320, Investments - Debt and Equity Securities. As such, the Company determined its investments in debt securities held at December 31, 2021 should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income and expense. Realized gains and losses, as well as interest income, are also included in other income and expense. The fair values of securities are based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs.

 

The Company includes credit card receivables due from certain of its credit card processors in its cash and cash equivalents as the cash proceeds are received within two to five days.

 

The Company maintains certain cash balances at several institutions located in the United States, Hong Kong and elsewhere which at times may exceed insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.

 

40

 

Restricted Cash

 

In November 2019, the Company funded a bank deposit account in the amount of VND 10 billion ($438,000 and $433,000 at December 31, 2021 and 2020, respectively) for purposes of submitting a direct selling license application in Vietnam. Such deposit is required by Vietnamese law to establish a consumer protection fund for direct selling participants. In January 2022, the Company submitted an application to withdraw the bank deposit since no direct selling license has been successfully obtained to operate in Vietnam.

 

The Company periodically maintains a cash reserve with certain credit card processing companies to provide for potential uncollectible amounts and chargebacks. Those cash reserves held by credit card processing companies located in South Korea are reflected in noncurrent assets since they require the Company to provide 100% collateral before processing transactions, which must be maintained indefinitely.

 

Inventories

 

Inventories are stated at the lower of cost or net realizable value, using the first-in, first-out method. The Company reviews its inventory for obsolescence and any inventory identified as obsolete is reserved or written off. The Company’s determination of obsolescence is based on assumptions about the demand for its products, product expiration dates, estimated future sales, and management’s future plans.

 

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five years for office equipment, office software and capitalized internal-use software development costs and five to seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the assets. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation and amortization expenses are included in the statement of operations as selling, general and administrative expenses. Such expense totaled $299,000 and $410,000 during 2021 and 2020, respectively.

 

The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of these assets is measured by comparison of its carrying amounts to future undiscounted cash flows the assets are expected to generate. If property and equipment are considered to be impaired, the impairment to be recognized equals the amount by which the carrying value of the asset exceeds its fair value.

 

Income Taxes

 

The Company recognizes income taxes under the liability method of accounting for income taxes. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is a result of changes in deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be ultimately realized based on the more likely than not recognition criteria. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has evaluated its tax positions and determined that there are no significant uncertain tax positions for the current year or years prior. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution.  The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense.  Deferred taxes are not provided for state income tax purposes on the portion of undistributed earnings of subsidiaries outside of the United States when these earnings are considered permanently reinvested.

 

Amounts Held in eWallets

 

The Company requires commission payments of certain members in Hong Kong and other markets to be first recorded into an electronic wallet (eWallet) account in lieu of being paid out directly to members. The eWallet functionality allows members to place new product orders utilizing eWallet available balance and/or request commission payout via multiple payment methods. Amounts held in eWallets are reflected on the balance sheet as a current liability.

 

Foreign Currency

 

The functional currency of the Company’s international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates.  The resulting translation adjustments are recorded directly into stockholders' equity.

 

Aggregate transaction gains or losses, including gains or losses related to foreign-denominated cash and cash equivalents and the re-measurement of certain inter-company balances, are included in the statement of operations as other income and expense. Loss on foreign exchange totaling $248,000 and $335,000 was recognized during 2021 and 2020, respectively.

 

41

 

Commissions Expense

 

Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.  Each of the Company’s products are designated a specified number of bonus volume points, which is essentially a percentage of the product’s wholesale price.  The Company accrues commissions when earned and as the related revenue is recognized and pays commissions on product sales generally two weeks following the end of the weekly sales period.

 

In some markets, the Company also pays certain bonuses on purchases by up to three generations of personally sponsored members, as well as bonuses on commissions earned by up to seven generations of personally sponsored members. Independent members may also earn incentives based on meeting certain qualifications during a designated incentive period, which may range from several weeks to up to a year.  The Company estimates and accrues all costs associated with the incentives as the members meet the qualification requirements.

 

From time to time the Company makes modifications and enhancements to the Company’s compensation plan to help motivate members, which can have an impact on member commissions. The Company also enters into performance-based agreements for business or market development, which may result in additional compensation to specific members.

 

Net Income Per Common Share

 

Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized, if any, is assumed to be used to repurchase shares.

 

Certain Risks and Concentrations

 

In late 2019 or early 2020 an outbreak of COVID-19 was first identified in China and subsequently spread around the world. On March 11, 2020 the World Health Organization declared the COVID-19 outbreak a global pandemic. The outbreak caused the Chinese government to implement powerful measures to control the virus, such as requiring businesses to close throughout various areas of China and restricting public gatherings and certain travel within the country. The Company has significant business in China and in 2021 generated approximately 78% of its revenue in Hong Kong, substantially all of which was derived from the sale of products to members in China. The Chinese government continues to adjust the restrictive measures that it imposes to control COVID-19 based on then-current local circumstances, as have the governments of the other countries in which the Company operates. The scope and impact of the pandemic and related control measures are uncertain, but the Company has taken steps to adapt some of its marketing programs, such as relying on certain product promotions and webcast training, to overcome the physical restrictions imposed in response to the pandemic. The Company has also canceled or rescheduled a number of in-person member events over the course of the pandemic. The severity of the impact on the Company of the COVID-19 pandemic will depend on future developments, including the duration and spread of the virus, and related control measures, which the Company is unable to accurately predict. Regardless, these disruptions have materially negatively impacted the Company’s financial results throughout 2020 and 2021, and the Company expects that its financial results for the near-term may be adversely affected. These disruptions have also adversely impacted the operations of some of the Company’s third-party logistics providers, and it expects that the future operations of these logistics providers and other third parties with whom it works may be adversely affected by these disruptions. The Company will continue to assess the operational and financial impact of the COVID-19 pandemic.

 

In contrast to the Company’s business in other parts of the world, the Company’s China subsidiary has not implemented a direct sales model in China. The Chinese government permits direct selling only by organizations that have a license and has also adopted anti-pyramid selling and multi-level marketing legislation. The Company previously submitted a preliminary application for a direct selling license in China in August 2015, but in 2019 a Chinese governmental authority recommended that the Company withdraw its application. The Company understands that the governmental authorities recommended that other companies with pending direct selling license applications also withdraw their applications. The Company applied to withdraw its application in November 2019, and the governmental authorities approved the withdrawal of its application shortly thereafter. The Company operates an e-commerce direct selling platform in Hong Kong and recognizes the revenue derived from sales to both Hong Kong and Chinese members as being generated in Hong Kong. Products purchased by members in China are delivered to third parties that act as the importers of record under agreements to pay applicable duties. In addition, through a Chinese entity, the Company sells products in China using an e-commerce retail platform. The Chinese entity operates separately from the Hong Kong entity, and a Chinese member may elect to participate separately or in both.

 

The Company continually evaluates its business in China and Hong Kong for compliance with applicable laws and regulations, including seeking the input of outside professionals and certain Chinese authorities. This process can and has resulted in the identification of certain matters of potential noncompliance. The Company works on a continuing basis to satisfactorily address such matters, however there can be no assurance that adequate steps are taken or that applicable laws and regulations are properly interpreted. Should the government authorities determine that the Company’s activities violate applicable laws and regulations, including China’s direct selling, pyramid selling or multi-level marketing laws and regulations, or should new laws or regulations be adopted, there could be a material adverse effect on the Company’s business, financial condition and results of operations.

 

Although the Company attempts to work closely with both national and local Chinese governmental agencies in conducting its business, the Company’s efforts to comply with national and local laws may be harmed by a rapidly evolving regulatory climate, concerns about activities resembling violations of direct selling, pyramid selling or multi-level marketing legislation, subjective interpretations of laws and regulations, and activities by individual members that may violate laws notwithstanding the Company's policies prohibiting such activities. Any determination that the Company’s operations or activities, or the activities of its individual members or employee sales representatives, or importers of record are not in compliance with applicable laws and regulations could result in the imposition of substantial fines, extended interruptions of business, restrictions on the Company’s future ability to obtain business licenses or expand into new locations, changes to its business model, the termination of required licenses to conduct business, or other actions, any of which could materially harm the Company’s business, financial condition and results of operations.

 

42

 

No single market other than Hong Kong had net sales greater than 10% of total sales. Sales are made to the Company’s members and no single customer accounted for 10% or more of its net sales. However, the Company’s business model can result in a concentration of sales to several different members and their network of members. Although no single member accounted for 10% or more of net sales, the loss of a key member or that member’s network could have an adverse effect on the Company’s net sales and financial results.

 

The Company’s Premium Noni Juice, Enhanced Essential Probiotics and Triotein™ products each account for at least 10% of the Company’s total revenue. The Company currently sources each of these products from a single supplier. If demand decreases significantly, government regulation restricts their sale, the Company is unable to adequately source or deliver the products, or the Company ceases offering the products for any reason without suitable replacements, the Company’s business, financial condition and results of operations could be materially and adversely affected.

 

Fair Value of Financial Instruments

 

The carrying amounts of the Company’s financial instruments, including cash and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents.

 

Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.

 

Recent Accounting Pronouncements

 

In June 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost basis and added Topic 326 to the FASB ASC. In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments - Credit Losses.  The amendments to ASU 2019-11 clarify, correct and make improvements to Topic 326.  ASU 2016-13 as well as the updates in ASU 2019-11 are effective for interim and annual periods beginning after December 15, 2022, and early adoption is permitted.  The Company is currently evaluating the impact of this standard on its consolidated financial statements.

 

Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

 

43

 
 

2. REVENUE

 

Revenue Recognition

 

All revenue is recognized when the performance obligations under a contract, including any product vouchers sold on a stand-alone basis in Hong Kong, are satisfied. Product sales are recognized when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. These contracts are generally short-term in nature.

 

Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience. The reserve is based upon the return policy of each country, which varies from 14 days to one year, and their historical return rates, which range from 1% to 9% of sales. Sales returns were 1% of sales for each of 2021 and 2020No material changes in estimates have been recognized during the periods presented. See Note 4 for additional information.

 

The Company has elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrues for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.

 

Various taxes on the sale of products to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.

 

Deferred Revenue

 

The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product orders and unredeemed product vouchers are considered a contract liability and are recorded as deferred revenue. The increase in deferred revenue from December 31, 2020 to December 31, 2021 is primarily due to $6.5 million of cash received for unshipped product orders and unredeemed product vouchers offset by $1.0 million of revenue recognized during the year ended December 31, 2021 that was included in deferred revenue as of December 31, 2020. See Note 4 for additional information.

Disaggregation of Revenue

The Company sells products to a member network that operates in a seamless manner from market to market, except for the Chinese market where it sells to some consumers through an e-commerce retail platform and the Russia and Kazakhstan market where the Company operates through the engagement of a third-party service provider. See Note 13 for additional information.

 

Arrangements with Multiple Performance Obligations

 

The Company’s contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenues to each performance obligation based on its relative standalone selling price. The Company generally determines standalone selling prices based on the prices charged for individual products to similar customers.

 

Practical Expedients

 

The Company generally expenses sales commissions when incurred because the amortization period would be one year or less. These costs are recorded in commissions expense.

 

The Company does not provide certain disclosures about unsatisfied performance obligations for contracts with an original expected length of one year or less.

 

44

 
 

3.     NET INCOME PER COMMON SHARE

 

The following table illustrates the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data):

 

  

Year Ended December 31,

 
  

2021

  

2020

 
  

Income

  

Shares

  

Per Share

  

Income

  

Shares

  

Per Share

 

Basic net income per common share:

                        

Net income available to common stockholders

 $1,085   11,017  $0.10  $843   10,630  $0.08 

Effect of dilutive securities:

                        

Non-vested restricted stock

     407          794     

Diluted net income per common share:

                        

Net income available to common stockholders plus assumed conversions

 $1,085   11,424  $0.09  $843   11,424  $0.07 

 

 

 

 

4.     BALANCE SHEET COMPONENTS

 

The components of certain balance sheet amounts are as follows (in thousands):

 

  

December 31,

 
  

2021

  

2020

 

Cash and cash equivalents:

        

Cash

 $17,281  $23,977 

Cash equivalents

  66,562   68,390 
   83,843   92,367 

Restricted cash

  522   525 
  $84,365  $92,892 
         

Inventories:

        

Finished goods

 $4,476  $3,071 

Raw materials

  873   1,047 

Reserve for obsolescence

  (92)  (339)
  $5,257  $3,779 

Property and equipment:

        

Office equipment

 $460  $449 

Office software

  1,009   1,001 

Machinery

  22   30 

Furniture and fixtures

  252   254 

Leasehold improvements

  814   839 

Construction in progress

  173   41 

Property and equipment, at cost

  2,730   2,614 

Accumulated depreciation and amortization

  (2,267)  (2,075)
  $463  $539 

Other accrued expenses:

        

Sales returns

 $137  $189 

Employee-related expense

  988   1,149 

Warehousing, inventory-related and other

  808   584 
  $1,933  $1,922 

Deferred revenue:

        

Unshipped product and unredeemed product vouchers

 $6,525  $1,005 

Auto ship advances

  1,901   1,977 

Other

  110   109 
  $8,536  $3,091 

 

As of December 31, 2021, cash and cash equivalents include $4.1 million held in banks located within China subject to foreign currency controls.

 

46

 
 

5.     FAIR VALUE MEASUREMENTS

 

Investments by category included in cash equivalents at the end of each period were as follows (in thousands):

 

    

December 31, 2021

  

December 31, 2020

 
  

Fair Value Level1

 

Adjusted Cost

  

Gross Unrealized Losses

  

Fair Value

  

Adjusted Cost

  

Gross Unrealized Losses

  

Fair Value

 

Money market funds

 

Level 1

 $20,711  $  $20,711  $21,042  $  $21,042 

Time deposits

 

Level 2

           5,458      5,458 

Government and municipal debt securities

 

Level 2

  14,006   (2)  14,004   30,280   (5)  30,275 

Corporate debt securities

 

Level 2

  31,863   (16)  31,847   11,621   (6)  11,615 

Total investments

   $66,580  $(18) $66,562  $68,401  $(11) $68,390 

 


1 FASB Topic 820, Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

 

47

 
 

6.     LEASES

 

The Company leases 7,300 square feet of office space in Hong Kong and 4,900 square feet of office space in Rolling Hills Estates, California for its corporate staff. In June 2020, the Company extended the Rolling Hills Estates office lease for an additional five years with a term now expiring in September 2030. Effective  July 1, 2020, the Company modified the terms of its largest Hong Kong office lease resulting in a lease extension through  June 2023. To help further develop the market for its products in North America, the Company leases 1,600 square feet of retail space in each of Rowland Heights, California and Richmond, British Columbia and 2,000 square feet of retail space in Metuchen, New Jersey. The Rowland Heights, Richmond and Metuchen locations have terms expiring in November 2025, February 2024, and November 2022, respectively.

 

The Company leases seven branch offices throughout China, and additional office space in Peru, Japan, Taiwan, South Korea, Malaysia, Singapore, Thailand, India, and the Cayman Islands. The Company also leases a factory in Zhongshan, China. The Company contracts with third parties for fulfillment and distribution operations in all of its international markets. None of the Company’s third-party logistics contracts contain a lease as the Company does not have the right to access the warehouses or move its inventories at will.

 

The components of lease cost were as follows (in thousands):

 

  

Year Ended December 31,

 
  

2021

  

2020

 

Operating leases

 $1,334  $1,716 

Short-term leases

  180   299 

Total lease cost

 $1,514  $2,015 

 

Cash paid for amounts included in the measurement of operating leases liabilities was $1.4 million and $1.6 million for 2021 and 2020, respectively.

 

The weighted-average remaining lease term and discount rate related to operating leases as of December 31, 2021 were as follows:

 

Weighted-average remaining lease term (in years)

  5.1 

Weighted-average discount rate

  3.3%

 

As most of the Company’s leases do not provide an implicit rate, the Company used its incremental borrowing rate, or the rate of each of its subsidiaries if available, based on the information available at the lease commencement date to determine the present value of lease payments.

 

The annual scheduled lease payments of our operating lease liabilities as of December 31, 2021 were as follows (in thousands):

 

2022

 $1,261 

2023

  672 

2024

  272 

2025

  261 

2026

  201 

Thereafter

  789 

Total lease payments

 $3,456 

Less: imputed interest

  (289)

Present value of lease liabilities

 $3,167 

 

For all asset classes, the Company elected not to recognize assets or liabilities at the acquisition date for leases that, at the acquisition date, have a remaining lease term of 12 months or less. Additionally, for all asset classes, the Company choose not to separate nonlease components from lease components and instead account for the combined lease and nonlease components associated with that lease component as a single lease component.

 

48

 
 

7.     INCOME TAXES

 

The components of income before income taxes consist of the following (in thousands):

 

  

Year Ended December 31,

 
  

2021

  

2020

 

Domestic

 $(1,127) $(1,663)

Foreign

  2,637   3,153 

Income before income taxes

 $1,510  $1,490 

 

The components of the income tax provision consist of the following (in thousands):

 

  

Year Ended December 31,

 
  

2021

  

2020

 

Current taxes:

        

Federal

 $(207) $(512)

State

  9   1 

Foreign

  267   626 

Total current taxes

  69   115 
         

Deferred taxes:

        

Federal

  309   346 

State

  7   6 

Foreign

  40   180 

Total deferred taxes

  356   532 

Income tax provision

 $425  $647 

 

A reconciliation of the reported income tax provision to the provision that would result from applying the domestic federal statutory tax rate to pretax income is as follows (in thousands):

 

  

Year Ended December 31,

 
  

2021

  

2020

 

Income tax at federal statutory rate

 $317  $313 

Effect of permanent differences

  274   121 

Global Intangible Low-Taxed Income

  183   555 

Change in valuation allowance

  (37)  51 

Foreign rate differential

  (221)  72 

Foreign tax credits

  (32)  (98)

Stock-based compensation

  10   164 

Net operating loss carryback

  (84)  (512)

Other reconciling items

  15   (19)

Income tax provision

 $425  $647 

 

Income before income taxes and the statutory tax rate for each country that materially contributed to the foreign rate differential presented above is as follows (in thousands):

 

      

Year Ended December 31,

 
  

Statutory Tax Rate

  

2021

  

2020

 

Cayman Islands

  % $2,696  $2,589 

Hong Kong

  16.5%  742   267 

China

  25.0%  152   716 

 

49

 

Deferred income taxes consist of the following (in thousands):

 

  

December 31,

 
  

2021

  

2020

 

Deferred tax assets:

        

Net operating losses

 $490  $628 

Stock-based compensation

  170   510 

Operating lease liabilities

  396   460 

Other

  51   60 

Total deferred tax assets

  1,107   1,658 

Valuation allowance

  (303)  (340)

Net deferred tax assets

  804   1,318 

Deferred tax liabilities:

        

Operating lease assets

  (376)  (438)

Foreign deferreds

  (153)  (216)

Prepaids

  (113)  (113)

Other

  (6)  (36)

Total deferred tax liabilities

  (648)  (803)

Net deferred tax assets

 $156  $515 

 

The effective income tax rate for the year ended December 31, 2021 includes an estimate for the Global Intangible Low-Taxed Income (“GILTI”) inclusion. The effect of permanent differences in 2021 and 2020 is mainly due to compensation-related limitations under Internal Revenue Code Section 162(m). As of December 31, 2021, the Company does not have a valuation allowance against its U.S. deferred tax assets. The Company analyzed all sources of available income and determined that they are more likely than not to realize the tax benefits of their deferred assets. As of December 31, 2021, the Company has a valuation allowance against deferred taxes in certain foreign jurisdictions with an overall net operating loss. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision.

 

As of December 31, 2021, the Company no longer has U.S. federal net operating losses due to its filing in December 2021 to carry back $603,000 of losses generated in the tax year ended December 31, 2020 to offset taxable income from the tax year ended December 31, 2016. The Company has post-apportioned U.S. state net operating loss carryforwards of $427,000 that begin expiring in 2039. At December 31, 2021, the Company has foreign net operating loss carryforwards of approximately $1.9 million in various jurisdictions with various expirations.

 

As of December 31, 2021, income taxes payable for the repatriation tax on the deemed repatriation of deferred foreign income required the U.S. Tax Cuts and Jobs Act (the “Tax Act”), enacted on December 22, 2017 by the U.S. government, totaled $13.7 million, of which $12.1 million is reflected as a noncurrent liability.

 

As a result of capital return activities, the Company determined that a portion of its current undistributed foreign earnings is no longer deemed reinvested indefinitely by its non-U.S. subsidiaries. For state income tax purposes, the Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable state corporate income tax rate(s). As of December 31, 2021, the Company has not recorded a state deferred tax liability for earnings that the Company plans to repatriate out of accumulated earnings in future periods because all earnings as of December 31, 2021 have already been repatriated. Due to the Tax Act, repatriation from foreign subsidiaries will be offset with a dividends received deduction, resulting in little to no impact on federal tax expense. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of December 31, 2021.

 

The Company and its subsidiaries file tax returns in the United States, California, New Jersey, Texas and various foreign jurisdictions. During the fourth quarter of 2018, the Company was notified that it was selected for audit of the 2016 tax year by the U.S. Internal Revenue Service (the "IRS"). The audit was subsequently expanded to also include the 2017, 2018 and 2019 tax years. On October 12, 2021, the Company received notification from the IRS that it had completed the audit process for all tax years with no changes made to the Company's previously reported tax. The Company is no longer subject to state income tax examinations for years prior to 2017. No other jurisdictions are currently examining any income tax returns of the Company.

 

50

 
 
 

8.     COMMITMENTS AND CONTINGENCIES

 

The SEC conducted a non-public investigation since August 2016 to determine whether there have been violations of the federal securities laws relating to the trading of the Company’s securities and/or its public disclosures. On September 30, 2021, the Company was notified by the SEC that it had concluded its investigation and does not intend to recommend an enforcement action.

 

The Company has employment agreements with certain members of its management team that can be terminated by either the employee or the Company upon four weeks’ notice.  The employment agreements entered into with the management team contain provisions that guarantee the payments of specified amounts in the event of a change in control, as defined, or if the employee is terminated without cause, as defined, or terminates employment for good reason, as defined.

 

 

9.     STOCK-BASED INCENTIVE PLANS

 

Restricted Stock

 

At the Company’s annual meeting of stockholders held on April 7, 2016, the Company’s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “2016 Plan”) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units, stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to 2,500,000 shares of the Company’s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted. At December 31, 2021, 1,219,583 shares remained available for issuance under the 2016 Plan.

 

The following table summarizes the Company’s restricted stock activity under the 2016 Plan:

 

  

Shares

  

Wtd. Avg. Price at Date of Issuance

 

Nonvested at December 31, 2019

  957,682  $7.34 

Vested

  (391,410)  7.53 

Nonvested at December 31, 2020

  566,272   7.21 

Vested

  (380,027)  7.27 

Nonvested at December 31, 2021

  186,245   7.08 

 

Phantom Equity

 

On  March 15, 2021, the Company’s Board of Directors approved and adopted a Phantom Equity Plan (the “Phantom Plan”). Under the terms of the Phantom Plan, the Board of Directors' Compensation Committee  may grant to the Company’s employees, officers, directors, contractors, consultants, or advisors awards of phantom shares entitling grantees the right to receive a cash payment equal to the fair market value of an equal number of shares of the Company’s common stock upon the close of a vesting period, subject to any maximum payment value that the Compensation Committee  may set. The vesting of phantom shares is subject to such vesting conditions as the Compensation Committee  may specify in a grantee’s award agreement. Grantees of phantom shares shall not by virtue of their receipt of phantom shares have any ownership rights in shares of the Company’s common stock. The Phantom Plan shall continue for a period of ten years, after which no further phantom shares  may be awarded (although any phantom shares awarded prior to the expiration of such 10-year period shall be unaffected by the termination of the Phantom Plan).

 

Also on  March 15, 2021, awards for 223,307 phantom shares were granted to the Company’s employees and its non-employee directors.  The phantom shares vest in eight equal three-month vesting increments, subject to the satisfaction of both a time-based vesting condition and a performance vesting condition. These vesting conditions were deemed satisfied on the grant date for the initial vesting increment. In order for the time-based vesting condition to be satisfied for each vesting period, the grantee must remain continuously employed by, or be otherwise continuously providing services to, the Company through the end of the vesting period, and in order for the performance vesting condition to be satisfied for each vesting period, the performance criteria designated by the Compensation Committee must be satisfied. The initial performance vesting condition to be applied to measure performance for the period between  March 15, 2021 and  June 15, 2021 was designated by the Compensation Committee on or before  April 14, 2021, and will apply to all future performance periods unless the Compensation Committee elects to change the performance vesting condition on a prospective basis. Future changes to the performance vesting condition shall be made on or before the fifteenth day of any future performance period. If either vesting condition is not satisfied for a vesting date, then the phantom shares scheduled to vest on such date will be forfeited. These phantom shares are subject to a maximum payment value of $12.00 per phantom share. An additional award with similar vesting conditions for 9,074 phantom shares was granted on  May 14, 2021 to the Company's new non-employee director, while unvested 9,074 phantom shares granted to the Company's departing non-employee director were forfeited on or about the same date.

 

The phantom share awards are accounted for as liabilities in accordance with FASB ASC Topic 718, Compensation - Stock Compensation since they require cash settlement. The grant date of each vesting increment will be established when the Company and the grantees reach a mutual understanding of the key terms and conditions of an award, which is the date upon which each performance vesting condition is communicated to the grantees. Compensation expense is recognized over the requisite service period if it is probable that the performance vesting condition will be achieved. The fair value of the liability incurred is remeasured at the end of each reporting period with any changes in fair value recognized as compensation expense over the requisite service period.

 

Awards totaling 111,652 phantom shares vested during 2021, resulting in compensation expense of $773,000 related to their cash settlement.

 

 

 

10.     STOCKHOLDERS’ EQUITY

 

Authorized Shares

 

The Company is authorized to issue two classes of capital stock consisting of up to 5,000,000 shares of preferred stock, $0.001 par value, and 50,000,000 shares of common stock, $0.001 par value.

 

Dividends

 

The Company declared and paid cash dividends of $0.20 per common share during each quarter of 2021 and 2020, totaling an aggregate of $9.1 million each year. Declaration and payment of any future dividends on shares of common stock will be at the sole discretion of the Company’s Board of Directors.

 

Stock Repurchases

 

On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Any repurchases will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. As of December 31, 2021, $21.9 million of the $70.0 million stock repurchase program remained available for future purchases, inclusive of related estimated income tax.

 

Accumulated Other Comprehensive Loss

 

The changes in accumulated other comprehensive loss by component for 2021 were as follows (in thousands):

 

  

Foreign Currency Translation Adjustments

  

Unrealized Losses on Available-For-Sale Investments

  

Total

 

Balance, December 31, 2020

 $(325) $(11) $(336)

Other comprehensive loss

  (149)  (7)  (156)

Balance, December 31, 2021

 $(474) $(18) $(492)

 

52

  
 

11.     RELATED PARTY TRANSACTIONS

 

The Company is a party to a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called ReStor™. George K. Broady, a former director of the Company and beneficial owner of more than 5% of its outstanding common stock, is an indirect owner of BHS. Brunde E. Broady, a director of the Company and daughter of Mr. Broady, is the President and Chief Executive Officer of BHS. Under this agreement (as amended), the Company agreed to pay BHS a royalty based on a price per unit in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide by or through multi-level marketing or network marketing. The Company recognized royalties of $60,000 and $83,000 during 2021 and 2020, respectively, under this agreement.  The Company is not required to purchase any product under the agreement, and the agreement may be terminated under certain circumstances with no notice. The agreement terminates March 31, 2025, after which it shall be automatically renewed for successive one-year terms unless notice is given by either party at least 90 days in advance of the expiration of the then-current term.

 

 

12.     EMPLOYEE BENEFIT PLANS

 

The Company has a 401(k) defined contribution plan which permits participating employees in the United States to defer up to a maximum of 90% of their compensation, subject to limitations established by the Internal Revenue Service. Employees age 21 and older are eligible to contribute to the plan starting the first day of the month following the date of employment.  Participating employees are eligible to receive discretionary matching contributions and profit sharing, subject to certain conditions, from the Company.  In 2021 and 2020, the Company matched employee deferral contributions up to 4.5% of salary, which vested 100% immediately. No profit sharing has been paid under the plan. The Company recorded compensation expense of $69,000 and $68,000 for 2021 and 2020, respectively, related to its matching contributions to the plan. Certain of the Company’s employees located outside the United States participate in employee benefit plans that are statutory in nature.

 

 

13.    SEGMENT INFORMATION

 

The Company sells products to a member network that operates in a seamless manner from market to market, except for the China market where it sells to some consumers through an e-commerce retail platform, and the Russia and Kazakhstan market where the Company’s engagement of a third-party service provider results in a different economic structure than its other markets. Otherwise, the Company believes that all of its other operating segments have similar economic characteristics and are similar in the nature of the products sold, the product acquisition process, the types of customers products are sold to, the methods used to distribute the products, and the nature of the regulatory environment. Therefore, the Company aggregates its other operating segments (including its Hong Kong operating segment) into a single reporting segment (the “Primary Reporting Segment”).

 

The Company reviews its net sales and operating income (loss) by operating segment, and reviews its assets and capital expenditures on a consolidated basis and not by operating segment. As such, net sales and operating income (loss) are presented by reportable segment and assets and capital expenditures by operating segment are not presented. Segment operating income is adjusted for certain direct costs and commission allocation.

 

53

 

The Company’s operating information by geographic area are as follows (in thousands):

 

  

Year Ended December 31,

 
  

2021

  

2020

 

Net sales:

        

Primary Reporting Segment

 $56,914  $58,243 

China

  2,237   2,940 

Russia and Kazakhstan

  854   888 

Total net sales

 $60,005  $62,071 
         

Income (loss) from operations:

        

Primary Reporting Segment

 $10,366  $9,277 

China

  74   330 

Russia and Kazakhstan

  (146)  (96)

Income from operations for reportable segments, net

  10,294   9,511 

Unallocated corporate expenses

  (8,723)  (8,842)

Other income (expense), net

  (61)  821 

Income before income taxes

 $1,510  $1,490 

 

The Company’s net sales by geographic area are as follows (in thousands):

 

  

Year Ended December 31,

 
  

2021

  

2020

 

Net sales from external customers:

        

United States

 $1,278  $1,573 

Canada

  724   765 

Peru

  2,281   1,453 

Hong Kong1

  46,699   49,169 

China

  2,237   2,940 

Taiwan

  2,706   3,034 

Russia and Kazakhstan

  854   888 

Europe

  1,136   1,050 

Other foreign countries

  2,090   1,199 

Total net sales

 $60,005  $62,071 

 


1 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors.”

 

The Company’s net sales by product and service are as follows (in thousands):

 

  

Year Ended December 31,

 
  

2021

  

2020

 

Net sales by product and service:

        

Product sales

 $54,056  $55,840 

Administrative fees, freight and other

  6,340   6,991 

Less: sales returns

  (391)  (760)

Total net sales

 $60,005  $62,071 

 

Due to system constraints, it is impracticable for the Company to separately disclose sales by product category for the years presented.

 

54

 

The Company’s long-lived assets by geographic area are as follows (in thousands):

 

  

December 31,

 
  

2021

  

2020

 

Long-lived assets:

        

United States

 $221  $227 

Hong Kong

  105   146 

China

  90   47 

Other foreign countries

  47   119 

Total long-lived assets

 $463  $539 

 

 

14.     SUBSEQUENT EVENT

 

On February 7, 2022, the Board of Directors declared a quarterly cash dividend of $0.20 on each share of common stock outstanding. The dividend will be payable on March 4, 2022 to stockholders of record on February 22, 2022. Declaration and payment of any future dividends on shares of common stock will be at the sole discretion of the Company’s Board of Directors.

 

 

55

 
 

Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

Not applicable.

 

Item 9A. CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

Management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) as of December 31, 2021. Our disclosure controls and procedures are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation and as disclosed in “Management’s Annual Report on Internal Control over Financial Reporting” below, the principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of December 31, 2021.

 

Management’s Annual Report on Internal Control over Financial Reporting

 

Management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed by, or under the supervision of, our principal executive and principal financial officers and effected by our Board of Directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:

 

 

pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;

 

 

provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and

 

 

provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

 

 Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Management evaluates the effectiveness of our internal control over financial reporting by using the criteria established in Internal Control – Integrated Framework (2013), issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).  Based on this criteria, management concluded that our internal control over financial reporting as of December 31, 2021 was effective.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in internal control over financial reporting that occurred during the quarter ended December 31, 2021 that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.

 

Item 9B. OTHER INFORMATION

 

None.

 

Item 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

 

Not applicable.

 

 

Part III 

 

Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 

The information required by this Item is incorporated by reference from the definitive proxy statement to be filed with the SEC within 120 days after December 31, 2021.

 

Item 11. EXECUTIVE COMPENSATION

 

The information required by this Item is incorporated by reference from the definitive proxy statement to be filed with the SEC within 120 days after December 31, 2021.

 

Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

The information required by this Item is incorporated by reference from the definitive proxy statement to be filed with the SEC within 120 days after December 31, 2021.

 

Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 

The information required by this Item is incorporated by reference from the definitive proxy statement to be filed with the SEC within 120 days after December 31, 2021.

 

Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

 

The information required by this Item is incorporated by reference from the definitive proxy statement to be filed with the SEC within 120 days after December 31, 2021.

 

 

 

Part IV

 

Item 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 

Documents filed as part of this Form 10-K:

 

1.

Financial Statements. See Index to Consolidated Financial Statements under “Item 8. Financial Statements and Supplementary Data” of this report.

2.

Financial Statement Schedules. Financial statement schedules have been omitted because they are not required, not applicable, or because the required information is shown in the financial statements or notes thereto.

3.

Exhibits. The exhibits listed on the accompanying Exhibit Index are filed as a part of, and are incorporated by reference into, this report. We will furnish any of the exhibits referenced in the accompanying Exhibit Index to a requesting shareholder upon payment of a fee equal to our reasonable expenses in furnishing such exhibit(s).

 

EXHIBIT INDEX

 

Exhibit

Number

 

 

Exhibit Description

3.1

 

Certificate of Incorporation of Natural Health Trends Corp. dated March 21, 2005, and Certificate of Amendment to the Certificate of Incorporation dated May 15, 2020 (incorporated by reference to Exhibit 3.1 to Quarterly Report on Form 10-Q filed on August 5, 2020).

3.2

 

Second Amended and Restated Bylaws of Natural Health Trends Corp. effective February 6, 2020 (incorporated by reference to Exhibit 3.2 to Annual Report on Form 10-K filed on March 9, 2020).

4.1

 

Specimen Certificate for shares of common stock, $.001 par value per share, of Natural Health Trends Corp. (incorporated by reference to Exhibit 4.01 to Annual Report on Form 10-K filed on May 8, 2006).

4.2

 

Description of Securities (incorporated by reference to Exhibit 4.2 to Annual Report on Form 10-K filed on March 9, 2020).

+10.1

 

Natural Health Trends Corp. 2016 Equity Incentive Plan (incorporated by reference to Appendix C to Definitive Proxy Statement filed on March 4, 2016).

+10.2

 

First Amendment to the Natural Health Trends Corp. 2016 Equity Incentive Plan dated October 10, 2019 (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed October 11, 2019).

+10.3

 

Form of Restricted Stock Award Agreement under the 2016 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to Annual Report on Form 10-K filed March 4, 2016).

+10.4

 

Form of Restricted Stock Award Agreement under the 2016 Equity Incentive Plan (Exempt Award to “U.S. Person” Under Regulation D) (incorporated by reference to Exhibit 10.4 to Annual Report on Form 10-K filed on March 9, 2020).

+10.5

 

Form of Restricted Stock Award Agreement under the 2016 Equity Incentive Plan (Exempt Award to “Non-U.S. Person” Under Regulation S) (incorporated by reference to Exhibit 10.5 to Annual Report on Form 10-K filed on March 9, 2020).

+10.6

 

Natural Health Trends Corp. Annual Incentive Plan (Restated as of January 1, 2016) (incorporated by reference to Appendix A to Definitive Proxy Statement filed on March 4, 2016).

+10.7

 

Natural Health Trends Corp. 2014 Long-Term Incentive Plan (Restated as of January 1, 2016) (incorporated by reference to Appendix B to Definitive Proxy Statement filed on March 4, 2016).

+10.8

 

First Amendment to the Natural Health Trends Corp. 2014 Long-Term Incentive Plan (Restated as of January 1, 2016) (incorporated by reference to Exhibit 10.5 to Annual Report on Form 10-K filed on March 10, 2017).

+10.9

 

Second Amendment to the Natural Health Trends Corp. 2014 Long-Term Incentive Plan (Restated as of January 1, 2016) dated August 9, 2019 (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed August 13, 2019).

+10.10   Natural Health Trends Corp. Phantom Equity Plan (incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q filed on May 5, 2021).
+10.11   Form of Phantom Share Agreement under the Phantom Equity Plan (incorporated by reference to Exhibit 10.2 to Quarterly Report on Form 10-Q filed on May 5, 2021).

+10.12

 

Employment Agreement (including form of Non-Competition and Proprietary Rights Assignment Agreement) for Chris T. Sharng, dated April 23, 2007 (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed on April 26, 2007).

+10.13

 

Employment Agreement (including form of Non-Competition and Proprietary Rights Assignment Agreement) for Timothy S. Davidson dated April 23, 2007 (incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed on April 26, 2007).

+10.14

 

Form of Indemnification Agreement dated February 11, 2015, between Natural Health Trends Corp. and each of its directors and executive officers (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed on February 12, 2015).

21.1

 

Subsidiaries of Natural Health Trends Corp. (filed herewith).

24.1

 

Power of Attorney (see signature page).

31.1

 

Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).

31.2

 

Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).

32.1

 

Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith).

 

 

 

101.INS

 

Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

101.SCH

 

Inline XBRL Taxonomy Extension Schema

101.CAL   Inline XBRL Taxonomy Extension Calculation
101.DEF   Inline XBRL Taxonomy Extension Definition
101.LAB   Inline XBRL Taxonomy Extension Labels
101.PRE   Inline XBRL Taxonomy Extension Presentation
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
     
    + Management contract or compensatory plan

 

Item 16. FORM 10-K SUMMARY

 

None.

 

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.

  

 

NATURAL HEALTH TRENDS CORP.

 

 

 

Date: February 25, 2022

/s/ Chris T. Sharng

 

Chris T. Sharng

 

President

 

(Principal Executive Officer)

 

POWER OF ATTORNEY

 

KNOW ALL MEN BY THESE PRESENTS that each of Natural Health Trends Corp., a Delaware corporation, and the undersigned directors and officers of Natural Health Trends Corp., hereby constitutes and appoints Chris T. Sharng and Timothy S. Davidson, or any one of them, its, his or her true and lawful attorney-in-fact and agent, for it, him or her and in its, his or her name, place and stead, in any and all capacities, with full power to act alone, to sign any and all amendments to this report, and to file each such amendment to the report, with all exhibits thereto, and any and all other documents in connection therewith, with the Securities and Exchange Commission, hereby granting unto said attorney-in-fact and agent full power and authority to do and perform any and all acts and things requisite and necessary to be done in and about the premises as fully to all intents and purposes as it, he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Signature

 

Title

 

Date

 

 

 

 

 

/s/ Chris T. Sharng

 

President and Director

 

February 25, 2022

Chris T. Sharng

 

(Principal Executive Officer)

 

 

 

 

 

 

 

/s/ Timothy S. Davidson

 

Senior Vice President and Chief Financial Officer

 

February 25, 2022

Timothy S. Davidson

 

(Principal Financial and Accounting Officer)

 

 

 

 

 

 

 

/s/ Randall A. Mason

 

Chairman of the Board and Director

 

February 25, 2022

Randall A. Mason

 

 

 

 

 

 

 

 

 

/s/ Brunde E. Broady

 

Director

 

February 25, 2022

Brunde E. Broady

 

 

 

 

 

 

 

 

 

/s/ Yiu T. Chan

 

Director

 

February 25, 2022

Yiu T. Chan

 

 

 

 

 

 

 

 

 

/s/ Ching C. Wong

 

Director

 

February 25, 2022

Ching C. Wong

 

 

 

 

 

 

59
EX-21.1 2 ex_291461.htm EXHIBIT 21.1 ex_291461.htm

Exhibit 21.1

  

SUBSIDIARIES OF THE REGISTRANT

AS OF December 31, 2021

 

NATURAL HEALTH TRENDS CORP.

A DELAWARE CORPORATION

 

 

Name

 

Jurisdiction

 

 

 

NHT Global, Inc.

 

United States (Delaware)

NHTC International, LLC

 

United States (Delaware)

NHT Global (Canada) Company 

 

Canada

NHTC Holding Company

 

Cayman Islands

NHTC Trading Company

 

Cayman Islands

NHT Global Taiwan Company

 

Cayman Islands

NHT Global CIS Company

 

Cayman Islands

NHT Global (China) Commodities Co., Ltd.

 

China

NHT Global (Zhongshan) Cosmetics Co., Ltd.

 

China

NHT Global Hong Kong Limited

 

Hong Kong

Natural Health Trends Japan, Inc.

 

Japan

NHTC Global Singapore Pte. Ltd.

 

Singapore

NHTC Wellness Products Malaysia Sdn. Bhd.

 

Malaysia

NHTK Ltd.

 

South Korea

NHT Global Europe S.R.L.

 

Italy

NHT Global Peru S.A.C.

 

Peru

Natural Health Trends (Thailand) Ltd.

 

Thailand

NHT Global Limited Company

 

Vietnam

PT Natural Health Trends Indonesia

 

Indonesia

NHTC (India) Private Limited

 

India

NHTGLOBAL BOLIVIA S.R.L.

 

Bolivia

 

The names of omitted subsidiaries when considered in the aggregate as a single subsidiary do not constitute a significant subsidiary as of the end of the year covered by this report.

 

 

 

 
EX-31.1 3 ex_291462.htm EXHIBIT 31.1 ex_291462.htm

Exhibit 31.1

 

CERTIFICATION

 

I, Chris T. Sharng, certify that:

 

1.     I have reviewed this report on Form 10-K of Natural Health Trends Corp.;

 

2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.      The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)     Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.     The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

 
       

Date: February 25, 2022

 

/s/ Chris T. Sharng

 

 

 

Chris T. Sharng

 

 

 

President

 

 

 

(Principal Executive Officer)

 

 

 

 
EX-31.2 4 ex_291463.htm EXHIBIT 31.2 ex_291463.htm

Exhibit 31.2

 

CERTIFICATION

 

I, Timothy S. Davidson, certify that:

 

1.     I have reviewed this report on Form 10-K of Natural Health Trends Corp.;

 

2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.      The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)     Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.     The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

 
       

Date: February 25, 2022

 

/s/ Timothy S. Davidson

 

 

 

Timothy S. Davidson

 

 

 

Senior Vice President and Chief Financial Officer

 

 

 

(Principal Financial Officer)

 

 

 

 
EX-32.1 5 ex_291464.htm EXHIBIT 32.1 ex_291464.htm

Exhibit 32.1

 

 

CERTIFICATIONS PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Natural Health Trends Corp. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Chris T. Sharng, the Principal Executive Officer, and Timothy S. Davidson, the Principal Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:

 

1.        The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.        The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

  

 
       

Date: February 25, 2022

 

/s/ Chris T. Sharng

 

 

 

Chris T. Sharng

 

 

 

President

 

 

 

(Principal Executive Officer)

 

 

 

 
       

Date: February 25, 2022

 

/s/ Timothy S. Davidson

 

 

 

Timothy S. Davidson

 

 

 

Senior Vice President and Chief Financial Officer

 

 

 

(Principal Financial Officer)

 

  

The foregoing certifications are not deemed filed with the United States Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (Exchange Act), and are not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. 

 

 
EX-101.SCH 6 nhtc-20211231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Consolidated Balance Sheets link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Consolidated Balance Sheets (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Consolidated Statements of Operations link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Consolidated Statements of Comprehensive Income link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Consolidated Statements of Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Consolidated Statements of Stockholders' Equity (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 007 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 1 - Nature of Operations and Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 2 - Revenue link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 3 - Net Income Per Common Share link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 4 - Balance Sheet Components link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 5 - Fair Value Measurements link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 6 - Leases link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 7 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 8 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 9 - Stock-based Incentive Plans link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 10 - Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 11 - Related Party Transactions link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 12 - Employee Benefit Plans link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 13 - Segment Information link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 14 - Subsequent Event link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 3 - Net Income Per Common Share (Tables) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 4 - Balance Sheet Components (Tables) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 5 - Fair Value Measurements (Tables) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 6 - Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 7 - Income Taxes (Tables) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 9 - Stock-based Incentive Plans (Tables) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 10 - Stockholders' Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 13 - Segment Information (Tables) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 1 - Nature of Operations and Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 2 - Revenue (Details Textual) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 3 - Net Income Per Common Share - Basic and Diluted Net Income (Loss) Per Share (Details) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 4 - Balance Sheet Components (Details Textual) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 4 - Balance Sheet Components - Summary of Balance Sheet Amounts (Details) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 5 - Fair Value Measurements - Investments (Details) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 6 - Leases (Details Textual) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 6 - Leases - Lease Cost (Details) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 6 - Leases - Maturity of Lease Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 7 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 7 - Income Taxes - Components of Income (Loss) Before Income Taxes (Details) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note 7 - Income Taxes - Components of Income Tax Provision (Benefit) (Details) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note 7 - Income Taxes - Reconciliation of Reported Income Tax Provision (Details) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note 7 - Income Taxes - Foreign Rate Differentials (Details) link:calculationLink link:definitionLink link:presentationLink 045 - Disclosure - Note 7 - Income Taxes - Deferred Income Taxes (Details) link:calculationLink link:definitionLink link:presentationLink 046 - Disclosure - Note 9 - Stock-based Incentive Plans (Details Textual) link:calculationLink link:definitionLink link:presentationLink 047 - Disclosure - Note 9 - Stock-based Incentive Plans - Restricted Stock Activity (Details) link:calculationLink link:definitionLink link:presentationLink 048 - Disclosure - Note 10 - Stockholders' Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 049 - Disclosure - Note 10 - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details) link:calculationLink link:definitionLink link:presentationLink 050 - Disclosure - Note 11 - Related Party Transactions (Details Textual) link:calculationLink link:definitionLink link:presentationLink 051 - Disclosure - Note 12 - Employee Benefit Plans (Details Textual) link:calculationLink link:definitionLink link:presentationLink 052 - Disclosure - Note 13 - Segment Information - Operating Information by Geographic Area (Details) link:calculationLink link:definitionLink link:presentationLink 053 - Disclosure - Note 13 - Segment Information - Net Sales by Geographic Area (Details) link:calculationLink link:definitionLink link:presentationLink 054 - Disclosure - Note 13 - Segment Information - Net Sales by Product and Service (Details) link:calculationLink link:definitionLink link:presentationLink 055 - Disclosure - Note 13 - Segment Information - Long-lived Assets (Details) link:calculationLink link:definitionLink link:presentationLink 056 - Disclosure - Note 14 - Subsequent Event (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 7 nhtc-20211231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 nhtc-20211231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 nhtc-20211231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Note To Financial Statement Details Textual Significant Accounting Policies Note 3 - Net Income Per Common Share Income tax at federal statutory rate Note 4 - Balance Sheet Components Note 5 - Fair Value Measurements Note 6 - Leases Note 7 - Income Taxes Note 9 - Stock-based Incentive Plans Note 10 - Stockholders' Equity Note 13 - Segment Information Income Tax Disclosure [Text Block] Note 3 - Net Income Per Common Share - Basic and Diluted Net Income (Loss) Per Share (Details) Note 4 - Balance Sheet Components - Summary of Balance Sheet Amounts (Details) Unrealized gains (losses) on available-for-sale securities Note 5 - Fair Value Measurements - Investments (Details) Note 6 - Leases - Lease Cost (Details) Note 6 - Leases - Maturity of Lease Liabilities (Details) us-gaap_LiabilitiesCurrent Total current liabilities Note 7 - Income Taxes - Components of Income (Loss) Before Income Taxes (Details) Note 7 - Income Taxes - Components of Income Tax Provision (Benefit) (Details) Note 7 - Income Taxes - Reconciliation of Reported Income Tax Provision (Details) Note 7 - Income Taxes - Foreign Rate Differentials (Details) Other current liabilities Note 7 - Income Taxes - Deferred Income Taxes (Details) Note 9 - Stock-based Incentive Plans - Restricted Stock Activity (Details) Note 10 - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details) Note 13 - Segment Information - Operating Information by Geographic Area (Details) Note 13 - Segment Information - Net Sales by Geographic Area (Details) Note 13 - Segment Information - Net Sales by Product and Service (Details) Note 13 - Segment Information - Long-lived Assets (Details) Notes To Financial Statements Notes To Financial Statements [Abstract] Vested, wtd. avg. price (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Balance, weighted avg. price (in dollars per share) Balance, weighted avg. price (in dollars per share) Foreign currency translation adjustments Foreign currency translation adjustments us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Balance (in shares) Balance (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) Vested (in shares) Corporate Debt Securities [Member] Nonvested Restricted Stock Shares Activity [Table Text Block] Deferred revenue us-gaap_AccruedLiabilitiesCurrent Accrued Liabilities, Current, Total Income taxes payable Lessee, Operating Leases [Text Block] Accounts payable Employee-related expense Other accrued expenses us-gaap_PolicyTextBlockAbstract Accounting Policies Accrued commissions us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchases of property and equipment Non-vested restricted stock (in shares) SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month) Cash paid (refunded) for income taxes, net Product and Service, Other [Member] The Phantom Plan [Member] Information pertaining to the phantom plan. Current liabilities: Supplemental Balance Sheet Disclosures [Text Block] Phantom Shares [Member] Information pertaining to phantom shares. Product [Member] us-gaap_Assets Total assets Plan Name [Axis] Plan Name [Domain] Employees and Non-Employee Directors [Member] Information pertaining to employees and non-employee directors. Property and equipment: Net income available to common stockholders Net income available to common stockholders plus assumed conversions Non-vested restricted stock Deferred tax asset Share-based Payment Arrangement [Text Block] nhtc_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPaymentPerShare Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Maximum Payment Per Share (in dollars per share) Represents the maximum payment value per share of equity instruments other than options under share based compensation arrangement. Business Description and Basis of Presentation [Text Block] Award Type [Domain] us-gaap_RestrictedCashAndCashEquivalents Restricted Cash and Cash Equivalents, Total Award Type [Axis] Net income Net income Restricted Stock [Member] Office software Commitments and Contingencies Disclosure [Text Block] us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated depreciation and amortization Property and equipment, net Property, Plant and Equipment, Net, Ending Balance Bank Time Deposits [Member] us-gaap_PropertyPlantAndEquipmentGross Property and equipment, at cost Machinery Furniture and fixtures Construction in progress Leasehold improvements us-gaap_Dividends Dividends declared CASH FLOWS FROM INVESTING ACTIVITIES: Fair value Fair value Earnings Per Share [Text Block] Income taxes payable us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable Intersegment Eliminations [Member] CANADA Related Party Transactions Disclosure [Text Block] us-gaap_IncreaseDecreaseInAccruedLiabilities Other accrued expenses Income tax provision Income tax provision CHINA us-gaap_IncreaseDecreaseInAccountsPayable Accounts payable us-gaap_OperatingExpenses Total operating expenses us-gaap_DefinedContributionPlanCostRecognized Defined Contribution Plan, Cost us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch Defined Contribution Plan, Employer Matching Contribution, Percent of Match Cash Cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Ending Balance Cash and Cash Equivalents, at Carrying Value, Ending Balance us-gaap_IncreaseDecreaseInOtherCurrentLiabilities Other current liabilities UNITED KINGDOM us-gaap_AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense us-gaap_RoyaltyExpense Royalty Expense Amendment Flag Auditor Name Auditor Location Auditor Firm ID ICFR Auditor Attestation Flag HONG KONG Other comprehensive income (loss), net of tax: us-gaap_ComprehensiveIncomeNetOfTax Comprehensive income City Area Code Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] us-gaap_IncreaseDecreaseInContractWithCustomerLiability Increase (Decrease) in Contract with Customer, Liability us-gaap_SharesOutstanding BALANCE (in shares) BALANCE (in shares) Preferred stock, outstanding (in shares) Current Fiscal Year End Date us-gaap_LeaseCost Total lease cost Weighted-average discount rate Document Fiscal Period Focus Operating leases Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] Short-term leases Lease, Cost [Table Text Block] Document Period End Date Right-of-use assets obtained in exchange for operating lease liabilities KOREA, DEMOCRATIC PEOPLE'S REPUBLIC OF Weighted-average remaining lease term (in years) (Year) Entity File Number Entity Emerging Growth Company Document Type Entity Small Business Entity Shell Company Document Information [Line Items] Document Information [Table] Entity Public Float Entity Filer Category Entity Current Reporting Status Entity Voluntary Filers us-gaap_DividendsCommonStock Dividends, Common Stock, Total Entity Well-known Seasoned Issuer us-gaap_ConcentrationRiskPercentage1 Concentration Risk, Percentage Statement of Comprehensive Income [Abstract] Entity Tax Identification Number Entity Central Index Key us-gaap_DepreciationAndAmortization Depreciation, Depletion and Amortization, Nonproduction, Total Administrative Fees, Freight and Other [Member] Information related to administrative fees, freight and other. Entity Registrant Name Entity [Domain] Legal Entity [Axis] Entity Address, Address Line One Entity Address, City or Town Geographic Concentration Risk [Member] Entity Address, Country Concentration Risk Type [Axis] Concentration Risk Type [Domain] us-gaap_TreasuryStockValue Treasury stock, at cost; 1,556,875 shares at December 31, 2021 and 2020 PERU Entity Common Stock, Shares Outstanding Municipal Bonds [Member] us-gaap_IncreaseDecreaseInOtherCurrentAssets Other current assets us-gaap_IncreaseDecreaseInOtherNoncurrentAssets Other assets Investments [Domain] Revenue from Contract with Customer Benchmark [Member] us-gaap_IncreaseDecreaseInInventories Inventories Trading Symbol Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Investment Type [Axis] Local Phone Number us-gaap_TableTextBlock Notes Tables Related Party [Axis] Related Party [Domain] us-gaap_AreaOfLand Area of Land (Square Foot) Selling, general and administrative expenses Commissions expense TAIWAN, PROVINCE OF CHINA Total liabilities and stockholders’ equity UNITED STATES Related Party Transaction [Axis] Related Party Transaction [Domain] Retained earnings (accumulated deficit) VIET NAM Accumulated other comprehensive loss Money Market Funds [Member] Changes in assets and liabilities: Cash and cash equivalents: us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Commissions, Policy [Policy Text Block] Subsequent Event [Member] us-gaap_OperatingLeaseLiabilityNoncurrent Operating lease liabilities Restricted cash Present value of lease liabilities Subsequent Event Type [Axis] Operating lease liabilities us-gaap_ForeignCurrencyTransactionGainLossUnrealized Foreign Currency Transaction Gain (Loss), Unrealized Subsequent Event Type [Domain] Retirement Benefits [Text Block] Subsequent Events [Text Block] Operating lease right-of-use assets us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Total lease payments us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Less: imputed interest us-gaap_DeferredIncomeTaxExpenseBenefit Total deferred taxes 2024 2025 2026 Thereafter Fair Value of Financial Instruments, Policy [Policy Text Block] 2022 Debt Securities, Available-for-sale [Table Text Block] 2023 Foreign Currency Transactions and Translations Policy [Policy Text Block] Lessee, Operating Lease, Liability, Maturity [Table Text Block] Other assets Earnings Per Share, Policy [Policy Text Block] Operating expenses: us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage Income Tax, Policy [Policy Text Block] us-gaap_LesseeOperatingLeaseRenewalTerm Lessee, Operating Lease, Renewal Term (Year) Depreciation and amortization Office Equipment, Office Software and Capitalized Internal-use Software Development [Member] Represents office equipment, office software and capitalized internal-use software development. us-gaap_AssetsCurrent Total current assets nhtc_CashAndCashEquivalentsPeriodToReceiveCashProceedsFromCreditCardProcessors Cash and Cash Equivalents, Period to Receive Cash Proceeds From Credit Card Processors (Day) Represents period to receive cash proceeds from credit card processors for cash and cash equivalents. us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Total nhtc_RestrictedCashCollateralRequirementPercentage Restricted Cash, Collateral Requirement Percentage Represents collateral requirement percentage of restricted cash. Stockholders' Equity Note Disclosure [Text Block] Amounts Held in Distributor EWallets [Policy Text Block] Represents the policy of amounts held in customer eWallets. us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Noncurrent Treasury stock, shares (in shares) Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at December 31, 2021 and 2020 Office equipment Represents other equipment. Adjustments to reconcile net income to net cash provided by operating activities: Common stock, authorized (in shares) Common Stock, Shares Authorized (in shares) Common stock, issued (in shares) Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share (in dollars per share) Effect of permanent differences Effect of permanent differences. us-gaap_DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance, Total Valuation allowance Statistical Measurement [Domain] us-gaap_OperatingLeasePayments Operating Lease, Payments Maximum [Member] Net operating loss carryback The amount of income tax expense or benefit for the period computed by applying the net operating loss carryforward. Minimum [Member] Global Intangible Low-Taxed Income Amount of Tax Cuts and Jobs Act for Global Intangible Low-tax Income for effective income tax rate reconciliation. Product and Service [Axis] Other current assets Product and Service [Domain] us-gaap_DeferredTaxAssetsNet Net deferred tax assets Statistical Measurement [Axis] Income Tax Foreign Rate Differential [Table Text Block] Tabular disclosure of income tax foreign rate differential. Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding us-gaap_DeferredTaxAssetsLiabilitiesNet Net deferred tax assets Department for International Tax Cooperation [Member] Represents Department for International Tax Cooperation. Preferred stock, issued (in shares) Total long-lived assets Geographical [Axis] Geographical [Domain] Operating lease liabilities nhtc_DeferredTaxAssetsOperatingLeaseLiabilities Represents operating lease liabilities for deferred tax assets. us-gaap_DeferredTaxAssetsGross Total deferred tax assets Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized (in shares) us-gaap_DeferredIncomeTaxLiabilities Total deferred tax liabilities Europe [Member] Inventories Inventory, Net, Total Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share (in dollars per share) Raw materials us-gaap_InventoryValuationReserves Reserve for obsolescence Finished goods Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value Hierarchy and NAV [Axis] nhtc_AgeRequirementFor401kContributions Age Requirement For 401K Contributions (Year) Represents age requirement for 401 K contributions. Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Other us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities nhtc_ContractWithCustomerRefundLiabilitySalesReturns Less: sales returns Represents sales returns for refund liability for contract with customer. Inventories: us-gaap_PropertyPlantAndEquipmentUsefulLife Property, Plant and Equipment, Useful Life (Year) Deferred revenue us-gaap_IncreaseDecreaseInDeferredRevenue CASH FLOWS FROM OPERATING ACTIVITIES: Schedule of Segment Reporting Information, by Segment [Table Text Block] Statement [Line Items] Furniture and Fixtures [Member] AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] Stock-based compensation us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Additional paid-in capital Accumulated Foreign Currency Adjustment Attributable to Parent [Member] AOCI Attributable to Parent [Member] Stockholders’ equity: Property, Plant and Equipment, Policy [Policy Text Block] Other income (expense), net Long-Lived Tangible Asset [Axis] Segment Reporting Disclosure [Text Block] Long-Lived Tangible Asset [Domain] Net operating losses Amounts held in eWallets Amount liability recognized from cost incurred to obtain or fulfill contract with customer; classified as current. Current assets: Fair Value Disclosures [Text Block] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance Deferred tax assets: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period Inventory, Policy [Policy Text Block] Effect of exchange rates on cash, cash equivalents and restricted cash us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net decrease in cash, cash equivalents and restricted cash us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash used in financing activities us-gaap_Liabilities Total liabilities Commitments and contingencies (Note 8) Director [Member] Noncash lease expense Represents the amount of lessee's noncash lease expense during the period. Deferred income taxes Represents the amount of deferred income tax expense (benefit), excluding effects of foreign exchange. us-gaap_OperatingIncomeLoss Income from operations Income (loss) from operations us-gaap_ContractWithCustomerLiabilityRevenueRecognized Contract with Customer, Liability, Revenue Recognized us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash provided by operating activities Other us-gaap_DeferredTaxLiabilitiesOther us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities nhtc_RevenueFromContractWithCustomersHistoricalSalesReturnsPercent Revenue from Contract with Customers, Historical Sales Returns, Percent Represents the percentage of historical sales returns. nhtc_RevenueFromContractWithCustomersSalesReturnsPercent Revenue from Contract with Customers, Sales Returns, Percent Represents the percentage of sales returns. us-gaap_GrossProfit Gross profit nhtc_IncreaseDecreaseInAccruedSalesCommissions Accrued commissions Amount of increase (decrease) in accrued sales commissions. Cost of sales nhtc_IncreaseDecreaseInOperatingLeaseLiabilities Operating lease liabilities Amount of increase (decrease) in operating lease liabilities. nhtc_IncreaseDecreaseInCapitalizedContractCostLiability Amounts held in eWallets Amount of increase (decrease) in capitalized contract cost liability. nhtc_RevenueFromContractWithCustomerSalesReturnsPolicyTerm Revenue from Contract with Customer, Sales Returns Policy Term (Day) Represents the sales returns policy term. Deferred tax liability Consolidation Items [Domain] Operating lease assets us-gaap_DeferredTaxLiabilitiesLeasingArrangements Consolidation Items [Axis] us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings Foreign deferreds Concentration Risk, Credit Risk, Policy [Policy Text Block] Prepaids us-gaap_DeferredTaxLiabilitiesPrepaidExpenses us-gaap_PaymentsOfDividends Dividends paid Deferred tax liabilities: Unshipped Product [Member] Information pertaining to unshipped product. Auto ship advances [Member] Information pertaining to auto ship advances. Sales returns Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales returns. Schedule of Additional Balance Sheet Components [Table Text Block] Tabular disclosure of additional balance sheet components. Warehousing, inventory-related and other Carrying value as of the balance sheet date of obligations incurred through that date and payable for warehousing and inventory related expense. Retained Earnings [Member] Net sales Title of Individual [Domain] State Title of Individual [Axis] State us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit Treasury Stock [Member] us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 Stock Repurchase Program, Remaining Authorized Repurchase Amount us-gaap_CurrentForeignTaxExpenseBenefit Foreign Foreign us-gaap_DeferredForeignIncomeTaxExpenseBenefit Additional Paid-in Capital [Member] Federal Common Stock [Member] us-gaap_StockRepurchaseProgramAuthorizedAmount1 Stock Repurchase Program, Authorized Amount Federal us-gaap_DeferredFederalIncomeTaxExpenseBenefit Preferred Stock [Member] Equity Components [Axis] Equity Component [Domain] Current taxes: us-gaap_CurrentIncomeTaxExpenseBenefit Total current taxes nhtc_LesseeNumberOfBranches Lessee, Number of Branches Represents the lessees' number of branches. Rolling Hills Estates [Member] Information pertaining to Rolling Hills Estates. Foreign Richmond, British Columbia [Member] Information pertaining to Richmond, British Columbia. Metuchen, New Jersey [Member] Information pertaining to Metuchen, New Jersey. Income before income taxes Income before income taxes State Administration of Taxation, China [Member] Domestic nhtc_OperatingLossCarryforwardsSubjectToExpiration Operating Loss Carryforwards, Subject to Expiration Amount of operating loss carryforward subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws. Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] nhtc_CommonStockPercentageOfBeneficialStockOutstanding Common Stock, Percentage of Beneficial Stock Outstanding Represents the percentage of beneficial stock outstanding. Inland Revenue, Hong Kong [Member] BHS [Member] Information pertaining to BHS. State and Local Jurisdiction [Member] Equity Incentive Plan 2016 [Member] Information pertaining to the 2016 Equity Incentive Plan. Income Tax Authority, Name [Axis] Income Tax Authority, Name [Domain] Income Tax Authority [Axis] Income Tax Authority [Domain] Domestic Tax Authority [Member] Foreign Tax Authority [Member] Royalty Agreement and License [Member] Information pertaining to the Royalty Agreement and License. nhtc_RelatedPartyTransactionAutomaticRenewalPeriodOfAgreement Related Party Transaction, Automatic Renewal Period of Agreement (Year) Represents the automatic renewal period of the agreement in related party transaction. Revenue from Contract with Customer [Text Block] nhtc_NumberOfDaysTerminationNotice Number of Days Termination Notice (Day) Represents the number of days for termination notice. Document Annual Report Primary Reporting Segment [Member] Information pertaining to the primary reporting segment. Russia and Kazakhstan [Member] Information pertaining to Russia and Kazakhstan. Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Entity Incorporation, State or Country Code Accounting Policies [Abstract] Document Transition Report Basis of Accounting, Policy [Policy Text Block] Other Foreign Countries [Member] Information pertaining to other foreign countries. Selling, General and Administrative Expenses [Member] Entity Interactive Data Current Dividends declared, per share (in dollars per share) Common Stock, Dividends, Per Share, Declared (in dollars per share) Security Exchange Name Title of 12(b) Security Income Statement Location [Axis] Income Statement Location [Domain] NewNonEmployeeDirectorsMember Other accrued expenses: Segments [Axis] Segments [Domain] Weighted-average number of common shares outstanding: Diluted (in shares) us-gaap_OperatingLossCarryforwards Operating Loss Carryforwards, Total Net income per common share: Statement [Table] Statement of Financial Position [Abstract] Diluted (in dollars per share) Basic (in shares) Basic (in dollars per share) Deferred revenue: Statement of Cash Flows [Abstract] Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block] Statement of Stockholders' Equity [Abstract] Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block] Other comprehensive loss Income Statement [Abstract] Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] CASH FLOWS FROM FINANCING ACTIVITIES: Other reconciling items Statutory Tax Rate Change in valuation allowance Foreign tax credits us-gaap_StockholdersEquity Total stockholders’ equity Balance Balance us-gaap_AccruedIncomeTaxesNoncurrent Income taxes payable Class of Stock [Axis] Stock-based compensation Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Gross unrealized losses Operating Segments [Member] Adjusted cost Foreign rate differential EX-101.PRE 10 nhtc-20211231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Document And Entity Information - USD ($)
12 Months Ended
Dec. 31, 2021
Feb. 22, 2022
Jun. 30, 2021
Document Information [Line Items]      
Entity Central Index Key 0000912061    
Entity Registrant Name Natural Health Trends Corp.    
Amendment Flag false    
Current Fiscal Year End Date --12-31    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2021    
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2021    
Document Transition Report false    
Entity File Number 001-36849    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 59-2705336    
Entity Address, Address Line One 132 Nathan Road    
Entity Address, City or Town Tsimshatsui    
Entity Address, Country HK    
City Area Code 852    
Local Phone Number 3107-0800    
Title of 12(b) Security Common Stock, par value $0.001 per share    
Trading Symbol NHTC    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 48,628,270
Entity Common Stock, Shares Outstanding   11,422,539  
Auditor Name Marcum LLP    
Auditor Location Los Angeles, CA    
Auditor Firm ID 688    
ICFR Auditor Attestation Flag true    
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 83,843 $ 92,367
Inventories 5,257 3,779
Other current assets 4,369 3,595
Total current assets 93,469 99,741
Property and equipment, net 463 539
Operating lease right-of-use assets 3,021 3,745
Restricted cash 522 525
Deferred tax asset 309 731
Other assets 571 661
Total assets 98,355 105,942
Current liabilities:    
Accounts payable 761 580
Income taxes payable 1,345 1,481
Accrued commissions 3,636 3,496
Other accrued expenses 1,933 1,922
Deferred revenue 8,536 3,091
Amounts held in eWallets 6,341 8,503
Operating lease liabilities 1,239 1,163
Other current liabilities 865 1,270
Total current liabilities 24,656 21,506
Income taxes payable 12,130 13,748
Deferred tax liability 153 216
Operating lease liabilities 1,928 2,775
Total liabilities 38,867 38,245
Commitments and contingencies (Note 8)
Stockholders’ equity:    
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding 0 0
Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at December 31, 2021 and 2020 13 13
Additional paid-in capital 86,102 86,102
Retained earnings (accumulated deficit) (231) 7,822
Accumulated other comprehensive loss (492) (336)
Treasury stock, at cost; 1,556,875 shares at December 31, 2021 and 2020 (25,904) (25,904)
Total stockholders’ equity 59,488 67,697
Total liabilities and stockholders’ equity $ 98,355 $ 105,942
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Balance Sheets (Parentheticals) - $ / shares
Dec. 31, 2021
Dec. 31, 2020
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, authorized (in shares) 5,000,000 5,000,000
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, authorized (in shares) 50,000,000 50,000,000
Common stock, issued (in shares) 12,979,414 12,979,414
Treasury stock, shares (in shares) 1,556,875 1,556,875
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Net sales $ 60,005 $ 62,071
Cost of sales 15,010 16,990
Gross profit 44,995 45,081
Operating expenses:    
Commissions expense 25,578 26,204
Selling, general and administrative expenses 17,846 18,208
Total operating expenses 43,424 44,412
Income from operations 1,571 669
Other income (expense), net (61) 821
Income before income taxes 1,510 1,490
Income tax provision 425 647
Net income $ 1,085 $ 843
Net income per common share:    
Basic (in dollars per share) $ 0.10 $ 0.08
Diluted (in dollars per share) $ 0.09 $ 0.07
Weighted-average number of common shares outstanding:    
Basic (in shares) 11,017 10,630
Diluted (in shares) 11,424 11,424
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Comprehensive Income - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Net income $ 1,085 $ 843
Other comprehensive income (loss), net of tax:    
Foreign currency translation adjustments (149) 920
Unrealized gains (losses) on available-for-sale securities (7) 8
Comprehensive income $ 929 $ 1,771
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Treasury Stock [Member]
Total
BALANCE (in shares) at Dec. 31, 2019 0 12,979,414       (1,556,875)  
Balance at Dec. 31, 2019 $ 0 $ 13 $ 86,102 $ 16,117 $ (1,264) $ (25,904) $ 75,064
Net income 0 0 0 843 0 0 843
Dividends declared 0 0 0 (9,138) 0 0 (9,138)
Foreign currency translation adjustments 0 0 0 0 920 0 920
Unrealized gains (losses) on available-for-sale securities $ 0 $ 0 0 0 8 $ 0 8
BALANCE (in shares) at Dec. 31, 2020 0 12,979,414       (1,556,875)  
Balance at Dec. 31, 2020 $ 0 $ 13 86,102 7,822 (336) $ (25,904) 67,697
Net income 0 0 0 1,085 0 0 1,085
Dividends declared 0 0 0 (9,138) 0 0 (9,138)
Foreign currency translation adjustments 0 0 0 0 (149) 0 (149)
Unrealized gains (losses) on available-for-sale securities $ 0 $ 0 0 0 (7) $ 0 (7)
BALANCE (in shares) at Dec. 31, 2021 0 12,979,414       (1,556,875)  
Balance at Dec. 31, 2021 $ 0 $ 13 $ 86,102 $ (231) $ (492) $ (25,904) $ 59,488
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Stockholders' Equity (Parentheticals) - $ / shares
3 Months Ended
Dec. 31, 2021
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dividends declared, per share (in dollars per share) $ 0.20 $ 0.20 $ 0.20 $ 0.20 $ 0.20 $ 0.20 $ 0.20 $ 0.20
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income $ 1,085 $ 843
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 299 410
Noncash lease expense 1,163 1,532
Deferred income taxes 362 1,339
Changes in assets and liabilities:    
Inventories (1,547) 2,700
Other current assets (803) 2,322
Other assets 68 181
Accounts payable 182 (102)
Income taxes payable (1,753) (311)
Accrued commissions 212 566
Other accrued expenses 20 (471)
Deferred revenue 5,482 (1,433)
Amounts held in eWallets (2,122) (4,491)
Operating lease liabilities (1,237) (1,427)
Other current liabilities (395) 227
Net cash provided by operating activities 1,016 1,885
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of property and equipment (225) (211)
Net cash used in investing activities (225) (211)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Dividends paid (9,138) (9,138)
Net cash used in financing activities (9,138) (9,138)
Effect of exchange rates on cash, cash equivalents and restricted cash (180) 931
Net decrease in cash, cash equivalents and restricted cash (8,527) (6,533)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period 92,892 99,425
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period 84,365 92,892
SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION:    
Cash paid (refunded) for income taxes, net 1,865 (2,097)
Right-of-use assets obtained in exchange for operating lease liabilities $ 472 $ 2,747
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 1 - Nature of Operations and Summary of Significant Accounting Policies
12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Business Description and Basis of Presentation [Text Block]

1.     NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Nature of Operations

 

Natural Health Trends Corp., a Delaware corporation (whether or not including its subsidiaries, the “Company”), is an international direct-selling and e-commerce company. Subsidiaries controlled by the Company sell personal care, wellness, and “quality of life” products under the “NHT Global” brand.

 

The Company’s wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Malaysia, Singapore and Thailand; South Korea; Japan; India; and Europe. The Company also operates in Russia and Kazakhstan through an engagement with a local service provider.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.

 

Use of Estimates

 

The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period.

 

The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates associated with revenue recognition, as well as those used in the determination of liabilities related to sales returns, commissions and income taxes. Various assumptions and other factors prompt the determination of these significant estimates. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. The actual results may differ materially and adversely from the Company’s estimates. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.

 

Cash and Cash Equivalents

 

Cash and cash equivalents include the Company’s investments in money market funds, government and municipal debt securities, and corporate debt securities. The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Debt securities classified as cash equivalents are required to be accounted for in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 320, Investments - Debt and Equity Securities. As such, the Company determined its investments in debt securities held at December 31, 2021 should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income and expense. Realized gains and losses, as well as interest income, are also included in other income and expense. The fair values of securities are based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs.

 

The Company includes credit card receivables due from certain of its credit card processors in its cash and cash equivalents as the cash proceeds are received within two to five days.

 

The Company maintains certain cash balances at several institutions located in the United States, Hong Kong and elsewhere which at times may exceed insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.

 

Restricted Cash

 

In November 2019, the Company funded a bank deposit account in the amount of VND 10 billion ($438,000 and $433,000 at December 31, 2021 and 2020, respectively) for purposes of submitting a direct selling license application in Vietnam. Such deposit is required by Vietnamese law to establish a consumer protection fund for direct selling participants. In January 2022, the Company submitted an application to withdraw the bank deposit since no direct selling license has been successfully obtained to operate in Vietnam.

 

The Company periodically maintains a cash reserve with certain credit card processing companies to provide for potential uncollectible amounts and chargebacks. Those cash reserves held by credit card processing companies located in South Korea are reflected in noncurrent assets since they require the Company to provide 100% collateral before processing transactions, which must be maintained indefinitely.

 

Inventories

 

Inventories are stated at the lower of cost or net realizable value, using the first-in, first-out method. The Company reviews its inventory for obsolescence and any inventory identified as obsolete is reserved or written off. The Company’s determination of obsolescence is based on assumptions about the demand for its products, product expiration dates, estimated future sales, and management’s future plans.

 

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five years for office equipment, office software and capitalized internal-use software development costs and five to seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the assets. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation and amortization expenses are included in the statement of operations as selling, general and administrative expenses. Such expense totaled $299,000 and $410,000 during 2021 and 2020, respectively.

 

The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of these assets is measured by comparison of its carrying amounts to future undiscounted cash flows the assets are expected to generate. If property and equipment are considered to be impaired, the impairment to be recognized equals the amount by which the carrying value of the asset exceeds its fair value.

 

Income Taxes

 

The Company recognizes income taxes under the liability method of accounting for income taxes. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is a result of changes in deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be ultimately realized based on the more likely than not recognition criteria. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has evaluated its tax positions and determined that there are no significant uncertain tax positions for the current year or years prior. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution.  The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense.  Deferred taxes are not provided for state income tax purposes on the portion of undistributed earnings of subsidiaries outside of the United States when these earnings are considered permanently reinvested.

 

Amounts Held in eWallets

 

The Company requires commission payments of certain members in Hong Kong and other markets to be first recorded into an electronic wallet (eWallet) account in lieu of being paid out directly to members. The eWallet functionality allows members to place new product orders utilizing eWallet available balance and/or request commission payout via multiple payment methods. Amounts held in eWallets are reflected on the balance sheet as a current liability.

 

Foreign Currency

 

The functional currency of the Company’s international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates.  The resulting translation adjustments are recorded directly into stockholders' equity.

 

Aggregate transaction gains or losses, including gains or losses related to foreign-denominated cash and cash equivalents and the re-measurement of certain inter-company balances, are included in the statement of operations as other income and expense. Loss on foreign exchange totaling $248,000 and $335,000 was recognized during 2021 and 2020, respectively.

 

Commissions Expense

 

Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.  Each of the Company’s products are designated a specified number of bonus volume points, which is essentially a percentage of the product’s wholesale price.  The Company accrues commissions when earned and as the related revenue is recognized and pays commissions on product sales generally two weeks following the end of the weekly sales period.

 

In some markets, the Company also pays certain bonuses on purchases by up to three generations of personally sponsored members, as well as bonuses on commissions earned by up to seven generations of personally sponsored members. Independent members may also earn incentives based on meeting certain qualifications during a designated incentive period, which may range from several weeks to up to a year.  The Company estimates and accrues all costs associated with the incentives as the members meet the qualification requirements.

 

From time to time the Company makes modifications and enhancements to the Company’s compensation plan to help motivate members, which can have an impact on member commissions. The Company also enters into performance-based agreements for business or market development, which may result in additional compensation to specific members.

 

Net Income Per Common Share

 

Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized, if any, is assumed to be used to repurchase shares.

 

Certain Risks and Concentrations

 

In late 2019 or early 2020 an outbreak of COVID-19 was first identified in China and subsequently spread around the world. On March 11, 2020 the World Health Organization declared the COVID-19 outbreak a global pandemic. The outbreak caused the Chinese government to implement powerful measures to control the virus, such as requiring businesses to close throughout various areas of China and restricting public gatherings and certain travel within the country. The Company has significant business in China and in 2021 generated approximately 78% of its revenue in Hong Kong, substantially all of which was derived from the sale of products to members in China. The Chinese government continues to adjust the restrictive measures that it imposes to control COVID-19 based on then-current local circumstances, as have the governments of the other countries in which the Company operates. The scope and impact of the pandemic and related control measures are uncertain, but the Company has taken steps to adapt some of its marketing programs, such as relying on certain product promotions and webcast training, to overcome the physical restrictions imposed in response to the pandemic. The Company has also canceled or rescheduled a number of in-person member events over the course of the pandemic. The severity of the impact on the Company of the COVID-19 pandemic will depend on future developments, including the duration and spread of the virus, and related control measures, which the Company is unable to accurately predict. Regardless, these disruptions have materially negatively impacted the Company’s financial results throughout 2020 and 2021, and the Company expects that its financial results for the near-term may be adversely affected. These disruptions have also adversely impacted the operations of some of the Company’s third-party logistics providers, and it expects that the future operations of these logistics providers and other third parties with whom it works may be adversely affected by these disruptions. The Company will continue to assess the operational and financial impact of the COVID-19 pandemic.

 

In contrast to the Company’s business in other parts of the world, the Company’s China subsidiary has not implemented a direct sales model in China. The Chinese government permits direct selling only by organizations that have a license and has also adopted anti-pyramid selling and multi-level marketing legislation. The Company previously submitted a preliminary application for a direct selling license in China in August 2015, but in 2019 a Chinese governmental authority recommended that the Company withdraw its application. The Company understands that the governmental authorities recommended that other companies with pending direct selling license applications also withdraw their applications. The Company applied to withdraw its application in November 2019, and the governmental authorities approved the withdrawal of its application shortly thereafter. The Company operates an e-commerce direct selling platform in Hong Kong and recognizes the revenue derived from sales to both Hong Kong and Chinese members as being generated in Hong Kong. Products purchased by members in China are delivered to third parties that act as the importers of record under agreements to pay applicable duties. In addition, through a Chinese entity, the Company sells products in China using an e-commerce retail platform. The Chinese entity operates separately from the Hong Kong entity, and a Chinese member may elect to participate separately or in both.

 

The Company continually evaluates its business in China and Hong Kong for compliance with applicable laws and regulations, including seeking the input of outside professionals and certain Chinese authorities. This process can and has resulted in the identification of certain matters of potential noncompliance. The Company works on a continuing basis to satisfactorily address such matters, however there can be no assurance that adequate steps are taken or that applicable laws and regulations are properly interpreted. Should the government authorities determine that the Company’s activities violate applicable laws and regulations, including China’s direct selling, pyramid selling or multi-level marketing laws and regulations, or should new laws or regulations be adopted, there could be a material adverse effect on the Company’s business, financial condition and results of operations.

 

Although the Company attempts to work closely with both national and local Chinese governmental agencies in conducting its business, the Company’s efforts to comply with national and local laws may be harmed by a rapidly evolving regulatory climate, concerns about activities resembling violations of direct selling, pyramid selling or multi-level marketing legislation, subjective interpretations of laws and regulations, and activities by individual members that may violate laws notwithstanding the Company's policies prohibiting such activities. Any determination that the Company’s operations or activities, or the activities of its individual members or employee sales representatives, or importers of record are not in compliance with applicable laws and regulations could result in the imposition of substantial fines, extended interruptions of business, restrictions on the Company’s future ability to obtain business licenses or expand into new locations, changes to its business model, the termination of required licenses to conduct business, or other actions, any of which could materially harm the Company’s business, financial condition and results of operations.

 

No single market other than Hong Kong had net sales greater than 10% of total sales. Sales are made to the Company’s members and no single customer accounted for 10% or more of its net sales. However, the Company’s business model can result in a concentration of sales to several different members and their network of members. Although no single member accounted for 10% or more of net sales, the loss of a key member or that member’s network could have an adverse effect on the Company’s net sales and financial results.

 

The Company’s Premium Noni Juice, Enhanced Essential Probiotics and Triotein™ products each account for at least 10% of the Company’s total revenue. The Company currently sources each of these products from a single supplier. If demand decreases significantly, government regulation restricts their sale, the Company is unable to adequately source or deliver the products, or the Company ceases offering the products for any reason without suitable replacements, the Company’s business, financial condition and results of operations could be materially and adversely affected.

 

Fair Value of Financial Instruments

 

The carrying amounts of the Company’s financial instruments, including cash and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents.

 

Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.

 

Recent Accounting Pronouncements

 

In June 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost basis and added Topic 326 to the FASB ASC. In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments - Credit Losses.  The amendments to ASU 2019-11 clarify, correct and make improvements to Topic 326.  ASU 2016-13 as well as the updates in ASU 2019-11 are effective for interim and annual periods beginning after December 15, 2022, and early adoption is permitted.  The Company is currently evaluating the impact of this standard on its consolidated financial statements.

 

Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

 

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 2 - Revenue
12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Revenue from Contract with Customer [Text Block]

2. REVENUE

 

Revenue Recognition

 

All revenue is recognized when the performance obligations under a contract, including any product vouchers sold on a stand-alone basis in Hong Kong, are satisfied. Product sales are recognized when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. These contracts are generally short-term in nature.

 

Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience. The reserve is based upon the return policy of each country, which varies from 14 days to one year, and their historical return rates, which range from 1% to 9% of sales. Sales returns were 1% of sales for each of 2021 and 2020No material changes in estimates have been recognized during the periods presented. See Note 4 for additional information.

 

The Company has elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrues for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.

 

Various taxes on the sale of products to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.

 

Deferred Revenue

 

The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product orders and unredeemed product vouchers are considered a contract liability and are recorded as deferred revenue. The increase in deferred revenue from December 31, 2020 to December 31, 2021 is primarily due to $6.5 million of cash received for unshipped product orders and unredeemed product vouchers offset by $1.0 million of revenue recognized during the year ended December 31, 2021 that was included in deferred revenue as of December 31, 2020. See Note 4 for additional information.

Disaggregation of Revenue

The Company sells products to a member network that operates in a seamless manner from market to market, except for the Chinese market where it sells to some consumers through an e-commerce retail platform and the Russia and Kazakhstan market where the Company operates through the engagement of a third-party service provider. See Note 13 for additional information.

 

Arrangements with Multiple Performance Obligations

 

The Company’s contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenues to each performance obligation based on its relative standalone selling price. The Company generally determines standalone selling prices based on the prices charged for individual products to similar customers.

 

Practical Expedients

 

The Company generally expenses sales commissions when incurred because the amortization period would be one year or less. These costs are recorded in commissions expense.

 

The Company does not provide certain disclosures about unsatisfied performance obligations for contracts with an original expected length of one year or less.

 

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 3 - Net Income Per Common Share
12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Earnings Per Share [Text Block]

3.     NET INCOME PER COMMON SHARE

 

The following table illustrates the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data):

 

  

Year Ended December 31,

 
  

2021

  

2020

 
  

Income

  

Shares

  

Per Share

  

Income

  

Shares

  

Per Share

 

Basic net income per common share:

                        

Net income available to common stockholders

 $1,085   11,017  $0.10  $843   10,630  $0.08 

Effect of dilutive securities:

                        

Non-vested restricted stock

     407          794     

Diluted net income per common share:

                        

Net income available to common stockholders plus assumed conversions

 $1,085   11,424  $0.09  $843   11,424  $0.07 

 

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 4 - Balance Sheet Components
12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Supplemental Balance Sheet Disclosures [Text Block]

4.     BALANCE SHEET COMPONENTS

 

The components of certain balance sheet amounts are as follows (in thousands):

 

  

December 31,

 
  

2021

  

2020

 

Cash and cash equivalents:

        

Cash

 $17,281  $23,977 

Cash equivalents

  66,562   68,390 
   83,843   92,367 

Restricted cash

  522   525 
  $84,365  $92,892 
         

Inventories:

        

Finished goods

 $4,476  $3,071 

Raw materials

  873   1,047 

Reserve for obsolescence

  (92)  (339)
  $5,257  $3,779 

Property and equipment:

        

Office equipment

 $460  $449 

Office software

  1,009   1,001 

Machinery

  22   30 

Furniture and fixtures

  252   254 

Leasehold improvements

  814   839 

Construction in progress

  173   41 

Property and equipment, at cost

  2,730   2,614 

Accumulated depreciation and amortization

  (2,267)  (2,075)
  $463  $539 

Other accrued expenses:

        

Sales returns

 $137  $189 

Employee-related expense

  988   1,149 

Warehousing, inventory-related and other

  808   584 
  $1,933  $1,922 

Deferred revenue:

        

Unshipped product and unredeemed product vouchers

 $6,525  $1,005 

Auto ship advances

  1,901   1,977 

Other

  110   109 
  $8,536  $3,091 

 

As of December 31, 2021, cash and cash equivalents include $4.1 million held in banks located within China subject to foreign currency controls.

 

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 5 - Fair Value Measurements
12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Fair Value Disclosures [Text Block]

5.     FAIR VALUE MEASUREMENTS

 

Investments by category included in cash equivalents at the end of each period were as follows (in thousands):

 

    

December 31, 2021

  

December 31, 2020

 
  

Fair Value Level1

 

Adjusted Cost

  

Gross Unrealized Losses

  

Fair Value

  

Adjusted Cost

  

Gross Unrealized Losses

  

Fair Value

 

Money market funds

 

Level 1

 $20,711  $  $20,711  $21,042  $  $21,042 

Time deposits

 

Level 2

           5,458      5,458 

Government and municipal debt securities

 

Level 2

  14,006   (2)  14,004   30,280   (5)  30,275 

Corporate debt securities

 

Level 2

  31,863   (16)  31,847   11,621   (6)  11,615 

Total investments

   $66,580  $(18) $66,562  $68,401  $(11) $68,390 

 


1 FASB Topic 820, Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

 

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 6 - Leases
12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Lessee, Operating Leases [Text Block]

6.     LEASES

 

The Company leases 7,300 square feet of office space in Hong Kong and 4,900 square feet of office space in Rolling Hills Estates, California for its corporate staff. In June 2020, the Company extended the Rolling Hills Estates office lease for an additional five years with a term now expiring in September 2030. Effective  July 1, 2020, the Company modified the terms of its largest Hong Kong office lease resulting in a lease extension through  June 2023. To help further develop the market for its products in North America, the Company leases 1,600 square feet of retail space in each of Rowland Heights, California and Richmond, British Columbia and 2,000 square feet of retail space in Metuchen, New Jersey. The Rowland Heights, Richmond and Metuchen locations have terms expiring in November 2025, February 2024, and November 2022, respectively.

 

The Company leases seven branch offices throughout China, and additional office space in Peru, Japan, Taiwan, South Korea, Malaysia, Singapore, Thailand, India, and the Cayman Islands. The Company also leases a factory in Zhongshan, China. The Company contracts with third parties for fulfillment and distribution operations in all of its international markets. None of the Company’s third-party logistics contracts contain a lease as the Company does not have the right to access the warehouses or move its inventories at will.

 

The components of lease cost were as follows (in thousands):

 

  

Year Ended December 31,

 
  

2021

  

2020

 

Operating leases

 $1,334  $1,716 

Short-term leases

  180   299 

Total lease cost

 $1,514  $2,015 

 

Cash paid for amounts included in the measurement of operating leases liabilities was $1.4 million and $1.6 million for 2021 and 2020, respectively.

 

The weighted-average remaining lease term and discount rate related to operating leases as of December 31, 2021 were as follows:

 

Weighted-average remaining lease term (in years)

  5.1 

Weighted-average discount rate

  3.3%

 

As most of the Company’s leases do not provide an implicit rate, the Company used its incremental borrowing rate, or the rate of each of its subsidiaries if available, based on the information available at the lease commencement date to determine the present value of lease payments.

 

The annual scheduled lease payments of our operating lease liabilities as of December 31, 2021 were as follows (in thousands):

 

2022

 $1,261 

2023

  672 

2024

  272 

2025

  261 

2026

  201 

Thereafter

  789 

Total lease payments

 $3,456 

Less: imputed interest

  (289)

Present value of lease liabilities

 $3,167 

 

For all asset classes, the Company elected not to recognize assets or liabilities at the acquisition date for leases that, at the acquisition date, have a remaining lease term of 12 months or less. Additionally, for all asset classes, the Company choose not to separate nonlease components from lease components and instead account for the combined lease and nonlease components associated with that lease component as a single lease component.

 

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 7 - Income Taxes
12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Income Tax Disclosure [Text Block]

7.     INCOME TAXES

 

The components of income before income taxes consist of the following (in thousands):

 

  

Year Ended December 31,

 
  

2021

  

2020

 

Domestic

 $(1,127) $(1,663)

Foreign

  2,637   3,153 

Income before income taxes

 $1,510  $1,490 

 

The components of the income tax provision consist of the following (in thousands):

 

  

Year Ended December 31,

 
  

2021

  

2020

 

Current taxes:

        

Federal

 $(207) $(512)

State

  9   1 

Foreign

  267   626 

Total current taxes

  69   115 
         

Deferred taxes:

        

Federal

  309   346 

State

  7   6 

Foreign

  40   180 

Total deferred taxes

  356   532 

Income tax provision

 $425  $647 

 

A reconciliation of the reported income tax provision to the provision that would result from applying the domestic federal statutory tax rate to pretax income is as follows (in thousands):

 

  

Year Ended December 31,

 
  

2021

  

2020

 

Income tax at federal statutory rate

 $317  $313 

Effect of permanent differences

  274   121 

Global Intangible Low-Taxed Income

  183   555 

Change in valuation allowance

  (37)  51 

Foreign rate differential

  (221)  72 

Foreign tax credits

  (32)  (98)

Stock-based compensation

  10   164 

Net operating loss carryback

  (84)  (512)

Other reconciling items

  15   (19)

Income tax provision

 $425  $647 

 

Income before income taxes and the statutory tax rate for each country that materially contributed to the foreign rate differential presented above is as follows (in thousands):

 

      

Year Ended December 31,

 
  

Statutory Tax Rate

  

2021

  

2020

 

Cayman Islands

  % $2,696  $2,589 

Hong Kong

  16.5%  742   267 

China

  25.0%  152   716 

 

Deferred income taxes consist of the following (in thousands):

 

  

December 31,

 
  

2021

  

2020

 

Deferred tax assets:

        

Net operating losses

 $490  $628 

Stock-based compensation

  170   510 

Operating lease liabilities

  396   460 

Other

  51   60 

Total deferred tax assets

  1,107   1,658 

Valuation allowance

  (303)  (340)

Net deferred tax assets

  804   1,318 

Deferred tax liabilities:

        

Operating lease assets

  (376)  (438)

Foreign deferreds

  (153)  (216)

Prepaids

  (113)  (113)

Other

  (6)  (36)

Total deferred tax liabilities

  (648)  (803)

Net deferred tax assets

 $156  $515 

 

The effective income tax rate for the year ended December 31, 2021 includes an estimate for the Global Intangible Low-Taxed Income (“GILTI”) inclusion. The effect of permanent differences in 2021 and 2020 is mainly due to compensation-related limitations under Internal Revenue Code Section 162(m). As of December 31, 2021, the Company does not have a valuation allowance against its U.S. deferred tax assets. The Company analyzed all sources of available income and determined that they are more likely than not to realize the tax benefits of their deferred assets. As of December 31, 2021, the Company has a valuation allowance against deferred taxes in certain foreign jurisdictions with an overall net operating loss. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision.

 

As of December 31, 2021, the Company no longer has U.S. federal net operating losses due to its filing in December 2021 to carry back $603,000 of losses generated in the tax year ended December 31, 2020 to offset taxable income from the tax year ended December 31, 2016. The Company has post-apportioned U.S. state net operating loss carryforwards of $427,000 that begin expiring in 2039. At December 31, 2021, the Company has foreign net operating loss carryforwards of approximately $1.9 million in various jurisdictions with various expirations.

 

As of December 31, 2021, income taxes payable for the repatriation tax on the deemed repatriation of deferred foreign income required the U.S. Tax Cuts and Jobs Act (the “Tax Act”), enacted on December 22, 2017 by the U.S. government, totaled $13.7 million, of which $12.1 million is reflected as a noncurrent liability.

 

As a result of capital return activities, the Company determined that a portion of its current undistributed foreign earnings is no longer deemed reinvested indefinitely by its non-U.S. subsidiaries. For state income tax purposes, the Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable state corporate income tax rate(s). As of December 31, 2021, the Company has not recorded a state deferred tax liability for earnings that the Company plans to repatriate out of accumulated earnings in future periods because all earnings as of December 31, 2021 have already been repatriated. Due to the Tax Act, repatriation from foreign subsidiaries will be offset with a dividends received deduction, resulting in little to no impact on federal tax expense. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of December 31, 2021.

 

The Company and its subsidiaries file tax returns in the United States, California, New Jersey, Texas and various foreign jurisdictions. During the fourth quarter of 2018, the Company was notified that it was selected for audit of the 2016 tax year by the U.S. Internal Revenue Service (the "IRS"). The audit was subsequently expanded to also include the 2017, 2018 and 2019 tax years. On October 12, 2021, the Company received notification from the IRS that it had completed the audit process for all tax years with no changes made to the Company's previously reported tax. The Company is no longer subject to state income tax examinations for years prior to 2017. No other jurisdictions are currently examining any income tax returns of the Company.

 

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 8 - Commitments and Contingencies
12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Commitments and Contingencies Disclosure [Text Block]
 

8.     COMMITMENTS AND CONTINGENCIES

 

The SEC conducted a non-public investigation since August 2016 to determine whether there have been violations of the federal securities laws relating to the trading of the Company’s securities and/or its public disclosures. On September 30, 2021, the Company was notified by the SEC that it had concluded its investigation and does not intend to recommend an enforcement action.

 

The Company has employment agreements with certain members of its management team that can be terminated by either the employee or the Company upon four weeks’ notice.  The employment agreements entered into with the management team contain provisions that guarantee the payments of specified amounts in the event of a change in control, as defined, or if the employee is terminated without cause, as defined, or terminates employment for good reason, as defined.

 

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 9 - Stock-based Incentive Plans
12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Share-based Payment Arrangement [Text Block]

9.     STOCK-BASED INCENTIVE PLANS

 

Restricted Stock

 

At the Company’s annual meeting of stockholders held on April 7, 2016, the Company’s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “2016 Plan”) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units, stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to 2,500,000 shares of the Company’s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted. At December 31, 2021, 1,219,583 shares remained available for issuance under the 2016 Plan.

 

The following table summarizes the Company’s restricted stock activity under the 2016 Plan:

 

  

Shares

  

Wtd. Avg. Price at Date of Issuance

 

Nonvested at December 31, 2019

  957,682  $7.34 

Vested

  (391,410)  7.53 

Nonvested at December 31, 2020

  566,272   7.21 

Vested

  (380,027)  7.27 

Nonvested at December 31, 2021

  186,245   7.08 

 

Phantom Equity

 

On  March 15, 2021, the Company’s Board of Directors approved and adopted a Phantom Equity Plan (the “Phantom Plan”). Under the terms of the Phantom Plan, the Board of Directors' Compensation Committee  may grant to the Company’s employees, officers, directors, contractors, consultants, or advisors awards of phantom shares entitling grantees the right to receive a cash payment equal to the fair market value of an equal number of shares of the Company’s common stock upon the close of a vesting period, subject to any maximum payment value that the Compensation Committee  may set. The vesting of phantom shares is subject to such vesting conditions as the Compensation Committee  may specify in a grantee’s award agreement. Grantees of phantom shares shall not by virtue of their receipt of phantom shares have any ownership rights in shares of the Company’s common stock. The Phantom Plan shall continue for a period of ten years, after which no further phantom shares  may be awarded (although any phantom shares awarded prior to the expiration of such 10-year period shall be unaffected by the termination of the Phantom Plan).

 

Also on  March 15, 2021, awards for 223,307 phantom shares were granted to the Company’s employees and its non-employee directors.  The phantom shares vest in eight equal three-month vesting increments, subject to the satisfaction of both a time-based vesting condition and a performance vesting condition. These vesting conditions were deemed satisfied on the grant date for the initial vesting increment. In order for the time-based vesting condition to be satisfied for each vesting period, the grantee must remain continuously employed by, or be otherwise continuously providing services to, the Company through the end of the vesting period, and in order for the performance vesting condition to be satisfied for each vesting period, the performance criteria designated by the Compensation Committee must be satisfied. The initial performance vesting condition to be applied to measure performance for the period between  March 15, 2021 and  June 15, 2021 was designated by the Compensation Committee on or before  April 14, 2021, and will apply to all future performance periods unless the Compensation Committee elects to change the performance vesting condition on a prospective basis. Future changes to the performance vesting condition shall be made on or before the fifteenth day of any future performance period. If either vesting condition is not satisfied for a vesting date, then the phantom shares scheduled to vest on such date will be forfeited. These phantom shares are subject to a maximum payment value of $12.00 per phantom share. An additional award with similar vesting conditions for 9,074 phantom shares was granted on  May 14, 2021 to the Company's new non-employee director, while unvested 9,074 phantom shares granted to the Company's departing non-employee director were forfeited on or about the same date.

 

The phantom share awards are accounted for as liabilities in accordance with FASB ASC Topic 718, Compensation - Stock Compensation since they require cash settlement. The grant date of each vesting increment will be established when the Company and the grantees reach a mutual understanding of the key terms and conditions of an award, which is the date upon which each performance vesting condition is communicated to the grantees. Compensation expense is recognized over the requisite service period if it is probable that the performance vesting condition will be achieved. The fair value of the liability incurred is remeasured at the end of each reporting period with any changes in fair value recognized as compensation expense over the requisite service period.

 

Awards totaling 111,652 phantom shares vested during 2021, resulting in compensation expense of $773,000 related to their cash settlement.

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 10 - Stockholders' Equity
12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Stockholders' Equity Note Disclosure [Text Block]

10.     STOCKHOLDERS’ EQUITY

 

Authorized Shares

 

The Company is authorized to issue two classes of capital stock consisting of up to 5,000,000 shares of preferred stock, $0.001 par value, and 50,000,000 shares of common stock, $0.001 par value.

 

Dividends

 

The Company declared and paid cash dividends of $0.20 per common share during each quarter of 2021 and 2020, totaling an aggregate of $9.1 million each year. Declaration and payment of any future dividends on shares of common stock will be at the sole discretion of the Company’s Board of Directors.

 

Stock Repurchases

 

On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Any repurchases will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. As of December 31, 2021, $21.9 million of the $70.0 million stock repurchase program remained available for future purchases, inclusive of related estimated income tax.

 

Accumulated Other Comprehensive Loss

 

The changes in accumulated other comprehensive loss by component for 2021 were as follows (in thousands):

 

  

Foreign Currency Translation Adjustments

  

Unrealized Losses on Available-For-Sale Investments

  

Total

 

Balance, December 31, 2020

 $(325) $(11) $(336)

Other comprehensive loss

  (149)  (7)  (156)

Balance, December 31, 2021

 $(474) $(18) $(492)

 

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 11 - Related Party Transactions
12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Related Party Transactions Disclosure [Text Block]

11.     RELATED PARTY TRANSACTIONS

 

The Company is a party to a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called ReStor™. George K. Broady, a former director of the Company and beneficial owner of more than 5% of its outstanding common stock, is an indirect owner of BHS. Brunde E. Broady, a director of the Company and daughter of Mr. Broady, is the President and Chief Executive Officer of BHS. Under this agreement (as amended), the Company agreed to pay BHS a royalty based on a price per unit in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide by or through multi-level marketing or network marketing. The Company recognized royalties of $60,000 and $83,000 during 2021 and 2020, respectively, under this agreement.  The Company is not required to purchase any product under the agreement, and the agreement may be terminated under certain circumstances with no notice. The agreement terminates March 31, 2025, after which it shall be automatically renewed for successive one-year terms unless notice is given by either party at least 90 days in advance of the expiration of the then-current term.

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 12 - Employee Benefit Plans
12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Retirement Benefits [Text Block]

12.     EMPLOYEE BENEFIT PLANS

 

The Company has a 401(k) defined contribution plan which permits participating employees in the United States to defer up to a maximum of 90% of their compensation, subject to limitations established by the Internal Revenue Service. Employees age 21 and older are eligible to contribute to the plan starting the first day of the month following the date of employment.  Participating employees are eligible to receive discretionary matching contributions and profit sharing, subject to certain conditions, from the Company.  In 2021 and 2020, the Company matched employee deferral contributions up to 4.5% of salary, which vested 100% immediately. No profit sharing has been paid under the plan. The Company recorded compensation expense of $69,000 and $68,000 for 2021 and 2020, respectively, related to its matching contributions to the plan. Certain of the Company’s employees located outside the United States participate in employee benefit plans that are statutory in nature.

 

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 13 - Segment Information
12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

13.    SEGMENT INFORMATION

 

The Company sells products to a member network that operates in a seamless manner from market to market, except for the China market where it sells to some consumers through an e-commerce retail platform, and the Russia and Kazakhstan market where the Company’s engagement of a third-party service provider results in a different economic structure than its other markets. Otherwise, the Company believes that all of its other operating segments have similar economic characteristics and are similar in the nature of the products sold, the product acquisition process, the types of customers products are sold to, the methods used to distribute the products, and the nature of the regulatory environment. Therefore, the Company aggregates its other operating segments (including its Hong Kong operating segment) into a single reporting segment (the “Primary Reporting Segment”).

 

The Company reviews its net sales and operating income (loss) by operating segment, and reviews its assets and capital expenditures on a consolidated basis and not by operating segment. As such, net sales and operating income (loss) are presented by reportable segment and assets and capital expenditures by operating segment are not presented. Segment operating income is adjusted for certain direct costs and commission allocation.

 

The Company’s operating information by geographic area are as follows (in thousands):

 

  

Year Ended December 31,

 
  

2021

  

2020

 

Net sales:

        

Primary Reporting Segment

 $56,914  $58,243 

China

  2,237   2,940 

Russia and Kazakhstan

  854   888 

Total net sales

 $60,005  $62,071 
         

Income (loss) from operations:

        

Primary Reporting Segment

 $10,366  $9,277 

China

  74   330 

Russia and Kazakhstan

  (146)  (96)

Income from operations for reportable segments, net

  10,294   9,511 

Unallocated corporate expenses

  (8,723)  (8,842)

Other income (expense), net

  (61)  821 

Income before income taxes

 $1,510  $1,490 

 

The Company’s net sales by geographic area are as follows (in thousands):

 

  

Year Ended December 31,

 
  

2021

  

2020

 

Net sales from external customers:

        

United States

 $1,278  $1,573 

Canada

  724   765 

Peru

  2,281   1,453 

Hong Kong1

  46,699   49,169 

China

  2,237   2,940 

Taiwan

  2,706   3,034 

Russia and Kazakhstan

  854   888 

Europe

  1,136   1,050 

Other foreign countries

  2,090   1,199 

Total net sales

 $60,005  $62,071 

 


1 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors.”

 

The Company’s net sales by product and service are as follows (in thousands):

 

  

Year Ended December 31,

 
  

2021

  

2020

 

Net sales by product and service:

        

Product sales

 $54,056  $55,840 

Administrative fees, freight and other

  6,340   6,991 

Less: sales returns

  (391)  (760)

Total net sales

 $60,005  $62,071 

 

Due to system constraints, it is impracticable for the Company to separately disclose sales by product category for the years presented.

 

The Company’s long-lived assets by geographic area are as follows (in thousands):

 

  

December 31,

 
  

2021

  

2020

 

Long-lived assets:

        

United States

 $221  $227 

Hong Kong

  105   146 

China

  90   47 

Other foreign countries

  47   119 

Total long-lived assets

 $463  $539 

 

XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 14 - Subsequent Event
12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Subsequent Events [Text Block]

14.     SUBSEQUENT EVENT

 

On February 7, 2022, the Board of Directors declared a quarterly cash dividend of $0.20 on each share of common stock outstanding. The dividend will be payable on March 4, 2022 to stockholders of record on February 22, 2022. Declaration and payment of any future dividends on shares of common stock will be at the sole discretion of the Company’s Board of Directors.

 

 

XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.0.1
Significant Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Basis of Accounting, Policy [Policy Text Block]

 

Nature of Operations

 

Natural Health Trends Corp., a Delaware corporation (whether or not including its subsidiaries, the “Company”), is an international direct-selling and e-commerce company. Subsidiaries controlled by the Company sell personal care, wellness, and “quality of life” products under the “NHT Global” brand.

 

The Company’s wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Malaysia, Singapore and Thailand; South Korea; Japan; India; and Europe. The Company also operates in Russia and Kazakhstan through an engagement with a local service provider.

Consolidation, Policy [Policy Text Block]

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

 

The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period.

 

The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates associated with revenue recognition, as well as those used in the determination of liabilities related to sales returns, commissions and income taxes. Various assumptions and other factors prompt the determination of these significant estimates. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. The actual results may differ materially and adversely from the Company’s estimates. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

 

Cash and cash equivalents include the Company’s investments in money market funds, government and municipal debt securities, and corporate debt securities. The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Debt securities classified as cash equivalents are required to be accounted for in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 320, Investments - Debt and Equity Securities. As such, the Company determined its investments in debt securities held at December 31, 2021 should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income and expense. Realized gains and losses, as well as interest income, are also included in other income and expense. The fair values of securities are based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs.

 

The Company includes credit card receivables due from certain of its credit card processors in its cash and cash equivalents as the cash proceeds are received within two to five days.

 

The Company maintains certain cash balances at several institutions located in the United States, Hong Kong and elsewhere which at times may exceed insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.

 

Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]

Restricted Cash

 

In November 2019, the Company funded a bank deposit account in the amount of VND 10 billion ($438,000 and $433,000 at December 31, 2021 and 2020, respectively) for purposes of submitting a direct selling license application in Vietnam. Such deposit is required by Vietnamese law to establish a consumer protection fund for direct selling participants. In January 2022, the Company submitted an application to withdraw the bank deposit since no direct selling license has been successfully obtained to operate in Vietnam.

 

The Company periodically maintains a cash reserve with certain credit card processing companies to provide for potential uncollectible amounts and chargebacks. Those cash reserves held by credit card processing companies located in South Korea are reflected in noncurrent assets since they require the Company to provide 100% collateral before processing transactions, which must be maintained indefinitely.

Inventory, Policy [Policy Text Block]

Inventories

 

Inventories are stated at the lower of cost or net realizable value, using the first-in, first-out method. The Company reviews its inventory for obsolescence and any inventory identified as obsolete is reserved or written off. The Company’s determination of obsolescence is based on assumptions about the demand for its products, product expiration dates, estimated future sales, and management’s future plans.

 

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five years for office equipment, office software and capitalized internal-use software development costs and five to seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the assets. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation and amortization expenses are included in the statement of operations as selling, general and administrative expenses. Such expense totaled $299,000 and $410,000 during 2021 and 2020, respectively.

 

The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of these assets is measured by comparison of its carrying amounts to future undiscounted cash flows the assets are expected to generate. If property and equipment are considered to be impaired, the impairment to be recognized equals the amount by which the carrying value of the asset exceeds its fair value.

Income Tax, Policy [Policy Text Block]

Income Taxes

 

The Company recognizes income taxes under the liability method of accounting for income taxes. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is a result of changes in deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be ultimately realized based on the more likely than not recognition criteria. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has evaluated its tax positions and determined that there are no significant uncertain tax positions for the current year or years prior. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution.  The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense.  Deferred taxes are not provided for state income tax purposes on the portion of undistributed earnings of subsidiaries outside of the United States when these earnings are considered permanently reinvested.

Amounts Held in Distributor EWallets [Policy Text Block]

Amounts Held in eWallets

 

The Company requires commission payments of certain members in Hong Kong and other markets to be first recorded into an electronic wallet (eWallet) account in lieu of being paid out directly to members. The eWallet functionality allows members to place new product orders utilizing eWallet available balance and/or request commission payout via multiple payment methods. Amounts held in eWallets are reflected on the balance sheet as a current liability.

Foreign Currency Transactions and Translations Policy [Policy Text Block]

Foreign Currency

 

The functional currency of the Company’s international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates.  The resulting translation adjustments are recorded directly into stockholders' equity.

 

Aggregate transaction gains or losses, including gains or losses related to foreign-denominated cash and cash equivalents and the re-measurement of certain inter-company balances, are included in the statement of operations as other income and expense. Loss on foreign exchange totaling $248,000 and $335,000 was recognized during 2021 and 2020, respectively.

 

Commissions, Policy [Policy Text Block]

Commissions Expense

 

Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.  Each of the Company’s products are designated a specified number of bonus volume points, which is essentially a percentage of the product’s wholesale price.  The Company accrues commissions when earned and as the related revenue is recognized and pays commissions on product sales generally two weeks following the end of the weekly sales period.

 

In some markets, the Company also pays certain bonuses on purchases by up to three generations of personally sponsored members, as well as bonuses on commissions earned by up to seven generations of personally sponsored members. Independent members may also earn incentives based on meeting certain qualifications during a designated incentive period, which may range from several weeks to up to a year.  The Company estimates and accrues all costs associated with the incentives as the members meet the qualification requirements.

 

From time to time the Company makes modifications and enhancements to the Company’s compensation plan to help motivate members, which can have an impact on member commissions. The Company also enters into performance-based agreements for business or market development, which may result in additional compensation to specific members.

Earnings Per Share, Policy [Policy Text Block]

Net Income Per Common Share

 

Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized, if any, is assumed to be used to repurchase shares.

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Certain Risks and Concentrations

 

In late 2019 or early 2020 an outbreak of COVID-19 was first identified in China and subsequently spread around the world. On March 11, 2020 the World Health Organization declared the COVID-19 outbreak a global pandemic. The outbreak caused the Chinese government to implement powerful measures to control the virus, such as requiring businesses to close throughout various areas of China and restricting public gatherings and certain travel within the country. The Company has significant business in China and in 2021 generated approximately 78% of its revenue in Hong Kong, substantially all of which was derived from the sale of products to members in China. The Chinese government continues to adjust the restrictive measures that it imposes to control COVID-19 based on then-current local circumstances, as have the governments of the other countries in which the Company operates. The scope and impact of the pandemic and related control measures are uncertain, but the Company has taken steps to adapt some of its marketing programs, such as relying on certain product promotions and webcast training, to overcome the physical restrictions imposed in response to the pandemic. The Company has also canceled or rescheduled a number of in-person member events over the course of the pandemic. The severity of the impact on the Company of the COVID-19 pandemic will depend on future developments, including the duration and spread of the virus, and related control measures, which the Company is unable to accurately predict. Regardless, these disruptions have materially negatively impacted the Company’s financial results throughout 2020 and 2021, and the Company expects that its financial results for the near-term may be adversely affected. These disruptions have also adversely impacted the operations of some of the Company’s third-party logistics providers, and it expects that the future operations of these logistics providers and other third parties with whom it works may be adversely affected by these disruptions. The Company will continue to assess the operational and financial impact of the COVID-19 pandemic.

 

In contrast to the Company’s business in other parts of the world, the Company’s China subsidiary has not implemented a direct sales model in China. The Chinese government permits direct selling only by organizations that have a license and has also adopted anti-pyramid selling and multi-level marketing legislation. The Company previously submitted a preliminary application for a direct selling license in China in August 2015, but in 2019 a Chinese governmental authority recommended that the Company withdraw its application. The Company understands that the governmental authorities recommended that other companies with pending direct selling license applications also withdraw their applications. The Company applied to withdraw its application in November 2019, and the governmental authorities approved the withdrawal of its application shortly thereafter. The Company operates an e-commerce direct selling platform in Hong Kong and recognizes the revenue derived from sales to both Hong Kong and Chinese members as being generated in Hong Kong. Products purchased by members in China are delivered to third parties that act as the importers of record under agreements to pay applicable duties. In addition, through a Chinese entity, the Company sells products in China using an e-commerce retail platform. The Chinese entity operates separately from the Hong Kong entity, and a Chinese member may elect to participate separately or in both.

 

The Company continually evaluates its business in China and Hong Kong for compliance with applicable laws and regulations, including seeking the input of outside professionals and certain Chinese authorities. This process can and has resulted in the identification of certain matters of potential noncompliance. The Company works on a continuing basis to satisfactorily address such matters, however there can be no assurance that adequate steps are taken or that applicable laws and regulations are properly interpreted. Should the government authorities determine that the Company’s activities violate applicable laws and regulations, including China’s direct selling, pyramid selling or multi-level marketing laws and regulations, or should new laws or regulations be adopted, there could be a material adverse effect on the Company’s business, financial condition and results of operations.

 

Although the Company attempts to work closely with both national and local Chinese governmental agencies in conducting its business, the Company’s efforts to comply with national and local laws may be harmed by a rapidly evolving regulatory climate, concerns about activities resembling violations of direct selling, pyramid selling or multi-level marketing legislation, subjective interpretations of laws and regulations, and activities by individual members that may violate laws notwithstanding the Company's policies prohibiting such activities. Any determination that the Company’s operations or activities, or the activities of its individual members or employee sales representatives, or importers of record are not in compliance with applicable laws and regulations could result in the imposition of substantial fines, extended interruptions of business, restrictions on the Company’s future ability to obtain business licenses or expand into new locations, changes to its business model, the termination of required licenses to conduct business, or other actions, any of which could materially harm the Company’s business, financial condition and results of operations.

 

No single market other than Hong Kong had net sales greater than 10% of total sales. Sales are made to the Company’s members and no single customer accounted for 10% or more of its net sales. However, the Company’s business model can result in a concentration of sales to several different members and their network of members. Although no single member accounted for 10% or more of net sales, the loss of a key member or that member’s network could have an adverse effect on the Company’s net sales and financial results.

 

The Company’s Premium Noni Juice, Enhanced Essential Probiotics and Triotein™ products each account for at least 10% of the Company’s total revenue. The Company currently sources each of these products from a single supplier. If demand decreases significantly, government regulation restricts their sale, the Company is unable to adequately source or deliver the products, or the Company ceases offering the products for any reason without suitable replacements, the Company’s business, financial condition and results of operations could be materially and adversely affected.

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

 

The carrying amounts of the Company’s financial instruments, including cash and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents.

 

Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.

 

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

 

In June 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost basis and added Topic 326 to the FASB ASC. In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments - Credit Losses.  The amendments to ASU 2019-11 clarify, correct and make improvements to Topic 326.  ASU 2016-13 as well as the updates in ASU 2019-11 are effective for interim and annual periods beginning after December 15, 2022, and early adoption is permitted.  The Company is currently evaluating the impact of this standard on its consolidated financial statements.

 

Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

 

XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 3 - Net Income Per Common Share (Tables)
12 Months Ended
Dec. 31, 2021
Notes Tables  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
  

Year Ended December 31,

 
  

2021

  

2020

 
  

Income

  

Shares

  

Per Share

  

Income

  

Shares

  

Per Share

 

Basic net income per common share:

                        

Net income available to common stockholders

 $1,085   11,017  $0.10  $843   10,630  $0.08 

Effect of dilutive securities:

                        

Non-vested restricted stock

     407          794     

Diluted net income per common share:

                        

Net income available to common stockholders plus assumed conversions

 $1,085   11,424  $0.09  $843   11,424  $0.07 
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 4 - Balance Sheet Components (Tables)
12 Months Ended
Dec. 31, 2021
Notes Tables  
Schedule of Additional Balance Sheet Components [Table Text Block]
  

December 31,

 
  

2021

  

2020

 

Cash and cash equivalents:

        

Cash

 $17,281  $23,977 

Cash equivalents

  66,562   68,390 
   83,843   92,367 

Restricted cash

  522   525 
  $84,365  $92,892 
         

Inventories:

        

Finished goods

 $4,476  $3,071 

Raw materials

  873   1,047 

Reserve for obsolescence

  (92)  (339)
  $5,257  $3,779 

Property and equipment:

        

Office equipment

 $460  $449 

Office software

  1,009   1,001 

Machinery

  22   30 

Furniture and fixtures

  252   254 

Leasehold improvements

  814   839 

Construction in progress

  173   41 

Property and equipment, at cost

  2,730   2,614 

Accumulated depreciation and amortization

  (2,267)  (2,075)
  $463  $539 

Other accrued expenses:

        

Sales returns

 $137  $189 

Employee-related expense

  988   1,149 

Warehousing, inventory-related and other

  808   584 
  $1,933  $1,922 

Deferred revenue:

        

Unshipped product and unredeemed product vouchers

 $6,525  $1,005 

Auto ship advances

  1,901   1,977 

Other

  110   109 
  $8,536  $3,091 
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 5 - Fair Value Measurements (Tables)
12 Months Ended
Dec. 31, 2021
Notes Tables  
Debt Securities, Available-for-sale [Table Text Block]
    

December 31, 2021

  

December 31, 2020

 
  

Fair Value Level1

 

Adjusted Cost

  

Gross Unrealized Losses

  

Fair Value

  

Adjusted Cost

  

Gross Unrealized Losses

  

Fair Value

 

Money market funds

 

Level 1

 $20,711  $  $20,711  $21,042  $  $21,042 

Time deposits

 

Level 2

           5,458      5,458 

Government and municipal debt securities

 

Level 2

  14,006   (2)  14,004   30,280   (5)  30,275 

Corporate debt securities

 

Level 2

  31,863   (16)  31,847   11,621   (6)  11,615 

Total investments

   $66,580  $(18) $66,562  $68,401  $(11) $68,390 
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 6 - Leases (Tables)
12 Months Ended
Dec. 31, 2021
Notes Tables  
Lease, Cost [Table Text Block]
  

Year Ended December 31,

 
  

2021

  

2020

 

Operating leases

 $1,334  $1,716 

Short-term leases

  180   299 

Total lease cost

 $1,514  $2,015 

Weighted-average remaining lease term (in years)

  5.1 

Weighted-average discount rate

  3.3%
Lessee, Operating Lease, Liability, Maturity [Table Text Block]

2022

 $1,261 

2023

  672 

2024

  272 

2025

  261 

2026

  201 

Thereafter

  789 

Total lease payments

 $3,456 

Less: imputed interest

  (289)

Present value of lease liabilities

 $3,167 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 7 - Income Taxes (Tables)
12 Months Ended
Dec. 31, 2021
Notes Tables  
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]
  

Year Ended December 31,

 
  

2021

  

2020

 

Domestic

 $(1,127) $(1,663)

Foreign

  2,637   3,153 

Income before income taxes

 $1,510  $1,490 
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
  

Year Ended December 31,

 
  

2021

  

2020

 

Current taxes:

        

Federal

 $(207) $(512)

State

  9   1 

Foreign

  267   626 

Total current taxes

  69   115 
         

Deferred taxes:

        

Federal

  309   346 

State

  7   6 

Foreign

  40   180 

Total deferred taxes

  356   532 

Income tax provision

 $425  $647 
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
  

Year Ended December 31,

 
  

2021

  

2020

 

Income tax at federal statutory rate

 $317  $313 

Effect of permanent differences

  274   121 

Global Intangible Low-Taxed Income

  183   555 

Change in valuation allowance

  (37)  51 

Foreign rate differential

  (221)  72 

Foreign tax credits

  (32)  (98)

Stock-based compensation

  10   164 

Net operating loss carryback

  (84)  (512)

Other reconciling items

  15   (19)

Income tax provision

 $425  $647 
Income Tax Foreign Rate Differential [Table Text Block]
      

Year Ended December 31,

 
  

Statutory Tax Rate

  

2021

  

2020

 

Cayman Islands

  % $2,696  $2,589 

Hong Kong

  16.5%  742   267 

China

  25.0%  152   716 
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
  

December 31,

 
  

2021

  

2020

 

Deferred tax assets:

        

Net operating losses

 $490  $628 

Stock-based compensation

  170   510 

Operating lease liabilities

  396   460 

Other

  51   60 

Total deferred tax assets

  1,107   1,658 

Valuation allowance

  (303)  (340)

Net deferred tax assets

  804   1,318 

Deferred tax liabilities:

        

Operating lease assets

  (376)  (438)

Foreign deferreds

  (153)  (216)

Prepaids

  (113)  (113)

Other

  (6)  (36)

Total deferred tax liabilities

  (648)  (803)

Net deferred tax assets

 $156  $515 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 9 - Stock-based Incentive Plans (Tables)
12 Months Ended
Dec. 31, 2021
Notes Tables  
Nonvested Restricted Stock Shares Activity [Table Text Block]
  

Shares

  

Wtd. Avg. Price at Date of Issuance

 

Nonvested at December 31, 2019

  957,682  $7.34 

Vested

  (391,410)  7.53 

Nonvested at December 31, 2020

  566,272   7.21 

Vested

  (380,027)  7.27 

Nonvested at December 31, 2021

  186,245   7.08 
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 10 - Stockholders' Equity (Tables)
12 Months Ended
Dec. 31, 2021
Notes Tables  
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]
  

Foreign Currency Translation Adjustments

  

Unrealized Losses on Available-For-Sale Investments

  

Total

 

Balance, December 31, 2020

 $(325) $(11) $(336)

Other comprehensive loss

  (149)  (7)  (156)

Balance, December 31, 2021

 $(474) $(18) $(492)
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 13 - Segment Information (Tables)
12 Months Ended
Dec. 31, 2021
Notes Tables  
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]
  

Year Ended December 31,

 
  

2021

  

2020

 

Net sales:

        

Primary Reporting Segment

 $56,914  $58,243 

China

  2,237   2,940 

Russia and Kazakhstan

  854   888 

Total net sales

 $60,005  $62,071 
         

Income (loss) from operations:

        

Primary Reporting Segment

 $10,366  $9,277 

China

  74   330 

Russia and Kazakhstan

  (146)  (96)

Income from operations for reportable segments, net

  10,294   9,511 

Unallocated corporate expenses

  (8,723)  (8,842)

Other income (expense), net

  (61)  821 

Income before income taxes

 $1,510  $1,490 
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]
  

Year Ended December 31,

 
  

2021

  

2020

 

Net sales from external customers:

        

United States

 $1,278  $1,573 

Canada

  724   765 

Peru

  2,281   1,453 

Hong Kong1

  46,699   49,169 

China

  2,237   2,940 

Taiwan

  2,706   3,034 

Russia and Kazakhstan

  854   888 

Europe

  1,136   1,050 

Other foreign countries

  2,090   1,199 

Total net sales

 $60,005  $62,071 
Schedule of Segment Reporting Information, by Segment [Table Text Block]
  

Year Ended December 31,

 
  

2021

  

2020

 

Net sales by product and service:

        

Product sales

 $54,056  $55,840 

Administrative fees, freight and other

  6,340   6,991 

Less: sales returns

  (391)  (760)

Total net sales

 $60,005  $62,071 
Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]
  

December 31,

 
  

2021

  

2020

 

Long-lived assets:

        

United States

 $221  $227 

Hong Kong

  105   146 

China

  90   47 

Other foreign countries

  47   119 

Total long-lived assets

 $463  $539 
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 1 - Nature of Operations and Summary of Significant Accounting Policies (Details Textual)
₫ in Billions
12 Months Ended
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Nov. 30, 2019
VND (₫)
Foreign Currency Transaction Gain (Loss), Unrealized $ (248,000) $ (335,000)  
Selling, General and Administrative Expenses [Member]      
Depreciation, Depletion and Amortization, Nonproduction, Total 299,000 410,000  
VIET NAM      
Restricted Cash and Cash Equivalents, Total $ 438,000 $ 433,000 ₫ 10
KOREA, DEMOCRATIC PEOPLE'S REPUBLIC OF      
Restricted Cash, Collateral Requirement Percentage 100.00%    
HONG KONG | Revenue from Contract with Customer Benchmark [Member] | Geographic Concentration Risk [Member]      
Concentration Risk, Percentage 78.00%    
Minimum [Member]      
Cash and Cash Equivalents, Period to Receive Cash Proceeds From Credit Card Processors (Day) 2 days    
Minimum [Member] | Office Equipment, Office Software and Capitalized Internal-use Software Development [Member]      
Property, Plant and Equipment, Useful Life (Year) 3 years    
Minimum [Member] | Furniture and Fixtures [Member]      
Property, Plant and Equipment, Useful Life (Year) 5 years    
Maximum [Member]      
Cash and Cash Equivalents, Period to Receive Cash Proceeds From Credit Card Processors (Day) 5 days    
Maximum [Member] | Office Equipment, Office Software and Capitalized Internal-use Software Development [Member]      
Property, Plant and Equipment, Useful Life (Year) 5 years    
Maximum [Member] | Furniture and Fixtures [Member]      
Property, Plant and Equipment, Useful Life (Year) 7 years    
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 2 - Revenue (Details Textual) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Revenue from Contract with Customers, Sales Returns, Percent 1.00% 1.00%
Increase (Decrease) in Contract with Customer, Liability $ 6.5  
Contract with Customer, Liability, Revenue Recognized $ 1.0  
Minimum [Member]    
Revenue from Contract with Customer, Sales Returns Policy Term (Day) 14 days  
Revenue from Contract with Customers, Historical Sales Returns, Percent 1.00%  
Maximum [Member]    
Revenue from Contract with Customer, Sales Returns Policy Term (Day) 1 year  
Revenue from Contract with Customers, Historical Sales Returns, Percent 9.00%  
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 3 - Net Income Per Common Share - Basic and Diluted Net Income (Loss) Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Net income available to common stockholders $ 1,085 $ 843
Basic (in shares) 11,017 10,630
Basic (in dollars per share) $ 0.10 $ 0.08
Non-vested restricted stock $ 0 $ 0
Non-vested restricted stock (in shares) 407 794
Net income available to common stockholders plus assumed conversions $ 1,085 $ 843
Diluted (in shares) 11,424 11,424
Diluted (in dollars per share) $ 0.09 $ 0.07
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 4 - Balance Sheet Components (Details Textual) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Cash and Cash Equivalents, at Carrying Value, Ending Balance $ 83,843 $ 92,367
CHINA    
Cash and Cash Equivalents, at Carrying Value, Ending Balance $ 4,100  
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 4 - Balance Sheet Components - Summary of Balance Sheet Amounts (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Cash and cash equivalents:    
Cash $ 17,281 $ 23,977
Cash equivalents 66,562 68,390
Cash and Cash Equivalents, at Carrying Value, Ending Balance 83,843 92,367
Restricted cash 522 525
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance 84,365 92,892
Inventories:    
Finished goods 4,476 3,071
Raw materials 873 1,047
Reserve for obsolescence (92) (339)
Inventory, Net, Total 5,257 3,779
Property and equipment:    
Office equipment 460 449
Office software 1,009 1,001
Machinery 22 30
Furniture and fixtures 252 254
Leasehold improvements 814 839
Construction in progress 173 41
Property and equipment, at cost 2,730 2,614
Accumulated depreciation and amortization (2,267) (2,075)
Property, Plant and Equipment, Net, Ending Balance 463 539
Other accrued expenses:    
Sales returns 137 189
Employee-related expense 988 1,149
Warehousing, inventory-related and other 808 584
Accrued Liabilities, Current, Total 1,933 1,922
Deferred revenue:    
Deferred revenue 8,536 3,091
Unshipped Product [Member]    
Deferred revenue:    
Deferred revenue 6,525 1,005
Auto ship advances [Member]    
Deferred revenue:    
Deferred revenue 1,901 1,977
Product and Service, Other [Member]    
Deferred revenue:    
Deferred revenue $ 110 $ 109
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 5 - Fair Value Measurements - Investments (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Adjusted cost [1] $ 66,580 $ 68,401
Gross unrealized losses [1] (18) (11)
Fair value [1] 66,562 68,390
Fair value [1] (66,562) (68,390)
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]    
Adjusted cost [1] 20,711 21,042
Gross unrealized losses [1] 0 0
Fair value [1] 20,711 21,042
Fair value [1] (20,711) (21,042)
Bank Time Deposits [Member] | Fair Value, Inputs, Level 2 [Member]    
Adjusted cost [1] 0 5,458
Gross unrealized losses [1] 0 0
Fair value [1] 0 5,458
Fair value [1] 0 (5,458)
Municipal Bonds [Member] | Fair Value, Inputs, Level 2 [Member]    
Adjusted cost [1] 14,006 30,280
Gross unrealized losses [1] (2) (5)
Fair value [1] 14,004 30,275
Fair value [1] (14,004) (30,275)
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]    
Adjusted cost [1] 31,863 11,621
Gross unrealized losses [1] (16) (6)
Fair value [1] 31,847 11,615
Fair value [1] $ (31,847) $ (11,615)
[1] FASB Topic 820, Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data.
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 6 - Leases (Details Textual)
$ in Millions
12 Months Ended
Dec. 31, 2021
USD ($)
ft²
Dec. 31, 2020
USD ($)
Jun. 30, 2020
Operating Lease, Payments | $ $ 1.4 $ 1.6  
HONG KONG      
Area of Land (Square Foot) 7,300    
Rolling Hills Estates [Member]      
Area of Land (Square Foot) 4,900    
Lessee, Operating Lease, Renewal Term (Year)     5 years
Richmond, British Columbia [Member]      
Area of Land (Square Foot) 1,600    
Metuchen, New Jersey [Member]      
Area of Land (Square Foot) 2,000    
CHINA      
Lessee, Number of Branches 7    
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 6 - Leases - Lease Cost (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Operating leases $ 1,334 $ 1,716
Short-term leases 180 299
Total lease cost $ 1,514 $ 2,015
Weighted-average remaining lease term (in years) (Year) 5 years 1 month 6 days  
Weighted-average discount rate 3.30%  
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 6 - Leases - Maturity of Lease Liabilities (Details)
$ in Thousands
Dec. 31, 2021
USD ($)
2022 $ 1,261
2023 672
2024 272
2025 261
2026 201
Thereafter 789
Total lease payments 3,456
Less: imputed interest (289)
Present value of lease liabilities $ 3,167
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 7 - Income Taxes (Details Textual) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Deferred Tax Assets, Valuation Allowance, Total $ 303,000 $ 340,000
Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Total 13,700,000  
Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Noncurrent 12,100,000  
Domestic Tax Authority [Member]    
Deferred Tax Assets, Valuation Allowance, Total 0  
Operating Loss Carryforwards, Total 603,000  
State and Local Jurisdiction [Member]    
Operating Loss Carryforwards, Subject to Expiration 427,000  
Foreign Tax Authority [Member]    
Operating Loss Carryforwards, Total $ 1,900,000  
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 7 - Income Taxes - Components of Income (Loss) Before Income Taxes (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Domestic $ (1,127) $ (1,663)
Foreign 2,637 3,153
Income before income taxes $ 1,510 $ 1,490
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 7 - Income Taxes - Components of Income Tax Provision (Benefit) (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Current taxes:    
Federal $ (207) $ (512)
State 9 1
Foreign 267 626
Total current taxes 69 115
Federal 309 346
State 7 6
Foreign 40 180
Total deferred taxes 356 532
Income tax provision $ 425 $ 647
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 7 - Income Taxes - Reconciliation of Reported Income Tax Provision (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income tax at federal statutory rate $ 317 $ 313
Effect of permanent differences 274 121
Global Intangible Low-Taxed Income 183 555
Change in valuation allowance (37) 51
Foreign rate differential (221) 72
Foreign tax credits (32) (98)
Stock-based compensation 10 164
Net operating loss carryback (84) (512)
Other reconciling items 15 (19)
Income tax provision $ 425 $ 647
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 7 - Income Taxes - Foreign Rate Differentials (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Foreign $ 2,637 $ 3,153
Department for International Tax Cooperation [Member]    
Statutory Tax Rate 0.00%  
Foreign $ 2,696 2,589
Inland Revenue, Hong Kong [Member]    
Statutory Tax Rate 16.50%  
Foreign $ 742 267
State Administration of Taxation, China [Member]    
Statutory Tax Rate 25.00%  
Foreign $ 152 $ 716
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 7 - Income Taxes - Deferred Income Taxes (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Deferred tax assets:    
Net operating losses $ 490 $ 628
Stock-based compensation 170 510
Operating lease liabilities 396 460
Other 51 60
Total deferred tax assets 1,107 1,658
Valuation allowance (303) (340)
Net deferred tax assets 804 1,318
Deferred tax liabilities:    
Operating lease assets 376 438
Foreign deferreds (153) (216)
Prepaids 113 113
Other 6 36
Total deferred tax liabilities (648) (803)
Net deferred tax assets $ 156 $ 515
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 9 - Stock-based Incentive Plans (Details Textual) - USD ($)
12 Months Ended
May 14, 2021
Mar. 15, 2021
Dec. 31, 2021
Equity Incentive Plan 2016 [Member]      
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)     2,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)     1,219,583
The Phantom Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)   10 years  
The Phantom Plan [Member] | Phantom Shares [Member] | Employees and Non-Employee Directors [Member]      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)   223,307  
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)   3 months  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)     111,652
Share-based Payment Arrangement, Expense     $ 773,000
The Phantom Plan [Member] | Phantom Shares [Member] | Employees and Non-Employee Directors [Member] | Maximum [Member]      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Maximum Payment Per Share (in dollars per share)   $ 12.00  
The Phantom Plan [Member] | Phantom Shares [Member] | NewNonEmployeeDirectorsMember      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) 9,074    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) 9,074    
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 9 - Stock-based Incentive Plans - Restricted Stock Activity (Details) - Restricted Stock [Member] - $ / shares
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Balance (in shares) 566,272 957,682
Balance, weighted avg. price (in dollars per share) $ 7.21 $ 7.34
Vested (in shares) (380,027) (391,410)
Vested, wtd. avg. price (in dollars per share) $ 7.27 $ 7.53
Balance (in shares) 186,245 566,272
Balance, weighted avg. price (in dollars per share) $ 7.08 $ 7.21
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 10 - Stockholders' Equity (Details Textual) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended 12 Months Ended
Dec. 31, 2021
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Jan. 12, 2016
Jul. 28, 2015
Preferred Stock, Shares Authorized (in shares) 5,000,000       5,000,000       5,000,000 5,000,000    
Preferred Stock, Par or Stated Value Per Share (in dollars per share) $ 0.001       $ 0.001       $ 0.001 $ 0.001    
Common Stock, Shares Authorized (in shares) 50,000,000       50,000,000       50,000,000 50,000,000    
Common Stock, Par or Stated Value Per Share (in dollars per share) $ 0.001       $ 0.001       $ 0.001 $ 0.001    
Common Stock, Dividends, Per Share, Declared (in dollars per share) $ 0.20 $ 0.20 $ 0.20 $ 0.20 $ 0.20 $ 0.20 $ 0.20 $ 0.20        
Dividends, Common Stock, Total                 $ 9.1 $ 9.1    
Stock Repurchase Program, Authorized Amount                     $ 70.0 $ 15.0
Stock Repurchase Program, Remaining Authorized Repurchase Amount $ 21.9               $ 21.9      
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 10 - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2021
USD ($)
Balance $ 67,697
Balance 59,488
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]  
Balance (325)
Other comprehensive loss (149)
Balance (474)
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]  
Balance (11)
Other comprehensive loss (7)
Balance (18)
AOCI Attributable to Parent [Member]  
Balance (336)
Other comprehensive loss (156)
Balance $ (492)
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 11 - Related Party Transactions (Details Textual) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Director [Member]    
Common Stock, Percentage of Beneficial Stock Outstanding 5.00%  
BHS [Member] | Royalty Agreement and License [Member]    
Royalty Expense $ 60,000 $ 83,000
Related Party Transaction, Automatic Renewal Period of Agreement (Year) 1 year  
Number of Days Termination Notice (Day) 90 days  
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 12 - Employee Benefit Plans (Details Textual) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage 90.00%  
Age Requirement For 401K Contributions (Year) 21 years  
Defined Contribution Plan, Employer Matching Contribution, Percent of Match 4.50% 4.50%
Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage 100.00% 100.00%
Defined Contribution Plan, Cost $ 69,000 $ 68,000
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 13 - Segment Information - Operating Information by Geographic Area (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Net sales $ 60,005 $ 62,071
Income (loss) from operations 1,571 669
Other income (expense), net (61) 821
Income before income taxes 1,510 1,490
Operating Segments [Member]    
Income (loss) from operations 10,294 9,511
Intersegment Eliminations [Member]    
Income (loss) from operations (8,723) (8,842)
CHINA    
Net sales 2,237 2,940
CHINA | Operating Segments [Member]    
Income (loss) from operations 74 330
Russia and Kazakhstan [Member]    
Net sales 854 888
Russia and Kazakhstan [Member] | Operating Segments [Member]    
Income (loss) from operations (146) (96)
Primary Reporting Segment [Member]    
Net sales 56,914 58,243
Primary Reporting Segment [Member] | Operating Segments [Member]    
Income (loss) from operations $ 10,366 $ 9,277
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 13 - Segment Information - Net Sales by Geographic Area (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Net sales $ 60,005 $ 62,071
UNITED STATES    
Net sales 1,278 1,573
CANADA    
Net sales 724 765
PERU    
Net sales 2,281 1,453
HONG KONG    
Net sales [1] 46,699 49,169
CHINA    
Net sales 2,237 2,940
TAIWAN, PROVINCE OF CHINA    
Net sales 2,706 3,034
Russia and Kazakhstan [Member]    
Net sales 854 888
Europe [Member]    
Net sales 1,136 1,050
Other Foreign Countries [Member]    
Net sales $ 2,090 $ 1,199
[1] Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors”.
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 13 - Segment Information - Net Sales by Product and Service (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Net sales $ 60,005 $ 62,071
Less: sales returns (391) (760)
Product [Member]    
Net sales 54,056 55,840
Administrative Fees, Freight and Other [Member]    
Net sales $ 6,340 $ 6,991
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 13 - Segment Information - Long-lived Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Total long-lived assets $ 463 $ 539
UNITED STATES    
Total long-lived assets 221 227
UNITED KINGDOM    
Total long-lived assets 105 146
CHINA    
Total long-lived assets 90 47
Other Foreign Countries [Member]    
Total long-lived assets $ 47 $ 119
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 14 - Subsequent Event (Details Textual) - $ / shares
3 Months Ended
Feb. 07, 2022
Dec. 31, 2021
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Common Stock, Dividends, Per Share, Declared (in dollars per share)   $ 0.20 $ 0.20 $ 0.20 $ 0.20 $ 0.20 $ 0.20 $ 0.20 $ 0.20
Subsequent Event [Member]                  
Common Stock, Dividends, Per Share, Declared (in dollars per share) $ 0.20                
XML 68 nhtc20211231_10k_htm.xml IDEA: XBRL DOCUMENT 0000912061 2021-01-01 2021-12-31 0000912061 2021-06-30 0000912061 2022-02-22 0000912061 2021-12-31 0000912061 2020-12-31 0000912061 2020-01-01 2020-12-31 0000912061 us-gaap:PreferredStockMember 2019-12-31 0000912061 us-gaap:CommonStockMember 2019-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000912061 us-gaap:RetainedEarningsMember 2019-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000912061 us-gaap:TreasuryStockMember 2019-12-31 0000912061 2019-12-31 0000912061 us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0000912061 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0000912061 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0000912061 us-gaap:TreasuryStockMember 2020-01-01 2020-12-31 0000912061 us-gaap:PreferredStockMember 2020-12-31 0000912061 us-gaap:CommonStockMember 2020-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000912061 us-gaap:RetainedEarningsMember 2020-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000912061 us-gaap:TreasuryStockMember 2020-12-31 0000912061 us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0000912061 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000912061 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0000912061 us-gaap:TreasuryStockMember 2021-01-01 2021-12-31 0000912061 us-gaap:PreferredStockMember 2021-12-31 0000912061 us-gaap:CommonStockMember 2021-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000912061 us-gaap:RetainedEarningsMember 2021-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000912061 us-gaap:TreasuryStockMember 2021-12-31 0000912061 srt:MinimumMember 2021-01-01 2021-12-31 0000912061 srt:MaximumMember 2021-01-01 2021-12-31 0000912061 country:VN 2019-11-30 0000912061 country:VN 2021-12-31 0000912061 country:VN 2020-12-31 0000912061 country:KP 2021-12-31 0000912061 srt:MinimumMember nhtc:OfficeEquipmentOfficeSoftwareAndCapitalizedInternaluseSoftwareDevelopmentMember 2021-01-01 2021-12-31 0000912061 srt:MaximumMember nhtc:OfficeEquipmentOfficeSoftwareAndCapitalizedInternaluseSoftwareDevelopmentMember 2021-01-01 2021-12-31 0000912061 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2021-01-01 2021-12-31 0000912061 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2021-01-01 2021-12-31 0000912061 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-12-31 0000912061 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0000912061 country:HK us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-12-31 0000912061 nhtc:UnshippedProductMember 2021-12-31 0000912061 nhtc:UnshippedProductMember 2020-12-31 0000912061 nhtc:AutoShipAdvancesMember 2021-12-31 0000912061 nhtc:AutoShipAdvancesMember 2020-12-31 0000912061 us-gaap:ProductAndServiceOtherMember 2021-12-31 0000912061 us-gaap:ProductAndServiceOtherMember 2020-12-31 0000912061 country:CN 2021-12-31 0000912061 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2021-12-31 0000912061 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2020-12-31 0000912061 us-gaap:FairValueInputsLevel2Member us-gaap:BankTimeDepositsMember 2021-12-31 0000912061 us-gaap:FairValueInputsLevel2Member us-gaap:BankTimeDepositsMember 2020-12-31 0000912061 us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalBondsMember 2021-12-31 0000912061 us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalBondsMember 2020-12-31 0000912061 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000912061 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0000912061 country:HK 2021-12-31 0000912061 nhtc:RollingHillsEstatesMember 2021-12-31 0000912061 nhtc:RollingHillsEstatesMember 2020-06-30 0000912061 nhtc:RichmondBritishColumbiaMember 2021-12-31 0000912061 nhtc:MetuchenNewJerseyMember 2021-12-31 0000912061 nhtc:DepartmentForInternationalTaxCooperationMember 2021-01-01 2021-12-31 0000912061 nhtc:DepartmentForInternationalTaxCooperationMember 2020-01-01 2020-12-31 0000912061 us-gaap:InlandRevenueHongKongMember 2021-01-01 2021-12-31 0000912061 us-gaap:InlandRevenueHongKongMember 2020-01-01 2020-12-31 0000912061 us-gaap:StateAdministrationOfTaxationChinaMember 2021-01-01 2021-12-31 0000912061 us-gaap:StateAdministrationOfTaxationChinaMember 2020-01-01 2020-12-31 0000912061 us-gaap:DomesticCountryMember 2021-12-31 0000912061 us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0000912061 us-gaap:ForeignCountryMember 2021-12-31 0000912061 nhtc:EquityIncentivePlan2016Member 2021-12-31 0000912061 us-gaap:RestrictedStockMember 2019-12-31 0000912061 us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0000912061 us-gaap:RestrictedStockMember 2020-12-31 0000912061 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0000912061 us-gaap:RestrictedStockMember 2021-12-31 0000912061 nhtc:ThePhantomPlanMember 2021-03-15 2021-03-15 0000912061 nhtc:EmployeesAndNonEmployeeDirectorsMember nhtc:PhantomSharesMember nhtc:ThePhantomPlanMember 2021-03-15 2021-03-15 0000912061 srt:MaximumMember nhtc:EmployeesAndNonEmployeeDirectorsMember nhtc:PhantomSharesMember nhtc:ThePhantomPlanMember 2021-03-15 0000912061 nhtc:NewnonemployeedirectorsMember nhtc:PhantomSharesMember nhtc:ThePhantomPlanMember 2021-05-14 2021-05-14 0000912061 nhtc:EmployeesAndNonEmployeeDirectorsMember nhtc:PhantomSharesMember nhtc:ThePhantomPlanMember 2021-01-01 2021-12-31 0000912061 2020-01-01 2020-03-31 0000912061 2020-04-01 2020-06-30 0000912061 2020-07-01 2020-09-30 0000912061 2020-10-01 2020-12-31 0000912061 2021-01-01 2021-03-31 0000912061 2021-04-01 2021-06-30 0000912061 2021-07-01 2021-09-30 0000912061 2021-10-01 2021-12-31 0000912061 2015-07-28 0000912061 2016-01-12 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-12-31 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-12-31 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-01-01 2021-12-31 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-12-31 0000912061 srt:DirectorMember 2021-12-31 0000912061 nhtc:RoyaltyAgreementAndLicenseMember nhtc:BHSMember 2021-01-01 2021-12-31 0000912061 nhtc:RoyaltyAgreementAndLicenseMember nhtc:BHSMember 2020-01-01 2020-12-31 0000912061 nhtc:PrimaryReportingSegmentMember 2021-01-01 2021-12-31 0000912061 nhtc:PrimaryReportingSegmentMember 2020-01-01 2020-12-31 0000912061 country:CN 2021-01-01 2021-12-31 0000912061 country:CN 2020-01-01 2020-12-31 0000912061 nhtc:RussiaAndKazakhstanMember 2021-01-01 2021-12-31 0000912061 nhtc:RussiaAndKazakhstanMember 2020-01-01 2020-12-31 0000912061 us-gaap:OperatingSegmentsMember nhtc:PrimaryReportingSegmentMember 2021-01-01 2021-12-31 0000912061 us-gaap:OperatingSegmentsMember nhtc:PrimaryReportingSegmentMember 2020-01-01 2020-12-31 0000912061 us-gaap:OperatingSegmentsMember country:CN 2021-01-01 2021-12-31 0000912061 us-gaap:OperatingSegmentsMember country:CN 2020-01-01 2020-12-31 0000912061 us-gaap:OperatingSegmentsMember nhtc:RussiaAndKazakhstanMember 2021-01-01 2021-12-31 0000912061 us-gaap:OperatingSegmentsMember nhtc:RussiaAndKazakhstanMember 2020-01-01 2020-12-31 0000912061 us-gaap:OperatingSegmentsMember 2021-01-01 2021-12-31 0000912061 us-gaap:OperatingSegmentsMember 2020-01-01 2020-12-31 0000912061 us-gaap:IntersegmentEliminationMember 2021-01-01 2021-12-31 0000912061 us-gaap:IntersegmentEliminationMember 2020-01-01 2020-12-31 0000912061 country:US 2021-01-01 2021-12-31 0000912061 country:US 2020-01-01 2020-12-31 0000912061 country:CA 2021-01-01 2021-12-31 0000912061 country:CA 2020-01-01 2020-12-31 0000912061 country:PE 2021-01-01 2021-12-31 0000912061 country:PE 2020-01-01 2020-12-31 0000912061 country:HK 2021-01-01 2021-12-31 0000912061 country:HK 2020-01-01 2020-12-31 0000912061 country:TW 2021-01-01 2021-12-31 0000912061 country:TW 2020-01-01 2020-12-31 0000912061 srt:EuropeMember 2021-01-01 2021-12-31 0000912061 srt:EuropeMember 2020-01-01 2020-12-31 0000912061 nhtc:OtherForeignCountriesMember 2021-01-01 2021-12-31 0000912061 nhtc:OtherForeignCountriesMember 2020-01-01 2020-12-31 0000912061 us-gaap:ProductMember 2021-01-01 2021-12-31 0000912061 us-gaap:ProductMember 2020-01-01 2020-12-31 0000912061 nhtc:AdministrativeFeesFreightAndOtherMember 2021-01-01 2021-12-31 0000912061 nhtc:AdministrativeFeesFreightAndOtherMember 2020-01-01 2020-12-31 0000912061 country:US 2021-12-31 0000912061 country:US 2020-12-31 0000912061 country:GB 2021-12-31 0000912061 country:GB 2020-12-31 0000912061 country:CN 2020-12-31 0000912061 nhtc:OtherForeignCountriesMember 2021-12-31 0000912061 nhtc:OtherForeignCountriesMember 2020-12-31 0000912061 us-gaap:SubsequentEventMember 2022-02-07 2022-02-07 iso4217:USD shares thunderdome:item iso4217:USD shares utr:D iso4217:VND pure utr:Y utr:sqft utr:M 0000912061 Natural Health Trends Corp. false --12-31 FY 2021 0.001 0.001 5000000 5000000 0 0 0 0 0.001 0.001 50000000 50000000 12979414 12979414 1556875 1556875 P2D P5D P3Y P5Y P5Y P7Y 299000 P14D P1Y 0.01 P5Y 0 P10Y P3M 0.20 0.20 0.20 0.20 0.20 0.20 0.20 9100000 P1Y P90D 0.045 1 10-K true 2021-12-31 false 001-36849 DE 59-2705336 132 Nathan Road Tsimshatsui HK 852 3107-0800 Common Stock, par value $0.001 per share NHTC NASDAQ No No Yes Yes Non-accelerated Filer true false true false 48628270 11422539 688 Marcum LLP Los Angeles, CA 83843000 92367000 5257000 3779000 4369000 3595000 93469000 99741000 463000 539000 3021000 3745000 522000 525000 309000 731000 571000 661000 98355000 105942000 761000 580000 1345000 1481000 3636000 3496000 1933000 1922000 8536000 3091000 6341000 8503000 1239000 1163000 865000 1270000 24656000 21506000 12130000 13748000 153000 216000 1928000 2775000 38867000 38245000 0 0 13000 13000 86102000 86102000 -231000 7822000 -492000 -336000 25904000 25904000 59488000 67697000 98355000 105942000 60005000 62071000 15010000 16990000 44995000 45081000 25578000 26204000 17846000 18208000 43424000 44412000 1571000 669000 -61000 821000 1510000 1490000 425000 647000 1085000 843000 0.10 0.08 0.09 0.07 11017000 10630000 11424000 11424000 1085000 843000 -149000 920000 -7000 8000 929000 1771000 0 0 12979414 13000 86102000 16117000 -1264000 -1556875 -25904000 75064000 0 0 0 843000 0 0 843000 -0 -0 -0 9138000 -0 -0 9138000 0 0 0 0 920000 0 920000 0 0 0 0 8000 0 8000 0 0 12979414 13000 86102000 7822000 -336000 -1556875 -25904000 67697000 0 0 0 1085000 0 0 1085000 -0 -0 -0 9138000 -0 -0 9138000 0 0 0 0 -149000 0 -149000 0 0 0 0 -7000 0 -7000 0 0 12979414 13000 86102000 -231000 -492000 -1556875 -25904000 59488000 1085000 843000 299000 410000 1163000 1532000 362000 1339000 1547000 -2700000 803000 -2322000 -68000 -181000 182000 -102000 -1753000 -311000 212000 566000 20000 -471000 5482000 -1433000 -2122000 -4491000 -1237000 -1427000 -395000 227000 1016000 1885000 225000 211000 -225000 -211000 9138000 9138000 -9138000 -9138000 -180000 931000 -8527000 -6533000 92892000 99425000 84365000 92892000 1865000 -2097000 472000 2747000 <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"><b><em style="font: inherit;">1.</em>     NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 7.5pt;"/><p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 7.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"><i>Nature of Operations</i></p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">Natural Health Trends Corp., a Delaware corporation (whether or <em style="font: inherit;">not</em> including its subsidiaries, the “Company”), is an international direct-selling and e-commerce company. Subsidiaries controlled by the Company sell personal care, wellness, and “quality of life” products under the “NHT Global” brand.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">The Company’s wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Malaysia, Singapore and Thailand; South Korea; Japan; India; and Europe. The Company also operates in Russia and Kazakhstan through an engagement with a local service provider.</p><p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"> </p><p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"><i>Principles of Consolidation</i></p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.</p><p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"> </p><p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"><i>Use of Estimates</i></p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates associated with revenue recognition, as well as those used in the determination of liabilities related to sales returns, commissions and income taxes. Various assumptions and other factors prompt the determination of these significant estimates. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. The actual results <em style="font: inherit;"> may </em>differ materially and adversely from the Company’s estimates. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.</p><p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"> </p><p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"><i>Cash and Cash Equivalents</i></p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">Cash and cash equivalents include the Company’s investments in money market funds, government and municipal debt securities, and corporate debt securities. The Company considers all highly liquid investments with original maturities of <em style="font: inherit;">three</em> months or less when purchased to be cash equivalents. Debt securities classified as cash equivalents are required to be accounted for in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) <em style="font: inherit;">320,</em> <i>Investments - Debt and Equity Securities</i>. As such, the Company determined its investments in debt securities held at <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income and expense. Realized gains and losses, as well as interest income, are also included in other income and expense. The fair values of securities are based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">The Company includes credit card receivables due from certain of its credit card processors in its cash and cash equivalents as the cash proceeds are received within <span style="-sec-ix-hidden:c80953554">two</span> to <span style="-sec-ix-hidden:c80953556">five</span> days.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">The Company maintains certain cash balances at several institutions located in the United States, Hong Kong and elsewhere which at times <em style="font: inherit;"> may </em>exceed insured limits. The Company has <em style="font: inherit;">not</em> experienced any losses in such accounts and believes it is <em style="font: inherit;">not</em> exposed to any significant credit risk.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"> </p><p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt;"><i><span style="background-color:#ffffff;">Restricted Cash</span></i></p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">In <em style="font: inherit;"> November 2019, </em>the Company funded a bank deposit account in the amount of VND 10 billion ($438,000 and $433,000 at <em style="font: inherit;"> December 31, </em><em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> respectively) for purposes of submitting a direct selling license application in Vietnam. Such deposit is required by Vietnamese law to establish a consumer protection fund for direct selling participants. In <em style="font: inherit;"> January 2022, </em>the Company submitted an application to withdraw the bank deposit since <em style="font: inherit;">no</em> direct selling license has been successfully obtained to operate in Vietnam.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">The Company periodically maintains a cash reserve with certain credit card processing companies to provide for potential uncollectible amounts and chargebacks. Those cash reserves held by credit card processing companies located in South Korea are reflected in noncurrent assets since they require the Company to provide 100% collateral before processing transactions, which must be maintained indefinitely.</p><p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p><p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"><i>Inventories</i></p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">Inventories are stated at the lower of cost or net realizable value, using the <em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out method. The Company reviews its inventory for obsolescence and any inventory identified as obsolete is reserved or written off. The Company’s determination of obsolescence is based on assumptions about the demand for its products, product expiration dates, estimated future sales, and management’s future plans.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p><p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"/><p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"><i>Property and Equipment</i></p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally <span style="-sec-ix-hidden:c80953577">three</span> to <span style="-sec-ix-hidden:c80953578">five</span> years for office equipment, office software and capitalized internal-use software development costs and <span style="-sec-ix-hidden:c80953579">five</span> to <span style="-sec-ix-hidden:c80953580">seven</span> years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the assets. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation and amortization expenses are included in the statement of operations as selling, general and administrative expenses. Such expense totaled $<span style="background-color:#ffffff;"><span style="-sec-ix-hidden:c80953581">299</span></span><em style="font: inherit;">,000</em> and $410,000 during <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em>, respectively.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Recoverability of these assets is measured by comparison of its carrying amounts to future undiscounted cash flows the assets are expected to generate. If property and equipment are considered to be impaired, the impairment to be recognized equals the amount by which the carrying value of the asset exceeds its fair value.</p><p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"> </p><p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; "><i>Income Taxes</i></p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">The Company recognizes income taxes under the liability method of accounting for income taxes. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is a result of changes in deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be ultimately realized based on the more likely than <em style="font: inherit;">not</em> recognition criteria. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than <em style="font: inherit;">not</em> that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has evaluated its tax positions and determined that there are <em style="font: inherit;">no</em> significant uncertain tax positions for the current year or years prior. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than <em style="font: inherit;">fifty</em> percent likelihood of being realized upon ultimate resolution.  The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense.  Deferred taxes are <em style="font: inherit;">not</em> provided for state income tax purposes on the portion of undistributed earnings of subsidiaries outside of the United States when these earnings are considered permanently reinvested.</p><p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"> </p><p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; "><i>Amounts Held in eWallets</i></p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; "> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; ">The Company requires commission payments of certain members in Hong Kong and other markets to be <em style="font: inherit;">first</em> recorded into an electronic wallet (eWallet) account in lieu of being paid out directly to members. The eWallet functionality allows members to place new product orders utilizing eWallet available balance and/or request commission payout via multiple payment methods. Amounts held in eWallets are reflected on the balance sheet as a current liability.</p><p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; "/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; "> </p><p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; "/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; "><i>Foreign Currency</i></p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; "> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; ">The functional currency of the Company’s international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates.  The resulting translation adjustments are recorded directly into stockholders' equity.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; "> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Aggregate transaction gains or losses, including gains or losses related to foreign-denominated cash and cash equivalents and the re-measurement of certain inter-company balances, are included in the statement of operations as other income and expense. Loss on foreign exchange totaling $248,000 and $335,000 was recognized during <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em>, respectively.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0px;"> </p><p style="font-family: Times New Roman; font-size: 10pt; margin: 0px;"/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt;"><i style=" font-size: 10pt; text-indent: 0pt;">Commissions Expense</i></p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.  Each of the Company’s products are designated a specified number of bonus volume points, which is essentially a percentage of the product’s wholesale price.  The Company accrues commissions when earned and as the related revenue is recognized and pays commissions on product sales generally <em style="font: inherit;">two</em> weeks following the end of the weekly sales period.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">In some markets, the Company also pays certain bonuses on purchases by up to <em style="font: inherit;">three</em> generations of personally sponsored members, as well as bonuses on commissions earned by up to <em style="font: inherit;">seven</em> generations of personally sponsored members. Independent members <em style="font: inherit;"> may </em>also earn incentives based on meeting certain qualifications during a designated incentive period, which <em style="font: inherit;"> may </em>range from several weeks to up to a year.  The Company estimates and accrues all costs associated with the incentives as the members meet the qualification requirements.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">From time to time the Company makes modifications and enhancements to the Company’s compensation plan to help motivate members, which can have an impact on member commissions. The Company also enters into performance-based agreements for business or market development, which <em style="font: inherit;"> may </em>result in additional compensation to specific members.</p><p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"> </p><p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"><i>Net Income Per Common Share</i></p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has <em style="font: inherit;">not</em> yet recognized, if any, is assumed to be used to repurchase shares.</p><p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"> </p><p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"><i>Certain Risks and Concentrations</i></p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">In late <em style="font: inherit;">2019</em> or early <em style="font: inherit;">2020</em> an outbreak of COVID-<em style="font: inherit;">19</em> was <em style="font: inherit;">first</em> identified in China and subsequently spread around the world. On <em style="font: inherit;"> March 11, 2020 </em>the World Health Organization declared the COVID-<em style="font: inherit;">19</em> outbreak a global pandemic. The outbreak caused the Chinese government to implement powerful measures to control the virus, such as requiring businesses to close throughout various areas of China and restricting public gatherings and certain travel within the country. The Company has significant business in China and in <em style="font: inherit;">2021</em> generated approximately 78% of its revenue in Hong Kong, substantially all of which was derived from the sale of products to members in China. The Chinese government continues to adjust the restrictive measures that it imposes to control COVID-<em style="font: inherit;">19</em> based on then-current local circumstances, as have the governments of the other countries in which the Company operates. The scope and impact of the pandemic and related control measures are uncertain, but the Company has taken steps to adapt some of its marketing programs, such as relying on certain product promotions and webcast training, to overcome the physical restrictions imposed in response to the pandemic. The Company has also canceled or rescheduled a number of in-person member events over the course of the pandemic. The severity of the impact on the Company of the COVID-<em style="font: inherit;">19</em> pandemic will depend on future developments, including the duration and spread of the virus, and related control measures, which the Company is unable to accurately predict. Regardless, these disruptions have materially negatively impacted the Company’s financial results throughout <em style="font: inherit;">2020</em> and <em style="font: inherit;">2021,</em> and the Company expects that its financial results for the near-term <em style="font: inherit;"> may </em>be adversely affected. These disruptions have also adversely impacted the operations of some of the Company’s <em style="font: inherit;">third</em>-party logistics providers, and it expects that the future operations of these logistics providers and other <em style="font: inherit;">third</em> parties with whom it works <em style="font: inherit;"> may </em>be adversely affected by these disruptions. The Company will continue to assess the operational and financial impact of the COVID-<em style="font: inherit;">19</em> pandemic.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">In contrast to the Company’s business in other parts of the world, the Company’s China subsidiary has <em style="font: inherit;">not</em> implemented a direct sales model in China. The Chinese government permits direct selling only by organizations that have a license and has also adopted anti-pyramid selling and multi-level marketing legislation. The Company previously submitted a preliminary application for a direct selling license in China in <em style="font: inherit;"> August 2015, </em>but in <em style="font: inherit;">2019</em> a Chinese governmental authority recommended that the Company withdraw its application. The Company understands that the governmental authorities recommended that other companies with pending direct selling license applications also withdraw their applications. The Company applied to withdraw its application in <em style="font: inherit;"> November 2019, </em>and the governmental authorities approved the withdrawal of its application shortly thereafter. The Company operates an e-commerce direct selling platform in Hong Kong and recognizes the revenue derived from sales to both Hong Kong and Chinese members as being generated in Hong Kong. Products purchased by members in China are delivered to <em style="font: inherit;">third</em> parties that act as the importers of record under agreements to pay applicable duties. In addition, through a Chinese entity, the Company sells products in China using an e-commerce retail platform. The Chinese entity operates separately from the Hong Kong entity, and a Chinese member <em style="font: inherit;"> may </em>elect to participate separately or in both.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">The Company continually evaluates its business in China and Hong Kong for compliance with applicable laws and regulations, including seeking the input of outside professionals and certain Chinese authorities. This process can and has resulted in the identification of certain matters of potential noncompliance. The Company works on a continuing basis to satisfactorily address such matters, however there can be <em style="font: inherit;">no</em> assurance that adequate steps are taken or that applicable laws and regulations are properly interpreted. Should the government authorities determine that the Company’s activities violate applicable laws and regulations, including China’s direct selling, pyramid selling or multi-level marketing laws and regulations, or should new laws or regulations be adopted, there could be a material adverse effect on the Company’s business, financial condition and results of operations.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">Although the Company attempts to work closely with both national and local Chinese governmental agencies in conducting its business, the Company’s efforts to comply with national and local laws <em style="font: inherit;"> may </em>be harmed by a rapidly evolving regulatory climate, concerns about activities resembling violations of direct selling, pyramid selling or multi-level marketing legislation, subjective interpretations of laws and regulations, and activities by individual members that <em style="font: inherit;"> may </em>violate laws notwithstanding the Company's policies prohibiting such activities. Any determination that the Company’s operations or activities, or the activities of its individual members or employee sales representatives, or importers of record are <em style="font: inherit;">not</em> in compliance with applicable laws and regulations could result in the imposition of substantial fines, extended interruptions of business, restrictions on the Company’s future ability to obtain business licenses or expand into new locations, changes to its business model, the termination of required licenses to conduct business, or other actions, any of which could materially harm the Company’s business, financial condition and results of operations.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"> </p> <p style="text-align: left; text-indent: 25.5pt; margin: 0pt; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">No</em> single market other than Hong Kong had net sales greater than <em style="font: inherit;">10%</em> of total sales. Sales are made to the Company’s members and <em style="font: inherit;">no</em> single customer accounted for <em style="font: inherit;">10%</em> or more of its net sales. However, the Company’s business model can result in a concentration of sales to several different members and their network of members. Although <em style="font: inherit;">no</em> single member accounted for <em style="font: inherit;">10%</em> or more of net sales, the loss of a key member or that member’s network could have an adverse effect on the Company’s net sales and financial results.</p> <p style="text-align: left; text-indent: 27pt; margin: 0pt; font-family: Times New Roman; font-size: 10pt;"> </p> <p style="text-align: left; text-indent: 25.5pt; margin: 0pt; font-family: Times New Roman; font-size: 10pt;">The Company’s<i> Premium Noni Juice, Enhanced Essential Probiotics </i>and<i> Triotein™ </i>products each account for at least <em style="font: inherit;">10%</em> of the Company’s total revenue. The Company currently sources each of these products from a single supplier. If demand decreases significantly, government regulation restricts their sale, the Company is unable to adequately source or deliver the products, or the Company ceases offering the products for any reason without suitable replacements, the Company’s business, financial condition and results of operations could be materially and adversely affected.</p><p style="text-align: left; text-indent: 25.5pt; margin: 0pt; font-family: Times New Roman; font-size: 10pt;"/> <p style="text-align: left; text-indent: 27pt; margin: 0pt; font-family: Times New Roman; font-size: 10pt;"> </p><p style="text-align: left; text-indent: 27pt; margin: 0pt; font-family: Times New Roman; font-size: 10pt;"/> <p style="text-align: left; text-indent: 0pt; margin: 0pt; font-family: Times New Roman; font-size: 10pt;"><i>Fair Value of Financial Instruments</i></p> <p style="text-align: left; text-indent: 25.5pt; font-family: Times New Roman; font-size: 10pt; margin: 0px;"> </p> <p style="text-align: left; text-indent: 25.5pt; font-family: Times New Roman; font-size: 10pt; margin: 0px;">The carrying amounts of the Company’s financial instruments, including cash and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents.</p> <p style="text-align: left; text-indent: 27pt; margin: 0pt; font-family: Times New Roman; font-size: 10pt;"> </p> <p style="text-align: left; text-indent: 27pt; margin: 0pt; font-family: Times New Roman; font-size: 10pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to <em style="font: inherit;">not</em> fair value existing eligible items.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"> </p><p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"/><p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"><i>Recent Accounting Pronouncements</i></p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">In <em style="font: inherit;"> June </em><em style="font: inherit;">2016,</em> the FASB issued Accounting Standards Update (“ASU”) <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments - Credit Losses (Topic <em style="font: inherit;">326</em>): Measurement of Credit Losses on Financial Instruments</i>, which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost basis and added Topic <em style="font: inherit;">326</em> to the FASB ASC. In <em style="font: inherit;"> November 2019, </em>the FASB issued ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">11,</em> <i>Codification Improvements to Topic <em style="font: inherit;">326,</em> Financial Instruments - Credit Losses</i>.  The amendments to ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">11</em> clarify, correct and make improvements to Topic <em style="font: inherit;">326.</em>  ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> as well as the updates in ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">11</em> are effective for interim and annual periods beginning after <em style="font: inherit;"> December 15, 2022, </em>and early adoption is permitted.  The Company is currently evaluating the impact of this standard on its consolidated financial statements.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 27pt;">Other recently issued accounting pronouncements did <em style="font: inherit;">not</em> or are <em style="font: inherit;">not</em> believed by management to have a material impact on the Company’s present or future consolidated financial statements.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p><p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 7.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"><i>Nature of Operations</i></p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">Natural Health Trends Corp., a Delaware corporation (whether or <em style="font: inherit;">not</em> including its subsidiaries, the “Company”), is an international direct-selling and e-commerce company. Subsidiaries controlled by the Company sell personal care, wellness, and “quality of life” products under the “NHT Global” brand.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">The Company’s wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Malaysia, Singapore and Thailand; South Korea; Japan; India; and Europe. The Company also operates in Russia and Kazakhstan through an engagement with a local service provider.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"><i>Principles of Consolidation</i></p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"><i>Use of Estimates</i></p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates associated with revenue recognition, as well as those used in the determination of liabilities related to sales returns, commissions and income taxes. Various assumptions and other factors prompt the determination of these significant estimates. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. The actual results <em style="font: inherit;"> may </em>differ materially and adversely from the Company’s estimates. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"><i>Cash and Cash Equivalents</i></p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">Cash and cash equivalents include the Company’s investments in money market funds, government and municipal debt securities, and corporate debt securities. The Company considers all highly liquid investments with original maturities of <em style="font: inherit;">three</em> months or less when purchased to be cash equivalents. Debt securities classified as cash equivalents are required to be accounted for in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) <em style="font: inherit;">320,</em> <i>Investments - Debt and Equity Securities</i>. As such, the Company determined its investments in debt securities held at <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income and expense. Realized gains and losses, as well as interest income, are also included in other income and expense. The fair values of securities are based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">The Company includes credit card receivables due from certain of its credit card processors in its cash and cash equivalents as the cash proceeds are received within <span style="-sec-ix-hidden:c80953554">two</span> to <span style="-sec-ix-hidden:c80953556">five</span> days.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">The Company maintains certain cash balances at several institutions located in the United States, Hong Kong and elsewhere which at times <em style="font: inherit;"> may </em>exceed insured limits. The Company has <em style="font: inherit;">not</em> experienced any losses in such accounts and believes it is <em style="font: inherit;">not</em> exposed to any significant credit risk.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt;"><i><span style="background-color:#ffffff;">Restricted Cash</span></i></p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">In <em style="font: inherit;"> November 2019, </em>the Company funded a bank deposit account in the amount of VND 10 billion ($438,000 and $433,000 at <em style="font: inherit;"> December 31, </em><em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> respectively) for purposes of submitting a direct selling license application in Vietnam. Such deposit is required by Vietnamese law to establish a consumer protection fund for direct selling participants. In <em style="font: inherit;"> January 2022, </em>the Company submitted an application to withdraw the bank deposit since <em style="font: inherit;">no</em> direct selling license has been successfully obtained to operate in Vietnam.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">The Company periodically maintains a cash reserve with certain credit card processing companies to provide for potential uncollectible amounts and chargebacks. Those cash reserves held by credit card processing companies located in South Korea are reflected in noncurrent assets since they require the Company to provide 100% collateral before processing transactions, which must be maintained indefinitely.</p> 10000000000 438000 433000 1 <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"><i>Inventories</i></p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">Inventories are stated at the lower of cost or net realizable value, using the <em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out method. The Company reviews its inventory for obsolescence and any inventory identified as obsolete is reserved or written off. The Company’s determination of obsolescence is based on assumptions about the demand for its products, product expiration dates, estimated future sales, and management’s future plans.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"/><p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"><i>Property and Equipment</i></p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally <span style="-sec-ix-hidden:c80953577">three</span> to <span style="-sec-ix-hidden:c80953578">five</span> years for office equipment, office software and capitalized internal-use software development costs and <span style="-sec-ix-hidden:c80953579">five</span> to <span style="-sec-ix-hidden:c80953580">seven</span> years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the assets. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation and amortization expenses are included in the statement of operations as selling, general and administrative expenses. Such expense totaled $<span style="background-color:#ffffff;"><span style="-sec-ix-hidden:c80953581">299</span></span><em style="font: inherit;">,000</em> and $410,000 during <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em>, respectively.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Recoverability of these assets is measured by comparison of its carrying amounts to future undiscounted cash flows the assets are expected to generate. If property and equipment are considered to be impaired, the impairment to be recognized equals the amount by which the carrying value of the asset exceeds its fair value.</p> 410000 <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; "><i>Income Taxes</i></p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">The Company recognizes income taxes under the liability method of accounting for income taxes. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is a result of changes in deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be ultimately realized based on the more likely than <em style="font: inherit;">not</em> recognition criteria. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than <em style="font: inherit;">not</em> that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has evaluated its tax positions and determined that there are <em style="font: inherit;">no</em> significant uncertain tax positions for the current year or years prior. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than <em style="font: inherit;">fifty</em> percent likelihood of being realized upon ultimate resolution.  The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense.  Deferred taxes are <em style="font: inherit;">not</em> provided for state income tax purposes on the portion of undistributed earnings of subsidiaries outside of the United States when these earnings are considered permanently reinvested.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; "><i>Amounts Held in eWallets</i></p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; "> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; ">The Company requires commission payments of certain members in Hong Kong and other markets to be <em style="font: inherit;">first</em> recorded into an electronic wallet (eWallet) account in lieu of being paid out directly to members. The eWallet functionality allows members to place new product orders utilizing eWallet available balance and/or request commission payout via multiple payment methods. Amounts held in eWallets are reflected on the balance sheet as a current liability.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; "/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; "><i>Foreign Currency</i></p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; "> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; ">The functional currency of the Company’s international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates.  The resulting translation adjustments are recorded directly into stockholders' equity.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; "> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Aggregate transaction gains or losses, including gains or losses related to foreign-denominated cash and cash equivalents and the re-measurement of certain inter-company balances, are included in the statement of operations as other income and expense. Loss on foreign exchange totaling $248,000 and $335,000 was recognized during <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em>, respectively.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0px;"> </p> -248000 -335000 <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt;"><i style=" font-size: 10pt; text-indent: 0pt;">Commissions Expense</i></p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.  Each of the Company’s products are designated a specified number of bonus volume points, which is essentially a percentage of the product’s wholesale price.  The Company accrues commissions when earned and as the related revenue is recognized and pays commissions on product sales generally <em style="font: inherit;">two</em> weeks following the end of the weekly sales period.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">In some markets, the Company also pays certain bonuses on purchases by up to <em style="font: inherit;">three</em> generations of personally sponsored members, as well as bonuses on commissions earned by up to <em style="font: inherit;">seven</em> generations of personally sponsored members. Independent members <em style="font: inherit;"> may </em>also earn incentives based on meeting certain qualifications during a designated incentive period, which <em style="font: inherit;"> may </em>range from several weeks to up to a year.  The Company estimates and accrues all costs associated with the incentives as the members meet the qualification requirements.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">From time to time the Company makes modifications and enhancements to the Company’s compensation plan to help motivate members, which can have an impact on member commissions. The Company also enters into performance-based agreements for business or market development, which <em style="font: inherit;"> may </em>result in additional compensation to specific members.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"><i>Net Income Per Common Share</i></p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has <em style="font: inherit;">not</em> yet recognized, if any, is assumed to be used to repurchase shares.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"><i>Certain Risks and Concentrations</i></p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">In late <em style="font: inherit;">2019</em> or early <em style="font: inherit;">2020</em> an outbreak of COVID-<em style="font: inherit;">19</em> was <em style="font: inherit;">first</em> identified in China and subsequently spread around the world. On <em style="font: inherit;"> March 11, 2020 </em>the World Health Organization declared the COVID-<em style="font: inherit;">19</em> outbreak a global pandemic. The outbreak caused the Chinese government to implement powerful measures to control the virus, such as requiring businesses to close throughout various areas of China and restricting public gatherings and certain travel within the country. The Company has significant business in China and in <em style="font: inherit;">2021</em> generated approximately 78% of its revenue in Hong Kong, substantially all of which was derived from the sale of products to members in China. The Chinese government continues to adjust the restrictive measures that it imposes to control COVID-<em style="font: inherit;">19</em> based on then-current local circumstances, as have the governments of the other countries in which the Company operates. The scope and impact of the pandemic and related control measures are uncertain, but the Company has taken steps to adapt some of its marketing programs, such as relying on certain product promotions and webcast training, to overcome the physical restrictions imposed in response to the pandemic. The Company has also canceled or rescheduled a number of in-person member events over the course of the pandemic. The severity of the impact on the Company of the COVID-<em style="font: inherit;">19</em> pandemic will depend on future developments, including the duration and spread of the virus, and related control measures, which the Company is unable to accurately predict. Regardless, these disruptions have materially negatively impacted the Company’s financial results throughout <em style="font: inherit;">2020</em> and <em style="font: inherit;">2021,</em> and the Company expects that its financial results for the near-term <em style="font: inherit;"> may </em>be adversely affected. These disruptions have also adversely impacted the operations of some of the Company’s <em style="font: inherit;">third</em>-party logistics providers, and it expects that the future operations of these logistics providers and other <em style="font: inherit;">third</em> parties with whom it works <em style="font: inherit;"> may </em>be adversely affected by these disruptions. The Company will continue to assess the operational and financial impact of the COVID-<em style="font: inherit;">19</em> pandemic.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">In contrast to the Company’s business in other parts of the world, the Company’s China subsidiary has <em style="font: inherit;">not</em> implemented a direct sales model in China. The Chinese government permits direct selling only by organizations that have a license and has also adopted anti-pyramid selling and multi-level marketing legislation. The Company previously submitted a preliminary application for a direct selling license in China in <em style="font: inherit;"> August 2015, </em>but in <em style="font: inherit;">2019</em> a Chinese governmental authority recommended that the Company withdraw its application. The Company understands that the governmental authorities recommended that other companies with pending direct selling license applications also withdraw their applications. The Company applied to withdraw its application in <em style="font: inherit;"> November 2019, </em>and the governmental authorities approved the withdrawal of its application shortly thereafter. The Company operates an e-commerce direct selling platform in Hong Kong and recognizes the revenue derived from sales to both Hong Kong and Chinese members as being generated in Hong Kong. Products purchased by members in China are delivered to <em style="font: inherit;">third</em> parties that act as the importers of record under agreements to pay applicable duties. In addition, through a Chinese entity, the Company sells products in China using an e-commerce retail platform. The Chinese entity operates separately from the Hong Kong entity, and a Chinese member <em style="font: inherit;"> may </em>elect to participate separately or in both.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">The Company continually evaluates its business in China and Hong Kong for compliance with applicable laws and regulations, including seeking the input of outside professionals and certain Chinese authorities. This process can and has resulted in the identification of certain matters of potential noncompliance. The Company works on a continuing basis to satisfactorily address such matters, however there can be <em style="font: inherit;">no</em> assurance that adequate steps are taken or that applicable laws and regulations are properly interpreted. Should the government authorities determine that the Company’s activities violate applicable laws and regulations, including China’s direct selling, pyramid selling or multi-level marketing laws and regulations, or should new laws or regulations be adopted, there could be a material adverse effect on the Company’s business, financial condition and results of operations.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">Although the Company attempts to work closely with both national and local Chinese governmental agencies in conducting its business, the Company’s efforts to comply with national and local laws <em style="font: inherit;"> may </em>be harmed by a rapidly evolving regulatory climate, concerns about activities resembling violations of direct selling, pyramid selling or multi-level marketing legislation, subjective interpretations of laws and regulations, and activities by individual members that <em style="font: inherit;"> may </em>violate laws notwithstanding the Company's policies prohibiting such activities. Any determination that the Company’s operations or activities, or the activities of its individual members or employee sales representatives, or importers of record are <em style="font: inherit;">not</em> in compliance with applicable laws and regulations could result in the imposition of substantial fines, extended interruptions of business, restrictions on the Company’s future ability to obtain business licenses or expand into new locations, changes to its business model, the termination of required licenses to conduct business, or other actions, any of which could materially harm the Company’s business, financial condition and results of operations.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;"> </p> <p style="text-align: left; text-indent: 25.5pt; margin: 0pt; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">No</em> single market other than Hong Kong had net sales greater than <em style="font: inherit;">10%</em> of total sales. Sales are made to the Company’s members and <em style="font: inherit;">no</em> single customer accounted for <em style="font: inherit;">10%</em> or more of its net sales. However, the Company’s business model can result in a concentration of sales to several different members and their network of members. Although <em style="font: inherit;">no</em> single member accounted for <em style="font: inherit;">10%</em> or more of net sales, the loss of a key member or that member’s network could have an adverse effect on the Company’s net sales and financial results.</p> <p style="text-align: left; text-indent: 27pt; margin: 0pt; font-family: Times New Roman; font-size: 10pt;"> </p> <p style="text-align: left; text-indent: 25.5pt; margin: 0pt; font-family: Times New Roman; font-size: 10pt;">The Company’s<i> Premium Noni Juice, Enhanced Essential Probiotics </i>and<i> Triotein™ </i>products each account for at least <em style="font: inherit;">10%</em> of the Company’s total revenue. The Company currently sources each of these products from a single supplier. If demand decreases significantly, government regulation restricts their sale, the Company is unable to adequately source or deliver the products, or the Company ceases offering the products for any reason without suitable replacements, the Company’s business, financial condition and results of operations could be materially and adversely affected.</p> 0.78 <p style="text-align: left; text-indent: 27pt; margin: 0pt; font-family: Times New Roman; font-size: 10pt;"/> <p style="text-align: left; text-indent: 0pt; margin: 0pt; font-family: Times New Roman; font-size: 10pt;"><i>Fair Value of Financial Instruments</i></p> <p style="text-align: left; text-indent: 25.5pt; font-family: Times New Roman; font-size: 10pt; margin: 0px;"> </p> <p style="text-align: left; text-indent: 25.5pt; font-family: Times New Roman; font-size: 10pt; margin: 0px;">The carrying amounts of the Company’s financial instruments, including cash and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents.</p> <p style="text-align: left; text-indent: 27pt; margin: 0pt; font-family: Times New Roman; font-size: 10pt;"> </p> <p style="text-align: left; text-indent: 27pt; margin: 0pt; font-family: Times New Roman; font-size: 10pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to <em style="font: inherit;">not</em> fair value existing eligible items.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"/><p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"/> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"><i>Recent Accounting Pronouncements</i></p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">In <em style="font: inherit;"> June </em><em style="font: inherit;">2016,</em> the FASB issued Accounting Standards Update (“ASU”) <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments - Credit Losses (Topic <em style="font: inherit;">326</em>): Measurement of Credit Losses on Financial Instruments</i>, which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost basis and added Topic <em style="font: inherit;">326</em> to the FASB ASC. In <em style="font: inherit;"> November 2019, </em>the FASB issued ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">11,</em> <i>Codification Improvements to Topic <em style="font: inherit;">326,</em> Financial Instruments - Credit Losses</i>.  The amendments to ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">11</em> clarify, correct and make improvements to Topic <em style="font: inherit;">326.</em>  ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> as well as the updates in ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">11</em> are effective for interim and annual periods beginning after <em style="font: inherit;"> December 15, 2022, </em>and early adoption is permitted.  The Company is currently evaluating the impact of this standard on its consolidated financial statements.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 27pt;">Other recently issued accounting pronouncements did <em style="font: inherit;">not</em> or are <em style="font: inherit;">not</em> believed by management to have a material impact on the Company’s present or future consolidated financial statements.</p> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">2.</em> REVENUE</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Revenue Recognition</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">All revenue is recognized when the performance obligations under a contract, including any product vouchers sold on a stand-alone basis in Hong Kong, are satisfied. Product sales are recognized when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company’s sales arrangements do <em style="font: inherit;">not</em> contain right of inspection or customer acceptance provisions other than general rights of return. These contracts are generally short-term in nature.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience. The reserve is based upon the return policy of each country, which varies from <span style="-sec-ix-hidden:c80953650">14</span> days to <span style="-sec-ix-hidden:c80953651">one</span> year, and their historical return rates, which range from 1% to 9% of sales. Sales returns were 1% of sales for each of <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em>.  <em style="font: inherit;">No</em> material changes in estimates have been recognized during the periods presented. See Note <em style="font: inherit;">4</em> for additional information.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company has elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrues for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Various taxes on the sale of products to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><span style="background-color:#ffffff;">Deferred Revenue</span></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product orders and unredeemed product vouchers are considered a contract liability and are recorded as deferred revenue. The increase in deferred revenue from <em style="font: inherit;"> December 31, 2020 </em>to <em style="font: inherit;"> December 31, 2021 </em>is primarily due to $<span style="background-color:#ffffff;">6.5</span> million of cash received for unshipped product orders and unredeemed product vouchers offset by $1.0 million of revenue recognized during the year ended <em style="font: inherit;"> December 31, 2021 </em>that was included in deferred revenue as of <em style="font: inherit;"> December 31, 2020. </em>See Note <em style="font: inherit;">4</em> for additional information.</p> <p><i>Disaggregation of Revenue</i></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">The Company sells products to a member network that operates in a seamless manner from market to market, except for the Chinese market where it sells to some consumers through an e-commerce retail platform and the Russia and Kazakhstan market where the Company operates through the engagement of a <em style="font: inherit;">third</em>-party service provider. See Note <em style="font: inherit;">13</em> for additional information.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Arrangements with Multiple Performance Obligations</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company’s contracts with customers <em style="font: inherit;"> may </em>include multiple performance obligations. For such arrangements, the Company allocates revenues to each performance obligation based on its relative standalone selling price. The Company generally determines standalone selling prices based on the prices charged for individual products to similar customers.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Practical Expedients</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company generally expenses sales commissions when incurred because the amortization period would be <em style="font: inherit;">one</em> year or less. These costs are recorded in commissions expense.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company does <em style="font: inherit;">not</em> provide certain disclosures about unsatisfied performance obligations for contracts with an original expected length of <em style="font: inherit;">one</em> year or less.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> 0.01 0.09 0.01 6500000 1000000.0 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">3.</em>     NET INCOME PER COMMON SHARE</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The following table illustrates the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="22" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></em></em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2021</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2020</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Income</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Shares</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Per Share</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Income</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Shares</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Per Share</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Basic net income per common share:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net income available to common stockholders</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,085</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,017</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">843</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,630</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.08</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Effect of dilutive securities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Non-vested restricted stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">407</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">794</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Diluted net income per common share:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Net income available to common stockholders plus assumed conversions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,085</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,424</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.09</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">843</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,424</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.07</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="22" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></em></em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2021</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2020</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Income</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Shares</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Per Share</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Income</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Shares</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Per Share</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Basic net income per common share:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net income available to common stockholders</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,085</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,017</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">843</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,630</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.08</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Effect of dilutive securities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Non-vested restricted stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">407</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">794</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Diluted net income per common share:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Net income available to common stockholders plus assumed conversions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,085</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,424</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.09</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">843</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,424</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.07</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> 1085000 11017000 0.10 843000 10630000 0.08 0 407000 0 794000 1085000 11424000 0.09 843000 11424000 0.07 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">4.</em>     BALANCE SHEET COMPONENTS</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The components of certain balance sheet amounts are as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Cash</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">17,281</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">23,977</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">66,562</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">68,390</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">83,843</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">92,367</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Restricted cash</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">522</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">525</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">84,365</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">92,892</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Inventories:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Finished goods</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">4,476</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">3,071</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Raw materials</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">873</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,047</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Reserve for obsolescence</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(92</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(339</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,257</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,779</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Office equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">460</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">449</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Office software</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,009</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,001</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Machinery</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">22</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Furniture and fixtures</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">252</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">254</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Leasehold improvements</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">814</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">839</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Construction in progress</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">173</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">41</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Property and equipment, at cost</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,730</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,614</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,267</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,075</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">463</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">539</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other accrued expenses:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Sales returns</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">137</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">189</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Employee-related expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">988</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,149</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Warehousing, inventory-related and other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">808</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">584</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,933</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,922</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred revenue:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Unshipped product and unredeemed product vouchers</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">6,525</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,005</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Auto ship advances</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,901</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,977</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">110</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">109</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,536</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,091</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">As of <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em>, cash and cash equivalents include $4.1 million held in banks located within China subject to foreign currency controls.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Cash</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">17,281</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">23,977</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">66,562</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">68,390</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">83,843</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">92,367</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Restricted cash</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">522</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">525</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">84,365</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">92,892</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Inventories:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Finished goods</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">4,476</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">3,071</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Raw materials</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">873</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,047</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Reserve for obsolescence</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(92</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(339</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,257</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,779</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Office equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">460</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">449</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Office software</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,009</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,001</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Machinery</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">22</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Furniture and fixtures</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">252</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">254</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Leasehold improvements</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">814</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">839</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Construction in progress</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">173</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">41</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Property and equipment, at cost</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,730</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,614</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,267</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,075</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">463</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">539</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other accrued expenses:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Sales returns</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">137</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">189</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Employee-related expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">988</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,149</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Warehousing, inventory-related and other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">808</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">584</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,933</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,922</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred revenue:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Unshipped product and unredeemed product vouchers</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">6,525</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,005</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Auto ship advances</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,901</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,977</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">110</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">109</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,536</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,091</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 17281000 23977000 66562000 68390000 83843000 92367000 522000 525000 84365000 92892000 4476000 3071000 873000 1047000 92000 339000 5257000 3779000 460000 449000 1009000 1001000 22000 30000 252000 254000 814000 839000 173000 41000 2730000 2614000 2267000 2075000 463000 539000 137000 189000 988000 1149000 808000 584000 1933000 1922000 6525000 1005000 1901000 1977000 110000 109000 8536000 3091000 4100000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">5.</em>     FAIR VALUE MEASUREMENTS</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Investments by category included in cash equivalents at the end of each period were as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 18%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 25%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2021</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 25%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2020</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 18%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Fair Value Level<sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; border-bottom: thin solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Adjusted Cost</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Gross Unrealized Losses</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Fair Value</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Adjusted Cost</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Gross Unrealized Losses</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Fair Value</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 18%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Money market funds</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%; padding: 0pt; vertical-align: middle;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><em style="font: inherit;">Level 1</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20,711</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20,711</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,042</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,042</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 18%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Time deposits</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Level 2</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,458</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,458</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 18%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Government and municipal debt securities</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Level 2</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,006</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,004</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">30,280</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">30,275</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 18%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Corporate debt securities</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><em style="font: inherit;">Level 2</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">31,863</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(16</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">31,847</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,621</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,615</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 18%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total investments</p> </td><td style="width: 1%;"> </td><td style="width: 9%;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">66,580</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">66,562</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">68,401</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(11</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">68,390</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </p> <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><sup style="vertical-align:top;line-height:120%;font-size:pt"><em style="font: inherit;">1</em></sup><sup style="vertical-align:top;line-height:120%;font-size:pt"><i> </i></sup><i>FASB Topic <em style="font: inherit;">820,</em> Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories:</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><i>Level <em style="font: inherit;">1:</em> Quoted market prices in active markets for identical assets or liabilities.</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><i>Level <em style="font: inherit;">2:</em> Observable market-based inputs or unobservable inputs that are corroborated by market data.</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><i>Level <em style="font: inherit;">3:</em> Unobservable inputs that are <em style="font: inherit;">not</em> corroborated by market data.</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 18%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 25%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2021</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 25%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2020</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 18%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Fair Value Level<sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; border-bottom: thin solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Adjusted Cost</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Gross Unrealized Losses</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Fair Value</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Adjusted Cost</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Gross Unrealized Losses</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Fair Value</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 18%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Money market funds</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%; padding: 0pt; vertical-align: middle;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><em style="font: inherit;">Level 1</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20,711</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20,711</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,042</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,042</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 18%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Time deposits</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Level 2</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,458</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,458</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 18%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Government and municipal debt securities</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Level 2</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,006</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,004</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">30,280</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">30,275</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 18%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Corporate debt securities</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><em style="font: inherit;">Level 2</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">31,863</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(16</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">31,847</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,621</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,615</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 18%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total investments</p> </td><td style="width: 1%;"> </td><td style="width: 9%;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">66,580</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">66,562</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">68,401</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(11</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">68,390</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 20711000 -0 20711000 21042000 -0 21042000 0 -0 0 5458000 -0 5458000 14006000 2000 14004000 30280000 5000 30275000 31863000 16000 31847000 11621000 6000 11615000 66580000 18000 66562000 68401000 11000 68390000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">6.</em>     LEASES</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company leases 7,300 square feet of office space in Hong Kong and 4,900 square feet of office space in Rolling Hills Estates, California for its corporate staff. In <em style="font: inherit;"> June 2020, </em>the Company extended the Rolling Hills Estates office lease for an additional <span style="-sec-ix-hidden:c80953849">five</span> years with a term now expiring in <em style="font: inherit;"> September 2030. </em>Effective <em style="font: inherit;"> July 1, 2020,</em><i> </i>the Company modified the terms of its largest Hong Kong office lease resulting in a lease extension through <em style="font: inherit;"> June 2023</em><i>.</i> To help further develop the market for its products in North America, the Company leases 1,600 square feet of retail space in each of Rowland Heights, California and Richmond, British Columbia and 2,000 square feet of retail space in Metuchen, New Jersey. The Rowland Heights, Richmond and Metuchen locations have terms expiring in <em style="font: inherit;"> November 2025, </em><em style="font: inherit;"> February 2024, </em>and <em style="font: inherit;"> November 2022, </em>respectively.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company leases <span style="background-color:#ffffff;">seven</span> branch offices throughout China, and additional office space in Peru, Japan, Taiwan, South Korea, Malaysia, Singapore, Thailand, India, and the Cayman Islands. The Company also leases a factory in Zhongshan, China. The Company contracts with <em style="font: inherit;">third</em> parties for fulfillment and distribution operations in all of its international markets. <em style="font: inherit;">None</em> of the Company’s <em style="font: inherit;">third</em>-party logistics contracts contain a lease as the Company does <em style="font: inherit;">not</em> have the right to access the warehouses or move its inventories at will.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The components of lease cost were as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,334</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,716</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Short-term leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">299</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total lease cost</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,514</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,015</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">Cash paid for amounts included in the measurement of operating leases liabilities was $1.4 million and $1.6 million for <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> respectively.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The weighted-average remaining lease term and discount rate related to operating leases as of <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> were as follows:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted-average remaining lease term (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted-average discount rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">As most of the Company’s leases do <em style="font: inherit;">not</em> provide an implicit rate, the Company used its incremental borrowing rate, or the rate of each of its subsidiaries if available, based on the information available at the lease commencement date to determine the present value of lease payments.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The annual scheduled lease payments of our operating lease liabilities as of <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> were as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,261</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">672</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">272</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">261</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">201</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">789</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total lease payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,456</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less: imputed interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(289</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Present value of lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,167</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">For all asset classes, the Company elected <em style="font: inherit;">not</em> to recognize assets or liabilities at the acquisition date for leases that, at the acquisition date, have a remaining lease term of <em style="font: inherit;">12</em> months or less. Additionally, for all asset classes, the Company choose <em style="font: inherit;">not</em> to separate nonlease components from lease components and instead account for the combined lease and nonlease components associated with that lease component as a single lease component.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> 7300 4900 1600 2000 7 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,334</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,716</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Short-term leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">299</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total lease cost</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,514</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,015</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted-average remaining lease term (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted-average discount rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table> 1334000 1716000 180000 299000 1514000 2015000 1400000 1600000 P5Y1M6D 0.033 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,261</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">672</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">272</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">261</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">201</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">789</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total lease payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,456</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less: imputed interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(289</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Present value of lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,167</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 1261000 672000 272000 261000 201000 789000 3456000 289000 3167000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">7.</em>     <span style="background-color:#ffffff;">INCOME TAXES</span></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The components of income before income taxes consist of the following (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Domestic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,127</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,663</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,637</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,153</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income before income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,510</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,490</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The components of the income tax provision consist of the following (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Current taxes:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(207</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(512</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">267</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">626</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total current taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">69</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">115</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%"> <p style="margin-top: 0pt; margin-bottom: 0pt">Deferred taxes:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">309</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">346</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Total deferred taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">356</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">532</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income tax provision</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">425</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">647</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">A reconciliation of the reported income tax provision to the provision that would result from applying the domestic federal statutory tax rate to pretax income is as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income tax at federal statutory rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">317</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">313</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Effect of permanent differences</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">274</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">121</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Global Intangible Low-Taxed Income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">183</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">555</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Change in valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(37</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">51</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Foreign rate differential</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(221</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">72</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Foreign tax credits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(32</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(98</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">164</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Net operating loss carryback</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(84</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(512</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other reconciling items</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income tax provision</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">425</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">647</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Income before income taxes and the statutory tax rate for each country that materially contributed to the foreign rate differential presented above is as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Statutory Tax Rate</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cayman Islands</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,696</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,589</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Hong Kong</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">742</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">267</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">China</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">152</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">716</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Deferred income taxes consist of the following (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Net operating losses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">490</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">628</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">170</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">510</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Operating lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">396</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">460</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">51</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">60</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,107</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,658</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(303</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(340</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">804</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,318</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Operating lease assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(376</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(438</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Foreign deferreds</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(153</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(216</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Prepaids</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(113</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(113</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(36</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(648</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(803</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">156</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">515</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The effective income tax rate for the year ended <em style="font: inherit;"> December 31, </em><em style="font: inherit;">2021</em> includes an estimate for the Global Intangible Low-Taxed Income (“GILTI”) inclusion. The effect of permanent differences in <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> is mainly due to compensation-related limitations under Internal Revenue Code Section <em style="font: inherit;">162</em>(m). As of <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em>, the Company does <span style="-sec-ix-hidden:c80953901">not</span> have a valuation allowance against its U.S. deferred tax assets. The Company analyzed all sources of available income and determined that they are more likely than <em style="font: inherit;">not</em> to realize the tax benefits of their deferred assets. As of <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em>, the Company has a valuation allowance against deferred taxes in certain foreign jurisdictions with an overall net operating loss. The valuation allowance will be reduced at such time as management believes it is more likely than <em style="font: inherit;">not</em> that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 25.5pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">As of <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em>, the Company <em style="font: inherit;">no</em> longer has U.S. federal net operating losses due to its filing in <em style="font: inherit;"> December 2021 </em>to carry back $603,000 of losses generated in the tax year ended <em style="font: inherit;"> December 31, 2020 </em>to offset taxable income from the tax year ended <em style="font: inherit;"> December 31, 2016. </em>The Company has post-apportioned U.S. state net operating loss carryforwards of $427,000 that begin expiring in <em style="font: inherit;">2039.</em> At <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em>, the Company has foreign net operating loss carryforwards of approximately $1.9 million in various jurisdictions with various expirations.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 25.5pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">As of <em style="font: inherit;"> December 31, 2021, </em>income taxes payable for the repatriation tax on the deemed repatriation of deferred foreign income required the U.S. Tax Cuts and Jobs Act (the “Tax Act”), enacted on <em style="font: inherit;"> December 22, 2017 </em>by the U.S. government, totaled $13.7 million, of which $12.1 million is reflected as a noncurrent liability.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">As a result of capital return activities, the Company determined that a portion of its current undistributed foreign earnings is <em style="font: inherit;">no</em> longer deemed reinvested indefinitely by its non-U.S. subsidiaries. For state income tax purposes, the Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are <em style="font: inherit;">not</em> deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable state corporate income tax rate(s). As of <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em>, the Company has <em style="font: inherit;">not</em> recorded a state deferred tax liability for earnings that the Company plans to repatriate out of accumulated earnings in future periods because all earnings as of <em style="font: inherit;"> December 31, 2021 </em>have already been repatriated. Due to the Tax Act, repatriation from foreign subsidiaries will be offset with a dividends received deduction, resulting in little to <em style="font: inherit;">no</em> impact on federal tax expense. All undistributed earnings in excess of <em style="font: inherit;">50%</em> of current earnings on an annual basis are intended to be reinvested indefinitely as of <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em>.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 25.5pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">The Company and its subsidiaries file tax returns in the United States, California, New Jersey, Texas and various foreign jurisdictions. During the <em style="font: inherit;">fourth</em> quarter of <em style="font: inherit;">2018,</em> the Company was notified that it was selected for audit of the <em style="font: inherit;">2016</em> tax year by the U.S. Internal Revenue Service (the "IRS"). The audit was subsequently expanded to also include the <em style="font: inherit;">2017,</em> <em style="font: inherit;">2018</em> and <em style="font: inherit;">2019</em> tax years. On <em style="font: inherit;"> October 12, 2021, </em>the Company received notification from the IRS that it had completed the audit process for all tax years with <em style="font: inherit;">no</em> changes made to the Company's previously reported tax. The Company is <em style="font: inherit;">no</em> longer subject to state income tax examinations for years prior to <em style="font: inherit;">2017.</em> <em style="font: inherit;">No</em> other jurisdictions are currently examining any income tax returns of the Company.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Domestic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,127</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,663</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,637</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,153</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income before income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,510</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,490</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> -1127000 -1663000 2637000 3153000 1510000 1490000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Current taxes:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(207</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(512</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">267</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">626</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total current taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">69</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">115</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%"> <p style="margin-top: 0pt; margin-bottom: 0pt">Deferred taxes:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">309</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">346</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Total deferred taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">356</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">532</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income tax provision</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">425</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">647</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> -207000 -512000 9000 1000 267000 626000 69000 115000 309000 346000 7000 6000 40000 180000 356000 532000 425000 647000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income tax at federal statutory rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">317</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">313</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Effect of permanent differences</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">274</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">121</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Global Intangible Low-Taxed Income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">183</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">555</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Change in valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(37</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">51</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Foreign rate differential</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(221</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">72</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Foreign tax credits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(32</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(98</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">164</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Net operating loss carryback</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(84</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(512</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other reconciling items</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income tax provision</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">425</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">647</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 317000 313000 274000 121000 183000 555000 -37000 51000 -221000 72000 -32000 -98000 10000 164000 -84000 -512000 15000 -19000 425000 647000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Statutory Tax Rate</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cayman Islands</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,696</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,589</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Hong Kong</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">742</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">267</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">China</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">152</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">716</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 0 2696000 2589000 0.165 742000 267000 0.250 152000 716000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Net operating losses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">490</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">628</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">170</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">510</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Operating lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">396</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">460</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">51</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">60</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,107</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,658</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(303</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(340</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">804</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,318</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Operating lease assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(376</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(438</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Foreign deferreds</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(153</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(216</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Prepaids</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(113</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(113</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(36</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(648</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(803</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">156</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">515</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 490000 628000 170000 510000 396000 460000 51000 60000 1107000 1658000 303000 340000 804000 1318000 376000 438000 153000 216000 113000 113000 6000 36000 648000 803000 156000 515000 603000 427000 1900000 13700000 12100000 <div style="display: none;"> <b> </b> </div> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">8.</em>     COMMITMENTS AND CONTINGENCIES</b></p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: left; text-indent: 27pt;">The SEC conducted a non-public investigation since <em style="font: inherit;"> August 2016 </em>to determine whether there have been violations of the federal securities laws relating to the trading of the Company’s securities and/or its public disclosures. On <em style="font: inherit;"> September 30, 2021, </em>the Company was notified by the SEC that it had concluded its investigation and does <em style="font: inherit;">not</em> intend to recommend an enforcement action.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company has employment agreements with certain members of its management team that can be terminated by either the employee or the Company upon <em style="font: inherit;">four</em> weeks’ notice.  The employment agreements entered into with the management team contain provisions that guarantee the payments of specified amounts in the event of a change in control, as defined, or if the employee is terminated without cause, as defined, or terminates employment for good reason, as defined.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">9.</em>     STOCK-BASED INCENTIVE PLANS</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Restricted Stock</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">At the Company’s annual meeting of stockholders held on <em style="font: inherit;"> April 7, 2016, </em>the Company’s stockholders approved the Natural Health Trends Corp. <em style="font: inherit;">2016</em> Equity Incentive Plan (the <em style="font: inherit;">“2016</em> Plan”) to replace its <em style="font: inherit;">2007</em> Equity Incentive Plan. The <em style="font: inherit;">2016</em> Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units, stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to 2,500,000 shares of the Company’s common stock (subject to adjustment under certain circumstances) <em style="font: inherit;"> may </em>be issued pursuant to awards granted. At <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em>, 1,219,583 shares remained available for issuance under the <em style="font: inherit;">2016</em> Plan.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The following table summarizes the Company’s restricted stock activity under the <em style="font: inherit;">2016</em> Plan:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Shares</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Wtd. Avg. Price at Date of Issuance</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Nonvested at December 31, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">957,682</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.34</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(391,410</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.53</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">Nonvested at December 31, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">566,272</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(380,027</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">7.27</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Nonvested at December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">186,245</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">7.08</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><i>Phantom Equity</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 25.5pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">On <em style="font: inherit;"> March 15, 2021, </em>the Company’s Board of Directors approved and adopted a Phantom Equity Plan (the “Phantom Plan”). Under the terms of the Phantom Plan, the Board of Directors' Compensation Committee <em style="font: inherit;"> may </em>grant to the Company’s employees, officers, directors, contractors, consultants, or advisors awards of phantom shares entitling grantees the right to receive a cash payment equal to the fair market value of an equal number of shares of the Company’s common stock upon the close of a vesting period, subject to any maximum payment value that the Compensation Committee <em style="font: inherit;"> may </em>set. The vesting of phantom shares is subject to such vesting conditions as the Compensation Committee <em style="font: inherit;"> may </em>specify in a grantee’s award agreement. Grantees of phantom shares shall <em style="font: inherit;">not</em> by virtue of their receipt of phantom shares have any ownership rights in shares of the Company’s common stock. The Phantom Plan shall continue for a period of <span style="-sec-ix-hidden:c80954056">ten</span> years, after which <em style="font: inherit;">no</em> further phantom shares <em style="font: inherit;"> may </em>be awarded (although any phantom shares awarded prior to the expiration of such <em style="font: inherit;">10</em>-year period shall be unaffected by the termination of the Phantom Plan).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 25.5pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">Also on <em style="font: inherit;"> March 15, 2021, </em>awards for 223,307 phantom shares were granted to the Company’s employees and its non-employee directors.  The phantom shares vest in <em style="font: inherit;">eight</em> equal <span style="-sec-ix-hidden:c80954061">three</span>-month vesting increments, subject to the satisfaction of both a time-based vesting condition and a performance vesting condition. These vesting conditions were deemed satisfied on the grant date for the initial vesting increment. In order for the time-based vesting condition to be satisfied for each vesting period, the grantee must remain continuously employed by, or be otherwise continuously providing services to, the Company through the end of the vesting period, and in order for the performance vesting condition to be satisfied for each vesting period, the performance criteria designated by the Compensation Committee must be satisfied. The initial performance vesting condition to be applied to measure performance for the period between <em style="font: inherit;"> March 15, 2021 </em>and <em style="font: inherit;"> June 15, 2021 </em>was designated by the Compensation Committee on or before <em style="font: inherit;"> April 14, 2021, </em>and will apply to all future performance periods unless the Compensation Committee elects to change the performance vesting condition on a prospective basis. Future changes to the performance vesting condition shall be made on or before the <em style="font: inherit;">fifteenth</em> day of any future performance period. If either vesting condition is <em style="font: inherit;">not</em> satisfied for a vesting date, then the phantom shares scheduled to vest on such date will be forfeited. These phantom shares are subject to a maximum payment value of $12.00 per phantom share. An additional award with similar vesting conditions for 9,074 phantom shares was granted on <em style="font: inherit;"> May 14, 2021 </em>to the Company's new non-employee director, while unvested 9,074 phantom shares granted to the Company's departing non-employee director were forfeited on or about the same date.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 25.5pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">The phantom share awards are accounted for as liabilities in accordance with FASB ASC Topic <em style="font: inherit;">718,</em> <i>Compensation</i> <i>-</i> <i>Stock Compensation</i> since they require cash settlement. The grant date of each vesting increment will be established when the Company and the grantees reach a mutual understanding of the key terms and conditions of an award, which is the date upon which each performance vesting condition is communicated to the grantees. Compensation expense is recognized over the requisite service period if it is probable that the performance vesting condition will be achieved. The fair value of the liability incurred is remeasured at the end of each reporting period with any changes in fair value recognized as compensation expense over the requisite service period.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 25.5pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">Awards totaling 111,652 phantom shares vested during <em style="font: inherit;">2021,</em> resulting in compensation expense of $773,000 related to their cash settlement.</p> 2500000 1219583 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Shares</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Wtd. Avg. Price at Date of Issuance</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Nonvested at December 31, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">957,682</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.34</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(391,410</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.53</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">Nonvested at December 31, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">566,272</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(380,027</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">7.27</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Nonvested at December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">186,245</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">7.08</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> </tbody></table> 957682 7.34 391410 7.53 566272 7.21 380027 7.27 186245 7.08 223307 12.00 9074 9074 111652 773000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">10.</em>     STOCKHOLDERS’ EQUITY</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Authorized Shares</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company is authorized to issue <em style="font: inherit;">two</em> classes of capital stock consisting of up to 5,000,000 shares of preferred stock, $0.001 par value, and 50,000,000 shares of common stock, $0.001 par value.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Dividends</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company declared and paid cash dividends of $0.20 per common share during each quarter of <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> totaling an aggregate of $9.1 million each year. Declaration and payment of any future dividends on shares of common stock will be at the sole discretion of the Company’s Board of Directors.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Stock Repurchases</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">On <em style="font: inherit;"> January 12, 2016, </em>the Board of Directors authorized an increase to the Company’s stock repurchase program <em style="font: inherit;">first</em> approved on <em style="font: inherit;"> July 28, 2015 </em>from $15.0 million to $70.0 million. Any repurchases will be made in accordance with all applicable securities laws and regulations, including Rule <em style="font: inherit;">10b</em>-<em style="font: inherit;">18</em> of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company <em style="font: inherit;"> may </em>enter into <em style="font: inherit;">one</em> or more plans that are compliant with Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does <em style="font: inherit;">not</em> require the Company to acquire a specific number of shares, and <em style="font: inherit;"> may </em>be suspended from time to time or discontinued. As of <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em>, $21.9 million of the $70.0 million stock repurchase program remained available for future purchases, inclusive of related estimated income tax.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Accumulated Other Comprehensive Loss</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The changes in accumulated other comprehensive loss by component for <em style="font: inherit;">2021</em> were as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Foreign Currency Translation Adjustments</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Unrealized Losses on Available-For-Sale Investments</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Total</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance, December 31, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(325</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(11</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(336</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other comprehensive loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(149</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(156</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance, December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(474</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(492</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td></tr> </tbody></table> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </p> 5000000 0.001 50000000 0.001 0.20 9100000 15000000.0 70000000.0 21900000 70000000.0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Foreign Currency Translation Adjustments</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Unrealized Losses on Available-For-Sale Investments</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Total</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance, December 31, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(325</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(11</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(336</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other comprehensive loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(149</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(156</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance, December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(474</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(492</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td></tr> </tbody></table> -325000 -11000 -336000 -149000 -7000 -156000 -474000 -18000 -492000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">11.</em>     RELATED PARTY TRANSACTIONS</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 25.5pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">The Company is a party to a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called ReStor™. George K. Broady, a former director of the Company and beneficial owner of more than 5% of its outstanding common stock, is an indirect owner of BHS. Brunde E. Broady, a director of the Company and daughter of Mr. Broady, is the President and Chief Executive Officer of BHS. Under this agreement (as amended), the Company agreed to pay BHS a royalty based on a price per unit in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide by or through multi-level marketing or network marketing. The Company recognized royalties of $60,000 and $83,000 during <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em>, respectively, under this agreement.  The Company is <em style="font: inherit;">not</em> required to purchase any product under the agreement, and the agreement <em style="font: inherit;"> may </em>be terminated under certain circumstances with <em style="font: inherit;">no</em> notice. The agreement terminates <em style="font: inherit;"> March 31, 2025, </em>after which it shall be automatically renewed for successive <span style="-sec-ix-hidden:c80954141">one</span>-year terms unless notice is given by either party at least <span style="-sec-ix-hidden:c80954142">90</span> days in advance of the expiration of the then-current term.</p> 0.05 60000 83000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">12.</em>     EMPLOYEE BENEFIT PLANS</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt;">The Company has a <em style="font: inherit;">401</em>(k) defined contribution plan which permits participating employees in the United States to defer up to a maximum of 90% of their compensation, subject to limitations established by the Internal Revenue Service. Employees age 21 and older are eligible to contribute to the plan starting the <em style="font: inherit;">first</em> day of the month following the date of employment.  Participating employees are eligible to receive discretionary matching contributions and profit sharing, subject to certain conditions, from the Company.  In <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em>, the Company matched employee deferral contributions up to 4.5% of salary, which vested 100% immediately. <em style="font: inherit;">No</em> profit sharing has been paid under the plan. The Company recorded compensation expense of $69,000 and $68,000 for <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em>, respectively, related to its matching contributions to the plan. Certain of the Company’s employees located outside the United States participate in employee benefit plans that are statutory in nature.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> 0.90 P21Y 0.045 1 69000 68000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">13.</em>    SEGMENT INFORMATION</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company sells products to a member network that operates in a seamless manner from market to market, except for the China market where it sells to some consumers through an e-commerce retail platform, and the Russia and Kazakhstan market where the Company’s engagement of a <em style="font: inherit;">third</em>-party service provider results in a different economic structure than its other markets. Otherwise, the Company believes that all of its other operating segments have similar economic characteristics and are similar in the nature of the products sold, the product acquisition process, the types of customers products are sold to, the methods used to distribute the products, and the nature of the regulatory environment. Therefore, the Company aggregates its other operating segments (including its Hong Kong operating segment) into a single reporting segment (the “Primary Reporting Segment”).</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company reviews its net sales and operating income (loss) by operating segment, and reviews its assets and capital expenditures on a consolidated basis and <em style="font: inherit;">not</em> by operating segment. As such, net sales and operating income (loss) are presented by reportable segment and assets and capital expenditures by operating segment are <em style="font: inherit;">not</em> presented. Segment operating income is adjusted for certain direct costs and commission allocation.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"><span style="background-color:#ffffff;">The Company’s operating information by geographic area are as follows (in thousands):</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net sales:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Primary Reporting Segment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">56,914</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">58,243</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">China</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">2,237</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">2,940</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Russia and Kazakhstan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">854</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">888</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total net sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">60,005</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">62,071</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income (loss) from operations:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Primary Reporting Segment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">10,366</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">9,277</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">China</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">74</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">330</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Russia and Kazakhstan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(146</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(96</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income from operations for reportable segments, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,294</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,511</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Unallocated corporate expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(8,723</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(8,842</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Other income (expense), net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(61</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">821</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income before income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,510</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,490</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company’s net sales by geographic area are as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net sales from external customers:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">United States</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,278</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,573</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Canada</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">724</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">765</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Peru</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,281</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,453</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Hong Kong<sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">46,699</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">49,169</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">China</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,237</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,940</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Taiwan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,706</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,034</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Russia and Kazakhstan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">854</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">888</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Europe</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,136</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,050</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other foreign countries</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,090</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,199</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total net sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">60,005</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">62,071</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </p> <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><sup style="vertical-align:top;line-height:120%;font-size:pt"><em style="font: inherit;">1</em></sup> <i>Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item <em style="font: inherit;">1A.</em> Risk Factors.”</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company’s net sales by product and service are as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net sales by product and service:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Product sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">54,056</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">55,840</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Administrative fees, freight and other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,340</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,991</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less: sales returns</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(391</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(760</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total net sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">60,005</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">62,071</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Due to system constraints, it is impracticable for the Company to separately disclose sales by product category for the years presented.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company’s long-lived assets by geographic area are as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Long-lived assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">United States</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">221</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">227</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Hong Kong</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">105</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">146</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">China</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">90</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">47</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other foreign countries</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">47</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">119</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total long-lived assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">463</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">539</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net sales:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Primary Reporting Segment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">56,914</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">58,243</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">China</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">2,237</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">2,940</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Russia and Kazakhstan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">854</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">888</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total net sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">60,005</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">62,071</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income (loss) from operations:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Primary Reporting Segment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">10,366</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">9,277</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">China</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">74</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">330</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Russia and Kazakhstan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(146</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(96</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income from operations for reportable segments, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,294</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,511</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Unallocated corporate expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(8,723</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(8,842</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> <p style="margin-top: 0pt; margin-bottom: 0pt">Other income (expense), net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(61</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">821</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income before income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,510</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,490</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> 56914000 58243000 2237000 2940000 854000 888000 60005000 62071000 10366000 9277000 74000 330000 -146000 -96000 10294000 9511000 -8723000 -8842000 -61000 821000 1510000 1490000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net sales from external customers:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">United States</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,278</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,573</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Canada</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">724</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">765</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Peru</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,281</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,453</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Hong Kong<sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">46,699</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">49,169</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">China</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,237</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,940</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Taiwan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,706</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,034</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Russia and Kazakhstan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">854</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">888</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Europe</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,136</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,050</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other foreign countries</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,090</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,199</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total net sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">60,005</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">62,071</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 1278000 1573000 724000 765000 2281000 1453000 46699000 49169000 2237000 2940000 2706000 3034000 854000 888000 1136000 1050000 2090000 1199000 60005000 62071000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net sales by product and service:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Product sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">54,056</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">55,840</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Administrative fees, freight and other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,340</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,991</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less: sales returns</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(391</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(760</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total net sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">60,005</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">62,071</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 54056000 55840000 6340000 6991000 391000 760000 60005000 62071000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Long-lived assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">United States</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">221</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">227</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Hong Kong</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">105</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">146</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">China</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">90</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">47</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other foreign countries</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">47</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">119</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total long-lived assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">463</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">539</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 221000 227000 105000 146000 90000 47000 47000 119000 463000 539000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">14.</em>     SUBSEQUENT EVENT</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">On <em style="font: inherit;"> February 7, 2022, </em>the Board of Directors declared a quarterly cash dividend of $0.20 on each share of common stock outstanding. The dividend will be payable on <em style="font: inherit;"> March 4, 2022 </em>to stockholders of record on <em style="font: inherit;"> February 22, 2022. </em>Declaration and payment of any future dividends on shares of common stock will be at the sole discretion of the Company’s Board of Directors.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> 0.20 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors”. FASB Topic 820, Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. EXCEL 69 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

!651Q<80WHP0 '>D! 2(@ &@ @ $,!0$ >&PO7W)E;',O=V]R:V)O;VLN M>&UL+G)E;'-02P$"% ,4 " "G@5E4LFA)V-4! "_(0 $P M @ $M!P$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 00!! +X1 S %"0$ ! end XML 70 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 71 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 72 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 151 370 1 true 60 0 false 10 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets- Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-parentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations Consolidated Statements of Operations Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Comprehensive Income Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-comprehensive-income Consolidated Statements of Comprehensive Income Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-stockholders-equity- Consolidated Statements of Stockholders' Equity Statements 6 false false R7.htm 006 - Statement - Consolidated Statements of Stockholders' Equity (Parentheticals) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals Consolidated Statements of Stockholders' Equity (Parentheticals) Statements 7 false false R8.htm 007 - Statement - Consolidated Statements of Cash Flows Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows- Consolidated Statements of Cash Flows Statements 8 false false R9.htm 008 - Disclosure - Note 1 - Nature of Operations and Summary of Significant Accounting Policies Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies- Note 1 - Nature of Operations and Summary of Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Note 2 - Revenue Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-2-revenue Note 2 - Revenue Notes 10 false false R11.htm 010 - Disclosure - Note 3 - Net Income Per Common Share Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-3-net-income-per-common-share- Note 3 - Net Income Per Common Share Notes 11 false false R12.htm 011 - Disclosure - Note 4 - Balance Sheet Components Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components Note 4 - Balance Sheet Components Notes 12 false false R13.htm 012 - Disclosure - Note 5 - Fair Value Measurements Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements Note 5 - Fair Value Measurements Notes 13 false false R14.htm 013 - Disclosure - Note 6 - Leases Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases Note 6 - Leases Notes 14 false false R15.htm 014 - Disclosure - Note 7 - Income Taxes Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes Note 7 - Income Taxes Notes 15 false false R16.htm 015 - Disclosure - Note 8 - Commitments and Contingencies Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-8-commitments-and-contingencies Note 8 - Commitments and Contingencies Notes 16 false false R17.htm 016 - Disclosure - Note 9 - Stock-based Incentive Plans Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans Note 9 - Stock-based Incentive Plans Notes 17 false false R18.htm 017 - Disclosure - Note 10 - Stockholders' Equity Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity Note 10 - Stockholders' Equity Notes 18 false false R19.htm 018 - Disclosure - Note 11 - Related Party Transactions Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions Note 11 - Related Party Transactions Notes 19 false false R20.htm 019 - Disclosure - Note 12 - Employee Benefit Plans Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-12-employee-benefit-plans- Note 12 - Employee Benefit Plans Notes 20 false false R21.htm 020 - Disclosure - Note 13 - Segment Information Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information Note 13 - Segment Information Notes 21 false false R22.htm 021 - Disclosure - Note 14 - Subsequent Event Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-14-subsequent-event Note 14 - Subsequent Event Notes 22 false false R23.htm 022 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies- 23 false false R24.htm 023 - Disclosure - Note 3 - Net Income Per Common Share (Tables) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-3-net-income-per-common-share-tables Note 3 - Net Income Per Common Share (Tables) Tables http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-3-net-income-per-common-share- 24 false false R25.htm 024 - Disclosure - Note 4 - Balance Sheet Components (Tables) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-tables Note 4 - Balance Sheet Components (Tables) Tables http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components 25 false false R26.htm 025 - Disclosure - Note 5 - Fair Value Measurements (Tables) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements-tables Note 5 - Fair Value Measurements (Tables) Tables http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements 26 false false R27.htm 026 - Disclosure - Note 6 - Leases (Tables) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-tables Note 6 - Leases (Tables) Tables http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases 27 false false R28.htm 027 - Disclosure - Note 7 - Income Taxes (Tables) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-tables Note 7 - Income Taxes (Tables) Tables http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes 28 false false R29.htm 028 - Disclosure - Note 9 - Stock-based Incentive Plans (Tables) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-tables Note 9 - Stock-based Incentive Plans (Tables) Tables http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans 29 false false R30.htm 029 - Disclosure - Note 10 - Stockholders' Equity (Tables) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-tables Note 10 - Stockholders' Equity (Tables) Tables http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity 30 false false R31.htm 030 - Disclosure - Note 13 - Segment Information (Tables) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-tables Note 13 - Segment Information (Tables) Tables http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information 31 false false R32.htm 031 - Disclosure - Note 1 - Nature of Operations and Summary of Significant Accounting Policies (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual Note 1 - Nature of Operations and Summary of Significant Accounting Policies (Details Textual) Details 32 false false R33.htm 032 - Disclosure - Note 2 - Revenue (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-2-revenue-details-textual Note 2 - Revenue (Details Textual) Details http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-2-revenue 33 false false R34.htm 033 - Disclosure - Note 3 - Net Income Per Common Share - Basic and Diluted Net Income (Loss) Per Share (Details) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-3-net-income-per-common-share-basic-and-diluted-net-income-loss-per-share-details Note 3 - Net Income Per Common Share - Basic and Diluted Net Income (Loss) Per Share (Details) Details 34 false false R35.htm 034 - Disclosure - Note 4 - Balance Sheet Components (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-details-textual Note 4 - Balance Sheet Components (Details Textual) Details http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-tables 35 false false R36.htm 035 - Disclosure - Note 4 - Balance Sheet Components - Summary of Balance Sheet Amounts (Details) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details Note 4 - Balance Sheet Components - Summary of Balance Sheet Amounts (Details) Details 36 false false R37.htm 036 - Disclosure - Note 5 - Fair Value Measurements - Investments (Details) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements-investments-details Note 5 - Fair Value Measurements - Investments (Details) Details 37 false false R38.htm 037 - Disclosure - Note 6 - Leases (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-details-textual Note 6 - Leases (Details Textual) Details http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-tables 38 false false R39.htm 038 - Disclosure - Note 6 - Leases - Lease Cost (Details) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-lease-cost-details Note 6 - Leases - Lease Cost (Details) Details 39 false false R40.htm 039 - Disclosure - Note 6 - Leases - Maturity of Lease Liabilities (Details) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-maturity-of-lease-liabilities-details Note 6 - Leases - Maturity of Lease Liabilities (Details) Details 40 false false R41.htm 040 - Disclosure - Note 7 - Income Taxes (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-details-textual Note 7 - Income Taxes (Details Textual) Details http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-tables 41 false false R42.htm 041 - Disclosure - Note 7 - Income Taxes - Components of Income (Loss) Before Income Taxes (Details) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-loss-before-income-taxes-details Note 7 - Income Taxes - Components of Income (Loss) Before Income Taxes (Details) Details 42 false false R43.htm 042 - Disclosure - Note 7 - Income Taxes - Components of Income Tax Provision (Benefit) (Details) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details Note 7 - Income Taxes - Components of Income Tax Provision (Benefit) (Details) Details 43 false false R44.htm 043 - Disclosure - Note 7 - Income Taxes - Reconciliation of Reported Income Tax Provision (Details) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details Note 7 - Income Taxes - Reconciliation of Reported Income Tax Provision (Details) Details 44 false false R45.htm 044 - Disclosure - Note 7 - Income Taxes - Foreign Rate Differentials (Details) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-foreign-rate-differentials-details Note 7 - Income Taxes - Foreign Rate Differentials (Details) Details 45 false false R46.htm 045 - Disclosure - Note 7 - Income Taxes - Deferred Income Taxes (Details) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details Note 7 - Income Taxes - Deferred Income Taxes (Details) Details 46 false false R47.htm 046 - Disclosure - Note 9 - Stock-based Incentive Plans (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-details-textual Note 9 - Stock-based Incentive Plans (Details Textual) Details http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-tables 47 false false R48.htm 047 - Disclosure - Note 9 - Stock-based Incentive Plans - Restricted Stock Activity (Details) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-restricted-stock-activity-details Note 9 - Stock-based Incentive Plans - Restricted Stock Activity (Details) Details 48 false false R49.htm 048 - Disclosure - Note 10 - Stockholders' Equity (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-details-textual Note 10 - Stockholders' Equity (Details Textual) Details http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-tables 49 false false R50.htm 049 - Disclosure - Note 10 - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details Note 10 - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details) Details 50 false false R51.htm 050 - Disclosure - Note 11 - Related Party Transactions (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions-details-textual Note 11 - Related Party Transactions (Details Textual) Details http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions 51 false false R52.htm 051 - Disclosure - Note 12 - Employee Benefit Plans (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-12-employee-benefit-plans-details-textual Note 12 - Employee Benefit Plans (Details Textual) Details http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-12-employee-benefit-plans- 52 false false R53.htm 052 - Disclosure - Note 13 - Segment Information - Operating Information by Geographic Area (Details) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-operating-information-by-geographic-area-details Note 13 - Segment Information - Operating Information by Geographic Area (Details) Details 53 false false R54.htm 053 - Disclosure - Note 13 - Segment Information - Net Sales by Geographic Area (Details) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-net-sales-by-geographic-area-details Note 13 - Segment Information - Net Sales by Geographic Area (Details) Details 54 false false R55.htm 054 - Disclosure - Note 13 - Segment Information - Net Sales by Product and Service (Details) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-net-sales-by-product-and-service-details Note 13 - Segment Information - Net Sales by Product and Service (Details) Details 55 false false R56.htm 055 - Disclosure - Note 13 - Segment Information - Long-lived Assets (Details) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-longlived-assets-details Note 13 - Segment Information - Long-lived Assets (Details) Details 56 false false R57.htm 056 - Disclosure - Note 14 - Subsequent Event (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-14-subsequent-event-details-textual Note 14 - Subsequent Event (Details Textual) Details http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-14-subsequent-event 57 false false All Reports Book All Reports nhtc20211231_10k.htm ex_291461.htm ex_291462.htm ex_291463.htm ex_291464.htm nhtc-20211231.xsd nhtc-20211231_cal.xml nhtc-20211231_def.xml nhtc-20211231_lab.xml nhtc-20211231_pre.xml http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 75 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nhtc20211231_10k.htm": { "axisCustom": 0, "axisStandard": 20, "contextCount": 151, "dts": { "calculationLink": { "local": [ "nhtc-20211231_cal.xml" ] }, "definitionLink": { "local": [ "nhtc-20211231_def.xml" ] }, "inline": { "local": [ "nhtc20211231_10k.htm" ] }, "labelLink": { "local": [ "nhtc-20211231_lab.xml" ] }, "presentationLink": { "local": [ "nhtc-20211231_pre.xml" ] }, "schema": { "local": [ "nhtc-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 446, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 37, "http://www.naturalhealthtrendscorp.com/20211231": 7, "http://xbrl.sec.gov/dei/2021q4": 6, "total": 50 }, "keyCustom": 29, "keyStandard": 341, "memberCustom": 18, "memberStandard": 42, "nsprefix": "nhtc", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Note 2 - Revenue", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-2-revenue", "shortName": "Note 2 - Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Note 3 - Net Income Per Common Share", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-3-net-income-per-common-share-", "shortName": "Note 3 - Net Income Per Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Note 4 - Balance Sheet Components", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components", "shortName": "Note 4 - Balance Sheet Components", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Note 5 - Fair Value Measurements", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements", "shortName": "Note 5 - Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Note 6 - Leases", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases", "shortName": "Note 6 - Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Note 7 - Income Taxes", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes", "shortName": "Note 7 - Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Note 8 - Commitments and Contingencies", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-8-commitments-and-contingencies", "shortName": "Note 8 - Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Note 9 - Stock-based Incentive Plans", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans", "shortName": "Note 9 - Stock-based Incentive Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Note 10 - Stockholders' Equity", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity", "shortName": "Note 10 - Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Note 11 - Related Party Transactions", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions", "shortName": "Note 11 - Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Balance Sheets", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:OtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Note 12 - Employee Benefit Plans", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-12-employee-benefit-plans-", "shortName": "Note 12 - Employee Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Note 13 - Segment Information", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information", "shortName": "Note 13 - Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Note 14 - Subsequent Event", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-14-subsequent-event", "shortName": "Note 14 - Subsequent Event", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-significant-accounting-policies-policies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Note 3 - Net Income Per Common Share (Tables)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-3-net-income-per-common-share-tables", "shortName": "Note 3 - Net Income Per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nhtc:ScheduleOfAdditionalBalanceSheetComponentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Note 4 - Balance Sheet Components (Tables)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-tables", "shortName": "Note 4 - Balance Sheet Components (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nhtc:ScheduleOfAdditionalBalanceSheetComponentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Note 5 - Fair Value Measurements (Tables)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements-tables", "shortName": "Note 5 - Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Note 6 - Leases (Tables)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-tables", "shortName": "Note 6 - Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Note 7 - Income Taxes (Tables)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-tables", "shortName": "Note 7 - Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Note 9 - Stock-based Incentive Plans (Tables)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-tables", "shortName": "Note 9 - Stock-based Incentive Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-parentheticals", "shortName": "Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Note 10 - Stockholders' Equity (Tables)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-tables", "shortName": "Note 10 - Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Note 13 - Segment Information (Tables)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-tables", "shortName": "Note 13 - Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ForeignCurrencyTransactionGainLossUnrealized", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Note 1 - Nature of Operations and Summary of Significant Accounting Policies (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual", "shortName": "Note 1 - Nature of Operations and Summary of Significant Accounting Policies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ForeignCurrencyTransactionGainLossUnrealized", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "2", "first": true, "lang": null, "name": "nhtc:RevenueFromContractWithCustomersSalesReturnsPercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Note 2 - Revenue (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-2-revenue-details-textual", "shortName": "Note 2 - Revenue (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "2", "first": true, "lang": null, "name": "nhtc:RevenueFromContractWithCustomersSalesReturnsPercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Note 3 - Net Income Per Common Share - Basic and Diluted Net Income (Loss) Per Share (Details)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-3-net-income-per-common-share-basic-and-diluted-net-income-loss-per-share-details", "shortName": "Note 3 - Net Income Per Common Share - Basic and Diluted Net Income (Loss) Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Note 4 - Balance Sheet Components (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-details-textual", "shortName": "Note 4 - Balance Sheet Components (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "i_2021-12-31_StatementGeographicalAxis-CN", "decimals": "-5", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nhtc:ScheduleOfAdditionalBalanceSheetComponentsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Note 4 - Balance Sheet Components - Summary of Balance Sheet Amounts (Details)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details", "shortName": "Note 4 - Balance Sheet Components - Summary of Balance Sheet Amounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nhtc:ScheduleOfAdditionalBalanceSheetComponentsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Note 5 - Fair Value Measurements - Investments (Details)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements-investments-details", "shortName": "Note 5 - Fair Value Measurements - Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Note 6 - Leases (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-details-textual", "shortName": "Note 6 - Leases (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Note 6 - Leases - Lease Cost (Details)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-lease-cost-details", "shortName": "Note 6 - Leases - Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statements of Operations", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-4", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Note 6 - Leases - Maturity of Lease Liabilities (Details)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-maturity-of-lease-liabilities-details", "shortName": "Note 6 - Leases - Maturity of Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Note 7 - Income Taxes (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-details-textual", "shortName": "Note 7 - Income Taxes (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-5", "lang": null, "name": "us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Note 7 - Income Taxes - Components of Income (Loss) Before Income Taxes (Details)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-loss-before-income-taxes-details", "shortName": "Note 7 - Income Taxes - Components of Income (Loss) Before Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Note 7 - Income Taxes - Components of Income Tax Provision (Benefit) (Details)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details", "shortName": "Note 7 - Income Taxes - Components of Income Tax Provision (Benefit) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Note 7 - Income Taxes - Reconciliation of Reported Income Tax Provision (Details)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details", "shortName": "Note 7 - Income Taxes - Reconciliation of Reported Income Tax Provision (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Note 7 - Income Taxes - Foreign Rate Differentials (Details)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-foreign-rate-differentials-details", "shortName": "Note 7 - Income Taxes - Foreign Rate Differentials (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nhtc:IncomeTaxForeignRateDifferentialTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_IncomeTaxAuthorityNameAxis-DepartmentForInternationalTaxCooperationMember", "decimals": "0", "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Note 7 - Income Taxes - Deferred Income Taxes (Details)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details", "shortName": "Note 7 - Income Taxes - Deferred Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "i_2021-12-31_PlanNameAxis-EquityIncentivePlan2016Member", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Note 9 - Stock-based Incentive Plans (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-details-textual", "shortName": "Note 9 - Stock-based Incentive Plans (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "i_2021-12-31_PlanNameAxis-EquityIncentivePlan2016Member", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "i_2020-12-31_AwardTypeAxis-RestrictedStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Note 9 - Stock-based Incentive Plans - Restricted Stock Activity (Details)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-restricted-stock-activity-details", "shortName": "Note 9 - Stock-based Incentive Plans - Restricted Stock Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "i_2019-12-31_AwardTypeAxis-RestrictedStockMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2020-01-01_2020-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unitRef": "USDPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Note 10 - Stockholders' Equity (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-details-textual", "shortName": "Note 10 - Stockholders' Equity (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-5", "lang": null, "name": "us-gaap:DividendsCommonStock", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statements of Comprehensive Income", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-comprehensive-income", "shortName": "Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Note 10 - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details", "shortName": "Note 10 - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "i_2020-12-31_StatementEquityComponentsAxis-AccumulatedTranslationAdjustmentMember", "decimals": "-3", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "i_2021-12-31_RelatedPartyTransactionsByRelatedPartyAxis-DirectorMember", "decimals": "2", "first": true, "lang": null, "name": "nhtc:CommonStockPercentageOfBeneficialStockOutstanding", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "050 - Disclosure - Note 11 - Related Party Transactions (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions-details-textual", "shortName": "Note 11 - Related Party Transactions (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "i_2021-12-31_RelatedPartyTransactionsByRelatedPartyAxis-DirectorMember", "decimals": "2", "first": true, "lang": null, "name": "nhtc:CommonStockPercentageOfBeneficialStockOutstanding", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "1", "first": true, "lang": null, "name": "us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "051 - Disclosure - Note 12 - Employee Benefit Plans (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-12-employee-benefit-plans-details-textual", "shortName": "Note 12 - Employee Benefit Plans (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "1", "first": true, "lang": null, "name": "us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "052 - Disclosure - Note 13 - Segment Information - Operating Information by Geographic Area (Details)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-operating-information-by-geographic-area-details", "shortName": "Note 13 - Segment Information - Operating Information by Geographic Area (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_ConsolidationItemsAxis-OperatingSegmentsMember", "decimals": "-3", "lang": null, "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "053 - Disclosure - Note 13 - Segment Information - Net Sales by Geographic Area (Details)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-net-sales-by-geographic-area-details", "shortName": "Note 13 - Segment Information - Net Sales by Geographic Area (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_StatementGeographicalAxis-US", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "054 - Disclosure - Note 13 - Segment Information - Net Sales by Product and Service (Details)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-net-sales-by-product-and-service-details", "shortName": "Note 13 - Segment Information - Net Sales by Product and Service (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "lang": null, "name": "nhtc:ContractWithCustomerRefundLiabilitySalesReturns", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "055 - Disclosure - Note 13 - Segment Information - Long-lived Assets (Details)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-longlived-assets-details", "shortName": "Note 13 - Segment Information - Long-lived Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2020-01-01_2020-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unitRef": "USDPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "056 - Disclosure - Note 14 - Subsequent Event (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-14-subsequent-event-details-textual", "shortName": "Note 14 - Subsequent Event (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2022-02-07_2022-02-07_SubsequentEventTypeAxis-SubsequentEventMember", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "i_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Consolidated Statements of Stockholders' Equity", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-", "shortName": "Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "i_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2020-01-01_2020-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unitRef": "USDPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Consolidated Statements of Stockholders' Equity (Parentheticals)", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals", "shortName": "Consolidated Statements of Stockholders' Equity (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R8": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "007 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Note 1 - Nature of Operations and Summary of Significant Accounting Policies", "role": "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "shortName": "Note 1 - Nature of Operations and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 60, "tag": { "country_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CANADA" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-net-sales-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "country_CN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHINA" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-longlived-assets-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-operating-information-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-details-textual" ], "xbrltype": "domainItemType" }, "country_GB": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED KINGDOM" } } }, "localname": "GB", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-longlived-assets-details" ], "xbrltype": "domainItemType" }, "country_HK": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "HONG KONG" } } }, "localname": "HK", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-details-textual" ], "xbrltype": "domainItemType" }, "country_KP": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "KOREA, DEMOCRATIC PEOPLE'S REPUBLIC OF" } } }, "localname": "KP", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "country_PE": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PERU" } } }, "localname": "PE", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-net-sales-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "country_TW": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TAIWAN, PROVINCE OF CHINA" } } }, "localname": "TW", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-net-sales-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-longlived-assets-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-net-sales-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "country_VN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "VIET NAM" } } }, "localname": "VN", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r519", "r520", "r521" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r519", "r520", "r521" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r519", "r520", "r521" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r519", "r520", "r521" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r522" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "countryCodeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-comprehensive-income", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-12-employee-benefit-plans-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-12-employee-benefit-plans-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-longlived-assets-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-net-sales-by-product-and-service-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-operating-information-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-14-subsequent-event", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-14-subsequent-event-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-2-revenue-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-3-net-income-per-common-share-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-3-net-income-per-common-share-basic-and-diluted-net-income-loss-per-share-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-3-net-income-per-common-share-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements-investments-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-lease-cost-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-maturity-of-lease-liabilities-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-loss-before-income-taxes-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-foreign-rate-differentials-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-8-commitments-and-contingencies", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-restricted-stock-activity-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r523" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r524" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r519", "r520", "r521" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-comprehensive-income", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-12-employee-benefit-plans-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-12-employee-benefit-plans-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-longlived-assets-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-net-sales-by-product-and-service-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-operating-information-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-14-subsequent-event", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-14-subsequent-event-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-2-revenue-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-3-net-income-per-common-share-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-3-net-income-per-common-share-basic-and-diluted-net-income-loss-per-share-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-3-net-income-per-common-share-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements-investments-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-lease-cost-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-maturity-of-lease-liabilities-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-loss-before-income-taxes-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-foreign-rate-differentials-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-8-commitments-and-contingencies", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-restricted-stock-activity-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "nhtc_AccruedSalesReturns": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales returns.", "label": "Sales returns" } } }, "localname": "AccruedSalesReturns", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "nhtc_AccruedWarehousingAndInventoryRelatedExpense": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 0.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for warehousing and inventory related expense.", "label": "Warehousing, inventory-related and other" } } }, "localname": "AccruedWarehousingAndInventoryRelatedExpense", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "nhtc_AdministrativeFeesFreightAndOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to administrative fees, freight and other.", "label": "Administrative Fees, Freight and Other [Member]" } } }, "localname": "AdministrativeFeesFreightAndOtherMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-net-sales-by-product-and-service-details" ], "xbrltype": "domainItemType" }, "nhtc_AgeRequirementFor401kContributions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents age requirement for 401 K contributions.", "label": "nhtc_AgeRequirementFor401kContributions", "terseLabel": "Age Requirement For 401K Contributions (Year)" } } }, "localname": "AgeRequirementFor401kContributions", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-12-employee-benefit-plans-details-textual" ], "xbrltype": "durationItemType" }, "nhtc_AmountsHeldInDistributorEwalletsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the policy of amounts held in customer eWallets.", "label": "Amounts Held in Distributor EWallets [Policy Text Block]" } } }, "localname": "AmountsHeldInDistributorEwalletsPolicyTextBlock", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "nhtc_AutoShipAdvancesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to auto ship advances.", "label": "Auto ship advances [Member]" } } }, "localname": "AutoShipAdvancesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "domainItemType" }, "nhtc_BHSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to BHS.", "label": "BHS [Member]" } } }, "localname": "BHSMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_CapitalizedContractCostsLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount liability recognized from cost incurred to obtain or fulfill contract with customer; classified as current.", "label": "Amounts held in eWallets" } } }, "localname": "CapitalizedContractCostsLiabilityCurrent", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "nhtc_CashAndCashEquivalentsPeriodToReceiveCashProceedsFromCreditCardProcessors": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents period to receive cash proceeds from credit card processors for cash and cash equivalents.", "label": "nhtc_CashAndCashEquivalentsPeriodToReceiveCashProceedsFromCreditCardProcessors", "terseLabel": "Cash and Cash Equivalents, Period to Receive Cash Proceeds From Credit Card Processors (Day)" } } }, "localname": "CashAndCashEquivalentsPeriodToReceiveCashProceedsFromCreditCardProcessors", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "durationItemType" }, "nhtc_CommonStockPercentageOfBeneficialStockOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of beneficial stock outstanding.", "label": "nhtc_CommonStockPercentageOfBeneficialStockOutstanding", "terseLabel": "Common Stock, Percentage of Beneficial Stock Outstanding" } } }, "localname": "CommonStockPercentageOfBeneficialStockOutstanding", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions-details-textual" ], "xbrltype": "percentItemType" }, "nhtc_ContractWithCustomerRefundLiabilitySalesReturns": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents sales returns for refund liability for contract with customer.", "label": "nhtc_ContractWithCustomerRefundLiabilitySalesReturns", "negatedLabel": "Less: sales returns" } } }, "localname": "ContractWithCustomerRefundLiabilitySalesReturns", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-net-sales-by-product-and-service-details" ], "xbrltype": "monetaryItemType" }, "nhtc_DeferredIncomeTaxExpenseBenefitExcludingEffectsOfForeignExchange": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of deferred income tax expense (benefit), excluding effects of foreign exchange.", "label": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefitExcludingEffectsOfForeignExchange", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "nhtc_DeferredTaxAssetsOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents operating lease liabilities for deferred tax assets.", "label": "nhtc_DeferredTaxAssetsOperatingLeaseLiabilities", "verboseLabel": "Operating lease liabilities" } } }, "localname": "DeferredTaxAssetsOperatingLeaseLiabilities", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "nhtc_DepartmentForInternationalTaxCooperationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Department for International Tax Cooperation.", "label": "Department for International Tax Cooperation [Member]" } } }, "localname": "DepartmentForInternationalTaxCooperationMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-foreign-rate-differentials-details" ], "xbrltype": "domainItemType" }, "nhtc_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarrybackAmount": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the net operating loss carryforward.", "label": "Net operating loss carryback" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNetOperatingLossCarrybackAmount", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "nhtc_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActGlobalIntangibleLowtaxIncomeGiltiAmount": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Tax Cuts and Jobs Act for Global Intangible Low-tax Income for effective income tax rate reconciliation.", "label": "Global Intangible Low-Taxed Income" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActGlobalIntangibleLowtaxIncomeGiltiAmount", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "nhtc_EmployeesAndNonEmployeeDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to employees and non-employee directors.", "label": "Employees and Non-Employee Directors [Member]" } } }, "localname": "EmployeesAndNonEmployeeDirectorsMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_EquityIncentivePlan2016Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the 2016 Equity Incentive Plan.", "label": "Equity Incentive Plan 2016 [Member]" } } }, "localname": "EquityIncentivePlan2016Member", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_IncomeTaxForeignRateDifferentialTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income tax foreign rate differential.", "label": "Income Tax Foreign Rate Differential [Table Text Block]" } } }, "localname": "IncomeTaxForeignRateDifferentialTableTextBlock", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "nhtc_IncomeTaxReconciliationEffectOfPermanentDifferences": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Effect of permanent differences.", "label": "Effect of permanent differences" } } }, "localname": "IncomeTaxReconciliationEffectOfPermanentDifferences", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "nhtc_IncreaseDecreaseInAccruedSalesCommissions": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued sales commissions.", "label": "nhtc_IncreaseDecreaseInAccruedSalesCommissions", "terseLabel": "Accrued commissions" } } }, "localname": "IncreaseDecreaseInAccruedSalesCommissions", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "nhtc_IncreaseDecreaseInCapitalizedContractCostLiability": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in capitalized contract cost liability.", "label": "nhtc_IncreaseDecreaseInCapitalizedContractCostLiability", "terseLabel": "Amounts held in eWallets" } } }, "localname": "IncreaseDecreaseInCapitalizedContractCostLiability", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "nhtc_IncreaseDecreaseInOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating lease liabilities.", "label": "nhtc_IncreaseDecreaseInOperatingLeaseLiabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "nhtc_LesseeNoncashLeaseExpense": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of lessee's noncash lease expense during the period.", "label": "Noncash lease expense" } } }, "localname": "LesseeNoncashLeaseExpense", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "nhtc_LesseeNumberOfBranches": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the lessees' number of branches.", "label": "nhtc_LesseeNumberOfBranches", "terseLabel": "Lessee, Number of Branches" } } }, "localname": "LesseeNumberOfBranches", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-details-textual" ], "xbrltype": "integerItemType" }, "nhtc_MetuchenNewJerseyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Metuchen, New Jersey.", "label": "Metuchen, New Jersey [Member]" } } }, "localname": "MetuchenNewJerseyMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_NewnonemployeedirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NewNonEmployeeDirectorsMember" } } }, "localname": "NewnonemployeedirectorsMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_NoteToFinancialStatementDetailsTextual": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "localname": "NoteToFinancialStatementDetailsTextual", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "xbrltype": "stringItemType" }, "nhtc_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "xbrltype": "stringItemType" }, "nhtc_NumberOfDaysTerminationNotice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of days for termination notice.", "label": "nhtc_NumberOfDaysTerminationNotice", "terseLabel": "Number of Days Termination Notice (Day)" } } }, "localname": "NumberOfDaysTerminationNotice", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions-details-textual" ], "xbrltype": "durationItemType" }, "nhtc_OfficeEquipment": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents other equipment.", "label": "Office equipment" } } }, "localname": "OfficeEquipment", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "nhtc_OfficeEquipmentOfficeSoftwareAndCapitalizedInternaluseSoftwareDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents office equipment, office software and capitalized internal-use software development.", "label": "Office Equipment, Office Software and Capitalized Internal-use Software Development [Member]" } } }, "localname": "OfficeEquipmentOfficeSoftwareAndCapitalizedInternaluseSoftwareDevelopmentMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_OperatingLossCarryforwardsSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "nhtc_OperatingLossCarryforwardsSubjectToExpiration", "terseLabel": "Operating Loss Carryforwards, Subject to Expiration" } } }, "localname": "OperatingLossCarryforwardsSubjectToExpiration", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "nhtc_OtherForeignCountriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to other foreign countries.", "label": "Other Foreign Countries [Member]" } } }, "localname": "OtherForeignCountriesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-longlived-assets-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-net-sales-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "nhtc_PhantomSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to phantom shares.", "label": "Phantom Shares [Member]" } } }, "localname": "PhantomSharesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_PrimaryReportingSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the primary reporting segment.", "label": "Primary Reporting Segment [Member]" } } }, "localname": "PrimaryReportingSegmentMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "nhtc_RelatedPartyTransactionAutomaticRenewalPeriodOfAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the automatic renewal period of the agreement in related party transaction.", "label": "nhtc_RelatedPartyTransactionAutomaticRenewalPeriodOfAgreement", "terseLabel": "Related Party Transaction, Automatic Renewal Period of Agreement (Year)" } } }, "localname": "RelatedPartyTransactionAutomaticRenewalPeriodOfAgreement", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions-details-textual" ], "xbrltype": "durationItemType" }, "nhtc_RestrictedCashCollateralRequirementPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents collateral requirement percentage of restricted cash.", "label": "nhtc_RestrictedCashCollateralRequirementPercentage", "terseLabel": "Restricted Cash, Collateral Requirement Percentage" } } }, "localname": "RestrictedCashCollateralRequirementPercentage", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "percentItemType" }, "nhtc_RevenueFromContractWithCustomerSalesReturnsPolicyTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the sales returns policy term.", "label": "nhtc_RevenueFromContractWithCustomerSalesReturnsPolicyTerm", "terseLabel": "Revenue from Contract with Customer, Sales Returns Policy Term (Day)" } } }, "localname": "RevenueFromContractWithCustomerSalesReturnsPolicyTerm", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-2-revenue-details-textual" ], "xbrltype": "durationItemType" }, "nhtc_RevenueFromContractWithCustomersHistoricalSalesReturnsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of historical sales returns.", "label": "nhtc_RevenueFromContractWithCustomersHistoricalSalesReturnsPercent", "terseLabel": "Revenue from Contract with Customers, Historical Sales Returns, Percent" } } }, "localname": "RevenueFromContractWithCustomersHistoricalSalesReturnsPercent", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-2-revenue-details-textual" ], "xbrltype": "percentItemType" }, "nhtc_RevenueFromContractWithCustomersSalesReturnsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of sales returns.", "label": "nhtc_RevenueFromContractWithCustomersSalesReturnsPercent", "terseLabel": "Revenue from Contract with Customers, Sales Returns, Percent" } } }, "localname": "RevenueFromContractWithCustomersSalesReturnsPercent", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-2-revenue-details-textual" ], "xbrltype": "percentItemType" }, "nhtc_RichmondBritishColumbiaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Richmond, British Columbia.", "label": "Richmond, British Columbia [Member]" } } }, "localname": "RichmondBritishColumbiaMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_RollingHillsEstatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Rolling Hills Estates.", "label": "Rolling Hills Estates [Member]" } } }, "localname": "RollingHillsEstatesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_RoyaltyAgreementAndLicenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the Royalty Agreement and License.", "label": "Royalty Agreement and License [Member]" } } }, "localname": "RoyaltyAgreementAndLicenseMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_RussiaAndKazakhstanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Russia and Kazakhstan.", "label": "Russia and Kazakhstan [Member]" } } }, "localname": "RussiaAndKazakhstanMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "nhtc_ScheduleOfAdditionalBalanceSheetComponentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of additional balance sheet components.", "label": "Schedule of Additional Balance Sheet Components [Table Text Block]" } } }, "localname": "ScheduleOfAdditionalBalanceSheetComponentsTableTextBlock", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-tables" ], "xbrltype": "textBlockItemType" }, "nhtc_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPaymentPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the maximum payment value per share of equity instruments other than options under share based compensation arrangement.", "label": "nhtc_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPaymentPerShare", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Maximum Payment Per Share (in dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPaymentPerShare", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-details-textual" ], "xbrltype": "perShareItemType" }, "nhtc_ThePhantomPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the phantom plan.", "label": "The Phantom Plan [Member]" } } }, "localname": "ThePhantomPlanMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_UnshippedProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to unshipped product.", "label": "Unshipped Product [Member]" } } }, "localname": "UnshippedProductMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "domainItemType" }, "nhtc_statement-statement-note-10-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details)" } } }, "localname": "statement-statement-note-10-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-10-stockholders-equity-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Stockholders' Equity" } } }, "localname": "statement-statement-note-10-stockholders-equity-tables", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-13-segment-information-longlived-assets-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 13 - Segment Information - Long-lived Assets (Details)" } } }, "localname": "statement-statement-note-13-segment-information-longlived-assets-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-13-segment-information-net-sales-by-geographic-area-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 13 - Segment Information - Net Sales by Geographic Area (Details)" } } }, "localname": "statement-statement-note-13-segment-information-net-sales-by-geographic-area-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-13-segment-information-net-sales-by-product-and-service-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 13 - Segment Information - Net Sales by Product and Service (Details)" } } }, "localname": "statement-statement-note-13-segment-information-net-sales-by-product-and-service-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-13-segment-information-operating-information-by-geographic-area-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 13 - Segment Information - Operating Information by Geographic Area (Details)" } } }, "localname": "statement-statement-note-13-segment-information-operating-information-by-geographic-area-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-13-segment-information-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 13 - Segment Information" } } }, "localname": "statement-statement-note-13-segment-information-tables", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-3-net-income-per-common-share-basic-and-diluted-net-income-loss-per-share-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Net Income Per Common Share - Basic and Diluted Net Income (Loss) Per Share (Details)" } } }, "localname": "statement-statement-note-3-net-income-per-common-share-basic-and-diluted-net-income-loss-per-share-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-3-net-income-per-common-share-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Net Income Per Common Share" } } }, "localname": "statement-statement-note-3-net-income-per-common-share-tables", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Balance Sheet Components - Summary of Balance Sheet Amounts (Details)" } } }, "localname": "statement-statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-4-balance-sheet-components-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Balance Sheet Components" } } }, "localname": "statement-statement-note-4-balance-sheet-components-tables", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-5-fair-value-measurements-investments-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Fair Value Measurements - Investments (Details)" } } }, "localname": "statement-statement-note-5-fair-value-measurements-investments-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-5-fair-value-measurements-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Fair Value Measurements" } } }, "localname": "statement-statement-note-5-fair-value-measurements-tables", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-6-leases-lease-cost-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Leases - Lease Cost (Details)" } } }, "localname": "statement-statement-note-6-leases-lease-cost-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-6-leases-maturity-of-lease-liabilities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Leases - Maturity of Lease Liabilities (Details)" } } }, "localname": "statement-statement-note-6-leases-maturity-of-lease-liabilities-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-6-leases-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Leases" } } }, "localname": "statement-statement-note-6-leases-tables", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-7-income-taxes-components-of-income-loss-before-income-taxes-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Income Taxes - Components of Income (Loss) Before Income Taxes (Details)" } } }, "localname": "statement-statement-note-7-income-taxes-components-of-income-loss-before-income-taxes-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Income Taxes - Components of Income Tax Provision (Benefit) (Details)" } } }, "localname": "statement-statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-7-income-taxes-deferred-income-taxes-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Income Taxes - Deferred Income Taxes (Details)" } } }, "localname": "statement-statement-note-7-income-taxes-deferred-income-taxes-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-7-income-taxes-foreign-rate-differentials-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Income Taxes - Foreign Rate Differentials (Details)" } } }, "localname": "statement-statement-note-7-income-taxes-foreign-rate-differentials-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Income Taxes - Reconciliation of Reported Income Tax Provision (Details)" } } }, "localname": "statement-statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-7-income-taxes-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Income Taxes" } } }, "localname": "statement-statement-note-7-income-taxes-tables", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-9-stockbased-incentive-plans-restricted-stock-activity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Stock-based Incentive Plans - Restricted Stock Activity (Details)" } } }, "localname": "statement-statement-note-9-stockbased-incentive-plans-restricted-stock-activity-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-9-stockbased-incentive-plans-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Stock-based Incentive Plans" } } }, "localname": "statement-statement-note-9-stockbased-incentive-plans-tables", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-significant-accounting-policies-policies": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "statement-statement-significant-accounting-policies-policies", "nsuri": "http://www.naturalhealthtrendscorp.com/20211231", "xbrltype": "stringItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r98", "r153", "r166", "r167", "r168", "r169", "r171", "r173", "r177", "r214", "r215", "r216", "r217", "r218", "r219", "r221", "r222", "r224", "r226", "r227" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r98", "r153", "r166", "r167", "r168", "r169", "r171", "r173", "r177", "r214", "r215", "r216", "r217", "r218", "r219", "r221", "r222", "r224", "r226", "r227" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "srt_DirectorMember": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Europe [Member]" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-net-sales-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r229", "r235", "r290", "r291", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r469", "r472", "r513", "r514" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-2-revenue-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-details-textual" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r229", "r235", "r290", "r291", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r469", "r472", "r513", "r514" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-2-revenue-details-textual" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r179", "r263", "r267", "r422", "r468", "r470" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-net-sales-by-product-and-service-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r179", "r263", "r267", "r422", "r468", "r470" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-net-sales-by-product-and-service-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r229", "r235", "r270", "r290", "r291", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r469", "r472", "r513", "r514" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-2-revenue-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-details-textual" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r229", "r235", "r270", "r290", "r291", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r469", "r472", "r513", "r514" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-2-revenue-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-details-textual" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r180", "r181", "r263", "r268", "r471", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-longlived-assets-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-operating-information-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-details-textual" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r180", "r181", "r263", "r268", "r471", "r498", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-longlived-assets-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-operating-information-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-details-textual" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r185", "r400" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-details-textual" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r36", "r406" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r11", "r12", "r38" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related expense" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r19", "r440", "r456" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesNoncurrent": { "auth_ref": [ "r20", "r440", "r456" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.", "label": "us-gaap_AccruedIncomeTaxesNoncurrent", "terseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other accrued expenses:" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "stringItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_AccruedLiabilitiesCurrent", "totalLabel": "Accrued Liabilities, Current, Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalesCommissionCurrent": { "auth_ref": [ "r11", "r12", "r38" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued commissions" } } }, "localname": "AccruedSalesCommissionCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r34", "r202" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedLabel": "Accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r52", "r53", "r54", "r58", "r66", "r67", "r68" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r27", "r56", "r57", "r58", "r458", "r477", "r478" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r55", "r58", "r66", "r67", "r68", "r100", "r101", "r102", "r354", "r473", "r474", "r525" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r50", "r58", "r66", "r67", "r68", "r354", "r374", "r375", "r376", "r377", "r379" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r25", "r309", "r406" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r100", "r101", "r102", "r306", "r307", "r308", "r357" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r294", "r304", "r310" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "us-gaap_AllocatedShareBasedCompensationExpense", "terseLabel": "Share-based Payment Arrangement, Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits": { "auth_ref": [ "r128" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of stock options or restrictive stock units (RSUs).", "label": "Non-vested restricted stock" } } }, "localname": "AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-3-net-income-per-common-share-basic-and-diluted-net-income-loss-per-share-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AreaOfLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land held.", "label": "us-gaap_AreaOfLand", "terseLabel": "Area of Land (Square Foot)" } } }, "localname": "AreaOfLand", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-details-textual" ], "xbrltype": "areaItemType" }, "us-gaap_Assets": { "auth_ref": [ "r93", "r161", "r168", "r175", "r192", "r214", "r215", "r216", "r218", "r219", "r220", "r221", "r223", "r225", "r227", "r228", "r350", "r355", "r366", "r404", "r406", "r439", "r455" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r7", "r48", "r93", "r192", "r214", "r215", "r216", "r218", "r219", "r220", "r221", "r223", "r225", "r227", "r228", "r350", "r355", "r366", "r404", "r406" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r190" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "negatedLabel": "Gross unrealized losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements-investments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r188", "r194" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Adjusted cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements-investments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r187", "r189", "r194", "r443" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Fair value", "negatedLabel": "Fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements-investments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r295", "r305" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-restricted-stock-activity-details" ], "xbrltype": "stringItemType" }, "us-gaap_BankTimeDepositsMember": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.", "label": "Bank Time Deposits [Member]" } } }, "localname": "BankTimeDepositsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r3", "r99", "r148" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalizedComputerSoftwareGross": { "auth_ref": [ "r515" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.", "label": "Office software" } } }, "localname": "CapitalizedComputerSoftwareGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r31", "r406", "r481", "r482" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r31", "r86" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents", "terseLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r15", "r87" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r15", "r87", "r438" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r81", "r86", "r89" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents:" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r81", "r86", "r89" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodEndLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period", "periodStartLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r81", "r371" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net decrease in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r31" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 0.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommissionsPolicy": { "auth_ref": [ "r436", "r437" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fees earned by the broker dealer, acting as an agent in the buying and selling of securities and administrative efforts on behalf of customers and may include the timing of commission revenue recognition and presentation in the financial statements. Commissions earned are usually related to the broker dealer's customers' trading volume and the dollar amounts of the trades.", "label": "Commissions, Policy [Policy Text Block]" } } }, "localname": "CommissionsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r40", "r212", "r444", "r462" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (Note 8)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r209", "r210", "r211", "r213", "r501" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-8-commitments-and-contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Dividends declared, per share (in dollars per share)", "terseLabel": "Common Stock, Dividends, Per Share, Declared (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-14-subsequent-event-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r100", "r101", "r357" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)", "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, authorized (in shares)", "terseLabel": "Common Stock, Shares Authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r24", "r406" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at December 31, 2021 and 2020" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r61", "r63", "r64", "r71", "r447", "r464" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-comprehensive-income": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-comprehensive-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive income (loss), net of tax:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-comprehensive-income" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r143", "r144", "r183", "r364", "r365", "r500" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r143", "r144", "r183", "r364", "r365", "r480", "r500" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r143", "r144", "r183", "r364", "r365", "r480", "r500" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r139", "r453" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r143", "r144", "r183", "r364", "r365" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "us-gaap_ConcentrationRiskPercentage1", "terseLabel": "Concentration Risk, Percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r143", "r144", "r183", "r364", "r365", "r500" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r90", "r352" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressGross": { "auth_ref": [ "r201" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in progress" } } }, "localname": "ConstructionInProgressGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred revenue:" } } }, "localname": "ContractWithCustomerLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r252", "r253", "r264" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r265" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "us-gaap_ContractWithCustomerLiabilityRevenueRecognized", "terseLabel": "Contract with Customer, Liability, Revenue Recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-2-revenue-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r271", "r286", "r479" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r75", "r422" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 0.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r94", "r331", "r338" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r94", "r331" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details": { "order": 0.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_CurrentForeignTaxExpenseBenefit", "terseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r94", "r331", "r338", "r340" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "us-gaap_CurrentIncomeTaxExpenseBenefit", "totalLabel": "Total current taxes" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current taxes:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r94", "r331", "r338" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table Text Block]" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitment made to pay deferred cash remuneration expressed as a percentage of the individual's base salary.", "label": "us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage", "terseLabel": "Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage" } } }, "localname": "DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-12-employee-benefit-plans-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r94", "r332", "r338" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_DeferredFederalIncomeTaxExpenseBenefit", "verboseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r94", "r332", "r338" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_DeferredForeignIncomeTaxExpenseBenefit", "verboseLabel": "Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r314", "r315" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred tax asset" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r84", "r94", "r332", "r338", "r339", "r340" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_DeferredIncomeTaxExpenseBenefit", "totalLabel": "Total deferred taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r21", "r22", "r322", "r441", "r454" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "us-gaap_DeferredIncomeTaxLiabilities", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r314", "r315" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r94", "r332", "r338" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit", "verboseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r323" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "us-gaap_DeferredTaxAssetsGross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r325" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r325" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "us-gaap_DeferredTaxAssetsNet", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r329", "r330" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating losses" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r329", "r330" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "verboseLabel": "Stock-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r329", "r330" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "verboseLabel": "Other" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r324" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "us-gaap_DeferredTaxAssetsValuationAllowance", "negatedLabel": "Valuation allowance", "terseLabel": "Deferred Tax Assets, Valuation Allowance, Total" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "auth_ref": [ "r329", "r330" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.", "label": "us-gaap_DeferredTaxLiabilitiesLeasingArrangements", "verboseLabel": "Operating lease assets" } } }, "localname": "DeferredTaxLiabilitiesLeasingArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r329", "r330" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "us-gaap_DeferredTaxLiabilitiesOther", "verboseLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.", "label": "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses", "verboseLabel": "Prepaids" } } }, "localname": "DeferredTaxLiabilitiesPrepaidExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": { "auth_ref": [ "r329" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.", "label": "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings", "negatedLabel": "Foreign deferreds" } } }, "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r289" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "us-gaap_DefinedContributionPlanCostRecognized", "terseLabel": "Defined Contribution Plan, Cost" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-12-employee-benefit-plans-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "terseLabel": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-12-employee-benefit-plans-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.", "label": "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage", "terseLabel": "Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage" } } }, "localname": "DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-12-employee-benefit-plans-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r84", "r200" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "us-gaap_DepreciationAndAmortization", "terseLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r84", "r156" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-12-employee-benefit-plans-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-14-subsequent-event", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-3-net-income-per-common-share-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-8-commitments-and-contingencies", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans" ], "xbrltype": "stringItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r248", "r452" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "us-gaap_Dividends", "negatedLabel": "Dividends declared" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsCommonStock": { "auth_ref": [ "r248", "r452" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "us-gaap_DividendsCommonStock", "terseLabel": "Dividends, Common Stock, Total" } } }, "localname": "DividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r72", "r105", "r106", "r107", "r108", "r109", "r113", "r116", "r126", "r127", "r128", "r132", "r133", "r358", "r359", "r448", "r465" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-3-net-income-per-common-share-basic-and-diluted-net-income-loss-per-share-details" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net income per common share:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted-average number of common shares outstanding:" } } }, "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r72", "r105", "r106", "r107", "r108", "r109", "r116", "r126", "r127", "r128", "r132", "r133", "r358", "r359", "r448", "r465" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-3-net-income-per-common-share-basic-and-diluted-net-income-loss-per-share-details" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r129", "r130" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r129", "r130", "r131", "r134" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-3-net-income-per-common-share-" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r371" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of exchange rates on cash, cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r96", "r317", "r342" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Statutory Tax Rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-foreign-rate-differentials-details" ], "xbrltype": "percentItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r66", "r67", "r68", "r100", "r101", "r102", "r104", "r110", "r112", "r136", "r193", "r247", "r248", "r306", "r307", "r308", "r334", "r335", "r357", "r373", "r374", "r375", "r376", "r377", "r379", "r473", "r474", "r475", "r525" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r230", "r231", "r232", "r271", "r273", "r274", "r275", "r276", "r277", "r278", "r286", "r360", "r410", "r411", "r412" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements-investments-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r230", "r271", "r273", "r278", "r286", "r360", "r410" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r230", "r231", "r232", "r271", "r273", "r278", "r286", "r360", "r411" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r230", "r231", "r232", "r271", "r273", "r274", "r275", "r276", "r277", "r278", "r286", "r410", "r411", "r412" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r362", "r363" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "auth_ref": [ "r85", "r369", "r370" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.", "label": "us-gaap_ForeignCurrencyTransactionGainLossUnrealized", "terseLabel": "Foreign Currency Transaction Gain (Loss), Unrealized" } } }, "localname": "ForeignCurrencyTransactionGainLossUnrealized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesGross": { "auth_ref": [ "r201" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 4.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r142", "r500" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r74", "r93", "r161", "r167", "r171", "r174", "r177", "r192", "r214", "r215", "r216", "r219", "r220", "r221", "r223", "r225", "r227", "r228", "r366" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "us-gaap_GrossProfit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r95", "r341" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-loss-before-income-taxes-details": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Domestic" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-loss-before-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r69", "r161", "r167", "r171", "r174", "r177", "r435", "r445", "r450", "r466" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-loss-before-income-taxes-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income before income taxes", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-operating-information-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-loss-before-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r95", "r341" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-loss-before-income-taxes-details": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-loss-before-income-taxes-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-foreign-rate-differentials-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r204", "r206" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r206" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-foreign-rate-differentials-details" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-foreign-rate-differentials-details" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r96", "r318", "r320", "r327", "r336", "r343", "r345", "r346", "r347" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r97", "r111", "r112", "r159", "r316", "r337", "r344", "r467" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income tax provision", "totalLabel": "Income tax provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r65", "r312", "r313", "r320", "r321", "r326", "r333" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r317" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details": { "order": 8.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r317" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details": { "order": 7.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).", "label": "Foreign rate differential" } } }, "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r317" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Income tax at federal statutory rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r317" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Stock-based compensation" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": { "auth_ref": [ "r317" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.", "label": "Other reconciling items" } } }, "localname": "IncomeTaxReconciliationOtherReconcilingItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxContingenciesForeign": { "auth_ref": [ "r317" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in foreign income tax contingency.", "label": "Foreign tax credits" } } }, "localname": "IncomeTaxReconciliationTaxContingenciesForeign", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r88" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Cash paid (refunded) for income taxes, net" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r83" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r83" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable", "verboseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r83" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "us-gaap_IncreaseDecreaseInAccruedLiabilities", "terseLabel": "Other accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r83", "r420" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "us-gaap_IncreaseDecreaseInContractWithCustomerLiability", "terseLabel": "Increase (Decrease) in Contract with Customer, Liability" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-2-revenue-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r83" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "us-gaap_IncreaseDecreaseInDeferredRevenue", "verboseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r83" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r83" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "us-gaap_IncreaseDecreaseInOtherCurrentAssets", "negatedLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [ "r83" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities", "terseLabel": "Other current liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r83" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r117", "r118", "r119", "r128" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Non-vested restricted stock (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-3-net-income-per-common-share-basic-and-diluted-net-income-loss-per-share-details" ], "xbrltype": "sharesItemType" }, "us-gaap_InlandRevenueHongKongMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of Hong Kong.", "label": "Inland Revenue, Hong Kong [Member]" } } }, "localname": "InlandRevenueHongKongMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-foreign-rate-differentials-details" ], "xbrltype": "domainItemType" }, "us-gaap_IntersegmentEliminationMember": { "auth_ref": [ "r153", "r166", "r167", "r168", "r169", "r171", "r173", "r177" ], "lang": { "en-us": { "role": { "documentation": "Eliminating entries used in operating segment consolidation.", "label": "Intersegment Eliminations [Member]" } } }, "localname": "IntersegmentEliminationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r43" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r5", "r45", "r406" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventories", "totalLabel": "Inventory, Net, Total" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventories:" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r14", "r46", "r91", "r135", "r195", "r196", "r198", "r421" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsAndSupplies": { "auth_ref": [ "r44" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 0.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.", "label": "Raw materials" } } }, "localname": "InventoryRawMaterialsAndSupplies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r45", "r197" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "us-gaap_InventoryValuationReserves", "negatedLabel": "Reserve for obsolescence" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements-investments-details" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r392", "r394" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-lease-cost-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "us-gaap_LeaseCost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-lease-cost-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsGross": { "auth_ref": [ "r9", "r201" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.", "label": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r393" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-maturity-of-lease-liabilities-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r393" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-maturity-of-lease-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r393" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-maturity-of-lease-liabilities-details": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r393" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-maturity-of-lease-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r393" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-maturity-of-lease-liabilities-details": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r393" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-maturity-of-lease-liabilities-details": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r393" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-maturity-of-lease-liabilities-details": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r393" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_LesseeOperatingLeaseRenewalTerm", "terseLabel": "Lessee, Operating Lease, Renewal Term (Year)" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r37", "r93", "r169", "r192", "r214", "r215", "r216", "r219", "r220", "r221", "r223", "r225", "r227", "r228", "r351", "r355", "r356", "r366", "r404", "r405" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r30", "r93", "r192", "r366", "r406", "r442", "r460" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r39", "r93", "r192", "r214", "r215", "r216", "r219", "r220", "r221", "r223", "r225", "r227", "r228", "r351", "r355", "r356", "r366", "r404", "r405", "r406" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "stringItemType" }, "us-gaap_MachineryAndEquipmentGross": { "auth_ref": [ "r9", "r201" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 5.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery" } } }, "localname": "MachineryAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_MunicipalBondsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.", "label": "Municipal Bonds [Member]" } } }, "localname": "MunicipalBondsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r81" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r81" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r81", "r82", "r85" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r59", "r62", "r68", "r70", "r85", "r93", "r103", "r105", "r106", "r107", "r108", "r111", "r112", "r124", "r161", "r167", "r171", "r174", "r177", "r192", "r214", "r215", "r216", "r219", "r220", "r221", "r223", "r225", "r227", "r228", "r359", "r366", "r446", "r463" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-comprehensive-income": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net income", "totalLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-comprehensive-income", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r105", "r106", "r107", "r108", "r113", "r114", "r125", "r128", "r161", "r167", "r171", "r174", "r177" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net income available to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-3-net-income-per-common-share-basic-and-diluted-net-income-loss-per-share-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r115", "r120", "r121", "r122", "r123", "r125", "r128" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net income available to common stockholders plus assumed conversions" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-3-net-income-per-common-share-basic-and-diluted-net-income-loss-per-share-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "stringItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r181" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Total long-lived assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-longlived-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]" } } }, "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "us-gaap_OperatingExpenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r161", "r167", "r171", "r174", "r177" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "us-gaap_OperatingIncomeLoss", "terseLabel": "Income (loss) from operations", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r386", "r394" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-lease-cost-details": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating leases" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-lease-cost-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r383" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Present value of lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r383" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r383" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "us-gaap_OperatingLeaseLiabilityNoncurrent", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r384", "r388" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "us-gaap_OperatingLeasePayments", "terseLabel": "Operating Lease, Payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r382" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r391", "r394" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-lease-cost-details" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r390", "r394" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted-average remaining lease term (in years) (Year)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-lease-cost-details" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r328" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "us-gaap_OperatingLossCarryforwards", "terseLabel": "Operating Loss Carryforwards, Total" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r166", "r167", "r168", "r169", "r171", "r177" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r11", "r12", "r13", "r38" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r47", "r406" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r51", "r56", "r367", "r368", "r372" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-comprehensive-income": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Foreign currency translation adjustments", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-comprehensive-income", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r60", "r63", "r348", "r349", "r353" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r52", "r56" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-comprehensive-income": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Unrealized gains (losses) on available-for-sale securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-comprehensive-income", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r10", "r11", "r38", "r406" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r78" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r80" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "us-gaap_PaymentsOfDividends", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r79" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r270", "r272", "r278", "r279", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r292" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-12-employee-benefit-plans-" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r295", "r305" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r23", "r233" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value (in dollars per share)", "terseLabel": "Preferred Stock, Par or Stated Value Per Share (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, authorized (in shares)", "terseLabel": "Preferred Stock, Shares Authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r23", "r233" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r23", "r406" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductAndServiceOtherMember": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.", "label": "Product and Service, Other [Member]" } } }, "localname": "ProductAndServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "domainItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-net-sales-by-product-and-service-details" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and equipment:" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r34", "r203" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r33", "r201" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "us-gaap_PropertyPlantAndEquipmentGross", "totalLabel": "Property and equipment, at cost" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r16", "r17", "r203", "r406", "r451", "r461" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "totalLabel": "Property, Plant and Equipment, Net, Ending Balance" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r32", "r203", "r502", "r503" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r16", "r201" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife", "terseLabel": "Property, Plant and Equipment, Useful Life (Year)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r167", "r171" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r280", "r398", "r399" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r280", "r398", "r399", "r401" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r280", "r398", "r401", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r396", "r397", "r399", "r402", "r403" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r15", "r86", "r89", "r438", "r457" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_RestrictedCashAndCashEquivalents", "terseLabel": "Restricted Cash and Cash Equivalents, Total" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r8", "r18", "r89", "r499" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-restricted-stock-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r26", "r248", "r309", "r406", "r459", "r476", "r478" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained earnings (accumulated deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r100", "r101", "r102", "r104", "r110", "r112", "r193", "r306", "r307", "r308", "r334", "r335", "r357", "r473", "r475" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r152", "r153", "r166", "r172", "r173", "r179", "r180", "r183", "r262", "r263", "r422" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-net-sales-by-product-and-service-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r143", "r183" ], "lang": { "en-us": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue from Contract with Customer Benchmark [Member]" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r266", "r269" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-2-revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r389", "r394" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-use assets obtained in exchange for operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r76" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "us-gaap_RoyaltyExpense", "terseLabel": "Royalty Expense" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesCommissionsAndFees": { "auth_ref": [ "r77" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).", "label": "Commissions expense" } } }, "localname": "SalesCommissionsAndFees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r58", "r378", "r379" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-3-net-income-per-common-share-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock": { "auth_ref": [ "r181" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the names of foreign countries in which material long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets are located, and amount of such long-lived assets located in that country or foreign geographic area.", "label": "Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]" } } }, "localname": "ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": { "auth_ref": [ "r73", "r180" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]" } } }, "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r161", "r164", "r170", "r199" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r149", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r166", "r167", "r168", "r169", "r171", "r172", "r173", "r174", "r175", "r177", "r183", "r207", "r208", "r468" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r149", "r150", "r151", "r161", "r165", "r171", "r175", "r176", "r177", "r178", "r179", "r182", "r183", "r184" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r77" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-restricted-stock-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "periodEndLabel": "Balance, weighted avg. price (in dollars per share)", "periodStartLabel": "Balance, weighted avg. price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-restricted-stock-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "negatedLabel": "Vested (in shares)", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-restricted-stock-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Vested, wtd. avg. price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-restricted-stock-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r293", "r299" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-restricted-stock-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "us-gaap_SharesOutstanding", "periodEndLabel": "BALANCE (in shares)", "periodStartLabel": "BALANCE (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r387", "r394" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-lease-cost-details": { "order": 0.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term leases" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-lease-cost-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_StateAdministrationOfTaxationChinaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of China.", "label": "State Administration of Taxation, China [Member]" } } }, "localname": "StateAdministrationOfTaxationChinaMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-foreign-rate-differentials-details" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r1", "r149", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r166", "r167", "r168", "r169", "r171", "r172", "r173", "r174", "r175", "r177", "r183", "r199", "r205", "r207", "r208", "r468" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r42", "r66", "r67", "r68", "r100", "r101", "r102", "r104", "r110", "r112", "r136", "r193", "r247", "r248", "r306", "r307", "r308", "r334", "r335", "r357", "r373", "r374", "r375", "r376", "r377", "r379", "r473", "r474", "r475", "r525" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-comprehensive-income", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-12-employee-benefit-plans-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-12-employee-benefit-plans-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-longlived-assets-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-net-sales-by-product-and-service-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-operating-information-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-14-subsequent-event", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-14-subsequent-event-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-2-revenue-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-3-net-income-per-common-share-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-3-net-income-per-common-share-basic-and-diluted-net-income-loss-per-share-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-3-net-income-per-common-share-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements-investments-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-lease-cost-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-maturity-of-lease-liabilities-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-loss-before-income-taxes-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-foreign-rate-differentials-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-8-commitments-and-contingencies", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-restricted-stock-activity-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r100", "r101", "r102", "r136", "r422" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-cash-flows-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-comprehensive-income", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-11-related-party-transactions-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-12-employee-benefit-plans-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-12-employee-benefit-plans-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-longlived-assets-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-net-sales-by-product-and-service-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-operating-information-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-14-subsequent-event", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-14-subsequent-event-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-2-revenue-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-3-net-income-per-common-share-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-3-net-income-per-common-share-basic-and-diluted-net-income-loss-per-share-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-3-net-income-per-common-share-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements-investments-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-lease-cost-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-maturity-of-lease-liabilities-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-loss-before-income-taxes-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-deferred-income-taxes-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-foreign-rate-differentials-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-8-commitments-and-contingencies", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-details-textual", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-restricted-stock-activity-details", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "us-gaap_StockRepurchaseProgramAuthorizedAmount1", "terseLabel": "Stock Repurchase Program, Authorized Amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "terseLabel": "Stock Repurchase Program, Remaining Authorized Repurchase Amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r24", "r28", "r29", "r93", "r186", "r192", "r366", "r406" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "us-gaap_StockholdersEquity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r92", "r234", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r248", "r251" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r380", "r408" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-14-subsequent-event", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-14-subsequent-event-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r380", "r408" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-14-subsequent-event", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-14-subsequent-event-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r380", "r408" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-14-subsequent-event", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-14-subsequent-event-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r407", "r409" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-14-subsequent-event" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components" ], "xbrltype": "textBlockItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-10-stockholders-equity-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-13-segment-information-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-3-net-income-per-common-share-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-4-balance-sheet-components-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-5-fair-value-measurements-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-6-leases-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-tables", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-9-stockbased-incentive-plans-tables" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability": { "auth_ref": [ "r347" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.", "label": "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability", "terseLabel": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Total" } } }, "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent": { "auth_ref": [ "r347" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act, classified as noncurrent.", "label": "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent", "terseLabel": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Noncurrent" } } }, "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r41", "r249" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r41", "r249" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury stock, shares (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r41", "r249", "r250" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "us-gaap_TreasuryStockValue", "negatedLabel": "Treasury stock, at cost; 1,556,875 shares at December 31, 2021 and 2020" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r137", "r138", "r140", "r141", "r145", "r146", "r147" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r115", "r128" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-3-net-income-per-common-share-basic-and-diluted-net-income-loss-per-share-details" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r113", "r128" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20211231/role/statement-consolidated-statements-of-operations", "http://www.naturalhealthtrendscorp.com/20211231/role/statement-note-3-net-income-per-common-share-basic-and-diluted-net-income-loss-per-share-details" ], "xbrltype": "sharesItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r134": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r148": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r184": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r191": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r198": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r211": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r213": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r251": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r269": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r292": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r311": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r347": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r381": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r395": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r403": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r409": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41256-110953" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41261-110953" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4),(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Subparagraph": "b.", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123398031&loc=d3e60009-112784" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r49": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a-c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r516": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r517": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r518": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r519": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r520": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r521": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r522": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r523": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r524": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r99": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" } }, "version": "2.1" } ZIP 76 0001437749-22-004467-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-22-004467-xbrl.zip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c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�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end